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Background: Insulin is generally administered to people with type 1 diabetes mellitus (T1DM) using
multiple daily injections (MDIs), but can also be delivered using infusion pumps. In the UK, pumps are
recommended for patients with the greatest need and adult use is less than in comparable countries.
Previous trials have been small, of short duration and have failed to control for training in insulin adjustment.
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Objective: To assess the clinical effectiveness and cost-effectiveness of pump therapy compared with MDI
for adults with T1DM, with both groups receiving equivalent structured training in flexible insulin therapy.
Design: Pragmatic, multicentre, open-label, parallel-group cluster randomised controlled trial, including
economic and psychosocial evaluations. After participants were assigned a group training course, courses
were randomly allocated in pairs to either pump or MDI.
Setting: Eight secondary care diabetes centres in the UK.
Participants: Adults with T1DM for > 12 months, willing to undertake intensive insulin therapy, with no
preference for pump or MDI, or a clinical indication for pumps.
Interventions: Pump or MDI structured training in flexible insulin therapy, followed up for 2 years. MDI
participants used insulin analogues. Pump participants used a Medtronic Paradigm® VeoTM (Medtronic,
Watford, UK) with insulin aspart (NovoRapid, Novo Nordisk, Gatwick, UK).
Main outcome measures: Primary outcome – change in glycated haemoglobin (HbA1c) at 2 years in
participants whose baseline HbA1c was ≥ 7.5% (58 mmol/mol). Key secondary outcome – proportion of
participants with HbA1c ≤ 7.5% at 2 years. Other outcomes at 6, 12 and 24 months – moderate and severe
hypoglycaemia; insulin dose; body weight; proteinuria; diabetic ketoacidosis; quality of life (QoL); fear of
hypoglycaemia; treatment satisfaction; emotional well-being; qualitative interviews with participants and
staff (2 weeks), and participants (6 months); and ICERs in trial and modelled estimates of cost-effectiveness.
Results: We randomised 46 courses comprising 317 participants: 267 attended a Dose Adjustment For
Normal Eating course (132 pump; 135 MDI); 260 were included in the intention-to-treat analysis, of which
235 (119 pump; 116 MDI) had baseline HbA1c of ≥ 7.5%. HbA1c and severe hypoglycaemia improved in
both groups. The drop in HbA1c% at 2 years was 0.85 on pump and 0.42 on MDI. The mean difference
(MD) in HbA1c change at 2 years, at which the baseline HbA1c was ≥ 7.5%, was –0.24% [95% confidence
interval (CI) –0.53% to 0.05%] in favour of the pump (p = 0.098). The per-protocol analysis showed a
MD in change of –0.36% (95% CI –0.64% to –0.07%) favouring pumps (p = 0.015). Pumps were not
cost-effective in the base case and all of the sensitivity analyses. The pump group had greater improvement
in diabetes-specific QoL diet restrictions, daily hassle plus treatment satisfaction, statistically significant at
12 and 24 months and supported by qualitative interviews.
Limitation: Blinding of pump therapy was not possible, although an objective primary outcome was used.
Conclusion: Adding pump therapy to structured training in flexible insulin therapy did not significantly
enhance glycaemic control or psychosocial outcomes in adults with T1DM.
Research priority: To understand why few patients achieve a HbA1c of < 7.5%, particularly as glycaemic
control is worse in the UK than in other European countries.
Trial registration: Current Controlled Trials ISRCTN61215213.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 20.
See the NIHR Journals Library website for further project information.
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Plain English summary
People with type 1 diabetes (T1DM) need insulin therapy to sustain life. The most common treatment isinjecting insulin several times a day. Another approach uses insulin pumps, the size of mobile phones,
which are attached under the skin through fine tubing and which provide small amounts of insulin. In the
UK, pumps are recommended for people struggling to control their diabetes with injections, and are used
far less often than in other countries. The research conducted so far on pumps has weaknesses. We
wanted to conduct a fair test to see if pumps would benefit adults with T1DM.
We conducted a large study (a randomised controlled trial) in which 267 people attended a structured
education course: half were assigned to a pump for 2 years, whereas the other half used injections. We
compared average blood sugar levels [by a test measuring glycated haemoglobin (HbA1c)] to compare
diabetes control after 2 years.
Our results showed that both groups improved diabetes control after training. Participants using pumps
had slightly better control, but differences were small (HbA1c was 0.24% lower than in the injections
group). We found that pumps were not cost-effective, although people using pumps reported better
satisfaction with their treatment and in some aspects of their quality of life.
Our study suggests that making insulin pumps more widely available before structured training is unlikely
to improve diabetes control or be cost-effective. Providing structured education to more people could be
highly beneficial, with pumps made available to those needing better ways of delivering insulin to reach
glucose targets.
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Scientific summary
Background
People with type 1 diabetes mellitus (T1DM) require insulin therapy to sustain life. Insulin is generally
administered using multiple daily injections (MDIs), but can also be delivered using an infusion pump
(continuous subcutaneous insulin infusion). Pump therapy is a more costly option, but has potential benefits.
The UK National Institute for Health and Care Excellence (NICE) has approved the use of pumps only for
patients with the greatest need (such as inability to achieve reasonable control without hypoglycaemia). Far
fewer UK adults use pumps than in comparable countries. Previous trials of pump therapy have been small
and of short duration, and have failed to control for training in flexible insulin therapy.
Objectives
We aimed to assess the clinical effectiveness and cost-effectiveness of insulin pump therapy compared with
MDIs for people with T1DM, when both have received high-quality structured education.
The specific objectives were to:
1. measure, over 2 years, (1) biomedical, (2) psychosocial (quantitative and qualitative) and (3) adverse
event (AE) outcomes
2. undertake a cost-effectiveness analysis to determine whether or not the marginal benefits of pump
therapy over optimised MDI (if demonstrated) are commensurate with the marginal costs, as reflected
in a cost per quality-adjusted life-year (QALY) acceptable to NICE
3. conduct a mixed-methods psychosocial evaluation of pump therapy in order to identify factors that
predict and/or help explain outcomes on pump therapy.
Methods
Design
We undertook a pragmatic, multicentre, open-label, parallel-group cluster randomised controlled trial,
with embedded cost-effectiveness analysis and mixed-methods psychosocial evaluation. Participants were
allocated a place on a 1 week-long DAFNE (Dose Adjustment For Normal Eating) course in flexible insulin
therapy. The course groups were then randomly allocated in pairs to either pump or MDI treatment, with
allocation concealed. Following the course, participants received the trial treatment for 2 years.
Setting and participants
Eight secondary care diabetes centres in the UK took part (five in England and three in Scotland). DAFNE
courses (clusters) comprised between five and eight participants. Participants were adults with T1DM for at
least 12 months, willing to undertake intensive insulin therapy, with self-monitoring of blood glucose
levels, carbohydrate counting and insulin self-adjustment, who had no preference for either pump or MDI
and had a need for structured education to optimise diabetes control. People were excluded if they had
already completed a diabetes education course or used a pump within the past 3 years, or had strong
clinical indications or a strong desire for pump therapy.
Interventions
Participants in the MDI arm attended a standard DAFNE structured education course. Courses were
conducted over five consecutive days and were delivered to groups of five to eight adults in an outpatient
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setting. Participants in the pump arm attended a modified DAFNE course, which had been tested in a pilot
study. The 5-day structure of the course was maintained, while incorporating the additional skills and
learning outcomes that were considered necessary to use pumps successfully. The need to introduce ‘pump
skills’ required an additional pre-course group session, delivered 1–3 weeks before the ‘proper’ DAFNE
course. All of the participants were invited to an additional DAFNE follow-up group session at 6 weeks post
course. MDI participants used insulin analogues. Pump participants used a Medtronic Paradigm® VeoTM
(Medtronic, Watford, UK) insulin pump, loaded with insulin aspart (NovoRapid, Novo Nordisk, Gatwick, UK).
All of the participants had access to a bolus calculator to aid calculation of insulin doses.
Outcome measures
Clinical outcomes
The primary outcome was the change in glycated haemoglobin (HbA1c) at 2 years in those participants
whose baseline HbA1c was ≥ 7.5% (58 mmol/mol). The key secondary outcome was the proportion of all
participants meeting the NICE target of HbA1c of ≤ 7.5% at 2 years. Other outcomes measured at 6, 12
and 24 months included moderate and severe hypoglycaemia, insulin dose, body weight, proteinuria and
diabetic ketoacidosis.
All analyses were intention to treat (ITT) unless stated otherwise. A per-protocol analysis was also
performed, excluding participants who had switched treatment.
Health economic outcomes
Two economic analyses were undertaken: the Economic Evaluation alongside the Clinical Trials (EEACT)
and a model-based evaluation of lifetime outcomes. Both analyses took a UK NHS and Personal Social
Services perspective. All costs and health benefits were discounted at a rate of 3.5%. The yearly cost of
insulin pump therapy, including the cost of insulin pumps and consumables, was estimated using a survey
of REPOSE Trial centres. The economic analysis alongside the trial took a 2-year time horizon, and the
model-based evaluation took a lifetime time horizon. Both economic analyses measured outcomes in terms
of an incremental cost-effectiveness ratio (ICER).
The EEACT used EuroQol-5 Dimensions (EQ-5D) data collected in REPOSE to construct a QALY for each
trial participant and estimate their use of NHS resources. In the base case, differences in cost and QALYs
between the two trial arms were estimated in the ITT population. Uncertainty in the economic analysis
alongside the trial was explored using deterministic sensitivity analyses. In the deterministic sensitivity
analyses, the effects of the cost of insulin pumps and consumables, imputing missing data and estimating
the effects in the per-protocol population were explored.
The Sheffield Type 1 Diabetes Policy Model version 1.3, henceforth ‘the model’, was used to estimate the
lifetime costs and QALYs associated with both trial arms. The model is an individual-level simulation that
includes tracking of risk factors over time, including HbA1c, and the subsequent occurrence of clinical events,
including all microvascular, macrovascular and AEs associated with T1DM. Uncertainty in the long-term
modelling was explored using probabilistic and deterministic sensitivity analyses. In the deterministic
sensitivity analyses, the effects of the cost of insulin pumps and consumables, the use of different estimates
of clinical effectiveness and the effects in different participant subgroups were explored.
Psychosocial outcomes
We used both quantitative (questionnaires) and qualitative (interviews) methods. Quantitative psychosocial
outcomes were collected using participant self-report questionnaires at 6, 12 and 24 months. We measured
diabetes-specific quality of life (QoL) [Diabetes Quality of Life (DSQOL) scale], generic QoL [World Health
Organization Quality of Life Abbreviated Questionnaire (WHOQOL-BREF), Short Form questionnaire-12 items
(SF-12) and EQ-5D], fear of hypoglycaemia (Hypoglycaemia Fear Survey), diabetes treatment satisfaction
[Diabetes Treatment Satisfaction Questionnaire (DTSQ)], and anxiety and depression (Hospital Anxiety and
Depression Scale). We undertook in-depth qualitative interviews with participants and staff at 2 weeks post
course and again with participants at 6 months post course.
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Results
Between November 2011 and April 2013, we randomised 46 courses comprising 317 participants,
aged 18–77 years, of whom 267 attended a DAFNE course (132 pump and 135 MDI). A total of
260 participants was included in the ITT analysis set, of which 235 (119 pump and 116 MDI) had baseline
HbA1c of ≥ 7.5%. Among these, the mean HbA1c change at 2 years in the pump group was a decrease
of 0.85% (9.3 mmol/mol), whereas the mean decrease in the MDI group was 0.42% (4.5 mmol/mol).
After adjusting for centre, DAFNE course and baseline HbA1c, and accounting for missing data, the mean
difference (MD) in HbA1c change at 2 years in favour of the pump group was –0.24% [95% confidence
interval (CI) –0.53% to 0.05%] or –2.7 mmol/mol (95% CI –5.8 to 0.5 mmol/mol; p = 0.098). The
treatment difference was larger for the per-protocol analysis; MD in change of –0.36% (95% CI –0.64%
to –0.07%) or –3.9 mmol/mol (95% CI –7.0 to –0.8 mmol/mol) in favour of the pump (p = 0.015). The
proportion of participants with HbA1c of ≤ 7.5% (58 mmol/mol) at 2 years was similar across the groups:
29 (22.7%) in pump and 25 (20.8%) in MDI, translating to an odds ratio of 1.26 (95% CI 0.62 to 2.58;
p = 0.523). The number of severe hypoglycaemia episodes/participant episodes per year was 25/0.10 in the
pump group and 24/0.10 in the MDI group. After adjusting for centre, DAFNE course, baseline HbA1c and
presence of at least one severe hypoglycaemic episode in the 12 months before baseline, there were no
statistically significant differences between the treatment groups [incidence rate ratio (IRR) 1.13, 95% CI
0.51 to 2.51; p = 0.766]. Across both treatment groups, the IRR for the number of severe hypoglycaemic
episodes in the 24-month follow-up, compared with the year before baseline, was 0.46 (95% CI 0.24 to
0.89; p = 0.021).
The annual cost of an insulin pump and insulin pump consumables was estimated to be £2060. In the
EEACT base case, insulin pump therapy generated fewer QALYs (–0.004) at a higher cost (£2959) than
MDI. This meant that in the base case the insulin pump therapy was dominated by MDI. In the long-term
modelling base case, insulin pump therapy, compared with MDI, generated more discounted lifetime
QALYs (0.1447) at a higher discounted lifetime cost (£20,448). The ICER was £141,312 per QALY gained.
The most favourable ICER was in the sensitivity analysis, for which the cost of insulin pumps and insulin
pump consumables was reduced by 50% in the long-term model. In this sensitivity analysis, the ICER
was £46,578 per QALY gained. This ICER is above the usual cost-effectiveness threshold range of
£20,000–30,000 per QALY gained used by NICE.
The quantitative psychosocial questionnaires had high completion rates at 2 years (90%). In total,
45 participants (25 pump and 20 MDI) and 18 educators took part in qualitative interviews post course.
Three participants could not be contacted for the follow-up interview. The quantitative measures showed
improvement across most outcomes and time points for both treatment groups. The generic quality-of-life
and health status instruments (SF-12, WHOQOL-BREF and EQ-5D) and the HADS score for depression
and anxiety showed no between-group differences. The overall DSQOL score (on a 100-point scale) was
improved by mean (standard deviation) of 8.2 (13.1) points in the pump group and 4.2 (13.2) points in
the MDI group, translating to a MD in improvement of 3.8 points (95% CI 1.1 to 6.5 points; p = 0.006).
The improvement in DSQOL diet restrictions was larger for the pump group than the MDI group at both
12 and 24 months (12-month adjusted MD in change from baseline –4.1, 95% CI –7.2 to –1.0; p = 0.010;
24-month adjusted MD in change from baseline –5.1, 95% CI –8.6 to –1.6; p = 0.004; lower scores
represent better outcomes). A slightly smaller difference was observed at 6 months, which was just outside
the 5% significance threshold (MD –3.3, 95% CI –6.9 to 0.2; p = 0.061). The pump group also had a
better improvement in DSQOL daily hassle or functions at both 12 and 24 months; at 24 months the score
had decreased by 10 points in the pump group compared with 4 points in the MDI group (adjusted MD
–6.3, 95% CI –10.9 to –1.8; p = 0.006). Participants in the pump group had better improvement in
treatment satisfaction at all time points. The difference was statistically significant at 12 and 24 months
only (p = 0.067 at 6 months; p < 0.001 at both 12 and 24 months). These observations were supported by
findings from the qualitative interviews. A recurrent theme was that after doing the DAFNE course,
patients in both arms felt more in control and more confident in self-management. However, those on
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pump therapy reported some additional benefits from the pump, including increased flexibility of lifestyles,
avoidance of the frequent injections with MDI, more effective self-management around sporting activities
and dietary variations, and the ability to administer very small doses of insulin, with different basal rates,
at different times of day and night.
Conclusions
Insulin pump therapy did not provide additional significant improvement in glycaemic control compared
with MDI, when both groups had received structured education in flexible insulin therapy. Our study
suggests that extending the availability of pumps to adults with T1DM in suboptimal glycaemic control,
and no firm desire to use this form of insulin delivery, is unlikely to result either in lower levels of
glycaemia, as measured by HbA1c, or lower rates of hypoglycaemia, and is unlikely to be cost-effective.
Implications for health care
1. Extending the availability of pumps to adults with T1DM with suboptimal glycaemic control, and no
firm desire to use them, is unlikely to result either in lower levels of glycaemia, as measured by HbA1c,
or lower rates of hypoglycaemia or be cost-effective.
2. It is important that REPOSE is not considered to be a ‘negative trial’ of pumps. The failure to show a
significant benefit of pump over MDI was because both groups improved following DAFNE training.
3. The current clinical pathway, as proposed by NICE, seems appropriate, in which people desiring
improved diabetes control should initially undertake structured training in flexible insulin therapy with
MDI alone.
4. The NICE guideline on the importance of providing structured training programmes is reinforced.
Most individuals with T1DM are still not being offered evidence-based structured education despite
considerable evidence for its effectiveness.
5. The evidence from REPOSE suggests that far more people with T1DM should participate in high-quality,
structured self-management training. They may recognise the limitations of insulin delivery by MDI only
once they are attempting to maintain flexible intensive insulin therapy following training. Those individuals
could then be offered pump therapy to help them reach the stringent glucose target, as recommended by
NICE, which is necessary to achieve an optimal HbA1c or overcome problematic hypoglycaemia.
Recommendations for future research
1. It is important to understand why so few patients achieve the target for glycaemic control of HbA1c of
< 7.5%, particularly as there is evidence that levels of glycaemic control are worse in the UK than in
other European countries.
2. There is an urgent need to explore the barriers to successful self-management in adults with TD1M in
the UK and understand why accessing appropriate training is left so long and rates of participation are
so low.
3. Further research is needed to explain why some people do so well after training, whereas others
do not.
Trial registration
This trial is registered as ISRCTN61215213.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background
Type 1 diabetes mellitus and its treatment
People with type 1 diabetes mellitus (T1DM), around 250,000 individuals in the UK, have lost the ability to
make insulin because of autoimmune destruction of the insulin-secreting β cells within the islets of the
pancreas. Insulin is essential in the short term to prevent the onset of ketoacidosis, a potentially fatal condition.
In the long term, the aim of insulin therapy is to keep blood glucose close to normal and so prevent the
development of microvascular complications, such as retinopathy, neuropathy and diabetic kidney disease.
Insulin is generally administered by intermittent subcutaneous injection, with the dose adjusted according to
eating and other activities, such as exercise. Traditionally, insulin was given twice a day, often as premixed
insulin, but such an approach imposes a rigid lifestyle and makes it difficult to maintain a glucose level close to
normal. The need for intensification of therapy and its integration into flexible lifestyles is promoted in DAFNE
(Dose Adjustment for Normal Eating) and other structured education courses. It involves giving quick-acting
insulin just before eating and administering longer-acting background insulin, preferably twice daily, to
maintain blood glucose levels in between meals.1,2 This multiple daily injection (MDI) regimen involves a total of
five or six injections a day. Blood glucose levels are monitored from finger-prick samples using a portable meter,
and insulin dose calculations are based on self-assessed carbohydrate estimations on a meal-by-meal basis.
Insulin given subcutaneously cannot reproduce the physiological insulin profiles of non-diabetic individuals
because of the limitations of insulin formulations and the site of delivery. The relatively slow rate of insulin
absorption leads initially to postprandial hyperglycaemia, followed, 1 or 2 hours later, by an increased risk
of postabsorptive hypoglycaemia, particularly during the night. Thus, keeping blood glucose close to
normal can delay or prevent complications, but brings with it frequent periods of hypoglycaemia. These are
categorised as mild, moderate or severe episodes, ranging from mild symptoms, self-managed by ingesting
rapid-acting carbohydrate, through to greater disruption in daily routine due to cerebral dysfunction,
through to major episodes of coma and seizure requiring third-party assistance. The inability of intermittent
injection therapy to control blood glucose tightly without an attendant risk of hypoglycaemia results in
many individuals keeping their blood glucose at higher than desirable levels. This leads to an increased risk
of serious diabetic complications, which can affect the eyes, feet and kidneys. These complications, plus the
associated high risk of cardiovascular disease, reduce both the length and quality of the individuals’ lives.
Insulin analogues
Short- and long-acting insulin analogues have slightly more physiological profiles than insulins of human or
animal structure, but cannot reproduce those observed in people without diabetes.2 Systematic reviews
of clinical trials of insulin analogues involving people with T1DM have reported only minor advantages
compared with human insulin, with a reduced risk of symptomatic hypoglycaemia, particularly at night.3,4
This may be, in part, because those people who are at the greatest risk of hypoglycaemia are frequently
excluded from clinical trials. Interestingly, in a recent crossover trial comparing MDI of human insulin with
analogue insulin, the investigators specifically recruited individuals who had experienced problems with
hypoglycaemia, and found that those using analogue insulin had significantly lower risks of severe
hypoglycaemia, particularly at night.5
Insulin pumps
There is clearly an urgent need for better methods of insulin delivery. Insulin pumps were first used
clinically in the early 1980s, but randomised controlled trials (RCTs) conducted in the UK failed to show
any clinical benefit. At the time, the technology was poorly developed, but has advanced considerably,
particularly in the last few years. Insulin pumps are now the size of a small mobile phone and deliver
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insulin continuously under the skin via a small plastic tube and cannula [continuous subcutaneous insulin
infusion (CSII)].6,7 These devices are filled with reservoirs of quick-acting insulin only (usually an insulin
analogue), which provides insulin replacement by delivering both the mealtime and background insulin.
When infused continuously at low rates they ‘mimic’ basal insulin secretion, and this is generally delivered
more consistently and accurately than is achievable by the longer-acting insulins, particularly at night. The
insulin boluses used to cover meals and correct high blood glucose levels are delivered much more rapidly.
All of the insulin doses can be controlled by the patient, based on calculations similar to those required for
insulin dosing with a MDI regimen.
The purchase and use of pumps is more expensive than MDI, with pumps at current prices costing around
£2500 each, plus £1500 per year extra for running costs.8 The marginal cost per annum over MDI is about
£1800.9 The potential advantages are more stable blood glucose levels, a reduced risk of hypoglycaemia
and a more flexible lifestyle. Pump treatment may deliver insulin more effectively than MDI but does not
provide a technological ‘cure’. The same competencies needed for successful insulin self-management,
previously described for MDI, are required for pumps, but with additional skills required to operate the
pump device itself. Thus, pumps are probably more useful to those individuals who are actively and
effectively self-managing their diabetes rather than those who expect the pump to ‘manage’ their diabetes
for them.
Pumps are currently used by around 40% of people with T1DM in the USA and > 15% in Europe.10
In contrast, the proportion in the UK was around 6% in adults in 2012.11,12 Proponents of pump treatment
have proposed that far more patients should be offered treatment in the UK and that current policies are
depriving many of the opportunity to improve glycaemic control, reduce hypoglycaemia and improve
quality of life (QoL).12 The UK’s National Institute for Health and Care Excellence (NICE) has recently
extended recommendations for the use of pumps for adults with T1DM. The guidance suggests that pump
treatment be considered for individuals who are experiencing problems with hypoglycaemia, particularly
when this limits the ability to improve glycaemic control. NICE has noted the paucity of evidence for
efficacy from RCTs.13
Problems with evidence in National Institute for Health and Care Excellence appraisals
There have been two appraisals9,14 of pumps by NICE, both supported by technology assessment reports
undertaken by some of the present authors, which reviewed the evidence on clinical effectiveness and
cost-effectiveness. The first report14 noted that there were no trials of pumps against ‘best MDI’ with
long- and short-acting analogue insulins; some trials had unequal amounts of education in the arms (with
more in the pump arms); and the trials had focused on easily measurable outcomes such as glycated
haemoglobin (HbA1c), rather than on benefits in terms of flexibility of lifestyle and QoL. The report
recommended trials of pumps against analogue-based MDI.
The second report9 found that few such trials had been done: one in children, not relevant to this work,
and three in adults. Furthermore, the three adult studies15–17 presented data for a small number of
participants who were followed over a short period only. The first of these studies was a 24-week pilot
study15 in adults with altered hypoglycaemia awareness and debilitating hypoglycaemia. The three study
arms consisted of seven patients each and compared (1) analogue MDI, (2) pump and (3) education and
relaxation of glycaemic targets. All of the subjects were naive to analogue insulin use and some had never
tried MDI, and so were not representative of the type of patients for whom NICE recommends pumps.
The second trial16 recruited 39 adults with T1DM, who had already been on pump therapy for at least
6 months, and who were randomised to stay on pump or switch to glargine (Lantus, Sanofi-Aventis,
Guildford, UK)-based MDI for 4 months. The primary end point was glucose variability, which was 5–12%
less with the pump. Despite this, there was no significant difference in the frequency of hypoglycaemic
episodes or HbA1c.
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The third study17 studied 50 patients with T1DM from Italy, UK (Newcastle, Bournemouth) and France,
who were naive to pumps and glargine, to which they were switched for the trial, having been previously
managed on neutral protamine Hagedorn (NPH)-based regimens. Follow-up was for 24 weeks. Patients
were randomised to pump or analogue MDI in an equivalence study. The difference in HbA1c at the study
end was only 0.1% (approximately 1 mmol/mol) and the costs with the pump were three times higher.
Thus, the evidence base from trials for comparing pumps and ‘best MDI’ remains weak in terms of
numbers, with a total of only 103 patients and short-term follow-up. Furthermore, the patients in the trials
were dissimilar to those considered suitable for a pump by NICE, which expects patients to have tried
analogue-based MDI before using the pump.
Given the paucity of RCTs, the assessment group also looked at observational studies of adults in which
a pump was clinically indicated, mostly because of the limitations of intermittent injections. This comparison
has the advantage of measuring change in glycaemic control and hypoglycaemia in those who have
most to gain, and these studies showed improved HbA1c of the order of around 0.5% (5.5 mmol/mol).
Interpretation of data from observational studies face limitations from bias, and, furthermore, of the 48
observational studies, only nine reported QoL. Study numbers were small and duration was usually short.
The longest study noted that initial benefits from pumps might not be sustained.
Therefore, again, NICE was faced with an evidence base with considerable shortcomings, too few trials,
durations too short, numbers too small and a need to use observational studies. A recent meta-analysis
by Monami et al.18 concluded that ‘available data justify the use of CSII for basal-bolus insulin therapy in
type 1 diabetic patients unsatisfactorily controlled with MDI’. However, most of the RCTs in their analysis
were NPH-based and the Bolli et al.17 trial, with its negative result, was missed.
A systematic review of the cost-effectiveness of insulin pump therapy in adults with T1DM was conducted
by Roze et al.19 They identified four cost-effectiveness studies in the UK setting, three of which presented
an incremental cost-effectiveness ratio (ICER).9,14,20,21 The ICERs in these studies were £11,461 per
quality-adjusted life-year (QALY) gained, £25,648 per QALY gained and £37,712 per QALY gained.
Two out of the three studies had ICERs that lie within, or below, the £20,000 to £30,000-per-QALY-
gained range that NICE usually uses to determine if a health technology is cost-effective.22 These two
studies did receive commercial sponsorship, whereas the study with an ICER of £37,712 was commissioned
on behalf of NICE.
Rationale for the trial
We hypothesised that much of the benefit of pumps may come from the retraining and education in
intensive insulin management, which allows patients to use pumps safely.23 In many DAFNE centres,
reimbursement for pump use is conditional on patients having attended a DAFNE education course and so
some patients undertake DAFNE training with the intention of moving to pump treatment thereafter. It has
been our clinical experience that many individuals decide not to switch to the pump after attending a
DAFNE course, as they then realise that what they required was training in insulin self-adjustment rather
than a different technical way of delivering insulin. Ray et al.24 found that 69% of those being considered
for insulin pump therapy stay on MDI after completing DAFNE. Importantly, trials and observational studies
of high-quality training alone (with standard insulin injections) show benefits in blood glucose control,
hypoglycaemia and QoL, which are as good, if not better, than those reported after pump therapy.2,25,26
To our knowledge, no trials in adults, comparing pump treatment with modern MDI, used the same
structured training in insulin adjustment, resulting in the added benefit of the pump technology remaining
unclear.23 There was an urgent need to establish this, and identify patients who benefit the most. A RCT
was needed to establish these outcomes without bias.
The DAFNE course is a 1-week structured education course, teaching adults with T1DM the skills in insulin
self-adjustment and carbohydrate counting.2 DAFNE courses are currently delivered in more than 70 centres
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across the UK, with over 37,000 individuals (DAFNE graduates) now trained. We therefore set out to
conduct a novel study in which adults waiting for a DAFNE course were randomly allocated to undertake
either the standard MDI course or DAFNE incorporating use of pump therapy.
The investigators involved in this work have been undertaking research into other aspects of DAFNE for
many years. During recent work funded by a National Institute for Health Research (NIHR) programme
grant [Programme Grants for Applied Research (PGfAR)] we measured cost-effectiveness and identified
which components of the course are crucial, as well as identifying the factors determining which DAFNE
patients managed their diabetes more effectively.27 This work included funding to pilot a combined DAFNE
and pump course, which enabled us to develop a pump curriculum and associated pump-specific
resources, ensure that the outcome measures that we wanted to use were feasible and estimate the likely
recruitment and retention rates.
We then assembled a study group with expertise in structured T1DM education, pump therapy (having
trained in total over 700 pump patients) and health economic assessment of diabetes interventions.
Decision problem: aim of the REPOSE Trial
The aim of our trial was to establish for patients, professionals and those funding the service, the added
benefit of using a pump during intensive insulin therapy. We conducted a RCT comparing optimised MDI
therapy (using rapid and twice-daily, long-acting insulin analogues) with pump therapy in adults with
T1DM, for which both were provided with high-quality structured education (DAFNE).
Research objectives
The project had the following specific objectives:
1. To measure, over 2 years, (1) biomedical, (2) psychosocial (quantitative and qualitative) and (3) adverse
event (AE) outcomes. The primary outcome was HbA1c at 2 years, with a minimum clinically significant
difference defined as 0.5% (5.5 mmol/mol).
2. To undertake a cost-effectiveness analysis to determine whether or not the marginal benefits of pump
therapy over optimised MDI (if demonstrated) are commensurate with the marginal costs, as reflected in
an ICER, expressed in terms of a cost per QALY gained that is acceptable to NICE.
3. To conduct a mixed-methods psychosocial evaluation of pump therapy in order to identify factors that
predict and/or help explain outcomes on the pump.
Members of the research team have been involved in the NICE appraisal of insulin pumps, have been
members of NICE appraisal committees and have a good understanding of what evidence NICE needs.
Thus, a further objective was to inform the next NICE reviews of insulin pumps and structured education.
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Chapter 2 Overview of evidence base for
pump therapy
As noted in Chapter 1, the evidence on the clinical effectiveness and cost-effectiveness up to June 2007was reviewed in the two assessment reports for NICE,9,14 both published in this monograph series. This
chapter is concerned mainly with studies that have emerged since 2007, but we also provide a complete
overview of all of the trials.
Methods
Searches were performed for RCTs that compared the clinical effectiveness of pump and MDI in adults,
from June 2007 to the present in MEDLINE and EMBASE (see Appendix 1 for search methods). We
checked inclusion lists of seven past systematic reviews.9,14,18,28–31
Reasons for exclusion included:
l control group not on MDI
l pump therapy from diagnosis of diabetes
l studies in pregnancy
l paediatric age group
l studies in type 2 diabetes mellitus
l pump plus continuous glucose monitoring (CGM) versus MDI plus self-monitoring of blood glucose
(SMBG) levels
l closed-loop trials
l low-glucose suspend (LGS) pumps
l all on pump therapy, with different pumps
l trials of catheter duration in pump therapy
l not a trial
l peritoneal infusion
l protocols
l pumps infusing substances other than insulin
l reviews
l trials of exercise on pump therapy.
During the course of the REPOSE Trial, weekly auto-alerts were run in MEDLINE and EMBASE to identify
any emerging research that might affect the trial. The search strategy used was:
1. (insulin and pump*).tw.
2. (CSII or continuous subcutaneous insulin infusion).tw.
3. (continuous adj3 insulin adj3 infusion).tw.
4. (subcutaneous adj3 insulin adj3 infusion).tw.
5. 1 or 2 or 3 or 4.
6. DAFNE.tw.
7. (dose adjust* adj2 normal eating).tw.
8. 6 or 7.
9. 5 or 8.
In addition, final searches were performed for RCTs that compared the clinical effectiveness of pump and
MDI in adults, from 2007 to 7 January 2016 in MEDLINE, EMBASE, Web of Science and the Cochrane
Central Register of Controlled Trials.
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Trials may be done in selected groups of patients and, as noted in Chapter 1, they are often of short
duration. We therefore carried out a search for longer-term observational studies in large groups of
patients as a guide to the results of pump therapy in routine care. We selected studies with at least 3 years
of follow-up, and ≥ 100 patients, published since January 2008. Older observational studies were reviewed
in a previous monograph,9 and the findings summarised as follows:
l There were much greater improvements in HbA1c in observational studies than reported in the RCTs.
l There were considerable reductions in severe hypoglycaemia. This may reflect selection for pump
therapy of people having particular problems with hypoglycaemia, but that would make the results
more applicable to the patients who would get a pump in routine care.
l The majority of studies showed no increase in diabetic ketoacidosis (DKA).
l Weight gain was reported but usually minor.
l There was a reduction in daily insulin dose, which will provide some savings to offset the cost of
pump therapy.
l There were gains in QoL, with comments on items such as flexibility of meal choices and timings and
other aspects of lifestyle, and diabetes being easier to manage.
During the course of the REPOSE Trial, we looked for any important developments in:
l pump therapy
l structured education
l new insulins used in MDI or pump
l the evidence base on QoL on pump and MDI.
Findings
Pump therapy
Table 1 shows the trials of pump therapy against MDI in adults with T1DM, excluding those in pregnancy.
There have been only four trials of pump versus MDI with analogue insulin use in both arms, and the
longest follow-up period was 24 weeks, which, as we will show in Chapter 3, is insufficient to achieve the
full potential of pump therapy.
Table 1 shows that only five trials (assuming that Lepore et al.44 is a trial – the paper does not mention
randomisation but Misso et al.31 in the Cochrane review say it was a RCT and that it had access to
unpublished data) had a duration of ≥ 12 months, and none used analogue MDI. Lepore et al.44 report
HbA1c only at baseline and 12 months.44 Dahl-Jørgensen et al.54 reported a steep drop in HbA1c with a
plateau after 3 months, but this reduction started in the 2-month run-in period before pump therapy
was started.
Four trials15–17,40 used analogue insulin in both arms. The Hirsch et al.40 trial had patients on pump and MDI
for only 4 weeks. The Thomas et al.15 trial was a pilot, with only seven patients per arm.
One new trial has been published since the last appraisal by NICE: Bruttomesso et al.16 This trial recruited
42 patients already well controlled on the pump (mean HbA1c 7.4% at randomisation) and randomised
them to continuing pump therapy, or to MDI with lispro and glargine. The aim was to see if the need for
pump therapy was reduced by the arrival of the analogue insulins. Patients had only 4 months on MDI.
Three patients withdrew shortly after starting MDI because of poorer glycaemic control. After 4 months
the patients switched to the other treatment arm. The primary outcome was glucose variability, as assessed
by SMBG. HbA1c during the study was 7.3% in both arms. There was no difference in the frequency of
severe hypoglycaemia, but moderate hypoglycaemia was about 23% less frequent on pump therapy,
although the definition of this is not stated in the published study. Glucose variability was 5–12% less on
pump therapy, depending on time of day and method used. At the study end, patients could choose between
OVERVIEW OF EVIDENCE BASE FOR PUMP THERAPY
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TABLE 1 Previous trials of pump vs. MDI: adults only, T1DM only, excluding pregnancy studies
Trial
Year of
publication
n of
participants Design Pump MDI
Duration
on pump
Bak et al., 198732 1987 20 Crossover Actrapida Actrapid and NPH 6 months
Bode et al., 199633 1996 55 Crossover Soluble 12 months
Bolli et al., 200917 2009 43 Parallel Lisprob Lispro t.i.d.,
glargine once
24 weeks
Bruttomesso et al.,
200816 – incorporates
Maran et al., 200534
2008, 2005 42 Crossover Lispro Lispro, glargine 4 months
on each
Chiasson et al.,
198435
1984, 1985 12 Crossover Regular Regular and
Ultralente
3 months
on each
DeVries et al., 200236 2002 55 completed
of 79 starters
Started as
crossover
but reduced
to parallel
Aspart Aspart and NPH 16 weeks
Düsseldorf Study
group (Ziegler et al.,
199037)
1990 96 Parallel Not
specified
Mixture of b.i.d.
and MDI with
regular and NPH
2 years
Haakens et al., 199038 1990 52 started,
35 completed
Crossover Soluble Soluble, Ultralente,
isophane
6 months
Hanaire-Broutin et al.,
200039
2000 40 Crossover Lispro Lispro and NPH 4 months
on each
Hirsch et al., 200540 2005 100 Crossover Aspart Aspart and
glargine
4 weeks
Home et al., 198241 1982 10 Crossover Actrapid Actrapid,
Ultralente
10 weeks
Hoogma et al.,
200642,43
2006 256 Crossover Lispro Lispro and NPH 6 months
on each
Lepore et al., 200344 2003 32 Parallel Lispro Lispro and NPH 12 months
Nathan et al., 198245 1982 5 Crossover Soluble NPH and regular 8–12 weeks
Nosadini et al., 198846 1988 44 Parallel Soluble Soluble t.i.d. and
NPH
1 year
Oslo, 1988,47 198648 1985–92 30 Parallel Velosulina Regular porcine
and NPH
4 years
Saurbrey et al., 198849 1988 21 Crossover Actrapid Actrapid (NovoPena)
and NPH
10 weeks
Schiffrin and
Belmonte, 198250
1982 16 Crossover Soluble Three soluble,
one NPH
6 months
Schmitz et al., 198951 1989 10 Crossover Velosulin,
porcine
regular
Velosulin and
Insulatarda NPH
6 months
on each
Schottenfeld-Naor
et al., 198552
1985 9 Crossover Velosulin Velosulin and
Insulatard
4 months
on each
Thomas et al., 200715 2007 14 Parallel Lispro Lispro and glargine 24 weeks
Tsui et al., 200153 2001 27 Parallel Lispro Lispro and NPH 9 months
b.i.d., twice a day; t.i.d., three times a day.
a Novo Nordisk, Gatwick, UK.
b Eli Lilly, Basingstoke, UK.
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pump therapy and glargine-based MDI. Thirty patients chose pump, five chose MDI and four opted for
summer MDI and winter pump. The study was supported by Disetronic and one author worked for
the company.16
The Bolli et al.17 trial (see Table 1) was published in 2009 but had been available in abstract form for the
last assessment report.
Overall, therefore, there was still a poor evidence base with only one new trial, and that being of short
duration (4 months on each arm) and limited sample size (only 39 patients).
Observational studies
Bacon et al.55 reported 10-year follow-up data on 197 patients on pump therapy. The main indications for
the pump were recurrent hypoglycaemia and poor control. HbA1c improved by about 0.7% and the
number of severe hypoglycaemic episodes by about 80%. Only about 5% discontinued pump therapy.
Beato-Vibora et al.,56 from King’s College Hospital, looked back over 12 years of pump therapy in 327
patients, with a mean duration of 4.3 years on the pump. An initial reduction in HbA1c of 8 mmol/mol or
0.7% was partially maintained with reduction at year 5 of 0.4%. The proportion of people having
frequent mild-to-moderate hypoglycaemia fell from 29% to 12% and the frequency of severe
hypoglycaemia was halved.
Bruttomesso et al.,57 from the Veneto region of Italy, provide a retrospective study of all patients in their
region who started pump therapy. Of 138 patients, 20 stopped pump therapy, although mostly in the
earlier years. Strict eligibility criteria had to be met, including ‘the technical, physical and intellectual
abilities’, plus motivation, stable personality and realistic expectations of pump therapy. All were familiar
with MDI and received extra education. HbA1c was 9.3% when starting pump therapy, fell to 7.9 by end
of year 1 and was largely sustained there for 7 years.
Carlsson et al.,58 from Sweden, reported results of 272 patients with at least 5.5 years of follow-up. They
compared their results with a much larger group on MDI. HbA1c was reduced by 0.42% at 1 year and 0.43%
at 2 years, but some of the effect was lost by 5 years when the reduction compared with the MDI group was
only 0.2%.58 A later paper59 reported that the reduction in HbA1c varied by baseline levels, with a small
reduction of 0.29% (85% CI 0.11% to 0.47%) in those with baseline HbA1c of 7%, a reduction of 0.39%
(85% CI 0.27% to 0.52%) in those with baseline HbA1c of 8% and a larger reduction of 0.50% (85% CI
0.36% to 0.67%) in those with baseline HbA1c of 9%, which would take them nowhere near target.
Cohen et al.60 compared two cohorts from Melbourne in a non-randomised comparison. One group
received pump therapy and the other received intensified MDI. Both were previously on analogue MDI.
Among 126 patients on the pump, HbA1c fell by 0.64% at 6 months, but then rose again, with a
reduction of about 0.4% at 2 years and about 0.2% at 5 years. The reduction in HbA1c on intensified MDI
was smaller: 0.15% at 6 months. This was despite a similar programme of education, based on DAFNE but
shorter, in both pump and MDI groups.
Lepore et al.,61 from three Italian centres, compared results in two matched groups of 110 patients on
pump therapy and 110 on MDI, followed for 3 years. HbA1c fell by 0.7% in the pump group and this
reduction persisted for the 3 years. HbA1c fell by 0.3% in the MDI group at 3 years.
Nixon et al.62 reported a study of 35 patients on pump therapy. There was an initial fall of 1.7% in HbA1c
but by 5 years the reduction was only 0.9%. However, this reflected a mix of results, with one-third of
patients reducing HbA1c by 2.2% and maintaining it there, whereas others had no change on the pump or
had an initial reduction not sustained.
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Orr et al.,63 from Ontario, report results among 235 patients on pump therapy. The overall baseline HbA1c
was 8.7%, which was reduced to 7.5% after 6 months on the pump, after which it drifted up again to
8.2% in years 3–10. In 39 patients who were followed for 10–15 years, the mean HbA1c was 8.03%.
However, two groups of patients who started with high baselines (8.5–10% and > 10%) reduced their
HbA1c to about 8% by 8–10 years.
Quiros et al.,64 from Barcelona, followed 151 patients on pump therapy for 5 years. Overall, HbA1c was
reduced from a mean of 8.0% at baseline to 7.8% at 5 years. However, in the 61% of patients who
started pump therapy because of poor glycaemic control, HbA1c fell from 8.4% at baseline to 8.0% at
5 years. There was a marked reduction in severe hypoglycaemia.64
Rosenlund et al.65 from Denmark looked at the effects of 4 years of pump therapy on albuminuria
compared with an unmatched group on MDI. On pump therapy, HbA1c fell from 8.4% to 7.8%,
maintained to 4 years.65
Steineck et al.66 from Sweden reported mortality data from a cohort of 18,168 people with T1DM in
Sweden, of whom 13% were on pump therapy. Total mortality at 7 years was 6% in the pump group and
8% in the MDI group. There were many small differences that would increase the risk in the MDI group –
more hypertension, more on lipid-lowering drugs, more with low physical activity, more smokers and more
with low education levels. Steineck et al.66 used propensity matching to adjust for the differences, and
concluded that those on pump therapy had a 0.73 hazard ratio for total mortality. However, there could
have been confounding factors for which they could not allow.
Most long-term studies show a disappointing waning of the initial HbA1c improvement. Perhaps there is a
case for educational updates. In a small trial with only 23 patients, Carlone et al.67 randomised patients on
long-standing pump therapy to standard care or to six educational weekly group meetings on advanced
features of the pump, carbohydrate counting and other aspects of diet. After 6 months, the intervention
group had reduced their HbA1c by 1%. The control group did not change.
New developments
The main developments in pump therapy have been the use in combination with CGM systems, of which
there are two forms that are now relevant to the pump. The first is when the CGM device is integrated
with the pump, which means that it sends glucose results to the pump every 5 minutes or so, from a
sensor just under the skin. Strictly speaking this means that the glucose result is for the level in interstitial
tissue, not in the bloodstream, but the two are closely related. With the integrated CGM system, the pump
can send alarms to the user, following which they can take action. This helps users to avoid hypoglycaemic
episodes, but some find the alarms to be a nuisance and may disable the alarms. False alarms are not
uncommon.
Four trials of CGM compared the pump with CGM against MDI with SMBG, which confounds things
[Hermanides et al. (Eurythmic trial),68 Lee et al.,69 Peyrot and Rubin,70 Bergenstal et al. (STAR-3)71]. The
durations of these trials were only 6, 3.5, 3.7 and 12 months, respectively.
Continuous glucose monitoring would have implications for the use of pump therapy rather than MDI if
the effectiveness of CGM differed between the two forms of treatment. Garg et al.72 found that the
effects of real-time CGM in reducing HbA1c and hypoglycaemia were similar in two matched groups on
MDI and pump.
More recently, the Medtronic Veo (Medtronic, Watford, UK) has been introduced, which has a facility to
link with a CGM system and suspend insulin infusion (the LGS facility) if the glucose level goes too low, for
up to 2 hours. This means that the pump can take action. In practice, most suspensions are for much less
than 2 hours because the wearer takes action. However, at night when the wearer is asleep, this may
not happen.73
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There have been two trials of the Veo suspend pump. In the ASPIRE (Automation to Simulate Pancreatic
Insulin Response) trial74 in the USA and Canada, the recruits were familiar with pump therapy. They had a
2-week run-in period and were selected for the trial if they had nocturnal hypoglycaemia (defined as plasma
glucose < 3.7 mmol/l) at least twice in that period. They also had to be prepared to wear the sensors at least
80% of the time. They were randomised to the Veo with its LGS facility, or to the Medtronic Paradigm
Revel, which has integrated CGM but no LGS action. The trial was sponsored by Medtronic, and Medtronic
staff were involved in data analysis and editorial assistance.74 The trial showed no difference in HbA1c after
3 months, perhaps not surprisingly because the baseline HbA1c was very good at 7.2% or 55 mmol/mol.
There was reduced hypoglycaemia, especially nocturnal. In the Veo group, 111 of 121 patients had at
least one nocturnal suspension on the pump that lasted 2 hours. A 2-hour suspension does not lead to
significant ketosis. QoL measures, EuroQol-5 Dimensions (EQ-5D) and the Hypoglycaemia Fear Survey (HFS)
score, showed no difference between the arms of the trial. There were only four severe hypoglycaemic
episodes, none in the Veo arm.
So the main benefit of the Veo LGS over the integrated CGM pump system is reduction of nocturnal
hypoglycaemia. There is quite a large extra capital cost for the device (£2692) with an annual cost,
including consumables, of £4862. This will make it difficult to prove cost-effectiveness. The group in which
the Veo is most likely to be cost-effective will be patients with recurrent severe hypoglycaemia, but that
group is covered by existing NICE guidance on the pump and is not recruited to the REPOSE Trial.
The other trial of the Veo was by Ly et al.75 in Australia. This trial recruited mainly children and adolescents,
with only 31% aged > 18 years. Patients were selected on the basis of impaired awareness of
hypoglycaemia. They had been on pump therapy for an average of 4 years. They were randomised to the
Veo suspend pump or to stay on their previous pump and use SMBG – not CGM. This immediately raises a
problem because the Veo arm has both the LGS facility and CGM. It would have been better to have CGM
in both arms. A more serious problem with the study is that, despite reasonable numbers (49 to pump
plus SMBG, 45 to the Veo) and randomisation, there was a very marked baseline mismatch in previous
severe (defined as seizure or coma) and moderate (defined as requiring assistance) hypoglycaemia, with a
rate of 130 per 100 patient-months [95% confidence interval (CI) 111 to 150 patient-months] in the Veo
group, but only 21 per 100 patient-months in the control arm (95% CI 14 to 30 patient-months). At study
end after 6 months, the rate of moderate and severe hypoglycaemic episodes was 28.4 in the Veo group
and 11.9 in the control arm. However, these figures were reversed when the authors adjusted for baseline
rates, from 28.4 to 9.5, and from 11.9 to 34.2, all per 100 patient-months. There were no significant
changes in HbA1c, but both groups started with quite reasonable levels of 7.6% and 7.4%.
The analysis by Ly et al.75 has been strongly criticised by the German Institute for Quality and Efficiency in
Healthcare [Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)], as reported by
Heinemann and Hermanns.76
The Veo has been appraised by the NICE Diagnostics Assessment Programme. Their guidance is shown
in Box 1.
The patient group in which it has been recommended is different from that in the REPOSE Trial, and so
the arrival of the Veo and its LGS facility has no implications for the implementations of the results of the
REPOSE Trial.
Findings: structured education
The DAFNE course has changed little since the original trial published in 2002.2 A programme of work has
included a trial comparing the 5-day course in 1 week with 1 day a week for 5 weeks, which found little
difference in outcomes.78
One finding from the DAFNE research programme has been that many patients doing the DAFNE course,
in preparation for going on to pump therapy, no longer need to progress to a pump after completing
OVERVIEW OF EVIDENCE BASE FOR PUMP THERAPY
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the course. Ray et al.24 reported that after DAFNE education, 69% of patients previously being considered
for pump therapy could remain on MDI.
However, another study from the programme (Mansell et al.79) found that some patients who had been
through DAFNE education still benefited from pump therapy in terms of a reduction in stress [measured by
the PAID (Problem Areas in Diabetes Questionnaire) score] and improved glycaemic control at 12 months
of follow-up. This may have been because individuals who progress to the pump after doing a DAFNE
course have higher pre-course stress levels.80
Conversely, attendance at DAFNE courses sometimes identifies individuals for whom pump therapy is
indicated because of a troublesome dawn phenomenon.
Research into DAFNE education has also been undertaken by the Irish DAFNE group.81 They carried out
a large randomised trial of group follow-up compared with individual clinic visits for patients who had
BOX 1 National Institute for Health and Care Excellence guidance on the MiniMed Veo insulin pump77
1.1 The MiniMed Paradigm Veo system is recommended as an option for managing blood glucose levels in
people with type 1 diabetes only if:
l they have episodes of disabling hypoglycaemia despite optimal management with continuous
subcutaneous insulin infusion and
l the company arranges to collect, analyse and publish data on the use of the MiniMed Paradigm Veo system
(see section 7.1).
1.2 The MiniMed Paradigm Veo system should be used under the supervision of a trained multidisciplinary
team who are experienced in continuous subcutaneous insulin infusion and continuous glucose monitoring for
managing type 1 diabetes only if the person or their carer:
l agrees to use the sensors for at least 70% of the time
l understands how to use it and is physically able to use the system and
l agrees to use the system while having a structured education programme on diet and lifestyle,
and counselling.
1.3 People who start to use the MiniMed Paradigm Veo system should only continue to use it if they have
a decrease in the number of hypoglycaemic episodes that is sustained. Appropriate targets for such
improvements should be set.
1.4 The Vibe and G4 PLATINUM CGM system shows promise but there is currently insufficient evidence to
support its routine adoption in the NHS for managing blood glucose levels in people with type 1 diabetes.
Robust evidence is needed to show the clinical effectiveness of using the technology in practice.
1.5 People with type 1 diabetes who are currently provided with the MiniMed Paradigm Veo system or the
Vibe and G4 PLATINUM CGM system by the NHS for clinical indications that are not recommended in this NICE
guidance should be able to continue using them until they and their NHS clinician consider it appropriate to stop.
Reproduced with permission from NICE. © National Institute for Health and Care Excellence 2016. Integrated
sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes (the MiniMed
Paradigm Veo system and the Vibe and G4 PLATINUM CGM system). Available from: www.nice.org.uk/
guidance/dg21. NICE guidance is prepared for the NHS in England, and is subject to regular review and may be
updated or withdrawn. NICE has not checked the use of its content in this article to confirm that it accurately
reflects the NICE publication from which it is taken.
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completed the DAFNE course. The intervention group received group education at 6 and 12 months after
DAFNE, following a semistructured curriculum, whereas the control group had individual clinic appointments
with doctor, nurse or dietitian. The additional education conferred no benefit over individual clinic visits.
The Irish DAFNE group also carried out a qualitative study to identify factors that influenced how well
DAFNE graduates incorporated what they had learned into long-term daily living.82 They identified
four themes:
1. Being empowered, and feeling able to manage their diabetes, which some people did not manage
to do.
2. Embedded knowledge, which increased over time, for example as patients got better at
carbohydrate counting.
3. Maintaining motivation, including coping with uncertainty. The researchers commented that this was
most marked at 6 months but improved later. Reducing the risk of complications was a strong
motivation factor.
4. Continued support from health-care professionals.
The Australian OzDAFNE group83 also looked at psychological changes after the DAFNE course, and found
increases in what they called ‘mastery/control’ and a reduction in diabetes-related distress. One of their
key points was that the mean duration of diabetes in their participants was 18 years, but they had low
self-assessment of their ability to manage their diabetes, so they recommended that referral to DAFNE
courses should not be restricted to recently diagnosed patients.
Findings: new insulins
Some new basal insulins have been introduced, including degludec (Tresiba, Novo Nordisk, Gatwick, UK) and
glargine 300 (Toujeo, Sanofi-Aventis, Guildford, UK). However, these are very long-acting basal insulins,
and may not have the flexibility in dosing that is needed in MDI for T1DM, and with no data to date about
how these might be used effectively in patients with T1DM who are undergoing structured education.
Newer short-acting insulins include ‘fast aspart’, which, in pump therapy, is reported to have a faster
glucose-lowering effect but with the same effect overall. The implications for glycaemic control and
hypoglycaemia were not reported by Zijlstra et al.84
Findings: quality of life
Past reviews found a disappointingly low amount of evidence on QoL. This has implications for
cost-effectiveness analysis. The Thomas et al.15 pilot trial of pump therapy versus analogue MDI reported
QoL as measured by the Diabetes Quality of Life questionnaire (DQOL) but found no difference. With only
seven patients in each arm this may not be surprising. The 2008 health technology assessment (HTA)9 for
NICE identified 48 observational studies of pump therapy, but only one reported QoL in adults, and it was
a before-and-after study in which patients switched to the pump from conventional insulin therapy, not
analogue MDI.
One observational study85 published since then has compared QoL. This study85 by the EQuality1 Study
Group from Italy, has both strengths and weaknesses. It was a very large case–control study, with
1341 people with T1DM from 62 clinics, with 481 on the pump and 860 on MDI. The MDI patients came
from centres both with and without pump services. Reliable instruments were used: the diabetes-specific
quality of life scale (DSQOL) for QoL, Diabetes Treatment Satisfaction Questionnaire (DTSQ) for treatment
satisfaction and Short Form questionnaire-36 items (SF-36) for health status. Eighty-four per cent of
patients on the pump had been on it for > 1 year; 90% of the MDI group were on glargine-based MDI
with the rest using NPH. All of the MDI patients had been on at least four insulin injections a day for
> 6 months. The pump and MDI groups were well matched on some variables, but there were striking
differences in carbohydrate counting (56% of pump group vs. 40% on MDI) and self-adjustment of insulin
doses (80.5% vs. 66.5%), suggesting a marked educational imbalance.
OVERVIEW OF EVIDENCE BASE FOR PUMP THERAPY
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Some DSQOL results were slightly better among the pump group, but this was statistically significant only for
diet restrictions (65.5 vs. 60.8; p = 0.0003). DTSQ scores were better on pump (30.2 vs. 26.2; p < 0.0001).
SF-36 scores were better on MDI, but in most domains, not statistically significantly so. However, the authors
report that multiple regression analysis (details not provided, but adjusted for clinical factors including
complications, which were more common in the pump group) showed that the pump group had
significantly better scores in DSQOL diet, daily hassles and fear of hypoglycaemia. No differences were
found between NPH and glargine-based MDI. The study was supported by Medtronic.
The lack of difference between the QoL effects of NPH and glargine-based MDI may not apply to detemir
(Levemir, Novo Nordisk, Gatwick, UK)-based MDI, because detemir given twice daily may provide a more
flexible lifestyle than once-daily glargine.
The Five Nations Study43 was a good-quality trial completed before long-acting analogues became available.
It compared pump therapy with lispro and NPH-based MDI, but, unusually, the NPH insulin could be given
up to four times a day and only 41% of patients had it once daily, with 32% getting it twice a day and
23% thrice daily. The study reported QoL using DQOL and Short Form questionnaire-12 items (SF-12).
With SF-12 there was no difference in physical state but the pump group did better on mental health.
The end of trial DQOL was 75 on pump and 71 on MDI, a small but statistically significant difference
(p < 0.001). The difference reflected gains in treatment satisfaction, flexibility of eating and lifestyle, and
reduced worry.
Conclusions
The evidence base for pump therapy compared with modern MDI is still quite sparse, and REPOSE has more
participants than in all of the previous trials put together, even if we include the Hirsch et al. trial40 with its
100 patients on very short duration of 4 weeks on each therapy. If we exclude the Hirsch et al. trial,40
REPOSE has more than double the number in the other three trials, which had a total of 99 patients.15–17 It
also recruited a different group of patients from most previous trials, as it excluded those who met the NICE
criteria for pump therapy. So it recruited patients in a band of need below those for whom the pump has
been approved by NICE.
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Chapter 3 Methods
Methods for the randomised controlled trial
The trial protocol was published in a separate paper.86
Study design
The REPOSE Trial was a pragmatic, multicentre, parallel-group, open-label, confirmatory cluster RCT.
Participants were allocated a place on a week-long DAFNE course, depending on their availability to attend
the course. The course (cluster element) groups were then randomly allocated in pairs to either pump or
MDI treatment, with allocation concealed. A cluster design was chosen because of the impracticality of
randomising individuals and then finding suitable times for that participant to attend a course of the
correct allocation.23 Such an approach was more likely to have resulted in significantly higher attrition rates
pre course. Following the course, participants received the trial treatment for 2 years and outcome
measures were collected at 6, 12 and 24 months post course. Outcome measurement was not blinded
(see Data collection).
Approvals obtained
The protocol was approved by the Research Ethics Committee (REC) North West, Liverpool East, on
26 April 2011 (REC reference number 11/H1002/10). Each participating centre gave UK NHS Research and
Development (R&D) approval (see Appendix 2). The protocol received Medicines and Healthcare products
Regulatory Agency (MHRA) clinical trials authorisation on 26 May 2011 [European Union Drug Regulating
Authorities Clinical Trials (EudraCT) reference no: 2010-023198-21].
Setting
The trial was conducted in eight secondary care diabetes centres in Sheffield, Cambridge, Dumfries and
Galloway, Edinburgh, Glasgow, Harrogate, London and Nottingham (see Table 11). Participating centres
all had experience in delivering high-quality structured education using DAFNE and had variable levels of
experience delivering pump therapy; most were established pump centres but some were relatively new to
pump therapy. Nottingham was a reserve centre, activated midway through the trial. The seven centres
involved from the outset were asked to recruit 40 participants to three pump and three MDI courses
(5–8 patients on each course) over 11 months. Owing to a higher than anticipated dropout rate prior to
the DAFNE courses we then recruited to an additional pair of courses at Harrogate, and a pair of courses
at the reserve centre, Nottingham.
Participants
Participants were eligible for the trial if they met the following inclusion criteria:
1. were aged ≥ 18 years
2. had T1DM for at least 12 months at the time of the DAFNE course
3. were fluent in speaking, reading and understanding English
4. were willing to undertake intensive insulin therapy with SMBG, carbohydrate counting and insulin
self-adjustment
5. had no preference for either pump or MDI, and were happy to be randomised
6. were currently using, or willing to switch to, insulin detemir
7. had a need for structured education to optimise diabetes control.
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Furthermore, participants were excluded if they met any of the following criteria:
1. had already completed a diabetes education course
2. used a pump in the previous 3 years (defined as > 2 weeks’ use in the last 3 years) or had strong
clinical indications for pump therapy in the view of the investigator
3. had renal impairment with a chance of needing renal replacement therapy within the next 2 years
(enrolment staff to check that creatinine levels not > 200 µmol/l).
4. had uncontrolled hypertension (diastolic blood pressure of > 100 mmHg and/or sustained systolic level
of > 160 mmHg)
5. had a history of heart disease within the past 3 months
6. had severe needle phobia (severity of phobia assessed, considering if the phobia might preclude full
participation in either treatment arm or influence the participant’s preference for pump therapy)
7. had a current history of alcohol or drug abuse
8. had serious or unstable medical or psychological conditions that are active enough to preclude the
participant safely taking part in the trial (based on investigatory judgement)
9. had recurrent episodes of skin infections
10. were pregnant or planning to become pregnant within the next 2 years
11. had taken part in any other investigational clinical trial during the 4 months prior to screening
12. had any other issue that might have precluded them from satisfactory participation in the study based
on investigatory judgement
13. were unable to give informed consent.
Interventions
Dose Adjustment For Normal Eating with multiple daily injection
Participants on the MDI arm attended a standard DAFNE structured education course, described in detail
elsewhere.2 Courses are conducted over 5 consecutive days, providing an average of 38 hours of
structured education, delivered to groups of 5–8 adults, aged ≥ 18 years, in an outpatient setting. Courses
are delivered by diabetes specialist nurses and dietitians who attend an educator training course, the
DAFNE education programme, a seven-part programme consisting of 105 hours of structured training.
The DAFNE curriculum uses a progressive modular-based structure to improve self-management in a variety
of medical and social situations. Content is designed to deliver key learning topics at the appropriate time
during the week. In this way, knowledge and skills are built up throughout the course with active
participant involvement and problem-solving as key methods of learning. The key modules are: ‘What is
diabetes?’, ‘Food and diabetes’, ‘Insulin management’, ‘Management of hypoglycaemia’ and ‘Sick day
rules’. Lesson plans give guidance on timing and a student activity section serves to give an idea of
expected responses. Each meal and snack during the course is used as an opportunity to practise
carbohydrate estimation and insulin dose adjustment.
Dose Adjustment For Normal Eating with pump
Participants on the pump arm attended a modified DAFNE course, which had been tested in a pilot study,
previously published.27 The 5-day structure of the standard adult DAFNE course was maintained while
incorporating the additional skills and learning outcomes that were considered necessary to use pumps
successfully. The principles of insulin dose adjustment taught on the standard adult course were
maintained.23 The need to introduce ‘pump skills’ required the addition of a pre-course group session,
delivered 1–3 weeks before the DAFNE course. This session gave participants the opportunity to learn
about the basics of insulin pump therapy, including how to set up the pump, so that they could practise
using it with saline before starting on insulin at the beginning of the course. The session included the
theory of pump therapy, understanding cannulas and infusion sets, skin care, pump maintenance and the
advantages and disadvantages of the insulin pump. Participants switched to insulin on the evening before
the DAFNE course or on the first day of the course.
METHODS
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Ongoing treatment
After attending the DAFNE course, participants received the trial treatment for 2 years from the secondary
care service. All of the participants in both groups were invited to an additional DAFNE follow-up group
session at 6 weeks post course, which is standard for DAFNE course attendees.
Multiple daily injection participants used a combination of quick-acting insulin analogues and twice-daily
injections of insulin detemir. Pump participants used a Medtronic Paradigm® VeoTM insulin pump (Model X54)
with short-acting analogue insulin, as in a meta-analysis87 this was shown to lower HbA1c to a greater extent
than traditional soluble insulin. As insulin is already marketed and licensed for use, and as the participants
were already accessing insulin through prescription on a regular basis, there was no need to change how the
insulin was accessed for the trial – participants collected insulin from their pharmacist as normal.
The insulin pumps include, as standard, a Medtronic Bolus Wizard (Medtronic, Watford UK) to aid
calculation of insulin doses. In order to reduce any potential bias, MDI participants were also given access
to a bolus calculator (Accu-Chek Aviva Expert Bolus Advisor System, Roche Diagnostics Ltd, Burgess
Hill, UK).
Fidelity testing (FT) of pump courses was undertaken in order to assess whether or not courses were
delivered in accordance with DAFNE philosophy and principles, and that the educators had the necessary
skills to deliver these principles. The results of the FT are reported in Chapter 5. Standard DAFNE courses
were not tested, as there is a rigorous quality assurance programme of MDI courses in standard care.
Treatment was changed (pump to MDI or MDI to pump) at the discretion of the local principal investigator
(PI) if self-management of diabetes had become ineffective and was considered a risk to the individual.
If the participant failed to attend the pump course then they were withdrawn from pump treatment.
Primary outcomes
The main primary end point was the change in HbA1c at 24 months, in those participants whose baseline
HbA1c was ≥ 7.5% (58 mmol/mol). The key secondary end point was the proportion of participants
reaching the NICE target of a HbA1c level of ≤ 7.5% (58 mmol/mol) at 24 months (of all participants).
Glycated haemoglobin is the accepted gold standard measure of glycaemic control and provides a measure
of efficacy. Most health economic models of T1DM estimate the cost-effectiveness by primarily modifying
HbA1c levels, which subsequently affect the risk of diabetic complications.88 However, it is important to note
that HbA1c may not have fallen in patients who entered the trial with low baseline levels of HbA1c, but who
might have been experiencing frequent hypoglycaemia or wished to increase dietary freedom. Success for
such individuals would be a HbA1c level that is maintained, or even rises slightly, with a reduction in the
frequency of hypoglycaemia.23 We included such patients as they could provide important information
about QoL and the potential of pump therapy to reduce rates of hypoglycaemia. However, as their
glycaemic control may not alter, including their HbA1c data would have reduced our statistical power to
establish improvement in our primary end point. We therefore powered the trial on the number of
participants with a baseline HbA1c of ≥ 7.5% (58 mmol/mol) and in whom a fall would reflect a worthwhile
improvement in glycaemic control. We ensured standardisation by testing HbA1c in a central laboratory.
Exploratory outcomes on the primary end points
The primary outcome and key secondary outcome were also evaluated at 6 and 12 months in order to
explore the short- and medium-term effects of the intervention.
Secondary outcomes
Secondary outcomes were evaluated in all participants and were measured at 6, 12 and 24 months. Blood
and urine samples for secondary outcomes were tested in local laboratories.
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Hypoglycaemia
We recorded episodes of both moderate and severe hypoglycaemia and specifically recorded episodes at night
(those occurring between 23.00 and 07.00). We used a standard definition of severe hypoglycaemia,89,90
being ‘an episode leading to cognitive impairment sufficient to cause either coma or requiring the assistance
of another person to recover’. The number of severe episodes are reliably recorded by patients for up to
1 year.91
During the last NICE appraisal of pump therapy, the question of the impact of moderate hypoglycaemia
was raised.13 The modelling had included only severe hypoglycaemia, and the point was made that
moderate hypoglycaemia, sufficient to interrupt activities of daily living, might, because of greater
frequency, have a more cumulative effect on QoL than severe hypoglycaemia. We therefore also recorded
rates of moderate hypoglycaemia in an attempt to increase power and identify the ability of pumps to
reduce rates of hypoglycaemia. With no standard definition of moderate hypoglycaemia, the Trial
Management Group (TMG) agreed to define these as ‘any episodes which could be treated by that
individual, but where hypoglycaemia caused significant interruption of current activity, such as having
caused impaired performance or embarrassment or having been woken during nocturnal sleep’. As these
episodes are more frequent, reliable recall of such events is unlikely to be sustained for more than a few
weeks. We therefore asked participants to record the number and timing of moderate episodes over the
4 weeks prior to each follow-up visit. We used this approach successfully to record the frequency of mild
episodes in a recent epidemiological study of hypoglycaemic burden in diabetes.89
Insulin dose and body weight
Pump treatment may result in the use of less insulin, leading to a favourable effect on body weight.
We recorded total insulin dose at each time point and calculated units per kilogram of body weight.
Lipids and proteinuria
A recent study61 reported little difference in HbA1c on pump therapy compared with MDI but found less
progression to microalbuminuria in the pump group, and also lower cholesterol levels. We measured
high-density lipoprotein (HDL) cholesterol and total cholesterol (TC). Proteinuria was measured using the
albumin-to-creatinine ratio (ACR).
Diabetic ketoacidosis
Diabetic ketoacidosis was measured throughout the trial through the assessment of serious adverse events
(SAEs).23 As all significant episodes of ketosis require hospital admission, we were confident in capturing all
of the relevant episodes.
Quantitative psychosocial outcomes
The quantitative psychosocial outcomes are described later (see Outcomes).
Sample size
It is generally accepted that a difference of 0.5% (5.5 mmol/mol) in HbA1c is clinically worthwhile. To
detect this difference with a standard deviation (SD) of 1% at 80% power and 5% two-sided significance
using a t-test requires 64 patients per group, for subjects > 7.5% HbA1c. To allow for a clustering effect
of the educators, with an average of seven patients per DAFNE group and a within-course intraclass
correlation coefficient (ICC) of 0.05, common in diabetes care, the sample size increases to 84. Allowing
for a 10% dropout over 24 months, the sample size per group becomes 93. Audit of the DAFNE database
showed us that 75% of subjects had a HbA1c of ≥ 7.5%, therefore requiring 124 subjects per group and
248 in total. We planned to recruit 280 subjects, which increased the power to 85% but allowed for some
variation in dropout rates and the proportion of patients with HbA1c ≥ 7.5%. However, monitoring of
baseline data showed that the actual proportion of participants with HbA1c ≥ 7.5% was around 90%
rather than 75%. A modelling exercise undertaken during recruitment, with conservative estimates of 85%
(HbA1c ≥ 7.5%) and dropout rate of 15%, suggested that the trial would require at least 240 participants
with primary outcome data at 2 years in order to preserve power of at least 85%.23
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Recruitment
A number of methods were used to approach potential participants:
l PIs or educators identified people from DAFNE waiting lists. They then telephoned or wrote to
potentially eligible individuals.
l Individuals attending a clinic appointment with a trial PI or educator were offered the option of a
future or immediate consultation regarding the trial.
l Clinicians [general practitioner (GP), dietitian, nurse] provided information to patients and referred
them to PIs to be screened and enrolled.
l Details of the trial were advertised through the use of posters and leaflets in clinics (diabetes
outpatient, dietetic, GP surgery).
l Reception staff in diabetes clinics were informed about the trial and provided with leaflets to give to
patients who expressed an interest.
l Participant identification centres were used at some research centres to assist in the identification of
suitable participants.
Interested individuals were given the opportunity to discuss the trial with the PI or educator. Those who
were still interested in taking part were screened for eligibility. Those who were eligible were either invited
to attend a local information meeting, at which the trial was discussed in detail and questions answered,
or were provided with a patient information sheet and consent form and given the opportunity to ask
further questions. Individuals who were still wanting to take part consented to the trial by one of three
methods: (1) by returning a completed consent form (see Appendix 3) in the post, (2) by completing
the form with the PI or educator or (3) by completing the form at a local information meeting.
The participants’ contact details, GP details and ethnicity were also collected.
Allocation to Dose Adjustment For Normal Eating courses and randomisation
Following consent, participants were allocated to a REPOSE DAFNE course, depending on the participants’
availability.23 Up to eight participants were allocated to each course, with a minimum of five preferable.
Courses were randomised, in pairs, to either DAFNE with pump or DAFNE with MDI.23 Participant
allocation to courses was finalised for each course pair before randomisation took place, no less than
6 weeks prior to the date of the first DAFNE course in that pair. For the first seven centres, a simple
randomisation procedure in block size of ‘2’, stratified by centre, was used for courses 1–4. Courses 5
onwards were allocated in pairs using minimisation of the overall and number of participants, with most
recent baseline HbA1c value of ≥ 7.5% or < 7.5% between the treatment groups. Any additional courses
were allocated using minimisation. Known dropouts prior to the DAFNE course were excluded from the
minimisation algorithm for future course allocation. A validated user-written Stata® 13 (StataCorp LP,
College Station, TX, USA) code was produced to generate the allocation by a statistician within Sheffield
Clinical Trials Research Unit (CTRU), who implemented the randomisation. The trial co-ordinator revealed
the allocation to study centres.23
Blinding of the course allocation was not possible because of the nature of the treatment. Course
allocations were revealed to centres 4–6 weeks prior to the date of the first course to allow sufficient
preparation time. Participants were informed of the allocation of their DAFNE course no earlier than
4 weeks prior to that course. At this point they were asked to keep a record of any new episodes of
moderate hypoglycaemia, which would be collected at the baseline assessment. If the course was a pump
course, the participant was booked into a pre-course pump session, up to 3 weeks prior to the course
date, in addition to the baseline assessment, which had to take place before the pump session.
If, for any reason, participants were unable to take part in the course at short notice, they could be
allocated to a later course date, but only in the same trial arm as in the course to which they were
originally allocated. Centres could also keep a list of reserve participants for courses, agreed prior to the
time when the course allocation had been revealed to the educators. In the case of participants dropping
out, the next person on the reserve list would be invited to participate in that course.
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Data collection
Study visits took place at the participants’ diabetes centre. A data collection form (DCF) (see Appendix 4)
was completed by the educator with the participant. Blood and urine samples were taken and analysed at
local laboratories. Two blood samples were taken for measurement of the primary outcome (HbA1c). One
of these was analysed at a central laboratory as the primary measure and the second was tested at the
local laboratory as a back-up. DCF data were entered at local centres on to the in-house Prospect web-
based electronic data capture system, managed by the CTRU.
Baseline assessments took place up to 3 weeks prior to the DAFNE course. The educator completed the
DCF with the participant and handed him/her the self-complete psychosocial questionnaire, asking for
return of the completed questionnaire at the forthcoming DAFNE course. Additional demographic data
collected at baseline were date of birth, sex, qualifications (highest qualification obtained) and current
occupation. Participants were also handed a SAE contact card to aid in contacting their diabetes centre in
the event of an AE.
At the DAFNE course, an attendance form was completed, detailing any missed sessions. The completed
baseline psychosocial questionnaire was collected and the baseline DCF moderate hypoglycaemic episodes
section was updated so that a full 4 weeks of hypoglycaemic episodes were recorded. At all time points,
psychosocial questionnaires were posted from centres to Sheffield CTRU and entered on to Prospect by
Sheffield CTRU clerical staff.
Participants were followed up at 6, 12 and 24 months after the DAFNE course. Participants were sent the
blood glucose diary (see Appendix 5) and instructions for recording moderate hypoglycaemic episodes
4 weeks prior to each visit. Additionally, participants were posted the self-complete psychosocial
questionnaire pack prior to the visit and asked to bring their completed questionnaire to the appointment,
along with the blood glucose diary and record of moderate hypoglycaemic episodes.
Severe hypoglycaemic episodes or SAEs were collected from participants if reported over the telephone or
in clinic. Any additional diabetes-related contacts (DRCs) were also recorded (see Appendix 6 for ongoing
data collection booklet).
Blinding of outcome measures was considered impractical because of the intervention-specific nature of
outcome measures and the necessity of a local diabetes nurse to collect the data. However, use of an
objective outcome (HbA1c) measured in a central laboratory will have minimised bias on the primary
end point.
Trial completion
Participants were deemed to have completed the study if they had trial data recorded at baseline and
24 months. Participants were withdrawn from the study if:
l The participant asked to fully withdraw from the trial. On requesting withdrawal from the trial,
participants were able to consent to continue to have their routine HbA1c results recorded.
l The participant died.
Participants who were changing treatment continued in the trial unless formally withdrawn. Participants
were deemed lost to follow-up if they failed to attend the baseline visit, DAFNE course or 24-month
follow-up.
Research governance
The trial sponsor was Sheffield Teaching Hospitals NHS Foundation Trust. The trial was conducted in
accordance with Good Clinical Practice (GCP) and the Medicines for Human Use (Clinical Trials)
Regulations 2004.92 All staff recruiting participants to the trial had undertaken GCP training. In line with
the three-level categorisation of clinical trial risk in the Medical Research Council/Department of Health
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(DH)/MHRA report on risk-adapted approaches to the management of clinical trials of investigational
medicinal products93 (based on the classification by Brosteanu et al.94), the REPOSE Trial was classified as a
Type A study: no higher than the risk of standard medical care. The trial treatment in REPOSE was licensed
and administered according to its market authorisation. Trial-specific labelling was not used. Given the lack
of criticality of the investigational medicinal product (IMP) with the data analysis and trial results, and the
design of the trial being equivalent to standard care, there was no IMP tracking and accountability
undertaken.
Three committees were established to govern the conduct of the study: an independent Trial Steering
Committee (TSC), an independent Data Monitoring and Ethics Committee (DMEC) and a TMG. Full
membership of the TSC and DMEC are listed at the end of this report. The committees functioned in
accordance with Sheffield CTRU standard operating procedures (SOPs). The TSC was responsible for overall
supervision and monitoring of the trial; it considered any recommendations from the DMEC and provided
advice on any actions to be taken. The DMEC operated within a charter agreed by all members and was
responsible for monitoring efficacy and safety data. Any concerns were reported to the TSC with
recommendations. The TMG was responsible for supporting the implementation of the trial.
Reporting of adverse events
Adverse events were defined as any untoward medical occurrence in a participant to whom a medicinal
product has been administered, including occurrences that are not necessarily caused by or related to that
product. SAEs were defined as any AE that results in death; is life-threatening (subject at immediate risk
of death); requires inpatient hospitalisation or prolonging existing hospitalisation; results in persistent or
significant disability or incapacity, or consists of congenital anomaly or birth defect; or is another important
medical event that may jeopardise the participant. Pregnancy was also recorded as a SAE, so that any AEs
could be identified if and when the child was born.
Included as AEs were an increase in frequency of hypoglycaemia, a blood glucose reading > 30 mmol/l,
unexplained constantly raised blood glucose readings, suspicion of pump malfunction and pump site
infection. Excluded as AEs were non-serious episodes of hypoglycaemia and ketonuria.
Details of AEs were collected during follow-up appointments. Participants were also provided with a
contact card and encouraged to get in touch with their diabetes team if they had experienced any adverse
health events. SAEs were reported in accordance with the Sheffield CTRU and REPOSE SAE SOPs. SAEs
were assessed by the local PI and reported to Sheffield CTRU within 24 hours of becoming aware of the
event, with the exception of events that had been stated as exempt from immediate reporting, for which
28 days was allowed. These exemptions were episodes of severe hypoglycaemia requiring hospitalisation,
episodes of DKA and pregnancy. SAEs were assessed for seriousness, frequency, intensity, relationship to
study product and, when applicable, relationship to pump. The Summary of Product Characteristics for
NovoRapid and Levemir (Novo Nordisk, Gatwick, UK) were kept on file as the reference safety information
for the assessment of events. AEs were reviewed at regular intervals by the three study oversight committees.
The chief investigator and DMEC chairperson were notified of all SAEs on the event being reported.
Reporting of protocol non-compliances
Protocol non-compliances were reported and assessed in accordance with the Sheffield CTRU and REPOSE
non-compliances SOPs. A non-compliance was defined as ‘a departure from the protocol or GCP that
has been identified retrospectively’. Non-compliances were addressed with staff training or, when
appropriate, an amendment to the protocol. In line with MHRA guidance, deliberate prospective protocol
non-compliances or ‘waivers’ were deemed to be unacceptable. A prospective list of exemptions from
reporting and of pre-specified major and minor non-compliances was drawn up by the CTRU, the chief
investigator and the sponsor.
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Trial monitoring
Responsibility for monitoring was delegated to the CTRU and conducted in accordance with CTRU SOPs.
Both on-site and central monitoring methods were adopted. Onsite monitoring visits took place at all
centres at study set-up, prior to delivery of the first DAFNE course, post delivery of DAFNE course 2 and
at study closeout. A further monitoring visit took place during follow-up at seven centres. At each visit,
the study site file and key essential logs were reviewed for completeness. Source data verification was
conducted for 100% of consent and SAE forms. Patient hospital records were reviewed to substantiate
participant existence and eligibility (for which criteria were verifiable from hospital records). Monitoring
reports were issued after each visit detailing any remedial actions required. Central monitoring tasks
included point of entry validation, verification of data and post-entry validation checks. One participant
per DAFNE course per centre was randomly selected for verification. Case report forms at all data
collection time points were reviewed for completeness and quality, and verified to monitor data entry.
Source data verification also took place for 100% of central laboratory HbA1c results. Feedback on
verification was provided and additional verification was undertaken when concerns were identified.
Statistical methods
All statistical analyses were performed in Stata 13 onwards. The MDI is the reference group for all
treatment comparisons.
Analysis populations
The intention-to-treat (ITT) data set includes all participants who were randomised according to
randomised treatment assignments (ignoring any occurrences post randomisation, such as protocol or
treatment non-compliance and withdrawals) with at least one HbA1c assessment measure after baseline.
Sensitivity analysis of the ITT primary outcome set was performed using six additional analysis sets, as
described later in this section.
The per-protocol group is a subset of the ITT group who complied with the protocol. Protocol compliance
was defined as adhering to both the DAFNE course and to pump/MDI. Compliance was reviewed and
assessed on a case-by-case basis with the following general considerations applied:
l adherence to DAFNE course – in general, a participant was adherent to the course if they attended at
least 4 of the 5 days, including the first 2 days (as adjudicated by the course leader)
l adherence to the pump or MDI – a participant was classed as adherent to treatment if he/she adhered
to the pump/MDI for the full 2 years (excluding any reasonable temporary interruptions of around
2 weeks).
A review group (SH and JE), ‘blinded’ to patient outcome data, convened to decide any contentious cases
for treatment interruptions with the help of the trial statistician (EL).
The complete-case group is a subset of the ITT group who had outcome measurements at a specific
follow-up time.
An additional four analysis sets were performed to examine the sensitivity of primary results to multiple
imputation and exclusions, as described later in this section.
Data completeness
A CONSORT (Consolidated Standards Of Reporting Trials) flow diagram was used to display data
completeness and patient throughput from first contact to final follow-up.
Baseline characteristics
The baseline participant characteristics, diabetes history and laboratory tests were summarised and assessed
for comparability between the intervention and control group. No statistical significance testing was carried
out to test baseline imbalances between the arms, but any noted differences are reported descriptively.
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Primary effectiveness analysis
The primary end point for this study is the change in HbA1c after 2 years in participants whose baseline
HbA1c was ≥ 7.5% (58 mmol/mol). The mean change in HbA1c at 24 months post DAFNE course was
compared between participants allocated to pump and participants allocated to MDI using a mixed-effects
model. The model was adjusted for clustering by DAFNE course (random effects), centre and baseline
HbA1c as a continuous covariate (fixed effects).
The mean (SD) HbA1c change from baseline for the pump and MDI groups, and the number in each group,
are displayed. The efficacy of the intervention is reported as mean difference (MD) in HbA1c change at
2 years, with its associated 95% CI and p-value, adjusted for the factors stated above.
Multiple imputation of missing data
Multiple imputation was used to impute missing data on the primary outcome in order to fulfil the ITT
principle and for sensitivity analysis. Multiple imputation was used to impute 24-month HbA1c data for
patients with at least one assessment after randomisation (i.e. at 6 or 12 months), but without 24-month
primary outcome data. Participants’ baseline characteristics were summarised and compared between
completers and non-completers. Data were imputed using chained equations (regression) with 50 imputations
using baseline, 6- and 12-month HbA1c measurements, DAFNE course, centre, age, sex and HFS behaviour as
covariates in the imputation equation. Initially, 10 imputation replicates were planned; however, this was
increased to 50 in order to produce a stable and reliable estimate of variability.
The following sensitivity analyses were undertaken on the primary outcome and displayed alongside the
ITT results:
1. per-protocol cases (subset of ITT who did not deviate from the protocol)
2. complete cases (subset of ITT including only participants with complete HbA1c data at 24 months)
3. multiple imputation of all missing cases (including those without any follow-up data who are excluded
from the ITT analysis)
4. horizontal mean value imputation of all missing cases
5. excluding participants who withdrew from the study because of pregnancy
6. excluding participants with measurements outside a time window of 6 weeks before and after the
24-month follow-up.
A sensitivity analysis on the primary outcome – adjusted for duration of diabetes, number of moderate
hypoglycaemic episodes and number of severe hypoglycaemic episodes – was to be performed if notable
baseline imbalances were observed; however, none was observed.
An exploratory analysis (on available data) to assess whether or not there were differences in primary
outcome between DAFNE lead course educators was conducted using a multilevel model with three
levels – patients nested in DAFNE course, which, in turn, are nested within the course lead. Baseline HbA1c,
treatment group and centre were treated as fixed effects in the model. The ICCs from this model are
presented.
The effect of centre was explored using a mixed-effects regression model. The primary outcome was
regressed against treatment, centre (fixed effects) and an interaction term between treatment and centre,
and it was also adjusted for course (random effects). The p-value for the interaction between treatment
and centre is presented. The MDs between treatment groups with associated 95% CIs, estimated from the
mixed-effects model, are presented by centre with the aid of forest plots.
Key secondary effectiveness analysis
The key secondary end point is the proportion of patients reaching the NICE target of a HbA1c level of
≤ 7.5% (58 mmol/mol) at 2 years (including all participants regardless of baseline HbA1c value). The
treatment effect was investigated using a mixed-effects logistic regression model adjusted for baseline
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HbA1c, centre (fixed effect), and a random effect around DAFNE course. The proportion of patients with
HbA1c of ≤ 7.5% is presented by treatment group alongside the odds ratio (OR) of HbA1c ≤ 7.5% on pump
compared with HbA1c ≤ 7.5% on MDI and its associated 95% CI and p-value.
Secondary effectiveness analysis
Glycated haemoglobin at 6 and 12 months
Secondary analyses on the primary outcome and key secondary outcome were repeated for HbA1c at
6 and 12 months to explore the short- and medium-term effects of the intervention:
l the change in HbA1c at 6 and 12 months in participants whose baseline HbA1c was ≥ 7.5% (58mmol/mol)
l the proportion of participants reaching the NICE target of HbA1c level of ≤ 7.5% (58 mmol/mol) at
6 and 12 months.
These outcomes were analysed using statistical models as for the primary and key secondary outcome.
Episodes of severe and moderate hypoglycaemia
The number of episodes of moderate hypoglycaemia reported in the 4-week period prior to the 6-, 12-
and 24-month visits were compared between treatment groups using a mixed-effects negative binomial
linear regression model, with centre and baseline continuous HbA1c included as fixed effects and course as
a random effect. The occurrence of at least one moderate hypoglycaemic episode in the 4 weeks prior to
starting the DAFNE course was also included as a covariate.
Each episode of moderate hypoglycaemia was classed as ‘confirmed’ or ‘unconfirmed’ by an educator and
the blood glucose level was recorded by the participant. The following outcomes were analysed:
1. all recorded episodes
2. confirmed episodes, defined as episodes that were confirmed and for which the blood glucose level
(if recorded) was < 3.5 mmol/l
3. confirmed episodes (US definition), defined as episodes that were both confirmed and for which the
blood glucose level (if recorded) was < 4 mmol/l.
Severe hypoglycaemic episodes were collected on an ongoing basis. The number of episodes recorded post
baseline was analysed in a similar manner to moderate hypoglycaemic episodes, but with the addition of
study follow-up time as the exposure. A sensitivity analysis was conducted in the same manner by
excluding the first 6 months of data in order to explore any effect of a ‘settling in’ period on the pump.
The incidence rates of moderate hypoglycaemic episodes in the 4 weeks before each time point are
displayed by treatment group, and the treatment effect is reported as an adjusted incidence rate ratio (IRR)
with its associated 95% CI and p-value. The incidence rates of severe hypoglycaemic episodes over the
study duration are displayed as episodes per patient-year and are reported alongside the IRR, its associated
95% CI and p-value.
The overall change in the rate of episodes of severe hypoglycaemia was estimated for the treatment
groups combined using a mixed-effects negative binomial linear regression model. The numbers of
episodes were compared pre and post baseline, using participant as the random effect, adjusted for
treatment, time by treatment interaction, baseline HbA1c and centre. Length of follow-up was included as
the exposure variable. Length of follow-up before baseline was set at 365 days, as participants recorded a
12-month history of severe hypoglycaemic episodes at baseline.
The proportions of participants who experienced at least one moderate hypoglycaemic episode at 6, 12
and 24 months were compared between treatment groups using a mixed-effects logistic regression model
adjusted for DAFNE course (random effect), centre, presence of at least one episode before baseline and
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baseline HbA1c (fixed effects). The proportion of patients who experienced at least one episode of severe
hypoglycaemia during the study period was compared between groups using a mixed-effects logistic
regression adjusted for DAFNE course, centre and baseline HbA1c. Presence of at least one severe episode
before baseline was not used as a covariate in the logistic regression model as all participants with at least
one episode before baseline experienced at least one episode post baseline. The proportion of patients
reporting hypoglycaemic episodes is presented by treatment group alongside the adjusted OR and its
associated 95% CI and p-value.
Insulin dose, body weight and lipids
Insulin dose was calculated as:
Insulin dose (pump) =
24 ‐hour basal dose + typical daily bolus total
body weight (kg)
;
Insulin dose (MDI) =
typical daily dose of background insulin + typical daily dose of quick‐acting insulin
body weight (kg)
.
(1)
In the calculation of insulin dose, weight was taken as the value on the same visit the dose was recorded.
If weight was not recorded, it was estimated from other study visits as follows:
l If 24-month weight was missing, 12-month weight was used.
l If 12-month weight was missing, it was imputed as the time-weighted average of 6- and 24-month
weight or as 6- or 24-month weight if only one observation was available.
l If 6-month weight was missing, it was imputed as the average of baseline and 12-month data, or
imputed as baseline or 12-month data if only one observation was available.
l In all other situations the missing data were left blank.
The analysis of weight was based on available data only.
The mean change from baseline in insulin dose, weight, TC and HDL cholesterol was compared between
treatment groups using a mixed-effects linear regression model with independent correlation adjusted for
clustering by DAFNE course (random effect), centre and baseline HbA1c (fixed effects). The MD between
the groups in change from baseline is displayed with its associated 95% CI and p-value.
Proteinuria
Proteinuria was defined from the ACR at each visit. At each visit a patient was defined as:
l macroalbuminuria – if ACR ≥ 30
l microalbuminuria – if 3 ≤ ACR < 30
l normal – if ACR < 3.
If ACR was missing at a time point, proteinuria status was imputed, based on data from recorded
conditions at the same time point.
Proteinuria was analysed using mixed-effects ordered logistic regression adjusted for clustering by DAFNE
course (random effect), centre and baseline HbA1c (fixed effects). The OR of being in a higher category
(for which macroalbuminuria is the highest category) compared with a lower category is displayed with its
associated 95% CI and p-value.
Blood glucose testing
The self-reported number of blood glucose tests performed in the 2 weeks prior to 24-month follow-up
was compared between treatment groups, in a post hoc analysis, using a mixed-effects model adjusted for
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clustering by DAFNE course (random effect), centre and baseline number of blood glucose tests (fixed
effects). For both treatment groups combined, the change in the number of tests performed at 24 months
compared with baseline was analysed using a paired t-test. Blood glucose testing is presented as number
of tests per day, taken as an average over the 2 weeks reported.
Psychosocial questionnaires
Methods for the analysis of questionnaire data are described later (see Methods for the psychosocial
evaluation).
Subgroup analysis
Pre-planned subgroup analyses were undertaken and regarded as exploratory; significant results from the
analysis were interpreted with caution, as recommended for subgroup analyses.95 The following subgroups
were investigated:
l baseline HbA1c (< 7.5% or 58 mmol/mol, ≥ 7.5% to < 8.5% or 69 mmol/mol, ≥ 8.5%)
l duration of diabetes (< 15 years, ≥ 15 years)
l symptoms of hypoglycaemia (do not feel symptoms or < 3 mmol/l, ≥ 3 mmol/l)
l self-reported use of the bolus advisor over the study duration (never or rarely, sometimes, often
or always)
l age (< 35, 35–49, ≥ 50 years)
l sex
l body mass index (BMI) (normal, < 25 kg/m2; overweight, 25–29.9 kg/m2; obese, ≥ 30 kg/m2)
l level of education [up to Advanced level (A-level) equivalent, vocational/beyond A-level]
l occupational status (Office for National Statistics levels 1–4)
l socioeconomic status as defined by the Office for National Statistics Index of Multiple Deprivation
(above/below median in England, and above/below median in Scotland)
l insulin dose at start of therapy (< 0.7 or ≥ 0.7 IU/weight)
l frequency of moderate hypoglycaemic episodes within the 4 weeks prior to baseline (none, 1, 2 or 3,
4–9, 10+)
l experience of lead DAFNE course educator {‘less experienced’ [six courses or fewer within previous
3 years or completed the DAFNE Educator Programme (DEP) within previous year] vs. ‘higher-level
experience [seven or more courses within previous 3 years or had continuous ‘educator’ status for
> 6 years]}.
The subgroup analysis used mixed-effects linear regression modelling with the primary outcome, change in
HbA1c (%), as the response. The model included main effects of the treatment group and subgroup,
an interaction term between treatment and subgroup, and covariates of centre (fixed effect) and DAFNE
course (random effect). Treatment effect estimates and 95% CIs are presented within each subgroup
category. We used a statistical test for interaction between the randomised intervention group and the
subgroup to examine the evidence for treatment effect varying between subgroup; the p-value for this
interaction is reported unadjusted for multiple testing. Subgroup analyses were also summarised visually
using forest plots.
Safety and harms analysis
Serious adverse events and AEs were summarised and assessed for similarity between the treatment
groups. Both SAEs and AEs are reported on an ITT basis (i.e. according to the group to which the
participants was randomised), but the number occurring following a treatment switch are highlighted.
Patient and public involvement
As part of our recent work funded by a NIHR programme grant (PGfAR),27 15 DAFNE graduates were
recruited to act as a ‘user group’ and contribute to different aspects of the work. We invited two members
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to join both the steering group and other investigator meetings. In addition, one of the project team is a
pump user. They provided input to the trial design, implementation and dissemination, including all
participant materials.23 The work supported by the programme grant included qualitative studies in which
the barriers to self-management in T1DM were explored. This work led to the development of a pilot study
within the PGfAR work, in which a modified DAFNE course incorporating a pump curriculum was developed
and piloted in three centres.
Methods of the fidelity assessment
Aim
To ensure that there was consistency in:
1. the delivery of the 5-day DAFNE pump curriculum
2. the timing and content of pump pre-assessment/setting up on pump session.
Multiple daily injection courses were not included in the FT, as there exists a rigorous quality assurance
programme of MDI courses in standard care, and trial centres are routinely audited.
Methods
An experienced DAFNE educator and peer reviewer from Sheffield Teaching Hospitals NHS Foundation
Trust was employed as the fidelity assessor (FA); this educator was not directly involved in the delivery of
REPOSE courses. The FA assessed whether or not the pump courses delivered the correct DAFNE content
and philosophy. The FA visited each centre to observe the ‘Wednesday’ of the pump DAFNE course.
Wednesday was chosen as pump curriculum sessions that incorporated key differences to MDI would be
delivered by DAFNE educators from both dietetic and nursing specialties. In addition, patients on the
course should have settled into the course, be more relaxed and be starting to establish patterns and
adjustments to their regimen by the third day. It was planned that the FT take place on the first or second
pump course at each centre.
Experienced educators who devised the pump curriculum and the national director of the DAFNE
programme discussed which sessions differed most between the pump and MDI DAFNE curricula and,
thus, warranted observation. These sessions were decided as follows:
l daily goals, blood glucose results and insulin doses
l insulin dose adjustment theory, basal rate testing
l dose adjustment practice – reducing and increasing insulin
l setting up Bolus Wizard
l sick day rules
l alcohol
l exercise.
All but one session was scheduled for observation on the FT visit, as it was not possible to timetable all
sessions that differed between the MDI and pump courses on 1 day. In lieu of observation, the FA
reviewed the lesson plan for the sick day rules session.
The following data and documents were requested to be made available for the FT visit:
l pre-course pump session details including patient attendance, session timings and lesson plan
l pump course timetable
l list of course participants and details
l lesson plan for all observed sessions and the sick day rules lesson plan.
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A DEP peer support learning outcomes form was completed for each session observed. This form listed
the essential learning outcomes for each session and the FA evaluated whether or not these were met
(or partially met). For each learning outcome, the FA provided evidence for its achievement. A template
report was devised and used to collate the data collected from the FT visit.
Once the FA had completed the assessment, feedback was given immediately so that educators could
resolve any problems. The report was completed within 3 days of the visit and sent to the trial
management office.
Methods for the economic evaluation
Setting and perspective
The health economic analyses are designed to inform UK decision-makers within the UK NHS on the
potential resource implications of choosing to use pump therapy with DAFNE structured education
(pump + DAFNE) or MDI with DAFNE structured education (MDI + DAFNE) for the group of adults with
T1DM in the REPOSE Trial, comprising adults with T1DM who are naive to pump therapy.
To ensure that all economic analyses were applicable to the UK decision-making setting, all economic
analyses took the NHS and Personal Social Services perspective in line with (NICE) guidance.22
Two approaches: economic evaluation alongside the clinical trial and long-term
cost-effectiveness modelling
The cost-effectiveness of ‘pump + DAFNE’ compared with ‘MDI + DAFNE’ was assessed using an Economic
Evaluation Alongside Clinical Trials (EEACT) and long-term modelling exercise. The EEACT took a 2-year
time horizon and the long-term modelling took a lifetime horizon. As the long-term modelling takes a
lifetime time horizon, and includes all clinically important complications of diabetes, this should be
considered as the primary analysis.
Price year and discounting
All costs are reported in 2013–14 prices; if costs were obtained from a previous financial year they were
inflated to 2013–14 prices using the Hospital and Community Health Services Pay and Prices index.96 All
costs and QALYs were discounted at a rate of 3.5% in line with NICE guidance.22 All costs and QALYs
were assumed to fall at the end of the year, apart from the cost of the structured education courses,
which were assumed to occur at the start of the first year.
Population and subgroups for analysis
The individuals in the REPOSE Trial were adults with T1DM who were eligible to receive a structured
education course. Furthermore, all individuals were naive to insulin pump therapy and did not have a
preference to receive the pump. The average age of participants was 40.4 years and their mean duration
of their diabetes was 18.0 years. Data were collected from individuals at baseline and at 6 months, 1 and
2 years post randomisation. In the MDI + DAFNE arm, 6, 3 and 5 individuals out of 135 were lost to
follow-up at 6 months, 1 and 2 years, respectively. A further individual in the MDI + DAFNE arm withdrew
from the trial at 6 months. In the pump + DAFNE arm, 0, 1 and 2 individuals out of 132 were lost to
follow-up at 6 months, 1 and 2 years, respectively. A further individual in the pump+ DAFNE arm withdrew
from the trial at 1 year.
The data collected in the REPOSE Trial were considered to be the only relevant evidence on the relative
effectiveness of pump + DAFNE compared with MDI + DAFNE. This is because REPOSE is the only large
study in a UK setting in which adults with T1DM in both trial arms have received equivalent diabetes
education in both the pump and MDI trial arms.
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There are two populations in the REPOSE Trial: (1) the ITT population and (2) the per-protocol population.
The ITT population includes all individuals who graduated their DAFNE course and had follow-up data for
at least one data collection period. In the ITT population, individuals were assigned to their randomised
treatment irrespective of whether or not they switched to the other insulin delivery mechanism. The
per-protocol population includes all of the individuals who were in the ITT population and adhered to their
insulin delivery mechanism (either pump or MDI). Unless otherwise stated, all analyses of the REPOSE Trial
data to inform the health economic analyses were conducted in the ITT population.
The population analysed in the primary health economic analyses is all individuals in the REPOSE Trial,
regardless of whether or not the individual’s baseline HbA1c was ≥ 58 mmol/mol (7.5%). The analysis
population differs from the population used in the primary clinical end point statistical analysis, as the
base-case health economic analysis focuses on the whole trial population rather than those individuals
with a HbA1c of < 58 mmol/mol (7.5%). For the health economic analyses, it is important to assess the
cost-effectiveness of pump + DAFNE compared with MDI + DAFNE for all adults with T1DM who would
be potentially eligible to receive either treatment if they were adopted as standard practice.
Subgroup analyses 1–6 were conducted in the long-term modelling only, because of concerns about the
reduction in sample size potentially producing spurious results in the EEACT. However, subgroup analysis 7
was conducted in the EEACT, as this was an important subgroup analysis for the estimation of treatment
effect of HbA1c (see Statistical methods). The subgroup analyses were conducted in following subgroups of
the REPOSE Trial participants:
1. baseline HbA1c ≥ 58 mmol/mol (7.5%)
2. baseline HbA1c ≥ 58 mmol/mol (7.5%) and < 69 mmol/mol (8.5%)
3. baseline HbA1c ≥ 69 mmol/mol (8.5%) and < 80 mmol/mol (9.5%)
4. baseline HbA1c ≥ 80 mmol/mol (9.5%)
5. baseline HbA1c < 69 mmol/mol (8.5%)
6. baseline HbA1c ≥ 69 mmol/mol (8.5%)
7. all individuals in the per-protocol population.
Cost of the Dose Adjustment For Normal Eating course
A detailed within-trial costing of the DAFNE courses was not undertaken because DAFNE is an already
established intervention within the NHS. The cost of DAFNE training for adults with T1DM using MDI has
been calculated by DAFNE UK as being £359.10 per course attendee in 2012–13 prices (£363.10 in
2013–14 prices).97
Based on discussion with experts involved in the REPOSE Trial, including a Professor of Clinical Diabetes
and Honorary Consultant Physician, and a Professor in Public Health and Health Technology Assessment,
it was assumed that the cost of a DAFNE course in the pump + DAFNE arm is identical to the cost of a
DAFNE course in the MDI + DAFNE arm, except for the cost of staff time spent conducting an additional
pre-course pump-fitting session.
Data were collected on the time spent delivering a pre-course fitting session for pump + DAFNE
participants in the FT process. The FT process was conducted for one pump + DAFNE course at each trial
centre to ensure that the pump + DAFNE course taught the principles of insulin adjustment in a similar
fashion to the MDI + DAFNE course. These data were utilised to estimate the additional cost of the
pre-course pump fitting session in the pump + DAFNE arm. Expert advice was sought from two centres
in which it was unclear whether reported time use as part of the FT referred to the educator time spent
or the total time individuals spent at the venue (which could include non-contact waiting time). To ensure
consistency between the estimated costs of a MDI + DAFNE course and a pump + DAFNE course, the cost
of staff time was obtained from the estimated cost of staff time for the MDI + DAFNE course. The cost of
the pre-course fitting session was estimated to be £28.82 per adult with T1DM.
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Economic analysis alongside the clinical trial of pump + Dose Adjustment For Normal
Eating versus multiple daily injection + Dose Adjustment For Normal Eating
Resource use by individuals in the REPOSE Trial over the 2-year follow-up period
Resource use was collected either on an ongoing basis or was self-reported by the individuals in the trial
at baseline or at a follow-up period (6 months, 1 and 2 years post randomisation). All unit costs used to
value the reported resource use in the EEACT, apart from the costs associated with insulin use, are
presented later (see Table 3). The unit costs associated with insulin use are reported separately later
(see Table 4).
Diabetes-related contacts were collected using two methods in the REPOSE Trial. Patient’s self-reported
number and type (either face to face or not face to face) of diabetes-related contacts since the last REPOSE
visit (or in the year prior to baseline) were collected in each of the REPOSE DCFs (baseline, 6, 12 and
24 months). Ongoing information was collected from the sites on the number of visits, the type of visit and
the time spent at each visit. The self-reported contacts were used in the health economic analysis for two
reasons: (1) this method was consistent with the method used to collect information on the baseline
number of contacts; and (2) national-level commissioning information provides only a cost per outpatient
appointment (rather than for a specified time for a specific health-care professional to conduct an
appointment), so from a costing perspective it is the number of contacts that is important rather than the
time spent at each contact.
Table 2 shows that numbers of diabetes-related contacts were higher in the CSII + DAFNE arm of the
REPOSE Trial than the MDI + DAFNE arm in the first year of the trial. However, most of these differences
disappear in the second year of the trial. It should also be noted that the average time spent delivering
diabetes-related contacts is higher for pump + DAFNE individuals than MDI + DAFNE individuals, except for
telephone contacts delivered between 12 and 24 months post randomisation. This indicates that there are
important differences in the number and time spent at diabetes-related contacts for MDI and pump users
in the NHS.
The unit costs used to estimate the total cost diabetes-related contacts are presented in Table 3.
The individual’s self-reported resource use was collected on whether they were using lipid-lowering,
antiplatelet or depression medication at the time of each REPOSE visit. No information was collected on
the type of drug or the quantity used. It was assumed that, if an individual reported use of medication
received medication, they had been receiving that specific medication since the last REPOSE visit. The
average quarterly cost of each type of medication is reported in Table 3.
Data were collected on an ongoing basis for all inpatient hospitalisations that were not scheduled to treat
a pre-existing condition. Therefore, the only missing data were for individuals who were lost to follow-up
or withdrew from the trial. At each admission, information was collected on the cause. The possible causes
for each admission were DKA, myocardial infarction (MI), severe hypoglycaemia, ischaemic heart disease,
unstable angina, heart failure (HF), foot ulcer and renal disease. If the admission was not due to one of
these causes, the reason was recorded. This occurred for only one inpatient admission in the REPOSE Trial.
The NHS Reference Costs 2013–1498 (and all previous years used to inform the unit costs) present the cost
of non-elective inpatient stays as short stays, excess bed-days and long stays. The cost of inpatient stays
were estimated as the cost of a short stay if the length of stay was ≤ 1 day. If the length of stay was
≥ 2 days then the cost of the visit was estimated using the following formula:
Cost of stay = cost of an inpatient short stay + cost of an inpatient excess bed-day
× (number of days in hospital −1).
(2)
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At baseline, self-reported data were collected on the number of diabetes-related admissions in the
past year, days spent in hospital and the reason for admission. The possible causes included DKA,
hypoglycaemia, MI, ischaemic heart disease, unstable angina, HF, foot ulcer and renal disease. It was
possible that individuals had missing information on the number of days that they were in hospital or the
reason for the admission. Mean value imputation was used to impute the number of missing days. All of
the admissions for which the reason was missing were treated as an ‘other cause inpatient stay’.
Data were also collected on an ongoing basis for individual’s severe hypoglycaemic events. Severe
hypoglycaemia was defined in the REPOSE Trial as been any hypoglycaemic episode that an individual
was unable to treat themselves. Information was collected on whether each severe hypoglycaemic event
required either a paramedic call-out and/or an inpatient admission. If it was reported that an individual
did not have an inpatient admission or a paramedic call-out then it was assumed that a friend or family
member provided aid to the individual, which meant that no admission or paramedic call-out was required.
This had no implications for NHS resource use, so these episodes of severe hypoglycaemia were assumed
to have no monetary cost to the NHS in the EEACT. The unit costs for a paramedic call-out or an inpatient
admission for severe hypoglycaemia are presented in Table 3.
Information was collected for all individuals in the REPOSE Trial (at baseline, 6, 12 and 24 months post
randomisation) on their current insulin regimen (including type of insulin used), the typical daily insulin
dose in the week preceding data collection, the number of injections per day, the type of insulin used by
the individual and the method of insulin delivery. As information on insulin type was available, the cost of
insulin and insulin pens was estimated separately for each insulin type.
The unit costs associated with insulin use are presented separately from the rest of the unit costs in Table 4.
The daily cost of insulin was multiplied by the number of days between each data collection period (6 months,
TABLE 2 Differences in the number of diabetes-related contacts in the MDI +DAFNE and pump +DAFNE arms of
the REPOSE Trial
Diabetes-related
contacts
Year prior to
baseline
Months post randomisation
0–6 6–12 12–24
Face
to face
Not face
to face
Face
to face
Not face
to face
Face
to face
Not face
to face
Face to
face
Not face
to face
MDI +DAFNE
Ongoing data
collection
(n = 95)
n, mean
(SD)
– – 0.432
(1.048)
0.474
(1.590)
0.621
(0.947)
0.516
(2.178)
1.295
(2.539)
1.263
(5.260)
Time
(minutes),
mean (SD)
– – 16.47
(52.89)
5.47
(23.90)
26.17
(44.23)
7.68
(48.05)
46.58
(90.73)
13.32
(53.99)
Self-reported
(n = 128)
n, mean
(SD)
4.125
(7.374)
1.242
(3.089)
1.531
(2.159)
0.477
(2.230)
1.156
(1.492)
0.336
(1.642)
2.875
(4.719)
1.094
(3.852)
Pump +DAFNE
Ongoing data
collection
(n = 118)
n, mean
(SD)
– – 0.814
(1.402)
1.220
(1.913)
0.924
(1.334)
0.788
(2.095)
1.576
(2.878)
0.703
(1.458)
Time
(minutes),
mean (SD)
– – 39.03
(76.63)
15.89
(28.24)
37.37
(68.36)
10.26
(28.66)
60.13
(155.82)
9.32
(21.22)
Self-reported
(n = 132)
n, mean
(SD)
4.197
(6.211)
2.167
(4.489)
1.795
(2.436)
1.076
(2.092)
1.242
(1.564)
0.962
(2.813)
2.787
(4.199)
0.576
(1.393)
DOI: 10.3310/hta21200 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 20
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Heller et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
31
TABLE 3 Unit costs used in the within-trial analysis of the REPOSE data
Costs used in the
within-trial analyses
Cost
(2013–14, £) Notes
DAFNE courses
Cost of a DAFNE course 363.10 DAFNE fact sheet 697
Cost of a pre-course
pump fitting session
28.82 REPOSE Trial data and DAFNE fact sheet 697
Hypoglycaemia
Cost of hypoglycaemia
admission
446.73 NHS Reference Costs 2013–14.98 Non-elective inpatient short stay. FCE
weighted average of the currency codes: KB01C, KB01D, KB01E, KB01F,
KB02G, KB02H, KB02J, KB02K
Paramedic cost per case 233.58 Elliot et al. 2014,99 table 5
Cost of inpatient admissions
DKA
Cost of the first day 527.78 NHS Reference Costs 2012–13.100 Non-elective inpatient short stay. Currency
code PA67Z
Cost of subsequent
days
284.42 NHS Reference Costs 2012–13.100 Non-elective inpatients excess bed-days.
Currency code PA67Z
Renal hospitalisation
Cost of the first day 471.70 NHS Reference Costs 2013–14.98 Non-elective inpatients short stay. Weighted
average of the currency codes: LA09J, LA09K, LA09L, LA09M, LA09N, LA09P,
LA09Q
Cost of subsequent
days
257.87 NHS Reference Costs 2013–14.98 Non-elective inpatients excess bed-days.
Currency codes: LA09J, LA09K, LA09L, LA09M, LA09N, LA09P, LA09Q
MI
Cost of the first day 560.60 NHS Reference Costs 2013–14.98 Non-elective inpatients short stay. Weighted
average of the currency codes: EB10A, EB10B, EB10C, EB10D, EB10E
Cost of subsequent
days
248.89 NHS Reference Costs 2013–14.98 Non-elective inpatients excess bed-days.
Currency codes: EB10A, EB10B, EB10C, EB10D, EB10E
Foot ulcer
Cost of the first day 509.39 NHS Reference Costs 2012–13.100 Non-elective inpatient short stay. Currency
codes: KB03C, KB03D, KB03E
Cost of subsequent
days
156.34 NHS Reference Costs 2012–13.100 Non-elective inpatient short stay day.
Currency codes: KB03C, KB03D, KB03E
Other inpatient stays
Cost of the first day 755.44 NHS Reference Costs 2012–13.100 Non-elective inpatient short stay. Currency
code PA68Z
Cost of subsequent
days
335.81 NHS Reference Costs 2012–13.100 Non-elective inpatient excess bed-day.
Currency code PA68Z
Medication costs (per quarter)
Cost of lipid medication 9.27 Prescription Cost Analysis: England 2011 (BNF,101 chapter 2, section 12)
Cost of antiplatelet
medication
1.87 Prescription Cost Analysis: England 2011 (BNF,101 chapter 2, section 9)
Cost of depression
medication
6.08 Prescription Cost Analysis: England 2011 (BNF,101 chapter 4, section 3)
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TABLE 3 Unit costs used in the within-trial analysis of the REPOSE data (continued )
Costs used in the
within-trial analyses
Cost
(2013–14, £) Notes
Cost of diabetes-related contacts
Cost of a face-to-face
clinic
105.49 NHS Reference Costs 2013–14.98 Non-consultant-led outpatient attendance.
Non-admitted face-to-face follow-up. Service description: Diabetic Medicine
Cost of a telephone
contact
75.80 NHS Reference Costs 2013–14.98 Non-consultant-led outpatient attendance.
Non-admitted non-face-to-face follow-up. Service description: Diabetic Medicine
BNF, British National Formulary; FCE, finished consultant episode.
TABLE 4 Unit costs of insulin
Item
Average
unit cost (£)
Number
of units
Cost per
unit (£)
Associated yearly cost
of an insulin pen (£) Source
Consumables related to MDI
Cost of an insulin needle 0.11 N/A N/A N/A HSCIC102
Cost of an insulin syringe 0.13 N/A N/A N/A HSCIC102
Quick-acting insulin
Human insulin
Vial 9.87 1000 0.01 N/A BNF,101 HSCIC102
Cartridges for a reusable pen 18.97 1500 0.01 8.78
Animal insulin
Vial 26.15 1000 0.03 N/A BNF,101 HSCIC102
Cartridges for a reusable pen 38.29 1500 0.03 5.97
Insulin aspart (NovoRapid)
Vial 14.08 1000 0.01 N/A BNF,101 HSCIC102
Cartridges for a reusable pen 28.31 1500 0.02 9.59
Disposable pen 30.63 1500 0.02 N/A
Insulin lispro (Humalog)
Vial 16.61 1000 0.02 N/A BNF,101 HSCIC102
Cartridges for a reusable pen 28.31 1500 0.02 8.86
Disposable pen 28.31 1500 0.02 N/A
Insulin glulisine (Apidra)
Vial 16.00 1000 0.02 N/A BNF,101 HSCIC102
Cartridges for a reusable pen 28.30 1500 0.02 7.86
Disposable pen 28.30 1500 0.02 N/A
Background insulin
Human insulin
Vial 10.41 988 0.01 N/A BNF,101 HSCIC102
Cartridges for a reusable pen 21.52 1500 0.01 9.30
Disposable pen 21.05 1500 0.01 N/A
continued
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1 and 2 years) to calculate the cost of insulin in the first and second year. If an individual was receiving insulin
pump therapy then the cost of needles, insulin pens and syringes were not applied, as these were already
included in the estimates of the cost of insulin pump consumables. From this information a cost of insulin for
each individual in the REPOSE Trial was calculated.
Cost of the insulin pumps and consumables
The annual cost of an insulin pump and insulin pump consumables was estimated using a survey, which
was conducted in all of the trial centres. This survey obtained information on the unit costs and the
quantities of insulin pumps and insulin pump consumables purchased by centres in routine clinical practice.
Information was also collected on the insulin pump consumables used by participants in the REPOSE Trial.
Data were collected over a 6-month period for the insulin pump consumables and a 12-month period for
the insulin pumps. The Scottish centres purchased insulin pumps and insulin pump consumables through
TABLE 4 Unit costs of insulin (continued )
Item
Average
unit cost (£)
Number
of units
Cost per
unit (£)
Associated yearly cost
of an insulin pen (£) Source
Animal insulin
Vial 26.17 1000 0.03 N/A BNF,101 HSCIC102
Cartridges for a reusable pen 38.32 1500 0.03 9.57
Insulin detemir (Levemir)
Cartridges for a reusable pen 42.00 1500 0.03 9.59 BNF,101 HSCIC102
Disposable pen 42.10 1500 0.03 N/A
Insulin glargine (Lantus)
Vial 30.68 1000 0.03 N/A BNF,101 HSCIC102
Cartridges for a reusable pen 41.50 1500 0.03 7.86
Disposable pen 41.50 1500 0.03 N/A
Mixed insulin
Biphasic isophane insulin
Animal insulin
Vial 25.20 1000 0.03 N/A BNF,101 HSCIC102
Cartridges for a reusable pen 37.80 1500 0.03 5.97
Human insulin
Vial 15.43 987 0.02 N/A BNF,101 HSCIC102
Cartridges for a reusable pen 18.94 1500 0.01 7.74
Disposable pen 21.43 1500 0.01 N/A
Biphasic insulin aspart
Cartridges for a reusable pen 28.79 28.79 0.02 9.59 BNF,101 HSCIC102
Disposable pen 29.89 29.89 0.02
Biphasic insulin lispro
Vial 16.61 1000 0.02 BNF,101 HSCIC102
Cartridge for reusable pen 29.03 1500 0.02 8.93
Disposable pen 30.13 1500 0.02
BNF, British National Formulary; HSCIC, Health and Social Care Information Centre; N/A, not applicable.
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the Scottish Government. Instead of completing the survey, information was obtained on the average price
that the Scottish Government paid for insulin pumps and consumables.
One centre did not report any price information and two centres did not report the quantities of insulin
pump consumables used by REPOSE participants. This missingness was addressed by using the mean price
and mean resource use at the other trial centres to calculate the cost of insulin pumps and consumables.
For some centres, data collection on individuals’ use of consumables was for a period that was somewhat
shorter than 6 months and we estimated their consumables use for 12 months assuming a pro rata uplift.
The cost of insulin pumps and insulin pump consumables during the trial duration was estimated by
multiplying the annual cost of insulin pumps and consumables by the fraction of each year that each
individual spent on insulin pump therapy.
The annual cost of an insulin pump was calculated assuming a pump lifetime of 4.5 years, based on the
clinical expert opinion of a diabetes specialist nurse. The annualised cost was multiplied by the number of
days that an individual spent on an insulin pump to give the total cost of insulin pump therapy in the
trial period.
The effect of a price reduction of insulin pumps and insulin pump consumables of 25% and 50% from the
pump costing survey prices was tested in scenario analyses. A further scenario analysis was conducted by
using a cost of £2002 per annum for a Medtronic pump and consumables reported in Riemsma et al.8
Riemsma et al.8 conducted an appraisal of integrated sensor-augmented pump therapy systems for
managing blood glucose levels compared with stand-alone insulin pumps with a separate CGM system in
the UK for NICE’s diagnostics advisory committee. One of the comparators in this appraisal was stand-alone
insulin pumps with an additional continuous blood glucose monitoring system. As such, this cost for a
Medtronic insulin pump was obtained from the estimated cost of a stand-alone insulin pump estimated in
this study. The costs were obtained from the stated prices of an insulin pump from the London New Drugs
Group in November 2014.103
Treatment switching
During the REPOSE Trial, it was possible for individuals to switch from insulin delivery mechanism to the
other, that is to switch from insulin pump therapy to MDI and vice versa. It is important to include
treatment switching in a health economic analysis, as it is unreasonable to assume that (1) people who
switch treatment will use the same resources over a lifetime as someone who does not use a pump and
(2) someone still receiving an insulin pump has the same benefit from treatment as someone who has
switched to using MDI. As a consequence of including treatment switching in the long-term model, the
mean cost and QALY gain per patient in the pump + DAFNE arm is more likely to represent the true
lifetime costs and QALYs than an analysis that ignored treatment switching.
It was possible to switch treatment twice, and two individuals did so in the REPOSE Trial. The data in
the REPOSE Trial were analysed to assess the number of people with diabetes who switched treatment.
The estimated cost of insulin and insulin pumps was adjusted to reflect the fact that individuals switch
treatments. As the EEACT uses a microcosting approach to estimate costs and obtains QALY data from the
self-reported EQ-5D data to calculate QALYs, all other cost and QALY effects due to switching are included
in the analysis.
The cost of insulin was adjusted for treatment switching by using the data on an individual’s insulin use.
If an individual switched treatment once, insulin use between the last follow-up period and the treatment
switching date was estimated using the reported insulin use at his/her last follow-up period (individuals
were followed up at 6 months, 1 and 2 years post randomisation). Similarly, insulin use between his/her
treatment switching date and the next follow-up period was estimated using the data observed in the next
follow-up period. For example, if an individual switched treatment 11 months post randomisation, his/her
insulin use reported at 6-month follow-up would be used to estimate the cost of insulin between 6 and
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11 months, and insulin use at 1-year follow-up would be used to estimate insulin use between 11 months
and 1 year. If an individual switched between the baseline and the 6-month follow-up period then
his/her data were treated as missing, as no information was available on insulin use when using his/her
randomised treatment allocation, after receiving DAFNE education. Furthermore, if an individual switched
treatment twice (n = 2) then the individual was excluded from the EEACT analysis population. This was
because individuals both switched and switched back to their original treatment within the time period
between two consecutive follow-up periods. Therefore, no information was available on their resource use
when they received the other treatment.
The cost of an individual’s use of insulin pumps and consumables in each year was calculated by
multiplying the fraction of the year for which they used insulin pumps by the associated yearly cost of
insulin pumps and insulin pump consumables.
Estimating the within-trial cost effects
The total cost for each individual consisted of the cost of the following components: inpatient admissions;
paramedic call-outs for severe hypoglycaemia; the cost of a pump fitting session for individuals who
received pump + DAFNE; the cost of pump-fitting session for individuals who switched from MDI to insulin
pump therapy and insulin; annual cost of an insulin pump; annual cost of insulin pump consumables; and
the cost of DAFNE course.
In the base-case analysis, complete cost information was used in the EEACT. Complete total cost information
was available for 98%, 90% and 92% of individuals in the ITT population at baseline, 1 and 2 years,
respectively.
In a scenario analysis, missing cost data were imputed for those individuals who attended at least one
REPOSE Trial follow-up visit. Total discounted cost data were imputed using chained equations (predictive
mean matching), utilising baseline HbA1c, treatment allocation, age at baseline and baseline cost values as
covariates in the imputation equations. Ten different imputed values were calculated for each individual
with missing data.
Estimating within-trial quality-adjusted life-year effects using the EuroQol-5 Dimensions
and the Short Form questionnaire-12 items
To generate QALY measures over the 2-year trial follow-up, information was collected on an individual’s
utility using two different instruments: the EQ-5D and the SF-12. The EQ-5D and SF-12 questionnaires
were completed by individuals at baseline and all follow-up visits (6, 12 and 24 months).
In the base-case within-trial analysis, the utility values measured by the EuroQol-5 Dimensions, 3-level version
(EQ-5D-3L) were used to calculate QALYs using an area-under-the-curve analysis. EQ-5D utility scores
were used in the base case because they are NICE’s preferred utility measure.1 In a scenario analysis, utility
values measured using the Short Form questionnaire-6 Dimensions (SF-6D) (a measure derived from the
SF-12) were used to calculate QALY values.104
In the base case, only individuals with complete QALY data were included in the analysis. Utilities,
as measured by the EQ-5D-3L, were completed by 99%, 93%, 88% and 90% of individuals at baseline,
6, 12 and 24 months, respectively. If an individual had a missing 6-month utility value, then it was
assumed that the 6-month utility value would be the average of the baseline and 1-year utility values.
If an individual had a missing utility score at 12 or 24 months, then they were excluded from the base-case
analysis. The 6-month utility values of individuals with missing utility data at 12 or 24 months were similar
in both model arms. The individuals in the pump + DAFNE arm, who did not have 1- or 2-year EQ-5D-3L
data, had a mean EQ-5D-3L utility score of 0.8177 [standard error (SE) 0.0602] at 6-month follow-up. The
individuals in the pump + DAFNE arm, who did not have 1- or 2-year EQ-5D-3L data, had a mean EQ-5D-3L
utility score of 0.904 (SE 0.0256) at 6-month follow-up. The hypothesis that the difference between these
two distributions was equal to zero could not be rejected using a two-sided t-test with equal variances at
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the 10% significance level. Therefore, there is no indication that excluding these individuals from the base
case would bias the results.
In a scenario analysis, multiple imputation was used to impute missing QALY values for individuals with
assessment data for least one follow-up point. Data were imputed using chained equations (predictive
mean matching), utilising baseline HbA1c, treatment allocation, age at baseline and baseline cost or QALY
values as covariates in the imputation equations. Ten imputed values were calculated for each individual,
with missing data in the analyses using imputed data.
Statistical model used for the within-trial analysis
A seemingly unrelated regression model was used to estimate the costs and QALYs in the EEACT. A
seemingly unrelated regression is a type of statistical model that allows for multiple outcome variables to
be modelled simultaneously.105 This approach is advantageous, as any covariances between covariates
across the different outcome variables are estimated. One seemingly unrelated regression was fitted to
four outcome variables: (1) total discounted costs in year 1, (2) total discounted costs in year 2, (3) total
discounted QALYs in year 1 and (4) total discounted QALYs in year 2, using the ‘mysureg’ command in the
‘ml_ado’ package in Stata version 13.1. For the QALY outcome variables, baseline HbA1c, treatment
allocation and baseline utility were included as covariates, and clustering was controlled for in each DAFNE
course. Baseline utility was included as a covariate to estimate QALYs so that any baseline differences in
health between the two treatment arms was controlled for.106 For the cost outcome variables, baseline
HbA1c, centre, treatment allocation and baseline resource use were included as covariates, and clustering
was controlled for in each DAFNE course.
A scenario analysis was conducted in which both missing cost and QALY data were imputed for individuals
with at least one assessment during the REPOSE Trial follow-up period. A regression was conducted in
each imputed data set and combined using Rubin’s rules.107 Details of the imputation procedures used in
this scenario analysis are given in Estimating the within-trial cost effects and Estimating within-trial quality-
adjusted life-year effects using the EuroQol-5 Dimensions and the Short Form questionnaire-12 items.
The impact of treatment allocation on total costs was calculated by adding the treatment allocation
parameters relating to the cost outcomes in years 1 and 2. Likewise, the impact of treatment allocation on
total QALYs was calculated by adding the treatment allocation parameters relating to the QALY outcomes
in years 1 and 2. CIs around the effect of treatment allocation on total costs and total QALYs were
calculated using the formula for calculating the variance of a variable that is a sum of correlated variables.
The variances and covariance used in this calculation were obtained from the variance–covariance matrix of
the seemingly unrelated regression.
Analysis
The key measure of cost-effectiveness in the EEACT was the ICER base on the mean incremental effect of
pump + DAFNE compared with MDI + DAFNE on total costs and total QALYs. The CIs around these effects
were estimated from the variance–covariance matrix of the regression model. The results were presented
on a cost-effectiveness plane and the uncertainty around the mean effect was presented using a
confidence ellipse.
Long-term cost-effectiveness
The Sheffield Type 1 Diabetes Policy Model Overview
The Sheffield Type 1 Diabetes Policy Model (henceforth, the Model) was used to estimate the lifetime costs
and QALYs for individuals receiving MDI + DAFNE and pump + DAFNE. The Model has been developed
and used over several years, and a detailed description is provided in a journal article108 and a detailed
report to the NIHR on the DAFNE programme grant research.27 In this analysis, we have updated some
aspects of the evidence used within the Model. We term the version used here as ‘The Sheffield Type 1
Diabetes Policy Model version 1.3’.
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The Model is an individual-level simulation model, which consists of a series of submodels that simulate the
progression of diabetic complications (microvascular and macrovascular), SAEs (severe hypoglycaemia and
DKA) and mortality in a given population with T1DM. Each of the modelled microvascular (nephropathy,
neuropathy, retinopathy and macular oedema) and macrovascular complications (MI, stroke, HF and
angina) are included in the model as separate Markov submodels with an annual time cycle. Short-term AEs
(severe hypoglycaemia and DKA) are modelled as the annual incidence of these complications, dependent on
each patient’s characteristics. The Model structure is also presented in Figure 1. The Model attaches utilities
and ongoing costs to health states and one-off costs to events (the move to another health state in a
submodel). These costs and utilities are combined with the length of time that a patient spends in a health
state to estimate lifetime costs and QALYs. The Model estimates patient’s disease progression over their
lifetime.
The disease progression parameters in the Model were not updated in these analyses. However, the costs
and utilities associated with health states and events were updated. A full probabilistic sensitivity analysis
(PSA) was conducted with 500 probabilistic runs, each with 5000 individuals in each Model arm. All Model
runs were conducted using the SIMUL8 2010 professional (Simul8 Corporation, Boston, MA, USA) programme.
Microvascular events and disease progression
For each microvascular complication (retinopathy, neuropathy and nephropathy), individuals progress to the
more severe health states within each annual time cycle according to the probabilities reported in table 29 of
Heller et al.27 The health states included for retinopathy include no retinopathy, background retinopathy,
proliferative retinopathy and blindness. The health states included for neuropathy include no neuropathy,
clinical neuropathy, clinically confirmed neuropathy, diabetic foot syndrome and peripheral arterial disease
(PAD) with amputation. The health states included for nephropathy include no nephropathy, microalbuminuria,
macroalbuminuria, end-stage renal disease (ESRD) and death from ESRD.
Macrovascular events and disease progression
The risks of fatal and non-fatal macrovascular complications (MI, stroke, HF and angina) are modelled in
three stages. First, the annual probability of experiencing any cardiovascular event is estimated based on
individual characteristics, as per the 5-year cardiovascular risk model of Cederholm et al.109 Second, if the
individual is deemed to experience a cardiovascular event, the type of event (MI, stroke, HF or angina)
is determined using methods outlined in Palmer,110 based on data from the Diabetes Control and
Complications Trial (DCCT) Epidemiology of Diabetes Interventions and Complications study.111 Third, is the
issue of fatality. If the event experienced is a MI, stroke or HF, it is determined whether or not the event is
fatal using methods outlined in Palmer110 and as shown in table 31 of Heller et al.27
Individuals can also die from other causes; this other-cause mortality is modelled based on UK life tables
from 2012–14, adjusted to exclude the causes either attributed to diabetes mellitus (either type 1, type 2
or unspecified) or modelled directly in the microvascular and macrovascular disease components (deaths
due to ESRD, MI, stroke and HF).
Utilities: health-related quality of life for health states in the long-term model
Heller et al.27 (pp. 108–9) detail the utility analyses undertaken to inform version 1.2 of the model. Since
that report, further analysis has taken place in the course of peer-reviewed journal publication, and the
utilities presented in this analysis are based primarily on those revised analyses, which are now published in
Peasgood et al.112 The main change in this analysis is that the preferred statistical model to estimate utility
values in the publication is a random-effects model rather than a Tobit model. Riemsma et al.8 conducted
the independent economic analysis for NICE on the cost-effectiveness of integrate CGM and insulin pump
therapy. For the independent analysis, a systematic review of utilities in type 2 diabetes mellitus published
in 2014 by Beaudet et al.113 was used for many of the health states of their economic model. The utilities
presented in version 1.2 of the model were considered for updating by the new information presented in
Peasgood et al.112 and Beaudet et al.113
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The following criteria were applied to decide if a utility value should be updated. Utility values estimated in
a population with T1DM were preferred to values estimated in a population with type 2 diabetes mellitus.
If multiple values were available in a T1DM population, utility values that were estimated using the EQ-5D
were preferred to other utility values. If a paper presented more than one parameter value, the parameter
from the best-fitting model was the preferred source. If two papers analysed the same data source then
the most recent paper was the preferred source. The utility parameters used in the Model version 1.3
base-case analyses, and the distributions used in the PSA, are given in Table 5.
Unit costs for health states in the long-term model
The base case unit costs, which are presented in Heller et al.,27 were inflated to 2013–14 prices using
the Hospital and Community Health Services Index.2 The base-case health-state costs used, and the
distributions used in the PSA, are given in Table 6.
Pre-specified subgroup analyses
A series of subgroup analyses were conducted in the long-term modelling. The same subgroup analyses
were not conducted in the within-trial analysis, as conducting analyses in these subgroups would lead to a
reduced sample size and increase the chance that a spurious result would be found. The cost-effectiveness
of pump + DAFNE against MDI + DAFNE was compared for subgroups:
1. baseline HbA1c ≥ 7.5% (58 mmol/mol)
2. baseline HbA1c ≥ 7.5% (58 mmol/mol) and < 8.5% (69 mmol/mol)
3. baseline HbA1c ≥ 8.5% (69 mmol/mol) and < 9.5% (80 mmol/mol)
4. baseline HbA1c ≥ 9.5% (80 mmol/mol)
5. baseline HbA1c < 8.5% (69 mmol/mol)
6. baseline HbA1c ≥ 8.5% (69 mmol/mol)
7. all individuals in the per-protocol population.
For people with a baseline HbA1c of < 7.5% (58 mmol/mol), there were insufficient numbers (n = 12
people in the MDI + DAFNE arm, n = 13 in the pump + DAFNE arm) to conduct a subgroup analysis.
The subgroup analyses were conducted by changing only the individual characteristics that were inputted
into the model. All of the other parameters and assumptions in the model were identical to those in the
base case.
Modelled cohort of 5000 simulated individuals
Individual characteristics were drawn from the baseline characteristics of all individuals, irrespective of
treatment arm, in the ITT population. The variables included in the baseline individual characteristics are
HbA1c, age, diabetes duration, triglycerides, TC, HDL cholesterol, low-density lipoprotein (LDL) cholesterol,
systolic blood pressure, baseline cost of insulin, baseline cost of diabetes-related contacts, sex, physical
activity (measured as being either low, medium or high, based on the time spent walking, fast walking or
running per week), smoking status, ethnicity, history of nephropathy, history of neuropathy, history of
retinopathy, history of MI, history of stroke, history of HF and history of angina.
The observed characteristics (including missing values) of the REPOSE Trial individuals were sampled
with replacement to generate a cohort of 5000 individuals to be used in the economic model. After the
cohort of 5000 individuals was obtained, missing data values were observed for TC, HDL cholesterol, LDL
cholesterol, systolic blood pressure and sex. To obtain the missing data, these values were imputed. The
data were imputed in the cohort of 5000 individuals, rather than for the individuals in the trial data set, as
this allowed the missing data to vary across different replications of an individual with missing data. If the
data were imputed before the sampling, then the missing data would take on a fixed value in the cohort
of 5000 individuals rather than being uncertain.
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TABLE 5 Base-case utility parameters
Health state for event Utility SE
Beta distribution
SourceAlpha Beta
Baseline utility value
Male with T1DM and no complications 0.866 0.010 947.789 146.898 Peasgood et al. 2016112
Disutility
Gamma distribution
Alpha Beta
Complications or covariates
Female with T1DM and no complications 0.0236 0.008 8.703 0.003 aPeasgood et al. 2016112
Nephropathy
Microalbuminuria 0 Assumption
Microalbuminuria –0.017 0.01 2.89 0.006 Coffey et al. 2002114
ESRD –0.078 0.026 9 0.009 Coffey et al. 2002114
Neuropathy
Clinical neuropathy –0.055 0.01 30.25 0.002 Coffey et al. 2002114
Clinically confirmed neuropathy –0.055 0.01 30.25 0.002 Coffey et al. 2002114
Diabetic foot syndrome –0.1042 –0.119 0.767 0.136 Peasgood et al. 2016112
PAD with amputation –0.1172 –0.055 4.541 0.026 aPeasgood et al. 2016112
Retinopathy
Background retinopathy –0.0544 –0.023 5.594 0.010 Peasgood et al. 2016112
Proliferative retinopathy –0.0288 –0.026 1.227 0.023 Peasgood et al. 2016112
Blindness –0.208 0.013 256 0.001 Coffey et al. 2002114
Cardiovascular
MI (first year) –0.065 0.03 4.694 0.014 Alva et al. 2014115
MI (subsequent years) –0.057 0.03 3.61 0.016 Alva et al. 2014115
HF –0.101 0.032 9.962 0.010 Alva et al. 2014115
Stroke –0.165 0.035 22.224 0.007 Alva et al. 2014115
Angina –0.09 0.018 25 0.004 bClarke et al. 2002116
AEs
Hypoglycaemia episode unable to treat
yourself
–0.002 –0.002 1 0.002 Peasgood et al. 2016112
DKA –0.0091 –0.01 0.828 0.011 aPeasgood et al. 2016112
a A parameter value was not available in the author’s preferred statistical model.
b Value is presented later (see Table 7) as ischaemic heart disease.
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TABLE 6 Base-case health state and transition costs
Health state
Mean
cost (£) SE
Gamma distribution
SourceAlpha Beta
Microalbuminuria (ongoing) 36 3.56 100 0.36 BNF 2012,117 McEwan et al. 2007118
Microalbuminuria (ongoing) 36 3.56 100 0.36
ESRD (ongoing) 24,436 2444 100 244.36 NHS Reference Costs 2011119
(activity-weighted average of LD01A,
LD02A, LD03A, LD04A, LD05A,
LD06A, LD07A, LD08A, LD09A,
LD010A and LD011A and LD012A)
Death due to ESRD 0 0 0 0.00 Assumption
Clinically confirmed neuropathy 271 27.14 100 2.71 Currie et al. 2007120
Clinical neuropathy 271 27.14 100 2.71 Assumed equal to clinically confirmed
neuropathy
Diabetic foot syndrome 2848 285 100 28.48 NHS Reference Costs 2011119
[activity-weighted average of
‘Non-Elective Inpatient (Long Stay)’,
‘Non-Elective Inpatient (Long Stay)
Excess Bed-day’ and ‘Non-Elective
Inpatient (Short Stay)’ for currency
code QZ17B]
PAD with amputation (year 1) 7221 722 100 72.21 NHS Reference Costs 2011119
[activity-weighted average of
‘Non-Elective Inpatient (Long Stay)’,
‘Non-Elective Inpatient (Long Stay)
Excess Bed-day’ and ‘Non-Elective
Inpatient (Short Stay)’ for currency
codes QZ12Z and QZ11B]
PAD with amputation (ongoing) 439 43.93 100 4.39 McEwan et al. 2007118
Background retinopathy 145 14.47 100 1.45
Proliferative retinopathy 661 66.11 100 6.61
Macular oedema 661 66.11 100 6.61 Assumed equal to proliferative
retinopathy
Blindness (year 1) 1584 158 100 15.84 Clarke et al. 2003121
Blindness (ongoing) 519 51.88 100 5.19
First MI (year 1) 6788 679 100 67.88 Clarke et al. 2003121
Second MI 6788 679 100 67.88
Final MI 6788 679 100 67.88
MI (ongoing) 904 90.43 100 9.04
Fatal MI 2101 210 100 21.01
First stroke (year 1) 4361 436 100 43.61
Second stroke 4361 436 100 43.61
First stroke (ongoing) 559 55.90 100 5.59
Fatal stroke 5684 568.45 100 56.84
HF (year 1) 3818 382 100 38.18
HF (ongoing) 1173 117 100 11.73
Fatal HF 3818 382 100 38.18
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
42
The imputation procedure depended on whether the missing value was a continuous or a categorical
variable. TC, HDL cholesterol, LDL cholesterol and systolic blood pressure were imputed using chained
equations, utilising the truncated regression procedure. Sex was imputed separately from TC, HDL
cholesterol and systolic blood pressure, using the Poisson procedure. In both sets of imputation models,
all of the complete individual characteristics were included as predictive covariates. LDL cholesterol was
calculated using the imputed data for TC and HDL cholesterol, using the following formula:
LDL cholesterol = total plasma cholesterol (cholesterol) – HDL cholesterol – (triglycerides/2:19). (3)122
All of the imputations were performed using single imputation. The reason for using one imputed value
was that as more imputations were performed, the average value of these imputations would converge for
the different replications of an individual from the trial population. Therefore, the uncertainty in the values
of the missing data would not be fully reflected in the model cohort.
Summaries of the baseline characteristics of the 5000 simulated individuals for the base-case cohort and
the 260 individuals sampled from the REPOSE Trial are given in Table 7. The summary of baseline
characteristics for the 5000 simulated individuals for each of the pre-specified subgroup analyses is
provided in Appendix 7.
Incorporating estimated clinical effectiveness from the REPOSE Trial:
glycated haemoglobin
The probability of switching treatment, changes in HbA1c, the probability of a severe hypoglycaemic event
and the probability of the DKA were based on data from the REPOSE Trial. These four clinical effects have
been included in the health economic model, as they all would impact on the costs of treatment and
QALYs gained by people if either option were to be adopted in routine clinical practice. HbA1c has been
included as it is the key driver of all modelled diabetic complications in the Model. Changes in HbA1c were
estimated using a beta regression. The probability of severe hypoglycaemia and DKA have been included,
so that any benefits of either arm in reducing the incidence of these events is included in the economic
TABLE 6 Base-case health state and transition costs (continued )
Health state
Mean
cost (£) SE
Gamma distribution
SourceAlpha Beta
Angina (year 1) 3397 340 100 33.97
Angina (ongoing) 951 95.09 100 9.51
Hypoglycaemia 187 18.69 100 1.87 Previous calculation (weighted
average of the following HRG codes,
with activities obtained from the
hypoglycaemia rates observed before
and after DAFNE: KB02D, KB02E,
KB02F. KB02D, KB02E, KB02F,
KB01B, KB01B, KB01A, KB01A,
PS13A, PS13B, PS13C, VB09Z,
VB09Z)
DKA with hospitalisation 1399 140 100 13.99 NHS Reference Costs 2011119
[activity-weighted average of
‘Non-Elective Inpatient (Long Stay)’,
‘Non-Elective Inpatient (Long Stay)
Excess Bed-day’ and ’Non-Elective
Inpatient (Short Stay)’ for currency
codes KB01B and PA67Z,
respectively]
BNF, British National Formulary; HRG, Healthcare Resource Group.
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TABLE 7 The baseline characteristics of REPOSE participants and the simulated cohort
Characteristic REPOSE ITT population (N= 260) Simulated cohort (N= 5000)
Continuous variables, mean (SD)
Baseline HbA1c (mmol/mol) 76.0 (18.6) 76.1 (18.8)
Age (years) 40.4 (13.4) 40.3 (13.3)
Diabetes duration (years) 18.0 (12.5) 18.0 (12.5)
Triglycerides (mmol/mol) 1.4 (1.0) 1.3 (1.0)
TC (mmol/mol) 4.9 (0.9) 4.9 (0.9)
HDL cholesterol (mmol/mol) 1.6 (0.4) 1.6 (0.4)
LDL cholesterol (mmol/mol) 2.8 (0.9) 2.8 (0.9)
Systolic blood pressure 131.4 (16.4) 131.3 (16.3)
Baseline cost of insulin (£) 357.24 (147.65) 360.39 (157.92)
Baseline cost of diabetes-related contacts (£) 561.61 (885.92) 571.63 (928.92)
Categorical variables n/N (%)
Sex
Female 104/260 (40.0) 2050/5000 (41.0)
Male 152/260 (58.5) 2950/5000 (59.0)
Missing 4/260 (1.5) 0/5000 (0.0)
Physical activity
Low 67/260 (25.8) 1245/5000 (24.9)
Medium 128/260 (49.2) 2440/5000 (48.8)
High 65/260 (25.0) 1320/5000 (26.4)
Smoking status
Current 50/260 (19.2) 960/5000 (19.2)
Former 67/260 (25.8) 1315/5000 (26.3)
Never 143/260 (55.0) 2725/5000 (54.5)
Ethnicity
White 258/260 (99.2) 4955/5000 (99.1)
Black 2/260 (0.8) 45/5000 (0.9)
Nephropathy
No complications 239/260 (91.9) 4645/5000 (92.2)
Microalbuminuria 13/260 (5.0) 235/5000 (4.7)
Macroalbuminuria 7/260 (2.7) 135/5000 (2.7)
Dialysis or transplant 1/260 (0.4) 20/5000 (0.4)
Neuropathy
No complications 238/260 (91.5) 4535/5000 (90.7)
Neuropathy or ulcers 22/260 (8.5) 465/5000 (9.3)
METHODS
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model. The probability of severe hypoglycaemia and DKA were estimated using negative binomial models.
Treatment switching has been included, as it is expected that when an individual switched treatment from
pump to MDI or from MDI to pump that the cost of managing their diabetes and their clinical outcomes
would change. The probability of switching treatment was estimated using parametric survival curves,
using treatment switching as the event of interest.
Incorporating treatment switching
During REPOSE, individuals in both trial arms could switch their insulin delivery mechanism; because of
effects on both costs and clinical outcomes, it was important to incorporate treatment switching into the
model. A total of 17 of 132 (12.88%) individuals, initially randomised to the pump, switched once to MDI
to deliver their insulin. A further two individuals, initially randomised to the pump, switched from pump to
MDI and then switched again from MDI back to pump. A total of 8 of 128 (6.25%) individuals, initially
randomised to MDI, switched to pump.
Kaplan–Meier curves were fitted to individual-level data using treatment switching as the event. Parametric
survival curves were fitted to the data with HbA1c prior to switching, number of DKAs and number of
severe hypoglycaemic events in the year prior to switching (or 2 years’ follow-up if no switching occurred)
included as covariates. The SEs of the parametric models were adjusted for clustering within each course.
Separate models were fitted to individuals initially randomised to insulin pump therapy and MDI, so no
assumption of proportion hazards or accelerated failure time was made. Exponential, Weibull, Gompertz,
log-logistic, log-normal and generalised gamma distributions for the parametric curves were considered.
The goodness of fit of the different curves was assessed using visual assessment of the Kaplan–Meier plots
and the Akaike information criterion (AIC) and the Bayesian information criterion (BIC).
Based on expert clinical opinion of a Professor of Clinical Diabetes and Honorary Consultant Physician, and
a Professor in Public Health and Health Technology Assessment, it was assumed, in the base case, that if
an individual was on an insulin pump after 2 years then they would remain on the pump; this assumption
was made, as, in their experience, once an adult with T1DM was successfully using an insulin pump then
they were unlikely to change the method of insulin delivery.
TABLE 7 The baseline characteristics of REPOSE participants and the simulated cohort (continued )
Characteristic REPOSE ITT population (N= 260) Simulated cohort (N= 5000)
Retinopathy
No complications 145/260 (55.8) 2800/5000 (56.0)
Background diabetic retinopathy 91/260 (35.0) 1740/5000 (34.8)
Proliferative diabetic retinopathy 24/260 (9.2) 465/5000 (9.3)
MI
No complications 255/260 (98.1) 4890/5000 (97.8)
MI 5/260 (1.9) 110/5000 (2.2)
Stroke
No complications 259/260 (99.6) 4985/5000 (99.7)
Stroke 1/260 (0.4) 15/5000 (0.3)
HF
No complications 259/260 (99.6) 4970/5000 (99.4)
HF 1/260 (0.4) 30/5000 (0.6)
Angina
No complications 257/260 (98.9) 4940/5000 (98.8)
Angina 3/260 (1.2) 60/5000 (1.2)
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In the model, treatment switching impacted on HbA1c and the cost of pumps, diabetes-related contacts
and insulin. Details on how the HbA1c of patients who switched are given later (see Estimation of each
individual’s glycated haemoglobin); details on how the costs of treatment were updated for people who
switched are also given later (see Cost of insulin, diabetes-related contacts and insulin pumps). No explicit
inclusion of treatment switching on the risk of DKA and severe hypoglycaemia was included in the model
because of the relatively small numbers of these events in each trial arm (see Table 7). However, the risk of
DKA and severe hypoglycaemia does depend on the HbA1c of the individual in the model; therefore, there
are differences in the risk of DKA and severe hypoglycaemia between those who switched treatment and
those who did not.
Estimation of each individual’s glycated haemoglobin
To develop the method to incorporate HbA1c treatment effect evidence into the model, several factors
were considered. Data were collected on each individual’s HbA1c at each follow-up visit. As HbA1c is the
key predictor of clinical events in the model, it is important that the distribution of HbA1c is reflective of
what was observed in the REPOSE Trial. Because 5000 replicated individuals are included in the model
from the n = 260 sample, we are able to incorporate heterogeneity of individual outcomes into the
cost-effectiveness analysis using statistical modelling of the REPOSE data set. A clinical expert (Senior
Clinical Lecturer/Honorary Consultant) commented that few adults with T1DM were able to sustain a
HbA1c level of < 31 mmol/mol (5%) for a full year, and that, in the expert’s experience, no adult with
T1DM had a HbA1c of > 200 mmol/mol (20.5%). A final consideration was that the lowest HbA1c observed
in the DAFNE research database was 30 mmol/mol (4.9%).27
The effect of pump + DAFNE treatment compared with MDI + DAFNE treatment on HbA1c was estimated
using a beta regression.123 Beta regressions estimate outcome parameters, which are bound by, but do
include, a range of 0–1. HbA1c from the trial data was transformed so that a HbA1c level of 29 mmol/mol
(4.8%) was equal to zero. The upper limit of HbA1c was taken to be 201 mmol/mol (20.5%). A beta
regression estimates two parameters of interest for simulating each individual’s HbA1c response to
pump + DAFNE in the model, the mean effect (µ) and a dispersion parameter (φ). The expectation and the
variance of each individual’s outcome, yi, are estimated using the following formulae:
E(yi) =bµl
Var(yi) =
bµl × (1−bµl)
1 +bφl
.
(4)
To estimate the mean effect on 1-year HbA1c, treatment allocation, baseline HbA1c and centre were
included as covariates. To estimate the dispersion parameter in the 1-year HbA1c regression, only baseline
HbA1c was included as a covariate. All of the parameters that were included in the mean effect regression
were tested as covariates, but were not statistically significant at the 5% level.
To estimate the mean effect on 2-year HbA1c, all of the covariates used to estimate the mean effect on
1-year HbA1c were used, and 1-year HbA1c was included as an additional covariate. To estimate the
dispersion parameter, HbA1c at 1 year was used. All of the parameters that were included in the mean
effect regression were tested as covariates, but were not statistically significant at the 5% level.
The uncertainty in each individual’s outcome was parameterised using a beta distribution, which was
individualised, based on their covariates. Independent beta distributions were fitted to 1- and 2-year HbA1c
outcomes, as they had different expectations of the mean effect and the variance in the mean effect in the
first and second year. For each individual, two independent random draws were taken: one from their
individualised beta distribution for 1-year HbA1c and the other from their individualised beta distribution for
2-year HbA1c, to determine their HbA1c at 1 and 2 years, respectively.
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In the base case, it was assumed that if an individual switched treatments then they had a change in HbA1c
equal to the difference between the predicted mean effect on HbA1c in their randomised treatment arm
and the predicted mean effect on HbA1c in their non-randomised treatment arm. The mean effects were
obtained from their individualised outcomes from the beta regressions. In the base case, the estimates of
changes in HbA1c were obtained from the per-protocol population, as individuals who switched insulin
delivery mechanism were not included in this population. Therefore, treatment effect parameters in this
population reflect the relative effectiveness of pump + DAFNE versus MDI + DAFNE for those individuals
who did not switch insulin delivery mechanism.
The Model is designed to use a mean HbA1c value, using the DCCT% scale, for each individual in each
yearly time cycle. In the base-case analysis, an individual’s HbA1c for the first model cycle (0–1 years) is
given by their baseline HbA1c, an individual’s HbA1c for the second model cycle (1–2 years) is given by their
1-year HbA1c sampled from their individualised beta distribution for 1-year HbA1c and an individual’s HbA1c
for the third model cycle (2–3 years) is given by their 2-year HbA1c sampled from their individualised beta
distribution for 2-year HbA1c. These sampled values of HbA1c on the beta scale were then transformed on
to the DCCT% scale for use in the long-term modelling.
The trial population – used to estimate HbA1c effect, changes to HbA1c on treatment switching and the
timing of changes in HbA1c – was tested in three deterministic scenario analyses. In the first scenario
analysis, the treatment effect was estimated in the ITT population, and when an individual switched insulin
delivery mechanism his/her HbA1c still changed so that it was reflective of the other trial arm of REPOSE.
In the second, the treatment effect was estimated in the ITT population, but there was no variation in
HbA1c changes for those individuals who switched. This scenario was conducted as in the ITT analysis
population: individuals who switched insulin delivery mechanism remained in the arm to which they were
originally randomised. In the third scenario analysis, HbA1c effects were modelled as occurring one model
cycle earlier than they did in the base case. For example, an individual’s 2-year HbA1c was used as their
modelled HbA1c value in the second model cycle in the scenario analysis rather than the third model cycle
in the base case.
Estimating severe hypoglycaemic events and diabetic ketoacidosis events
To develop the method to incorporate severe hypoglycaemic events and DKA treatment effect evidence into
the model, several factors were considered. Data on severe hypoglycaemic events and DKA were collected
on an ongoing basis throughout the trial. A summary of the numbers of DKAs and severe hypoglycaemic
events is given in Table 8. It can be seen that the number of DKAs and severe hypoglycaemic events
declines in the second year on every measure except self-reported DKAs in the MDI + DAFNE arm, where
the number of events was the same in both years. As such, the statistical models used in the economic data
estimated the incidence of severe hypoglycaemia and DKA in the first and second years separately.
Negative binomial regressions were used to predict the number of DKAs and severe hypoglycaemic
events in years 1 and 2 for each outcome separately. When the outcome variable was the number of
hypoglycaemic events in year 1, year-1 HbA1c and treatment group were included as covariates. When the
outcome variable was the number of hypoglycaemic events in year 2, year-2 HbA1c and treatment group
were included as covariates. When the outcome variable was the number of DKAs in year 1, year-1 HbA1c
and treatment group were included as covariates. When the outcome variable was the number of DKAs in
year 2, year-2 HbA1c and treatment group were included as covariates. The possibility of using the number
of events in the previous year, baseline events for the 1-year outcomes and year-1 events for the 2-year
outcomes, as a covariate was explored. However, because of the low number of events, the negative
binomial models often did not converge when this was included as a covariate.
The statistical models did not converge for DKAs reported as SAEs in the first year. This was not the case
for self-reported DKAs and there were more self-reported cases of DKA than were picked up through
the reporting of SAEs. Therefore, the rates of DKA were estimated using self-reported DKAs as the
outcome measure.
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The statistical models were fitted using the Zellig package in R version 3.2.0 (The R Foundation for
Statistical Computing, Vienna, Austria) and using specifications described above; it was used to simulate
the predicted number of severe hypoglycaemia and DKA events in each trial arm 10,000 times. The
simulations were separately in each trial arm and for HbA1c values every 0.1% between 4% and 20.5%.
The number of events observed in the simulations was truncated at 20 events per year to reduce the effect
of extreme values in the simulation on the cost-effectiveness results. These simulations were then used to
determine the probability that an individual would suffer a given number of severe hypoglycaemic events
and DKA events in 1 year, dependent on their HbA1c that year and the trial arm to which they were
allocated. The probability that an individual would suffer a given number of events was a fixed parameter
in the PSA; therefore, any differences in the rates of DKA or severe hypoglycaemia for an individual
between any two model runs will solely be due to differences in their HbA1c.
In the base case, the statistical models fitted to the incidence of severe hypoglycaemia and DKA in years
1 and 2 were used in the first and second model cycles, respectively, to predict the incidence of severe
hypoglycaemia and DKA. The statistical models for year 2 were also used in all subsequent model years
because we assumed that year 1 models might not be representative of ongoing event rates because of
‘teething problems’ with treatments given, which are in a sense ‘ironed out’ by year 2. This assumption
was based on the clinical opinion of the clinical members of the REPOSE TMG, including honorary
consultants in diabetes and diabetes nurse specialists.
In a scenario analysis, individuals in both model arms returned to their baseline rate of severe hypoglycaemia
and DKA after the second year. Self-reported information was collected at baseline on the number of severe
hypoglycaemic events and DKAs experienced by the individuals in the 12 months prior to baseline data
collection. The baseline incidence of these events was estimated using the same methods used to estimate
the probability of experiencing these events in year 1 or year 2; however, treatment allocation was not
included as covariate. This is because all of the events in the baseline rate models occurred prior to an
individual’s randomisation in the REPOSE Trial.
Cost of insulin, diabetes-related contacts and insulin pumps
The cost of insulin, diabetes-related contacts and insulin pumps (including consumables) in the long-term
model was estimated based on resource use data from the REPOSE Trial data and the unit costs used in
the EEACT (see Resource use by individuals in the REPOSE Trial over the 2-year follow-up period). Statistical
models were fitted to these subcomponents of total cost in the EEACT, as it is expected that the covariates
that predict the cost of insulin in year 1 may be correlated with the covariates that predict the cost of
insulin in year 2. It is also expected that this may be true for the cost of diabetes-related contacts and the
cost of insulin pumps (including consumables). Therefore, instead of fitting six independent regression
models, three seemingly unrelated regressions were fitted [one seemingly unrelated regression for the cost
of insulin, another for the cost of diabetes-related contacts and, finally, one for the cost of insulin pumps
(including consumables)].
In the ‘cost insulin seemingly unrelated regression model’, the cost of insulin in year 1 and the cost of
insulin in year 2 were used as the outcome variables for the seemingly unrelated regression model.
Baseline cost of insulin, baseline HbA1c, treatment allocation, whether or not the individual switched from
MDI to insulin pump infusion in year 1 and whether or not the individual switched from insulin pump
infusion to MDI in year 1 were included as covariates to predict the cost of insulin in year 1. Baseline cost
of insulin, baseline HbA1c, the actual method of insulin delivery that an individual was using at the end of
the first year, whether or not the individual switched from MDI to insulin pump infusion in year 2 and
whether or not the individual switched from insulin pump infusion to MDI in year 2 were included as
covariates to predict the cost of insulin in year 2. The SEs were adjusted for clustering in each DAFNE
course. For each individual in the model, their baseline cost of using insulin, their HbA1c, their treatment at
the start of the year and whether or not they switched treatment were used with the parameter values
from the regression to predict their cost of insulin.
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In the ‘cost of diabetes-related contacts seemingly unrelated regression model’, the cost of diabetes-related
contacts in year 1 and year 2 were used as the outcome variables for the seemingly unrelated regression
model. Baseline cost of diabetes-related contacts, baseline HbA1c, and treatment allocation – whether or
not the individual switched from MDI to insulin pump infusion in year 1 and whether or not the individual
switched from insulin pump infusion to MDI in year 1 – were included as covariates to predict the cost of
insulin in year 1. Baseline cost of diabetes-related contacts, baseline HbA1c, the actual method of insulin
delivery that an individual was using at the end of the first year, whether or not the individual switched
from MDI to insulin pump infusion in year 2 and whether or not the individual switched from insulin pump
infusion to MDI in year 2 were included as covariates to predict the cost of insulin in year 2. The SEs were
adjusted for clustering in each DAFNE course. For each individual in the model, their baseline cost of
diabetes-related contact resource use, their HbA1c, their treatment at the start of the year and whether or
not they switched treatment were used with the parameter values from the regression to predict their cost
of insulin pump therapy.
In the ‘cost of insulin pump seemingly unrelated regression model’, the cost of insulin pumps and
consumables in year 1 and the cost of insulin pumps and consumables in year 2 were the two outcome
variables used in the model. No control was made for baseline resource use or baseline HbA1c for either
outcome variable, as no individual in the REPOSE Trial had a previous history of using an insulin pump.
The individual’s randomised treatment arm, whether or not they switched from pump to MDI in the first
year and whether or not they switched from MDI to pump in the first year were included as covariates to
predict the cost of insulin pumps and consumables in year 1. An individual’s actual treatment at the end
of the first year, whether or not they switched from pump to MDI in year 2 and whether or not they
switched from MDI to pump in year 2 were included as covariates to predict the cost of insulin pumps
and consumables in year 2. For each individual in the model, their HbA1c, their treatment at the start of
the year and whether or not they switched treatment were used with the parameter values from the
regression to predict their cost of insulin pump therapy.
Duration of treatment effectiveness beyond the trial period
A key parameter for the long-term cost-effectiveness modelling is the duration of effectiveness of the two
interventions and, in particular, the length of time that HbA1c improvements last. The REPOSE Trial provides
data only up to 2 years after randomisation. Therefore, the available literature on the long-term duration
of treatment effectiveness for MDI individuals taking a DAFNE course and pump + DAFNE individuals
needs to be assessed to determine the assumptions to be used for HbA1c progression beyond the 2-year
trial period.
A literature search was conducted for studies on the duration of HbA1c improvements for MDI + DAFNE
individuals and insulin pump therapy individuals. Seven potentially relevant studies were identified. Two
studies124,125 were identified as being potentially relevant for MDI + DAFNE individuals. Five studies56–59,63
were identified as being potentially relevant for insulin pump therapy individuals. Two studies56,59 were
excluded: Beato-Vibora et al.56 was not included because fewer than one-quarter of the individuals in the
initial sample had follow-up data for any given year; Clements et al.59 was excluded because it was a
subgroup analysis of the data presented by Carlsson et al.58 As such, if Carlsson et al.58 was included to
estimate the long-term duration of treatment effect of pump therapy, the effect estimated from Clements
et al.59 would be given double the weight of the other studies because of a published subgroup analysis
being available.
For the five included studies56–59,63 (two studies for adults receiving MDI + DAFNE and three studies for
adults receiving pump + DAFNE), the average yearly increase in HbA1c was estimated, pragmatically, using
data from the point of largest reduction in HbA1c and the last observation in which the sample size was
greater than one-quarter of the initial sample size. A weighted average of these studies’ evidence
(using the initial sample size) calculated the mean yearly HbA1c increase for both trial arms (Table 9).
The weighted average yearly HbA1c increase for insulin pump therapy individuals was 0.052% per annum.
The weighted average yearly HbA1c increase for MDI + DAFNE individuals was 0.054% per annum.
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The uncertainty in these long-term changes was parameterised using a normal distribution in the PSA.
There was no SD for the mean HbA1c increases across the studies in each model arm; data were obtained
from the REPOSE Trial on the SD of the mean change in HbA1c between years 1 and 2. The mean observed
change in HbA1c between years 1 and 2 for individuals receiving MDI + DAFNE was –0.08%, with a SD of
0.84%. The mean observed change in HbA1c between years 1 and 2 for individuals receiving pump + DAFNE
was –0.09%, with a SD of 0.98%. To estimate the SE for each trial arm, the SD associated with each trial
arm was divided by the combined sample size of the studies used to estimate the long-term changes in
HbA1c. The estimated mean effect and the estimated SE for each model arm were used to parameterise a
normal distribution for the PSA.
In the base-case analysis, data from the studies on the HbA1c increases for MDI + DAFNE individuals and
pump individuals were used for each individual’s lifetime. To ensure that each individual could not have
implausibly high or low HbA1c values, their HbA1c was constrained so that it could not fall below 4.8% or
go above 20.5%.
In addition to these five studies, the cost-effectiveness model used by Riemsma et al.8 used an annual
progression of 0.045% per annum derived from the DCCT trial. This was assumed to apply equally to all
comparators analysed in the study. In a further sensitivity analysis it was assumed that individuals would return
to their baseline HbA1c at the end of the third year in the model with no further progression of their HbA1c.
Threshold analysis
A two-way price and effectiveness threshold analysis was conducted to assess the HbA1c reduction and/or
annual cost reduction necessary to potentially make CSII cost-effective in the UK for the whole UK
population of adults with T1DM who are eligible to receive a structured education course, are naive to
pump therapy and do not have a preference to receive the pump. A conservative assumption was made, in
that all HbA1c changes did not apply to 1-year HbA1c, but did apply to all future years. The treatment effect
associated with pump + DAFNE compared with MDI + DAFNE was varied between HbA1c changes of
–0.3% and –1.2%, in –0.1% increments.
TABLE 9 A summary of the observed changes in HbA1c over time for pump and MDI
Study
Treatment group
Pump MDI
aOrr et al.,
201563
Carlsson
et al., 201358
Bruttomesso
et al., 200257
Gunn and
Mansell, 2012125
Speight et al.,
2010124
Initial sample size 200 272 138 111 104
Baseline HbA1c, % 8.68 8.39 9.30 8.6 9.3
Peak HbA1c improvement, % –1.18 –0.43 –1.34 –0.5 –0.6
Time of peak HbA1c improvement,
years
0.5 2 1 1 1
Last observed HbA1c improvement
with n ≥ 25% the initial sample
size, %
–0.49 –0.20 –1.31 –0.37 –0.4
Time of last HbA1c improvement 9 years 5 years 10 years 7 years 44 months
Average yearly HbA1c increase
(from peak to last observed value)
0.08 0.06 0.00 0.03 0.08
Implied time to baseline (years
from baseline)
9.9 8.5 408.6
(lifetime effect)
19.0 8.2
Funding None stated Region of
Gotland in
Sweden
None stated NIHR Diabetes UK
and DAFNE
collaborative
a Data are assumed to be observed in the middle of a follow-up period for the analysis.
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There were two methods used for estimating the change in HbA1c due to receiving pump therapy. In the
first method, the following steps were taken: (1) all individuals’ HbA1c values were estimated as if they
were a MDI + DAFNE recipient and then (2) a treatment effect (HbA1c change) of pump + DAFNE versus
MDI + DAFNE was inputted into the model. In the second method (1) the reduction in HbA1c was applied
to the individual’s mean effect in the beta regression; (2) this reduction in HbA1c resulted in a different
variance to an equivalent MDI patient as their mean effect was lower; and (3) HbA1c was sampled from the
individualised beta distribution, which reflected the mean effect and variance parameters. The second
method of conducting the threshold analysis will help future investigators to understand the effect of
including heterogeneity in an individual’s response to CSII on the HbA1c reductions that are required to
make CSII cost-effective. However, it should be noted that this method assumes that the heterogeneity is
defined by the equations estimated from the REPOSE Trial and, as such, may not be valid if CSII were to be
clinically more effective.
In both scenario analyses, the cost of insulin pumps and insulin pump consumables was changed from
100% of the mean cost obtained from the pump costing survey to 50% of the mean price observed at
REPOSE sites in 5% price reduction increments. Deterministic model runs were used to produce all of the
results in the threshold analysis.
It should be noted that other than the method used to estimate HbA1c, all of the other parameters were
the same, and assumptions were the same as were used in the base case. As all assumptions were the
same as those presented for the base-case analysis, all individuals who switched from MDI + DAFNE to
pump + DAFNE received the HbA1c associated with pump + DAFNE, and the individuals who switched from
pump + DAFNE to MDI + DAFNE received their HbA1c associated with MDI + DAFNE. This means that the
modelled HbA1c reductions are equivalent to per-protocol analysis (treatment switchers removed) rather
than an ITT analysis (treatment switchers included in their originally randomised groups) of any future
study of pump + DAFNE versus MDI + DAFNE.
As no study other than REPOSE has been conducted to assess the cost-effectiveness of pump + DAFNE
versus MDI + DAFNE for adults in the UK with T1DM, the results should are indicative of the HbA1c
reductions that pump + DAFNE would need to achieve if it were to be deemed cost-effective compared
with MDI + DAFNE.
Methods for the psychosocial evaluation
Aims and objectives
As noted in Chapter 2, evidence on QoL effects of the pump has been inconsistent, with some studies
reporting no difference between the pump and MDI groups, and others reporting improved QoL on the
pump. A previous HTA report identified some gains in QoL that could be described as ‘social related’
rather than ‘health related’.14 These included flexibility of lifestyle and fewer problems dealing with
variations in daily life, such as timing of meals. For this reason, we included a range of psychosocial
measures alongside embedded qualitative research in the REPOSE Trial.
The psychosocial study employed a mixed-methods quantitative (questionnaires) and qualitative (interviews)
approach to:
1. establish whether or not, and why, there were any differences in QoL and other psychological or
psychosocial outcomes between participants using pump and MDI regimens
2. examine whether or not, and why, QoL and other outcomes changed over time
3. understand and explore the added benefit (if any) of pump technology over MDI from participants’ and
educators’ perspectives
4. explore why some patients may do better than others using the pump
5. examine acceptability of, and reasons for, discontinuing (pump) treatment
6. enhance understanding and assist in the interpretation of trial outcomes.
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Quantitative methods
Validated and reliable questionnaires were used to assess generic and health-specific QoL, treatment
satisfaction, fear of hypoglycaemia, hypoglycaemia unawareness, self-efficacy, social support, adherence
to treatment, emotional well-being and acceptability of technology. A repeated-measures longitudinal
questionnaire study explored both differences in outcomes between the two trial arms and the short- and
long-term predictors and mediators of outcomes. Outcomes were measured at baseline and at 6, 12 and
24 months after the DAFNE course. These time points were selected to capture both short- and long-term
post-treatment changes in psychosocial outcomes. Questionnaires were posted to participants and
self-completed within 6 weeks of the specified time point.
Outcomes
Quantitative psychosocial end points were measured via participant self-completed questionnaires, which
included items assessing QoL (generic and diabetes specific), fear of hypoglycaemia, treatment satisfaction
and emotional well-being. There has been limited examination of the impact of pump therapy on these
areas, on how and why these may change over time, and why individuals are able or unable to use pump
therapy to improve glycaemic control. Rubin and Peyrot126 reviewed the evidence on ‘patient-reported
outcomes’ and concluded that, at present, there is little evidence that pump therapy improves them.
Diabetes-specific QoL was assessed using the DSQOL, a reliable and valid measure.127 Specifically designed
for the German study on which UK DAFNE is based, it was included to facilitate important comparisons
between the UK and German studies. In addition, generic measures of QoL, the World Health Organization
Quality of Life Abbreviated Questionnaire (WHOQOL-BREF)128 and functional health status using the SF-12129
and EQ-5D130 were used. The SF-12 was used to facilitate comparison with ‘healthy controls’ and other
long-term conditions.
The HFS131 is a well-validated psychometric tool assessing participants’ fear of hypoglycaemia, both overall
and separately, for behaviour and worry. A specific benefit to the survey is that it may be able to identify
participants who are likely to maintain high blood glucose levels, thus aiding understanding of potential
reasons for poor glycaemic control. A study by Nixon and Pickup,132 in people who had been using a pump
for an average of 5 years, found that fear of hypoglycaemic episodes remained a problem.
The DTSQ133 has proven to be highly sensitive in clinical trials.134 Treatment satisfaction refers to an
individual’s subjective appraisal of their experience of treatment, including ease of use, side effects and
efficacy. Improvements in satisfaction are not necessarily accompanied by improvements in QoL; treatment
satisfaction can be high despite diabetes having a negative impact on QoL, which is why it is important to
measure both separately.
The Hospital Anxiety and Depression Scale (HADS)135 measures anxiety on one subscale and depression on
another through the use of seven questions for each characteristic. It was important to measure emotional
well-being in the trial, as participants may find it easier to manage their condition after DAFNE education
or with one of the treatments. This could have a substantial effect on their emotional well-being, which
the QoL measures are not sensitive enough to pick up.
The DAFNE Principles Questionnaire was completed at 24 months only. This questionnaire (12 items)
assesses the impact of the DAFNE course on self-management behaviours, such as bolus and basal rate
changes, correction dose practices, timing of injections/bolus doses and review of blood glucose data. It
was included partly in order to establish if there were differences in self-management practices between
participants in the pump and MDI arms, to aid interpretation of the final trial findings. The DAFNE
Principles Questionnaire was administered to all of the participants irrespective of treatment group. This
measure was previously used in DAFNE.78
Statistical power was calculated for the primary outcome of HbA1c, thus the psychosocial outcomes are
either over- or underpowered, depending on the underlying effect size. Statistically significant results are
considered in combination with qualitative data in order to answer the key psychosocial research aims.
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Statistical analysis of questionnaire data
Short Form questionnaire-12 items
The Physical Component Summary was calculated using physical functioning, body pain, role physical and
general health domain scores. The Mental Component Summary was calculated using vitality, social
functioning, role emotional and mental health domain scores. When the questionnaires were only partially
completed, missing items were imputed using a single imputation procedure based on the mean calculated
from complete items on that domain.136 The scores were standardised and scaled to range from 0 to 100,
with higher scores representing better outcomes.129,137
Diabetes-specific quality of life
The DSQOL domain scores (social relations, leisure time restrictions and flexibility, physical complaints,
worries about the future, daily hassle or functions, diet restrictions) and DSQOL total score were calculated
if at least 80% of the items from the domain were complete, using the following formula:
Domain score = sum of at least 80% items ×
number of items on domain
number of non missing items
. (5)
Preference-weighted treatment satisfaction was calculated by multiplying the various treatment goals with
the corresponding degree of satisfaction (scores of –2.5 = totally dissatisfied to 2.5 = extremely satisfied)
and summing the results.
Finally, all DSQOL scores were converted to a 0–100 scale, in which a higher value means worse outcome
(more burden) on all scores.
World Health Organization Quality of Life Abbreviated Questionnaire
Four subdomains of WHOQOL-BREF were calculated (physical health, psychological, social relationships and
environment) if at least 80% of the questions in that domain were present. The domains were scored by
calculating the mean of the items within each domain, and scaling to range from 0 to 100,138 with higher
scores representing better outcomes.
Hypoglycaemia Fear Survey
The HFS behaviour and worry scores were calculated if at least 80% of items within that domain were
complete, using Equation 5 (see Diabetes-specific quality of life).131
The HFS behaviour score ranges from 10 to 50 and the HFS worry score ranges from 17 to 85; in both
cases, higher scores represent more fear.
Diabetes Treatment Satisfaction Questionnaire
The DTSQ, which measured satisfaction with diabetes treatment, was administered at baseline and 6- and
24-month follow-up. The DTSQc [Diabetes Treatment Satisfaction Questionnaire (change)], which
measures change in satisfaction from pre-trial treatment, was administered at 12 months’ follow-up.
Treatment satisfaction (DTSQ) and treatment satisfaction change (DTSQc) were calculated if at least five of
the six items were complete using the following formula:
Treatment satisfaction (change) = sum of at least five items ×
6
number of non-missing items
. (6)
For the treatment satisfaction domain, higher scores represent higher satisfaction (range 0 to 36 on DTSQ
and –18 to 18 on DTSQc). Two further domains, perceived frequency (change) in hyperglycaemia and
perceived frequency (change) in hypoglycaemia, were calculated based on single items. Only complete
METHODS
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data were used for these scores and low scores represent good perceived blood glucose control (scoring
ranges of 0 to 6 in DTSQ, and –3 to 3 in DTSQc).
Hospital Anxiety and Depression Scale
Anxiety and depression domain scores were calculated by summing the items in the respective domains.
Mean value imputation based on the other six items of a domain was used to impute missing data if a
single item was missing. If more than one item was missing then the domain score was not calculated. The
HADS scores range from 0 to 21, with higher scores indicating more anxiety/depression (scoring: normal is
0–7; borderline abnormal 8–10; 11–21 abnormal).135
EuroQol-5 Dimensions
The EQ-5D-3L tariff was derived from five three-level questions using UK norms. The tariff was calculated
only if all five questions were answered. It is measured on a scale from –0.56 to 1.00 (good health).
The availability of questionnaire outcome data was summarised for each time point.
The DTSQ domains at 6, 12 and 24 months post course were compared between the treatment groups
using a non-parametric Wilcoxon–Mann–Whitney U-test. The median and interquartile range (IQR) of
change from baseline for the DTSQ domains at 6 and 24 months, and the median and IQR score for the
DTSQc domains at 12 months, are displayed by treatment group. The differences between groups post
course are displayed as the median difference (in change from baseline for DTSQ scores) with its associated
95% CI, which was calculated as described in the study by Newson.139
Other QoL outcomes (DSQOL, SF-12, WHOQOL-BREF, HFS, EQ-5D, HADS) at 6 months post course are
compared between the treatment groups using a mixed-effects linear regression model of change from
baseline adjusted for DAFNE course (random effect), baseline HbA1c, baseline score and centre. The means
and SDs for the treatment and control groups with adjusted MDs and associated CIs and p-values
(unadjusted for multiple testing) are reported. This analysis is repeated for the 12- and 24-month
outcomes. A complementary sensitivity analysis, in which the analysis described above was repeated only
including patients with complete data, was performed.
Qualitative methods
Study design
An inductive, thematic approach was used, informed by the principles of Grounded Theory research.140
This entailed concurrent data collection and analysis, allowing findings and themes arising from early
phases of data collection to inform the areas explored in later phases, as well as sampling. In-depth
interviews, informed by topic guides, were used as the main method of data collection, as these helped to
ensure that the discussion remained relevant to areas under investigation, while affording the flexibility
needed for participants to raise and discuss issues that they perceived as salient, including those
unforeseen at the study’s outset.141,142
Patient participants, recruited from both trial arms, were interviewed at two time points: within 2 weeks of
completing their DAFNE courses (round 1) and 6 months later (round 2). This longitudinal design permitted
patients’ initial understandings and experiences of using the pump and MDI regimens to be explored, and
any continuities and changes in their diabetes self-management practices to be tracked and compared over
time. Six months was selected as the time point for follow-up to coincide with collection of 6-month clinical
and psychological data, and because previous experience of undertaking longitudinal qualitative research
with DAFNE graduates had demonstrated that this allowed sufficient time to establish whether, and for what
reasons, patients are able/unable to put their skills training into practice.143–146 In addition, cost considerations
(including a request by the funder to reduce the costings for the qualitative component prior to the protocol
being finalised) meant that it was not possible to do follow-up interviews with patients at later time points.
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Educators were interviewed once, following completion of their centre’s sixth REPOSE DAFNE course.
This time point was chosen to avoid any risk of inadvertent contamination of the trial intervention by the
qualitative questioning, and also because, at this point, it was anticipated that staff would have had
considerable experience of trial recruitment and delivery on which they could reflect.
Recruitment and sampling
As per the original protocol, participants (patients and educators) were recruited from seven of the eight
trial centres (with roughly equal numbers recruited from each centre); recruitment to the qualitative
research was not undertaken in the eighth centre (Nottingham), as this centre came on board only in the
later phases of the trial and recruited patients to only one set of courses.
When they were consented to take part in the trial, patient participants were asked whether or not
they would be willing to be approached to take part in the qualitative research (see Appendix 8). Of the
317 patients who were randomised, 315 (99.37%) agreed to be approached. Participants who gave this
agreement were purposively sampled so that both those randomised to pump and MDI arms of the trial
were recruited and there was broad, and roughly equal, representation of ages, sex, diabetes duration and
occupational/socioeconomic groups in the final sample.
It was initially planned that one nurse and one dietitian would be recruited and interviewed from each of
the seven main trial centres. However, after initial interviews had been conducted and analysed, a decision
was made to increase the number of nurse educators interviewed. This is because the initial interviews had
made apparent that these staff members tended to have the greatest involvement in recruitment and
notifying patients of the outcome of randomisation, and, as reported elsewhere,147 these aspects of trial
work proved to be particularly challenging for staff. Educators were sent recruitment packs and invited to
‘opt in’ to the study; all of those approached agreed to take part.
Recruitment of patients and educators continued until data saturation occurred, that is until no new
findings or themes were identified in new data collected. All participants provided written consent prior to
their interviews.
Data collection
Baseline interviews with patients were undertaken face to face to establish rapport and were conducted at
a time and location convenient to them (mostly their own homes). Follow-up interviews were done by
telephone (again at a time most convenient to the interviewee). There was no apparent difference in the
quality and disclosure of information between interviews undertaken face to face and those done on the
telephone. All staff opted to be interviewed by telephone.
Topic guides for the patient interviews were developed in light of literature reviews, course observations,
inputs from the trial team and patient representatives, and revised in light of emerging findings. Full details
of the topics explored in patients’ round 1 and round 2 interviews are provided in Appendix 9. In brief,
round 1 interviews explored patients’ understandings of the trial and the pump, and their reasons for
agreeing to take part; their views about the outcome of randomisation; and their early experiences of
using a MDI or pump regimen to undertake diabetes self-management practices following course
attendance and training in DAFNE principles. Round 2 interviews were used to explore whether or not,
how and why patients’ experiences of managing their diabetes had changed since their last interview
(including reasons for adhering or not adhering to treatment recommendations, discontinuing treatment,
etc.); how the use of their regimen (pump or MDI) had impacted on their perceptions of their diabetes,
their confidence and perceived ability to undertake diabetes self-management practices; and their everyday
(work and family) lives. Although broadly the same areas were explored in the follow-up interviews, each
participant’s round 1 interview account was reviewed before their round 2 interview was undertaken to
enable follow-up of specific issues raised by particular individuals.
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Staff interviews explored their experiences of recruiting into the REPOSE Trial, delivering the 5-day courses
and undertaking patient follow-up as part of the trial; perceptions of patients’ engagement with pump
therapy compared with MDI during the trial; previous experiences (if any) of using insulin pumps in routine
clinical practice; and views about the potential benefits of the pump compared with MDI regimens. In light
of emerging findings, staff were also invited to reflect on whether or not their views about the potential
benefits, and beneficiaries, of insulin pumps had changed in light of their experiences of delivering, and
observing, patients during the REPOSE Trial. Full details of the areas explored in the staff interviews are
also contained within Appendix 9.
Interviews with patients were conducted between June 2012 and June 2013, and those with staff
between December 2012 and April 2013. All interviews averaged 1 hour, were digitally recorded and
transcribed in full for in-depth analysis.
Data analysis
Data were analysed thematically using the method of constant comparison.148 This entailed members of the
qualitative research team reading patient and educator transcripts (which were treated as ‘stand-alone’ data
sets) repeatedly before cross-comparing them to identify issues and experiences that cut across different
patient and educator accounts. To address the study aims and objectives, a longitudinal analysis of the
patient data was also undertaken. Each individual’s round 1 and round 2 accounts were cross-compared
and attention paid to continuities and changes in their experiences, views and diabetes self-management
practices (using pump or MDI) over time, and the reasons for these. A key aspect of this analysis also
focused on comparison of the (longitudinal) accounts of patients using pump and MDI regimens. This was
done to better understand the impact of using pump (compared with MDI) regimens on patients’ diabetes
self-management practices, disease perceptions and everyday life.
Members of the qualitative team undertook their own independent analyses and wrote separate reports
before meeting (both during and after data collection) to compare their interpretations, discuss discrepant
cases, and reach agreement on recurrent themes and findings. For both patient and educator interviews, a
final coding frame, which reflected the original study aims/questions and emergent themes, was developed
once all of the data had been reviewed and consensus reached on key themes and findings. NVivo9
(Doncaster, VIC, Australia), a qualitative software package, was used to facilitate data coding and retrieval.
Coded data sets were subjected to further analyses to allow for the identification of subthemes and
illustrative quotations.
Confidentiality
To protect participants’ identities, each individual was allocated a unique identifier and these identifiers
are used in the reporting of interview data. In the case of staff, ‘N’ is used to refer to a nurse and ‘D’ to a
dietitian. In the case of patients, data are tagged with the participant’s treatment arm (‘M’ for MDI, ‘P’ for
pump), identifying number and interview round (e.g. ‘M7.2’ refers to the second interview with MDI
participant 7).
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Chapter 4 Changes to the protocol
A ll study amendments are listed in Appendix 10. The most significant changes are explained below.
Inclusion/exclusion criteria
As NICE guidance advises that all patients who have poor diabetic control are considered for pump
therapy, early concern was raised at the TMG regarding the potential for inclusion of individuals who had
a definite need for pump therapy. Such participants were not the intended trial population for REPOSE.
Prior to the start of recruitment, the inclusion and exclusion criteria were therefore changed in order to
clarify that suitable participants were those who, in the opinion of the investigator, have a need for
structured education to optimise their diabetes control, but do not have a clear indication for pump
therapy. In the early stages of recruitment (January 2012), the criteria were clarified to exclude those who
have a strong need for pump therapy. Further clarifications of the exclusion criteria for patients who have
used pump therapy within the last 3 years were made in April 2012, defined as > 2 weeks’ use within the
last 3 years. Following early site monitoring visits in July 2012 some further minor clarifications were made
to the exclusion criteria to confirm that a severe needle phobia must preclude full participation in either
treatment arm or influence the participants’ preference for pump therapy, and an unstable psychological
condition must be active enough to preclude the participant safely taking part in the trial.
Recruitment target
The ITT population was defined as participants who consent to take part in the trial and who attend their
DAFNE course at least in part. Although the trial was on course to meet the set recruitment target, it
was noted that larger than anticipated numbers were withdrawing consent prior to the DAFNE course,
resulting in lower than anticipated numbers eligible for the ITT analysis. The trial statistician undertook a
review in August 2012 to determine the need for additional DAFNE courses and participants to maintain
study power. Scenarios were modelled based on the current and predicted HbA1c population prevalence
of ≥ 7.5%, dropout rate (10% or 15%) and size of DAFNE course (four, five, six or seven participants).
Assuming that these variables remained similar to those observed (as at August 2012), it was estimated
that the trial would need to run an additional two to seven courses in order to maintain power for the
primary outcome. Therefore, a reserve centre (Nottingham University Hospitals NHS Trust) was initiated.
The target recruitment was increased to ‘no more than 340 participants’, with 280 expected to attend the
DAFNE course (as originally planned).
Data collection procedures
The study power was calculated on a 90% retention rate at 24 months. Although in May 2013 the
6-month participant retention was high (95%), the trial team anticipated challenges in maintaining this
rate at 24 months. To ensure that follow-up rates remained adequate, we added the option for site staff
to collect appropriate data from participants over the telephone when participants had been unable to
attend for follow-up. Furthermore, we included the possibility of obtaining outcome data from participants’
medical records, for which participants had given consent. We also added an option for data to be collected
at participants’ homes or appropriate NHS location, if they had been unable to attend at their centre.
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Diabetic ketoacidosis/illness letter to participants
Episodes of DKA were expected to occur in some REPOSE participants – as this is a known complication for
individuals with T1DM – and were reported as SAEs. The TMG, TSC and DMEC regularly reviewed all SAEs
and it was noted early in the trial that some centres were reporting an unexpectedly high number of DKA
events. The DMEC reviewed the events and, although the numbers were not considered a major concern,
recommended that a troubleshooting document be issued to participants as a precautionary measure,
which was then agreed by the TSC. This provided written guidelines on how to manage illness. These
were sent to all participants, following approval by the REC in August 2013. The pump troubleshooting
document was based on a hand-out already issued to participants during the DAFNE education course and
an equivalent version was provided to MDI participants (see Appendix 11). The letter also served as a
reminder for participants to contact their diabetes team regarding any problems that they may be
experiencing and to report any adverse health events that may have occurred.
The 24-month letter incorporating information about severe
hypoglycaemia reporting
In October 2011 the UK Driver and Vehicle Licensing Agency released new medical standards for people
with diabetes, containing stricter rules advising that people experiencing more than one severe episode of
hypoglycaemia in 1 year should not drive. It was noted that reporting of severe hypoglycaemic events
during the trial had been low and the TMG had concerns that patients may have been under-reporting
events. The letter issued to all participants at 24 months – reminding them of their appointment and
enclosing a copy of the psychosocial questionnaire for completion – was updated to reassure them that all
of the information provided as part of the trial ‘is kept completely anonymous and not sent to any
organisation where participants could be identified’ (see Appendix 12).
Bolus calculators letter
Participants on both arms of the trial were provided with bolus calculators. These devices help patients to
calculate the correct pre-meal insulin dose to inject. Patients on MDI therapy would not always be provided
with these devices; however, this was deemed necessary to reduce any potential bias, as pump participants
had access to a bolus calculator via the pump. The qualitative research undertaken post course, and at
6 months, had indicated that some patients had become de-skilled and dependent on the devices, whereas
others misunderstood the need to change the parameters, believing they had been pre-programmed during
the DAFNE course. In some cases this could have been leading to ineffective management of their diabetes,
potentially affecting their health. The issue was discussed with the trial DMEC, who suggested that a brief,
light-touch intervention was administered to all of the participants in the trial, highlighting effective use of
the devices. The TSC chairperson agreed with this action. Therefore, as a precautionary safety measure, in
January 2014 we sent a document to all of the participants in the trial detailing appropriate use of the
devices (see Appendix 13).
CHANGES TO THE PROTOCOL
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Chapter 5 Results of the randomised
controlled trial
Trial recruitment
Participant recruitment initially took place at seven centres between November 2011 and December 2012.
A review of recruitment and retention in August 2012 revealed higher than expected dropout rates prior
to the DAFNE courses. The recruitment target was therefore increased to a maximum of 340, but with no
more than 280 in the ITT population. In order to achieve this we facilitated an additional pair of DAFNE
courses at an existing centre (Harrogate) and introduced a reserve centre (Nottingham) to facilitate a
further two courses. Recruitment continued until April 2013. Figure 2 illustrates recruitment and course
attendance rates against targets. Table 10 summarises course attendance by treatment group, with similar
mean participant numbers per course. Table 11 shows recruitment details by centre.
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FIGURE 2 Participant recruitment and attendance targets and rates.
TABLE 10 Summary of course attendance
Summary of course attendance
Treatment group
MDI Pump Total
Mean number of participants (SD) 5.87 (1.39) 5.74 (1.39) 5.80 (1.38)
Median number of participants (IQR) 6 (5–7) 6 (5–7) 6 (5–7)
Minimum to maximum 3–8 3–8 3–8
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TABLE 11 Recruitment by centre
Centres
Number of courses
per centre
Number of participants
attended
Sheffield Teaching Hospitals NHS Foundation Trust
Course 1: MDI 7
Total number of participants recruited: 41 Course 2: Pump 7
Recruited: Course 3: MDI 5
First participant 10 January 2012 Course 4: Pump 4
Last participant 19 October 2012 Course 5: MDI 8
Course 6: Pump 7
NHS Greater Glasgow and Clyde
Course 1: Pump 8
Total number of participants recruited: 45 Course 2: MDI 6
Recruited: Course 3: Pump 7
First participant 1 February 2012 Course 4: MDI 8
Last participant 27 November 2012 Course 5: MDI 5
Course 6: Pump 6
King’s College Hospital NHS Trust
Course 1: Pump 5
Total number of participants recruited: 41 Course 2: MDI 6
Recruited: Course 3: MDI 5
First participant 12 February 2012 Course 4: Pump 3
Last participant 5 December 2012 Course 5: Pump 6
Course 6: MDI 4
Cambridge University Hospitals NHS Foundation Trust
Course 1: Pump 6
Total number of participants recruited: 43 Course 2: MDI 4
Recruited: Course 3: MDI 7
First participant 23 November 2011 Course 4: Pump 5
Last participant 20 December 2012 Course 5: Pump 8
Course 6: MDI 4
Harrogate and District NHS Foundation Trust
Course 1: Pump 6
Total number of participants recruited: 55 Course 2: MDI 7
Recruited: Course 3: Pump 7
First participant 28 February 2012 Course 4: MDI 6
Last participant 10 April 2013 Course 5: MDI 7
Course 6: Pump 5
Course 7: Pump 7
Course 8: MDI 6
NHS Dumfries and Galloway
Course 1: Pump 5
Total number of participants recruited: 41 Course 2: MDI 7
RESULTS OF THE RANDOMISED CONTROLLED TRIAL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
62
Participant flow
Figure 3 shows the CONSORT flow of participants through the trial. In total 1278 people were invited to
take part, of which 885 responded. Of these responders, 362 were interested in taking part. Reasons given
for non-participation are listed in Table 12. Of those interested, 334 were assessed as eligible and 321 of
these consented to take part. Four of these dropped out prior to randomisation. Forty-six courses (23 course
pairs) were randomised, comprising 317 participants (156 pump and 161 MDI). Fifty patients were excluded
from the analysis: 40 patients withdrew before baseline data were collected and 10 withdrew before they
attended a DAFNE course. All randomised courses were delivered.23 One participant was deemed protocol
non-compliant, as he/she had not adhered to the DAFNE course (as adjudicated by the course leader). Of
the 267 participants (132 pump and 135 MDI) who were randomised, attended baseline visit and attended
a DAFNE course, 260 (132 pump and 128 MDI) had HbA1c data for at least one post-baseline follow-up visit
and these make the ITT set. A total of 248 participants (128 pump and 120 MDI) had complete primary
outcome data at 24 months’ follow-up.23
Baseline data
Table 13 shows the baseline demographics and characteristics of the trial population. Overall, eight centres
recruited to the study contributing between 10 and 51 participants per centre. Patients were more likely to
be male (60%) and were generally white British (91%). The average age of participants was 41 years.
Table 14 shows the history of diabetes among study participants at baseline. The median (IQR) duration of
diabetes was 16 (8–26) years, 12% of the participants had an episode of severe hypoglycaemia in the
12 months prior to baseline and around half of the participants had a prior history of complications (55%).
TABLE 11 Recruitment by centre (continued )
Centres
Number of courses
per centre
Number of participants
attended
Recruited: Course 3: Pump 7
First participant 3 February 2012 Course 4: MDI 4
Last participant 2 October 2012 Course 5: MDI 3
Course 6: Pump 4
NHS Lothian
Course 1: MDI 7
Total number of participants recruited: 43 Course 2: Pump 5
Recruited: Course 3: Pump 6
First participant 8 May 2012 Course 4: MDI 6
Last participant 20 November 2012 Course 5: MDI 7
Course 6: Pump 4
Nottingham University Hospitals NHS Trust
Course 1: MDI 6
Total number of participants recruited: 12 Course 2: Pump 4
Recruited:
First participant 21 February 2013
Last participant 15 March 2013
Total recruited: 321 Total attendance 267
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Non-responders
(n = 393; 31%)
Not interested
(n = 523; 59%)a
Eligible but did not consent
(n = 13; 4%)b
Dropped out prior to randomisation
(n = 4)
MDI
(n = 161)
Baseline data
(n = 138)
Dropped out prior to baseline
(n = 23)
Course attendees, n = 135
Baseline questionnaires
completed, n = 132
Courses, n = 23
Dropped out prior to DAFNE
(n = 3)
6-month follow-up data
(n = 123)
(5 continuing in study, 
missing HbA1c)
Lost to follow-up, n = 6
Withdrawn, n = 1c
12-month follow-up data
(n = 120)
(5 continuing in study, 
missing HbA1c)
e
Lost to follow-up
(n = 3)
24-month follow-up data
(n = 120)
Lost to follow-up
(n = 5)
Pump
(n = 156)
Baseline data
(n = 139)
Dropped out prior to baseline
(n = 17)
Course attendees, n = 132
Baseline questionnaires 
completed, n = 132
Courses, n = 23
Dropped out prior to DAFNE
(n = 7)
6-month follow-up data
(n = 132)
Lost to follow-up, n = 1
Withdrawn, n = 1d
12-month follow-up data
(n = 126)
(4 continuing in study, 
missing HbA1c)
24-month follow-up data
(n = 128)
Lost to follow-up
(n = 2)
Eligible
(n = 19; 5%)
Not screened
(n = 9; 2%)
Invited to take part
(n = 1278)
Responders
(n = 885; 69%)
Interested in taking part
(n = 362; 41%)
Eligible and consented to take part
(n = 321; 96%)
Randomised
(n = 317)
Eligible
(n = 334; 92%)
FIGURE 3 The CONSORT flow diagram. Note: for footnotes, see Table 12. Reproduced from The REPOSE Study
Group 2017.23 This is an Open Access article distributed in accordance with the Creative Commons Attribution
Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work
non-commercially, and license their derivative works on different terms, provided the original work is properly
cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
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TABLE 12 Reasons for non-participation (footnote to CONSORT flow diagram)
Reason n (%)
(a) Most common reasons for non-participation based on 521 completed forms (multiple reasons per individual)
Not interested in having a pump 189 (36)
Could not take week off work 123 (24)
Satisfied with my current treatment and management of diabetes 93 (18)
Lack of time 76 (15)
No reason documented/provided 29 (6)
Other 27 (5)
Does not meet eligibility criteria 26 (5)
Difficulty travelling to the course 21 (4)
Dependants at home 19 (4)
Moving/moved away from area/transferred care 16 (3)
Not willing to take part if not receiving a pump 13 (2)
Not interested in REPOSE 13 (2)
(b) Reasons for non-participation, based on seven completed forms (multiple reasons per individual)
Not interested in having a pump 2 (29)
Lack of time 2 (29)
Could not take week off work 2 (29)
Other 1 (14)
Satisfied with my current treatment and management of diabetes 1 (14)
Not willing to take part if not receiving a pump 1 (14)
Medical reasons: 1 (14)
(c) Participant does not wish to continue because of personal/family issues
(d) Participant does not wish to continue (switched from pump to MDI, did not like the practicalities of pump therapy)
(e) Of the five participants continuing in study at 12 months – but without 12-month data – three had available 6-month
data, two had no 6-month data
TABLE 13 Demographics and characteristics of participants at baseline
Variable Scoring
Treatment group
Pump (N= 132) MDI (N= 135) Total (N= 267)
Recruitment centre,
n (%)
London (King’s College Hospital) 14 (10.6) 15 (11.1) 29 (10.9)
Sheffield 18 (13.6) 20 (14.8) 38 (14.2)
Glasgow 21 (15.9) 19 (14.1) 40 (15.0)
Dumfries 16 (12.1) 14 (10.4) 30 (11.2)
Cambridge 19 (14.4) 15 (11.1) 34 (12.7)
Harrogate 25 (18.9) 26 (19.3) 51 (19.1)
Edinburgh 15 (11.4) 20 (14.8) 35 (13.1)
Nottingham 4 (3.0) 6 (4.4) 10 (3.7)
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TABLE 13 Demographics and characteristics of participants at baseline (continued )
Variable Scoring
Treatment group
Pump (N= 132) MDI (N= 135) Total (N= 267)
Sex, n (%) Male 78 (59.1) 82 (60.7) 160 (59.9)
Female 54 (40.9) 53 (39.3) 107 (40.1)
Smoking status, n (%) Smoker 23 (17.4) 30 (22.2) 53 (19.9)
Ex-smoker 42 (31.8) 27 (20.0) 69 (25.8)
Never smoker 67 (50.8) 78 (57.8) 145 (54.3)
Ethnicity, n (%) White Britisha 125 (94.7) 119 (88.1) 244 (91.4)
Irish 1 (0.8) 0 (0.0) 1 (0.4)
Any other white background 1 (0.8) 3 (2.2) 4 (1.5)
Indian 1 (0.8) 1 (0.7) 2 (0.7)
Chinese 0 (0.0) 1 (0.7) 1 (0.4)
African 0 (0.0) 1 (0.7) 1 (0.4)
Caribbean 0 (0.0) 1 (0.7) 1 (0.4)
Arab 0 (0.0) 1 (0.7) 1 (0.4)
Any other ethnic group 0 (0.0) 4 (3.0) 4 (1.5)
Prefer not to say 1 (0.8) 3 (2.2) 4 (1.5)
Missing 3 (2.3) 1 (0.7) 4 (1.5)
ONS occupational
status,b n (%)
Level 1 32 (24.2) 24 (17.8) 56 (21.0)
Level 2 37 (28.0) 43 (31.9) 80 (30.0)
Level 3 39 (29.5) 46 (34.1) 85 (31.8)
Level 4 12 (9.1) 14 (10.4) 26 (9.7)
Not classifiable 4 (3.0) 2 (1.5) 6 (2.2)
Missing 8 (6.1) 6 (4.4) 14 (5.2)
Highest qualification
obtained, n (%)
No formal qualifications 7 (5.3) 8 (5.9) 15 (5.6)
GCSE level 24 (18.2) 26 (19.3) 50 (18.7)
A-level 10 (7.6) 8 (5.9) 18 (6.7)
Vocational qualification 40 (30.3) 32 (23.7) 72 (27.0)
Undergraduate degree 25 (18.9) 32 (23.7) 57 (21.3)
Postgraduate degree 15 (11.4) 17 (12.6) 32 (12.0)
Other 9 (6.8) 9 (6.7) 18 (6.7)
Missing 2 (1.5) 3 (2.2) 5 (1.9)
Age (years) n (%) 132 (100.0) 135 (100.0) 267 (100.0)
Mean (SD) 41.5 (14.2) 39.9 (12.5) 40.7 (13.4)
Median (IQR) 40.7 (27.9–52.3) 41.0 (28.0–48.8) 40.8 (28.0–49.4)
Minimum to maximum 18.5–77.6 18.5–73.1 18.5–77.6
Body weight (kg) n (%) 132 (100.0) 135 (100.0) 267 (100.0)
Mean (SD) 82.4 (18.2) 80.0 (17.4) 81.2 (17.8)
Median (IQR) 81.2 (69.1–91.6) 78.1 (67.0–91.0) 79.6 (68.4–91.2)
Minimum to maximum 50.4–144.8 46.5–148.4 46.5–148.4
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Table 15 shows the history of severe hypoglycaemic episodes by baseline HbA1c category: 5 (20%) of the
25 participants with HbA1c of < 7.5% had an episode in the 12 months prior to baseline; 26 (11%) of the
242 participants with baseline HbA1c of ≥ 7.5% had an episode in the 12 months prior to baseline.
Table 16 shows laboratory results of participants at baseline. The mean HbA1c was 9.3% or 77.9 mmol/mol
in the pump group and 9.0% or 74.8 mmol/mol in the MDI group. Other than this difference in baseline
HbA1c, the data appear to be well balanced across treatment groups.
Table 17 summarises the proportion of participants with above and below 7.5% HbA1c at baseline in each
centre, stratified by treatment group.
TABLE 13 Demographics and characteristics of participants at baseline (continued )
Variable Scoring
Treatment group
Pump (N= 132) MDI (N= 135) Total (N= 267)
BMI (kg/m2) n (%) 132 (100.0) 135 (100.0) 267 (100.0)
Mean (SD) 27.4 (5.0) 27.0 (5.0) 27.2 (5.0)
Median (IQR) 27.1 (23.8–29.7) 26.6 (23.5–29.2) 26.9 (23.7–29.5)
Minimum to maximum 17.4–47.9 17.2–45.9 17.2–47.9
HFS behaviour score n (%) 130 (98.5) 132 (97.8) 262 (98.1)
Mean (SD) 30.3 (5.8) 29.1 (5.5) 29.7 (5.7)
Median (IQR) 29.0 (27.0–34.0) 29.5 (25.0–33.0) 29.0 (26.0–33.0)
Minimum to maximum 17.0–50.0 16.0–42.0 16.0–50.0
HFS worry score n (%) 131 (99.2) 132 (97.8) 263 (98.5)
Mean (SD) 40.7 (14.6) 37.9 (13.3) 39.3 (14.0)
Median (IQR) 37.0 (30.0–47.0) 36.0 (28.0–45.0) 37.0 (29.0–46.0)
Minimum to maximum 17.0–82.0 17.0–85.0 17.0–85.0
IMDc n (%) 78 (59.1) 79 (58.5) 157 (58.8)
Mean (SD) 15.9 (13.7) 17.2 (11.3) 16.5 (12.5)
Median (IQR) 11.0 (7.7–18.9) 13.3 (9.5–22.3) 13.0 (8.6–19.6)
Minimum to maximum 2.3–73.2 3.1–54.0 2.3–73.2
SIMDd n (%) 51 (38.6) 53 (39.3) 104 (39.0)
Mean (SD) 22.0 (18.3) 22.5 (17.0) 22.2 (17.6)
Median (IQR) 16.9 (8.0–26.4) 18.6 (10.5–29.9) 17.5 (8.8–28.5)
Minimum to maximum 2.4–73.8 1.9–74.7 1.9–74.7
GCSE, General Certificate of Secondary Education; ONS, Office for National Statistics; SIMD, Scottish Index of Multiple
Deprivation.
a White British = English/Welsh/Scottish/Northern Irish/British.
b Level 1: elementary trade, service and admin roles; level 2: construction, building trade and agricultural, caring,
protective services, public service workers or equivalent; level 3: managerial positions, public service professionals, skilled
construction, building trace and electrical trades, health and social welfare professionals, science and technology
professionals or equivalent; level 4: corporate managers and directors, research and teaching professionals, business and
public service higher level professionals or equivalent.149
c English Index of Multiple Deprivation (2010) displayed for English centres only.150
d Scottish Index of Multiple Deprivation (2012) displayed for Scottish centres only.151
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TABLE 14 History of diabetes among study participants at baseline
Variable Scoring
Treatment group
Pump (N= 132) MDI (N= 135) Total (N= 267)
Duration of diabetes (years) n (%) 132 (100.0) 135 (100.0) 267 (100.0)
Mean (SD) 18.5 (12.9) 17.5 (12.1) 18.0 (12.5)
Median (IQR) 16.5 (7.8–27.7) 14.9 (7.7–25.4) 15.8 (7.7–26.4)
Minimum to maximum 1.1–56.9 1.1–51.9 1.1–56.9
Prior history of complications No 63 (47.7) 56 (41.5) 119 (44.6)
Yes 69 (52.3) 79 (58.5) 148 (55.4)
Retinopathy as a complication Yes 51 (38.6) 65 (48.1) 116 (43.4)
No 81 (61.4) 70 (51.9) 151 (56.6)
Neuropathy as a complication Yes 13 (9.8) 6 (4.4) 19 (7.1)
No 119 (90.2) 129 (95.6) 248 (92.9)
Number of all forms of
complications
≥ 1 (%) 68 (51.5) 79 (58.5) 147 (55.1)
n (%) 132 (100) 135 (100) 267 (100)
Mean (SD) 1.0 (1.3) 1.1 (1.2) 1.1 (1.3)
Median (IQR) 1.0 (0–2) 1.0 (0–2) 1.0 (0–2)
Minimum to maximum 0–6 0–5 0–6
Number of confirmed moderate
hypoglycaemic episodesa
≥ 1 (%) 89 (67.4) 90 (66.7) 179 (67.0)
n (%) 132 (100) 135 (100) 267 (100)
Mean (SD) 2.6 (3.9) 2.0 (2.7) 2.3 (3.4)
Median (IQR) 1.0 (0–3) 1.0 (0–3) 1.0 (0–3)
Minimum to maximum 0–27 0–16 0–27
Number of moderate nocturnal
hypoglycaemic episodesa
≥ 1 (%) 41 (31.1) 46 (34.1) 87 (32.6)
n (%) 132 (100) 135 (100) 267 (100)
Mean (SD) 0.5 (1.0) 0.7 (1.3) 0.6 (1.2)
Median (IQR) 0.0 (0–1) 0.0 (0–1) 0.0 (0–1)
Minimum to maximum 0–5 0–10 0–10
Number of severe
hypoglycaemiab
≥ 1 (%) 16 (12.1) 15 (11.1) 31 (11.6)
n (%) 132 (100) 135 (100) 267 (100)
Mean (SD) 0.17 (0.52) 0.16 (0.50) 0.16 (0.51)
Median (IQR) 0.0 (0–0) 0.0 (0–0) 0.0 (0–0)
Minimum to maximum 0–3 0–3 0–3
a History in the previous 4 weeks prior to DAFNE course attendance.
b Twelve-month history prior to baseline.
Adapted from The REPOSE Study Group 2017.23 This is an Open Access article distributed in accordance with the Creative
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon
this work non-commercially, and license their derivative works on different terms, provided the original work is properly
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TABLE 15 History of severe hypoglycaemic episodes at baseline by baseline HbA1c category
Scoring
Number of severe hypoglycaemic episodesa
HbA1c< 7.5%
(N= 25)
HbA1c ≥ 7.5%
(N= 242) Total (N= 267)
≥ 1, n (%) 5 (20.0) 26 (10.7) 31 (11.6)
n (%) 25 (100) 242 (100) 267 (100)
Mean (SD) 0.36 (0.81) 0.14 (0.46) 0.16 (0.51)
Median (IQR) 0.0 (0–0) 0.0 (0–0) 0.0 (0–0)
Minimum to maximum 0–3 0–3 0–3
a 12-month history prior to baseline.
Adapted from The REPOSE Study Group 2017.23 This is an Open Access article distributed in accordance with the Creative
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon
this work non-commercially, and license their derivative works on different terms, provided the original work is properly
cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
TABLE 16 Laboratory test results of participants at baseline
Variable Scoring
Treatment group
Pump (N= 132) MDI (N= 135) Total (N= 267)
HbA1c, n (%) < 7.5 13 (9.8) 12 (8.9) 25 (9.4)
≥ 7.5 119 (90.2) 123 (91.1) 242 (90.6)
Proteinuria (unconfirmed),
n (%)
Normal 90 (68.2) 86 (63.7) 176 (65.9)
Microalbuminuria 18 (13.6) 14 (10.4) 32 (12.0)
Macroalbuminuria 3 (2.3) 9 (6.7) 12 (4.5)
Missing 21 (15.9) 26 (19.3) 47 (17.6)
Classification of chronic
kidney disease, n (%)
None 82 (62.1) 85 (63.0) 167 (62.5)
Mild 19 (14.4) 15 (11.1) 34 (12.7)
Moderate 5 (3.8) 2 (1.5) 7 (2.6)
Severe 2 (1.5) 7 (5.2) 9 (3.4)
Missing 24 (18.2) 26 (19.3) 50 (18.7)
HbA1c n (%) 132 (100.0) 135 (100.0) 267 (100.0)
Mean (SD) 9.3 (1.9) 9.0 (1.4) 9.1 (1.7)
Median (IQR) 8.9 (8.1–10.2) 8.6 (8.0–9.9) 8.7 (8.1–9.9)
Minimum to maximum 5.7–16.7 6.1–14.1 5.7–16.7
HbA1c (mmol/mol) n (%) 132 (100.0) 135 (100.0) 267 (100.0)
Mean (SD) 77.9 (21.0) 74.8 (15.6) 76.3 (18.5)
Median (IQR) 74.0 (65.0–88.0) 71.0 (64.0–85.0) 72.0 (65.0–85.0)
Minimum to maximum 39.0–159.0 43.0–131.0 39.0–159.0
Creatinine (µmol/l) n (%) 129 (97.7) 134 (99.3) 263 (98.5)
Mean (SD) 76.8 (17.4) 78.4 (20.5) 77.6 (19.0)
Median (IQR) 73.0 (64.0–85.0) 73.0 (64.0–89.0) 73.0 (64.0–86.0)
Minimum to maximum 49.0–163.0 42.0–158.0 42.0–163.0
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TABLE 16 Laboratory test results of participants at baseline (continued )
Variable Scoring
Treatment group
Pump (N= 132) MDI (N= 135) Total (N= 267)
ACR (mg/mol) n (%) 130 (98.5) 129 (95.6) 259 (97.0)
Unable to calculate 20 (15.4) 20 (15.5) 40 (15.4)
< 3 90 (69.2) 86 (66.7) 176 (68.0)
3–10 10 (7.7) 12 (9.3) 22 (8.5)
10–30 8 (6.2) 2 (1.6) 10 (3.9)
30+ 2 (1.5) 9 (7.0) 11 (4.2)
eGFR (mmol/l) n (%) 129 (97.7) 135 (100.0) 264 (98.9)
30–44 3 (2.3) 2 (1.5) 5 (1.9)
45–59 5 (3.9) 6 (4.4) 11 (4.2)
≤ 60–90 90 (69.8) 89 (65.9) 179 (67.8)
≥ 90 31 (24.0) 38 (28.1) 69 (26.1)
Cholesterol (mmol/l) n (%) 132 (100.0) 134 (99.3) 266 (99.6)
Mean (SD) 5.0 (1.0) 4.9 (0.9) 5.0 (0.9)
Median (IQR) 5.0 (4.4–5.6) 4.8 (4.2–5.4) 4.9 (4.3–5.6)
Minimum to maximum 2.8–8.6 2.7–8.0 2.7–8.6
Triglycerides (mmol/l) n (%) 132 (100.0) 135 (100.0) 267 (100.0)
Mean (SD) 1.4 (1.2) 1.4 (0.8) 1.4 (1.0)
Median (IQR) 1.1 (0.8–1.6) 1.2 (0.8–1.7) 1.1 (0.8–1.6)
Minimum to maximum 0.3–11.2 0.3–5.9 0.3–11.2
HDL cholesterol (mmol/l) n (%) 125 (94.7) 133 (98.5) 258 (96.6)
Mean (SD) 1.6 (0.4) 1.5 (0.4) 1.6 (0.4)
Median (IQR) 1.6 (1.3–1.9) 1.4 (1.2–1.7) 1.5 (1.2–1.8)
Minimum to maximum 0.6–3.2 0.5–2.7 0.5–3.2
QAID, units/body weight
(kg)
n (%) 128 (97.0) 133 (98.5) 261 (97.8)
Mean (SD) 0.37 (0.17) 0.37 (0.16) 0.37 (0.16)
Median (IQR) 0.33 (0.25–0.49) 0.35 (0.24–0.47) 0.33 (0.24–0.47)
Minimum to maximum 0.10–0.99 0.12–1.17 0.10–1.17
BID, units/body weight (kg) n (%) 128 (97.0) 134 (99.3) 262 (98.1)
Mean (SD) 0.35 (0.17) 0.38 (0.21) 0.37 (0.19)
Median (IQR) 0.32 (0.23–0.45) 0.34 (0.26–0.45) 0.33 (0.25–0.45)
Minimum to maximum 0.08–1.04 0.10–1.48 0.08–1.48
PMID, units/body weight
(kg)
n (%) 4 (3.0) 1 (0.7) 5 (1.9)
Mean (SD) 0.78 (0.32) 1.43a 0.91 (0.40)
Median (IQR) 0.84 (0.53–1.03) 1.43 (1.43–1.43) 0.99 (0.69–1.07)
Minimum to maximum 0.36–1.07 1.43–1.43 0.36–1.43
BID, background insulin dose; eGFR, estimated glomerular filtration rate; PMID, Pre-Mixed Insulin Dose; QAID, Quick-Acting
Insulin Dose.
a A SD cannot be provided here as this value is based on data for one person.
Adapted from The REPOSE Study Group 2017.23 This is an Open Access article distributed in accordance with the Creative
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Protocol deviations
One participant was excluded from the per-protocol analysis set, as they did not adhere to the DAFNE
course (this is not including the dropouts prior to the DAFNE course).
Twenty-five patients had a single treatment change form that recorded change across study treatments;
17 patients switched from pump to MDI and eight patients switched from MDI to pump. Two patients
on the pump arm changed to MDI and back again (recorded on treatment change forms), and other
participants recorded temporary treatment breaks at the follow-up appointments. After review, excluding
any reasonable temporary treatment interruptions, 236 out of the 260 ITT participants were considered
as compliant with the protocol. Of the 235 ITT participants with baseline HbA1c of ≥ 7.5%, 18 were
considered protocol deviations, leaving 217 in the per-protocol analysis set. Participants who deviated from
the protocol started with higher baseline HbA1c across both the treatment groups (Table 18); however,
greater improvement was seen for the protocol deviants in the MDI group. The reasons for protocol
deviation/treatment change are shown in Table 19.
Primary outcome
Table 20 shows the primary outcome, change in HbA1c at 24 months in participants whose baseline HbA1c
was ≥ 7.5%. The mean change in the pump group was a decrease of 0.85% or 9.3 mmol/mol, whereas
the mean decrease in the MDI group was 0.42% or 4.5 mmol/mol. After adjusting for centre, course and
baseline HbA1c, the MD in HbA1c change from baseline was –0.24% (95% CI –0.53% to 0.05%) or
–2.7 mmol/mol (95% CI –5.8 to 0.5 mmol/mol; p = 0.098).23 Figure 4 shows the distribution of HbA1c
change at 2 years, by treatment group.
TABLE 17 Baseline HbA1c level by centre
Recruitment centre HbA1c (%)
Treatment group
Pump (N= 132),
n (%)
MDI (N= 135),
n (%)
Total (N= 267),
n (%)
All ≥ 7.5 119 (90.2) 123 (91.1) 242 (90.6)
London (King’s College Hospital) < 7.5 1 (7.1) 5 (33.3) 6 (20.7)
≥ 7.5 13 (92.9) 10 (66.7) 23 (79.3)
Sheffield < 7.5 2 (11.1) 1 (5.0) 3 (7.9)
≥ 7.5 16 (88.9) 19 (95.0) 35 (92.1)
Glasgow < 7.5 0 (0.0) 1 (5.3) 1 (2.5)
≥ 7.5 21 (100.0) 18 (94.7) 39 (97.5)
Dumfries < 7.5 2 (12.5) 0 (0.0) 2 (6.7)
≥ 7.5 14 (87.5) 14 (100.0) 28 (93.3)
Cambridge < 7.5 3 (15.8) 1 (6.7) 4 (11.8)
≥ 7.5 16 (84.2) 14 (93.3) 30 (88.2)
Harrogate < 7.5 4 (16.0) 1 (3.8) 5 (9.8)
≥ 7.5 21 (84.0) 25 (96.2) 46 (90.2)
Edinburgh < 7.5 1 (6.7) 3 (15.0) 4 (11.4)
≥ 7.5 14 (93.3) 17 (85.0) 31 (88.6)
Nottingham < 7.5 0 (0.0) 0 (0.0) 0 (0.0)
≥ 7.5 4 (100.0) 6 (100.0) 10 (100.0)
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TABLE 18 Glycated haemoglobin (% and mmol/mol) by treatment group and protocol adherence
Timing HbA1c unit Statistics
Protocol deviation Per protocol
Pump (n= 11) MDI (n= 7) Pump (n= 108) MDI (n= 109)
Baseline n 11 7 108 109
% Mean (SD) 10.4 (2.4) 10.3 (1.4) 9.5 (1.7) 9.1 (1.3)
mmol/mol Mean (SD) 90.5 (26.1) 89.4 (15.3) 80.1 (18.7) 75.6 (14.0)
6 months n 11 7 108 104
% Mean (SD) 9.9 (2.5) 10.0 (2.6) 8.7 (1.4) 8.6 (1.4)
mmol/mol Mean (SD) 84.2 (26.9) 85.7 (28.8) 71.5 (15.8) 71.0 (15.1)
12 months n 7 7 106 101
% Mean (SD) 10.6 (2.3) 9.5 (2.0) 8.8 (1.5) 8.6 (1.4)
mmol/mol Mean (SD) 92.7 (25.4) 79.9 (21.4) 72.4 (16.6) 70.5 (15.0)
24 months n 9 7 106 102
% Mean (SD) 9.7 (2.1) 8.3 (1.6) 8.6 (1.4) 8.7 (1.4)
mmol/mol Mean (SD) 82.4 (23.1) 67.1 (17.8) 70.5 (15.7) 71.5 (15.5)
TABLE 19 Details of treatment change
Treatment
change ID
Month of
treatment
changea Reason for treatment change
Switched from
pump to MDI
1 0 Participant withdrawal from the DAFNE course
2 0 Participant did not tolerate trial treatment: risk of DKA as a result of not following
safety protocols
3 3 Participant did not tolerate trial treatment: problems with cannula sites
4 4 Participant did not tolerate trial treatment: problems with cannulas
5 7 Participant did not tolerate trial treatment: headaches, erratic blood glucose and stress
6 12 Participant did not tolerate trial treatment: inconvenience of delivery method
7 13 Participant did not tolerate trial treatment: found pump difficult to manage
8 13 Other: did not like the practicalities of being on a pump
9 14 Participant did not tolerate trial treatment: pump did not suit him
10 23 Other: patient decision without input from team
11 23 Participant did not tolerate trial treatment: painful cannula sites reported
Switched from
MDI to pump
12 9 Other: fear of disabling hypoglycaemia
13 14 Other: persistently elevated morning glycaemia
14 15 Other: pump therapy clinically appropriate
15 15 Other: clinical need for pump therapy
16 18 Investigator decision: deterioration in HbA1c; meets criteria for trial of pump therapy
17 19 Other: continuing problems with hypoglycaemia
18 20 Other: dawn phenomenon
a Calculated as months from the start of the DAFNE course.
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The treatment difference was larger for the per-protocol analysis: MD –0.36% (95% CI –0.64% to
–0.07%) or –3.9 mmol/mol (95% CI –7.0 to –0.8 mmol/mol) in favour of the pump; p = 0.015. However,
the observed point estimate was still smaller than the minimum clinically important difference of 0.5% or
5.5 mmol/mol,23 although the 95% CI includes this clinically important effect.
Table 21 shows sensitivity analysis on the primary outcome; the analysis was repeated for complete case,
imputing data for all participants, excluding mistimed measurements and excluding pregnant women. The
results from Tables 20 and 21 are presented graphically in Figure 5. All sensitivity analyses show similar
results to the primary analysis shown in Table 20.
Notes: (1) Thirteen local laboratory HbA1c values were used in the final analysis (two at 6 months, one at
12 months, 10 at 24 months), seven HbA1c values were taken from patient notes (one at 6 months, four at
12 months, two at 24 months). (2) ICC from complete case model at 24 months is 0.005. If centre is
excluded from the model (as a fixed effect), the ICC is 0.08.
TABLE 20 Effectiveness of the intervention: MD in change in HbA1c (% or mmol/mol) at 24 months in participants
whose baseline HbA1c was ≥ 7.5%
Primary outcome
Treatment group
Difference in mean
changea (95% CI) p-value
Pump MDI
n Mean (SD) n Mean (SD)
Change in HbA1c (%) 119 –0.85 (1.25) 116 –0.42 (1.21) –0.24 (–0.53 to 0.05) 0.098
Change in HbA1c (mmol/mol) 119 –9.3 (13.66) 116 –4.5 (13.19) –2.7 (–5.8 to 0.5)
a Adjusted for baseline HbA1c, centre and DAFNE course using a mixed-effects regression model. Multiple imputation,
using chained equations (regression), based on 50 imputed data sets with baseline, 6- and 12-month HbA1c
measurements, DAFNE course, centre, age, sex and HFS behaviour as covariates, was used to impute missing
24-month data, if a participant had some HbA1c follow-up data. SDs reported for complete data.
40
(a)
35
30
25
20
N
u
m
b
er
 o
f 
p
ar
ti
ci
p
an
ts
15
10
5
0
–7 –6 –5 –4 –3 –2
Change in HbA1c at 24 months (%)
–1 0 1 2 3
40
(b)
35
30
25
20
N
u
m
b
er
 o
f 
p
ar
ti
ci
p
an
ts
15
10
5
0
–7 –6 –5 –4 –3 –2
Change in HbA1c at 24 months (%)
–1 0 1 2 3
FIGURE 4 Changes in HbA1c (%) at 24 months in participants whose baseline HbA1c was ≥ 7.5%. (a) Pump; and (b) MDI.
DOI: 10.3310/hta21200 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 20
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Heller et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
73
TABLE 21 Sensitivity analysis on the primary outcome (change in HbA1c at 24 months in participants whose baseline
HbA1c was ≥ 7.5%)
Sensitivity
analysis set
HbA1c unit of
measurement
Treatment group
Differencea (95% CI) p-value
Pump MDI
n
Mean
change (SD) n
Mean
change (SD)
Per protocol % 108 –0.85 (1.28) 109 –0.31 (1.12) –0.36 (–0.64 to –0.07) 0.015
mmol/mol 108 –9.3 (13.96) 109 –3.4 (12.23) –3.9 (–7.0 to –0.8)
Multiple
imputationb
% 119 –0.85 (1.25) 123 –0.44 (1.21) –0.24 (–0.53 to 0.05) 0.104
mmol/mol 119 –9.3 (13.66) 123 –4.8 (13.19) –2.7 (–5.8 to 0.5)
Mean value
imputation
% 119 –0.83 (1.23) 123 –0.45 (1.14) –0.22 (–0.49 to 0.05) 0.105
mmol/mol 119 –9.1 (13.43) 123 –4.9 (12.44) –2.4 (–5.3 to 0.5)
Complete case % 115 –0.84 (1.25) 109 –0.43 (1.21) –0.22 (–0.50 to 0.06) 0.127
mmol/mol 115 –9.2 (13.66) 109 –4.7 (13.19) –2.4 (–5.4 to 0.7)
Excluding mistimed
measurements
% 114 –0.85 (1.25) 104 –0.44 (1.16) –0.19 (–0.47 to 0.09) 0.186
mmol/mol 114 –9.3 (13.69) 104 –4.8 (12.72) –2.1 (–5.2 to 1.0)
Excluding pregnant
women
% 115 –0.84 (1.25) 107 –0.41 (1.21) –0.23 (–0.52 to 0.05) 0.104
mmol/mol 115 –9.2 (13.66) 107 –4.5 (13.22) –2.6 (–5.7 to 0.5)
a Adjusted for baseline HbA1c, centre and course using a mixed-effects regression model.
b Multiple imputation using chained equations (regression) based on 50 imputed data sets with baseline, 6- and 12-month
HbA1c measurements, DAFNE course, centre, age, sex, and HFS behaviour as covariates: SDs reported for complete data.
Excluding pregnant 
women (n = 222)
Excluding mistimed 
measurements (n = 228)
Complete case (n = 224)
Adjusted MD in HbA1c change (%)
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FIGURE 5 Forest plot of MD in change from baseline in HbA1c (%) at 24 months between groups for the sensitivity
analysis samples. MCID, minimum clinically important difference, adjusted for baseline HbA1c, centre and DAFNE course.
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The change in HbA1c for participants with data at all four time points is displayed, by treatment group,
in Figure 6. The majority of improvement in HbA1c occurred in the first 6 months; HbA1c stayed roughly
constant between 6 and 24 months. The change in HbA1c over time is also displayed in Figure 7, but here
all of the participants with post-baseline data are included. Each coloured line represents a participant, and
the thick black line is the mean for each treatment group.
Table 22 shows the mean change at 24 months for the treatment groups combined; the change in all
participants with complete 24-month HbA1c data was a decrease of 0.54% (95% CI 0.38% to 0.69%) or
5.9 mmol/mol (95% CI 4.2 to 7.6 mmol/mol). For participants with baseline HbA1c ≥ 7.5%, the reduction
was slightly bigger, of 0.64% (95% CI 0.48% to 0.80%) or 7 mmol/mol (95% CI 5.2 to 8.8 mmol/mol).23
Sensitivity analysis: effect of centre and lead Dose Adjustment For Normal
Eating course educator
We undertook a further analysis that used a nested model of patients within courses, which, in turn,
are nested within course lead educators, to investigate differences in outcomes between lead educators.
For this nested model, the ICC of the lower-level clustering variable, DAFNE course, is 0.5%; for the
upper-level clusters, lead educator, ICC < 0.1%. We found no evidence of notable differences in outcomes
between lead course educators. This analysis was performed for available data only.
We explored the centre effect through an interaction test between centre and treatment group. Results of
estimated MD in HbA1c change (% or mmol/mol) at 24 months are presented by centre with the aid of
forest plots (Figure 8). The overall p-value for the interaction between treatment and centre was 0.565,
suggesting that there is no centre effect. The centre with the largest difference between treatments was
Nottingham, although the CI for this centre is large because of the small number of participants with
outcome data at that centre.
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FIGURE 7 Glycated haemoglobin (mmol/mol) over time in participants whose baseline HbA1c was ≥ 7.5%
(58mmol/mol) (including participants with any post-baseline HbA1c data, n= 235). (a) Pump; and (b) MDI.
RESULTS OF THE RANDOMISED CONTROLLED TRIAL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
76
Secondary outcomes
Glycated haemoglobin
The proportion of participants reaching the NICE target of HbA1c of ≤ 7.5% (58 mmol/mol) after 2 years is
displayed in Table 23 (including all participants regardless of baseline HbA1c value). The proportion of
patients with HbA1c ≤ 7.5% was similar across the groups. The results are very similar at 6 and 12 months
(Table 24).
Table 25 shows the distribution of HbA1c categories at baseline and 24 months. Of the participants who
ended with HbA1c of ≤ 7.5% at 24 months, 12 began the study with baseline HbA1c of ≥ 8.5%.
The primary analysis at 24 months displayed above (see Primary outcome) is repeated for 6- and 12-month
follow-up visits among participants with complete data. The results for these interim follow-ups are
0.0
Favours pump Favours MDI
–0.5
MCID
Centre (n) (n) Difference (95% CI)
KCH London 13 10 –0.38 (–1.34 to 0.57)
Sheffield 16 16 –0.11 (–0.92 to 0.69)
Glasgow 20 18 –0.65 (–1.39 to 0.09)
Dumfries 13 9 –0.54 (–1.53 to 0.44)
Addenbrookes 15 13 0.27 (–0.59 to 1.13)
Harrogate 21 23 –0.78 (–1.46 to –0.09)
Edinburgh 14 15 –0.02 (–0.86 to 0.83)
Nottingham 3 5 –1.02 (–2.68 to 0.64)
Pump
Treatment group
MDI
–1.0 1.51.00.5–1.5
FIGURE 8 Forest plot of MD in 24-month HbA1c change (%) at 24 months between groups for participants with
baseline HbA1c ≥ 7.5% by centre (complete cases with HbA1c ≥ 7.5% at baseline, n= 224). MDs are calculated from
mixed-effects regression analysis adjusted for DAFNE course. KCH, King’s College Hospital; MCID, minimum
clinically important difference.
TABLE 22 Change in HbA1c (% or mmol/mol) from baseline to 24-month follow-up, treatment groups combined
HbA1c (mmol/mol) HbA1c units n Mean change (95% CI)
All participants with complete 24-month data % 248 –0.54 (–0.69 to –0.38)
mmol/mol 248 –5.9 (–7.6 to –4.2)
Participants with baseline HbA1c ≥ 7.5% and
complete 24-month data
% 224 –0.64 (–0.80 to –0.48)
mmol/mol 224 –7.0 (–8.8 to –5.2)
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TABLE 23 Effectiveness of the intervention: proportion of participants with HbA1c of ≤ 7.5% (58mmol/mol) at
24 months (including all participants regardless of HbA1c at baseline)
Outcome
Treatment group, n/N (%)
ORa (95% CI) p-valuePump MDI
HbA1c ≤ 7.5% 32/128 (25.0) 28/120 (23.3) 1.22 (0.62 to 2.39) 0.566
a Adjusted for baseline HbA1c, centre and DAFNE course using a mixed-effects logistic regression model.
Adapted from The REPOSE Study Group 2017.23 This is an Open Access article distributed in accordance with the Creative
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon
this work non-commercially, and license their derivative works on different terms, provided the original work is properly
cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
TABLE 24 Effectiveness of the intervention: proportion of participants with HbA1c ≤ 7.5% (58mmol/mol) at 6 and
12 months
Outcome Follow-up (months)
Treatment group, n/N (%)
ORa (95% CI) p-valuePump MDI
HbA1c ≤ 7.5%
(58mmol/mol)
6 26/132 (20.5) 26/123 (21.1) 1.03 (0.51 to 2.10) 0.930
12 29/126 (23.0) 27/120 (22.5) 1.32 (0.62 to 2.80) 0.478
a Adjusted for baseline HbA1c, centre and DAFNE course using a logistic mixed-effects model.
Adapted from The REPOSE Study Group 2017.23 This is an Open Access article distributed in accordance with the Creative
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon
this work non-commercially, and license their derivative works on different terms, provided the original work is properly
cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
TABLE 25 Distribution of HbA1c categories at 24 months for all participants
Outcome Category
Treatment group, n (%)
Total (N= 267),
n (%)Pump (n= 132) MDI (n= 135)
HbA1c (%) at baseline < 7 10 (7.6) 7 (5.2) 17 (6.4)
≥ 7 to < 7.5 3 (2.3) 5 (3.7) 8 (3.0)
≥ 7.5 to < 8 18 (13.6) 15 (11.1) 33 (12.4)
≥ 8 to < 8.5 21 (15.9) 31 (23.0) 52 (19.5)
≥ 8.5 to < 9 15 (11.4) 21 (15.6) 36 (13.5)
≥ 9 to < 10 28 (21.2) 29 (21.5) 57 (21.3)
≥ 10 37 (28.0) 27 (20.0) 64 (24.0)
HbA1c (%) at 24 months < 7 15 (11.4) 12 (8.9) 27 (10.1)
≥ 7 to < 7.5 14 (10.6) 13 (9.6) 27 (10.1)
≥ 7.5 to < 8 26 (19.7) 18 (13.3) 44 (16.5)
≥ 8 to < 8.5 25 (18.9) 29 (21.5) 54 (20.2)
≥ 8.5 to < 9 9 (6.8) 20 (14.8) 29 (10.9)
≥ 9 to < 10 17 (12.9) 12 (8.9) 29 (10.9)
≥ 10 22 (16.7) 16 (11.9) 38 (14.2)
No data 4 (3.0) 15 (11.1) 19 (7.1)
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consistent with the primary outcome analysis and are displayed in Table 26. The largest MD in HbA1c change
from baseline was observed at 6 months, –0.25% (95% CI –0.52% to 0.02%) or –2.7 mmol/mol (95% CI
–5.6 to 0.2 mmol/mol), but is not clinically relevant or statistically significant at the 5% nominal level.
Episodes of moderate and severe hypoglycaemia
Few severe hypoglycaemic episodes were observed post baseline; 49 episodes recorded from 25 participants23
(Table 27). All severe hypoglycaemic episodes occurred while participants were on their allocated treatment.
Across both treatment groups the number of severe hypoglycaemic episodes reduced: the average number
TABLE 26 Effectiveness of the intervention: MD in change in HbA1c at 6 and 12 months in participants whose
baseline HbA1c was ≥ 7.5%
Follow-up
(months) HbA1c units
Treatment group
MD in changea
(95% CI) p-value
Pump MDI
n
Mean
change (SD) n
Mean
change (SD)
6 % 118 –0.76 (1.19) 111 –0.36 (1.06) –0.25 (–0.52 to 0.02) 0.069
mmol/mol 118 –8.3 (12.05) 111 –3.9 (11.56) –2.7 (–5.6 to 0.2)
12 % 111 –0.70 (1.10) 107 –0.40 (1.02) –0.13 (–0.40 to 0.14) 0.349
mmol/mol 111 –7.6 (12.04) 107 –4.4 (11.10) –1.4 (–4.3 to 1.5)
a Adjusted for baseline HbA1c, centre and DAFNE course using a mixed-effects regression model.
Adapted from The REPOSE Study Group 2017.23 This is an Open Access article distributed in accordance with the Creative
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon
this work non-commercially, and license their derivative works on different terms, provided the original work is properly
cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
TABLE 27 Severe hypoglycaemic episodes per patient-year in study (n= 267, all participants with baseline data and
who attended a DAFNE course)
Time period
Number of events: event per patient-year, incidence rate
Pump (n= 132) MDI (n= 135) Total (N= 267)
Before baseline 24, 0.18 21, 0.16 45, 0.17
Between baseline and 6-month follow-up 13, 0.18 7, 0.10 20, 0.14
Between 6 and 12 months’ follow-up 8, 0.13 5, 0.09 13, 0.11
Between 12 and 24 months’ follow-up 4, 0.03 12, 0.11 16, 0.07
Overall (post baseline) 25, 0.10 24, 0.10 49, 0.10
(Excluding first 6 months) 12, 0.06 17, 0.10 29, 0.08
IRR (95% CI):a 1.13 (0.51 to 2.51); p = 0.766
(Excluding first 6 months) IRR (95% CI):b 1.05 (0.44 to 2.53); p = 0.912
Test of overall change over time: IRRc (95% CI) (study follow-up compared with the year before baseline, treatment groups
combined) 0.46 (0.24 to 0.89); p = 0.021
a IRR calculated using mixed-effects negative binomial regression adjusted for centre, DAFNE course, baseline HbA1c and
presence of at least one severe hypoglycaemic episode before baseline. IRR was calculated on the ITT set only (n = 260).
b IRR calculated as above, but not adjusted for centre, as a result of the model failing to converge. IRR was calculated on
the ITT set that were followed up for > 6 months (n= 255).
c IRR calculated using mixed-effects negative binomial regression, with participant as the random effect, adjusted for
treatment group, treatment group × time interaction, baseline HbA1c and centre, based on the ITT set n= 260.
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of episodes per patient-year in the study reduced from 0.17 before baseline to 0.10 during follow-up.
The IRR for the number of severe hypoglycaemic episodes in the 24-month follow-up, compared with
the year before baseline, is 0.46 (95% CI 0.24 to 0.89; p = 0.021).23 Therefore, compared with the year
before baseline, the number of severe hypoglycaemic episodes per year were roughly halved in the
2 years of follow-up post baseline. There was no statistically significant difference in the rate of severe
hypoglycaemia during follow-up between the treatment groups having adjusted for centre, DAFNE
course, baseline HbA1c and presence of at least one severe hypoglycaemic episode in the 12 months before
baseline (IRR 1.13; 95% CI 0.51 to 2.51; p = 0.766). The comparison of severe hypoglycaemic episodes
between groups was repeated excluding the first 6 months of follow-up, which is the ‘settling in’ period on
the pump. This time the estimated IRR was almost equivocal, but the large CI around this reflects the
amount of uncertainty as a result of these analyses being based on so few episodes from few participants
(IRR 1.05; 95% CI 0.44 to 2.53; p = 0.912).
Across both treatment arms, on average, three moderate hypoglycaemic episodes were recorded per
patient over a 4-week history at 6 months (Table 28). By 24 months, the average number of recorded
moderate hypoglycaemic episodes during a 4-week history was slightly lower (2.6 for pump, 2.3 for MDI).
There was no statistically significant difference between the groups in the rate of moderate hypoglycaemic
episodes at any time point.23
Few participants reported one or more severe hypoglycaemic episode during study follow-up: 14 (10.6%)
in the pump group and 11 (8.6%) in the MDI group (Table 29). There was no evidence that the number of
patients reporting at least on severe hypoglycaemic episode was different in the two groups: OR 1.22
(95% CI 0.49 to 3.03). More than half of the participants reported at least one moderate hypoglycaemic
episode in the 4 weeks prior to follow-up at each time point and across both treatment groups. Slightly
more participants reported at least one episode at 6 months in the pump group than in the MDI group
(p = 0.088). However, a smaller proportion of participants reported episodes in the pump group at 12 and
14 months, although not statistically significant.
TABLE 28 Moderate hypoglycaemic episodes: IRR between pump and MDI
Outcome
Follow-up
(months) Classification
Treatment group,
n, IRa
IRRb (95% CI) p-valuePump MD
Episodes of moderate
hypoglycaemia in
4 weeks before
follow-up visit
6 All recorded episodes 131, 2.95 125, 3.04 1.21 (0.87 to 1.66) 0.258
Confirmed episodes 131, 2.29 125, 2.14 1.24 (0.91 to 1.68) 0.168
Confirmed episodes
(US definition)
131, 2.92 125, 2.66 1.17 (0.87 to 1.57) 0.299
12 All recorded episodes 124, 2.73 119, 2.90 0.89 (0.66 to 1.19) 0.416
Confirmed episodes 124, 2.03 119, 2.22 0.88 (0.65 to 1.20) 0.433
Confirmed episodes
(US definition)
124, 2.71 119, 2.82 0.88 (0.66 to 1.18) 0.402
24 All recorded episodes 127, 2.56 119, 2.26 1.00 (0.71 to 1.41) 0.992
Confirmed episodes 127, 1.81 119, 1.76 1.02 (0.72 to 1.46) 0.894
Confirmed episodes
(US definition)
127, 2.51 119, 2.16 1.04 (0.73 to 1.48) 0.832
IR, incidence rate.
a Incidence rate is number of moderate hypoglycaemic episodes per 4-week period.
b Incidence rate ratio is calculated using mixed-effects negative binomial regression adjusted for centre, DAFNE course,
baseline HbA1c and presence of at least one moderate hypoglycaemic episode before baseline. Episodes are classed as
‘confirmed’ if both confirmed by an educator and with a blood glucose level (if recorded) of < 3.5 mmol/l or, for the US
definition, < 4mmol/l.
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Figure 9 shows the distribution of the number of severe hypoglycaemic episodes for those who had one
or more episodes post baseline. The majority of participants had only one severe hypoglycaemic episode,
10 participants recorded more than one episode during the follow-up period and the maximum recorded
by a participant was seven. The number of patients who had an episode makes up a small proportion of
the study population (10%).
Figure 10 shows the timing of severe hypoglycaemic episodes. Each dot represents a severe hypoglycaemic
episode. Dots connected by a line represent severe hypoglycaemic episodes experienced by the same person.
There is no statistically significant difference in the odds of proteinuria between the treatment groups
(Table 30). At 6 months, the odds of being in a higher proteinuria category (where macroalbuminuria is
the highest category) are estimated to be 21% lower in the pump group than the MDI group (OR 0.79),
but 14% higher at 12 months, and almost identical at 24 months.
Table 31 shows exploratory descriptive analyses of self-reported physical activity for the two groups at each
study visit; no formal statistical tests have been performed on these data. The amount of physical activity
appears similar across the groups.
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FIGURE 9 Distribution of number of severe hypoglycaemic episodes in participants with at least one episode post
baseline, by treatment group. (a) Pump, n= 14; and (b) MDI, n= 11.
TABLE 29 Effectiveness of the intervention: proportion of participants who experienced at least one moderate or
severe episode of hypoglycaemia
Outcome Follow-up
Treatment group, n/N (%)
ORa (95% CI) p-valuePump MDI
Severe hypoglycaemic episode Entire duration 14/132 (10.6) 11/128 (8.6) 1.22 (0.49 to 3.03) 0.666
Moderate hypoglycaemic episode 6 months 89/131 (67.9) 72/125 (57.6) 1.64 (0.93 to 2.91) 0.088
12 months 68/124 (54.8) 76/119 (63.9) 0.66 (0.37 to 1.19) 0.171
24 months 70/127 (55.1) 67/119 (56.3) 0.95 (0.49 to 1.85) 0.890
a Adjusted for baseline HbA1c, centre, DAFNE course and presence of at least one moderate hypoglycaemic episode before
baseline using mixed-effects logistic regression.
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Table 32 shows the results of comparing secondary continuous outcomes across treatment groups.
Weight remained roughly constant throughout the study duration, and was not statistically significantly
different between the treatment groups at any follow-up.23 A slight increase in HDL cholesterol and a slight
decrease in TC was observed across both treatment groups.23 There was no evidence of a difference
between treatment groups in cholesterol change from baseline, with p-values ranging from 0.219 to 0.856.
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FIGURE 10 Severe hypoglycaemic episodes over time per participant with at least one episode post baseline, by
treatment group. (a) Pump, n= 14; and (b) MDI, n= 11.
TABLE 30 Secondary outcomes: proteinuria – proportion of participants in each proteinuria category at 6, 12 and
24 months
Follow-up (months) Secondary outcome
Treatment group, n (%)
ORa (95% CI) p-valuePump MDI
6 Normal 76 (80.0) 81 (81.0)
Microalbuminuria 17 (17.9) 14 (14.0)
Macroalbuminuria 2 (2.1) 5 (5.0) 0.79 (0.36 to 1.73) 0.558
12 Normal 65 (75.6) 67 (80.7)
Microalbuminuria 16 (18.6) 10 (12.0)
Macroalbuminuria 5 (5.8) 6 (7.2) 1.14 (0.53 to 2.48) 0.736
24 Normal 77 (81.1) 70 (83.3)
Microalbuminuria 16 (16.8) 9 (10.7)
Macroalbuminuria 2 (2.1) 5 (6.0) 1.04 (0.46 to 2.32) 0.932
a Adjusted for centre, DAFNE course and baseline HbA1c level. OR is odds of combined microalbuminuria and
macroalbuminuria vs. normal, or macroalbuminuria vs. combined categories of microalbuminuria and normal for pump
compared with MDI.
Reproduced from The REPOSE Study Group 2017.23 This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt,
build upon this work non-commercially, and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
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TABLE 31 Physical activity level by treatment group at baseline, 6, 12 and 24 months
Follow-up Physical activity
Treatment group, n (%)
All, N (%)Pump MDI
Baseline High 33 (25.0) 33 (24.4) 66 (24.7)
Medium 63 (47.7) 70 (51.9) 133 (49.8)
Low 36 (27.3) 32 (23.7) 68 (25.5)
6 months High 36 (27.7) 36 (28.8) 72 (28.2)
Medium 60 (46.2) 63 (50.4) 123 (48.2)
Low 34 (26.2) 26 (20.8) 60 (23.5)
12 months High 35 (28.5) 39 (32.8) 74 (30.6)
Medium 60 (48.8) 51 (42.9) 111 (45.9)
Low 28 (22.8) 29 (24.4) 57 (23.6)
24 months High 41 (32.3) 37 (31.4) 78 (31.8)
Medium 61 (48.0) 53 (44.9) 114 (46.5)
Low 25 (19.7) 28 (23.7) 53 (21.6)
High physical activity = equivalent to > 8 hours’ normal walking, 4 hours’ fast walking or 2.5 hours’ running per week;
medium= equivalent to between 4 and 8 hours’ normal walking, 2 and 4 hours’ fast walking or 1.25 and 2.5 hours’
running per week; low = equivalent to < 4 hours’ normal walking, 2 hours’ fast walking or 1.25 hours’ running per week.
TABLE 32 Secondary continuous outcomes: MD in change from baseline at 6, 12 and 24 months
Outcome
Follow-up
(months)
Treatment group
Adjusted differencea
(95% CI) p-value
Pump MDI
n
Mean
change (SD) n
Mean
change (SD)
Body weight (kg) 6 131 –0.05 (4.35) 124 –0.61 (4.32) 0.45 (–0.66 to 1.55) 0.430
12 123 0.78 (4.95) 116 –0.05 (4.65) 0.67 (–0.64 to 1.98) 0.316
24 127 0.71 (5.45) 117 0.20 (6.37) 0.42 (–1.17 to 2.01) 0.607
HDL cholesterol
(mmol/l)
6 123 0.01 (0.28) 116 0.04 (0.36) –0.05 (–0.13 to 0.03) 0.264
12 109 0.04 (0.29) 113 0.04 (0.38) –0.01 (–0.10 to 0.08) 0.801
24 117 0.03 (0.30) 112 0.06 (0.39) –0.04 (–0.12 to 0.05) 0.428
Cholesterol (mmol/l) 6 130 –0.17 (0.84) 122 –0.01 (0.84) –0.14 (–0.35 to 0.08) 0.219
12 121 –0.14 (1.02) 116 –0.08 (0.83) –0.02 (–0.26 to 0.22) 0.856
24 127 –0.21 (0.95) 116 –0.19 (1.03) 0.03 (–0.25 to 0.30) 0.848
Total insulin dose
(IU/weight)
6 130 –0.07 (0.27) 124 –0.03 (0.21) –0.04 (–0.10 to 0.02) 0.199
12 123 –0.09 (0.26) 117 –0.02 (0.22) –0.07 (–0.13 to –0.01) 0.017
24 125 –0.06 (0.27) 116 –0.01 (0.23) –0.05 (–0.11 to 0.02) 0.152
a Adjusted for centre, DAFNE course and baseline HbA1c level.
Reproduced from The REPOSE Study Group 2017.23 This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt,
build upon this work non-commercially, and license their derivative works on different terms, provided the original work is
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Insulin dose decreased across both pump and MDI arms. There was evidence of a difference in the mean
change in insulin dose at 12 months between treatment groups; on average, participants in the pump
group had a 0.07-IU/weight larger decrease (95% CI 0.01 to 0.013 IU/weight; p = 0.017) in insulin dose
than those in the MDI group. However, the difference between treatments in insulin dose was slightly
smaller at 6 and 24 months, but not statistically significant.
Table 33 summarises blood glucose testing per day averaged over a 2-week recorded period, stratified by
the baseline HbA1c category. A post hoc analysis indicated that there was no difference in the mean blood
glucose testing frequency between treatment groups at 24 months, having adjusted for baseline number
of blood glucose tests, centre and DAFNE course.23 The adjusted MD in blood glucose tests (95% CI)
was 0.22 (–0.24 to 0.68) per day or 3.1 (–3.4 to 9.6) over 2 weeks; p = 0.352. Overall, the number of
blood glucose tests increased from 3.6 at baseline to 4.1 per day at 24 months (95% CI 0.33 to 0.82;
p < 0.001).23
Subgroup analysis
The potential moderating effects of subgroups were explored using mixed-effects linear regression, with an
interaction between treatment and subgroup. Results of the subgroup analyses are presented in Tables 34–37,
and the results are summarised graphically using forest plots in Figures 11 and 12.
We found no reliable statistical evidence of any subgroup effects or interactions between the pump and
MDI groups. However, there was some indication that participants with qualifications up to A-level/
equivalent did better in the pump arm than in the MDI arm – MD in HbA1c change (95% CI) at 24 months of
–0.67% (–1.21% to –0.14%) vs. –0.07% (–0.47% to 0.33%) or –7.4 mmol (–13.2 to –1.5 mmol) vs. –0.8
(–5.1 to 3.6 mmol) – although the interaction test was not statistically significant (p = 0.07).23
TABLE 33 Blood glucose testing frequency over a 2-week period at baseline and 24 months, comparison by
treatment group and baseline HbA1c (%) category
Outcome
Baseline HbA1c
category (%)
Treatment group
Adjusted MDa
(95% CI) p-value
Pump MDI
n Mean (SD) n Mean (SD)
Baseline number of blood
glucose tests performed
per day (averaged over
2 weeks)
< 7.5 13 3.8 (1.7) 11 4.9 (2.1)
≥ 7.5% and< 8.5 38 3.9 (1.8) 43 3.8 (1.9)
≥ 8.5 76 3.3 (1.7) 65 3.2 (1.8)
All 127 3.6 (1.8) 119 3.6 (1.9)
24 months: number of
blood glucose tests
performed per day
(averaged over 2 weeks)
< 7.5 13 4.8 (1.0) 11 4.3 (1.9)
≥ 7.5 and < 8.5 38 5.2 (2.4) 43 3.8 (1.9)
≥ 8.5 76 3.7 (2.1) 64 4.1 (1.7)
All 127 4.3 (2.2) 118 4.0 (1.8) 0.22
(–0.24 to 0.68)
0.352
a Adjusted for centre, DAFNE course and baseline number of blood tests.
RESULTS OF THE RANDOMISED CONTROLLED TRIAL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
84
Ancillary analyses
Adverse events
Table 38 shows the AEs recorded throughout study follow-up. More participants in the pump arm (66%)
reported AEs than in the MDI arm (37%). However, part of this difference can be attributed to the 23
cases of suspicion of pump malfunction, which, by definition, could occur only for participants using pump
therapy. Table 39 shows the AEs that were recorded over different time periods during study follow-up.
TABLE 34 Subgroup evaluation (demographics): change in HbA1c (%) at 24 months within subgroup and subgroup
treatment interaction tests
Variable Subgroup
Treatment group
MD in change
(95% CI)a p-valueb
Pump MDI
n Mean (SD) n Mean (SD)
Sex Male 75 –5.97 (11.61) 73 –3.55 (11.72) –0.19 (–0.59 to 0.21) 0.441
Female 53 –9.85 (16.73) 47 –4.98 (14.57) –0.43 (–0.91 to 0.05)
Level of
education
Up to A level/
equivalent
43 –10.58 (16.46) 40 –2.92 (15.75) –0.67 (–1.21 to –0.14) 0.07
Vocational/
beyond A level
82 –5.61 (12.46) 75 –4.76 (11.57) –0.07 (–0.47 to 0.33)
IMD IMD below
median
22 –2.64 (14.69) 23 0.57 (13.40) –0.25 (–0.95 to 0.46) 0.929
IMD above
median
54 –6.20 (13.62) 49 –3.94 (12.34) –0.21 (–0.68 to 0.26)
SIMD SIMD below
median
24 –13.21 (14.27) 24 –5.38 (14.48) –0.54 (–1.29 to 0.21) 0.351
SIMD above
median
25 –8.36 (13.10) 22 –8.05 (11.43) –0.07 (–0.80 to 0.66)
Age (years) < 35 43 –0.89 (1.59) 42 –0.36 (1.35) –0.53 (–1.05 to –0.01) 0.538
35–49 49 –0.60 (1.19) 55 –0.43 (1.16) –0.15 (–0.62 to 0.32)
≥ 50 36 –0.59 (0.98) 23 –0.28 (0.89) –0.22 (–0.85 to 0.41)
BMI (kg/m2) Normal < 25 45 –0.65 (1.43) 47 –0.52 (1.22) –0.10 (–0.60 to 0.40) 0.626
Overweight
25–29.9
53 –0.69 (1.16) 48 –0.27 (0.94) –0.42 (–0.90 to 0.05)
Obese ≥ 30 30 –0.77 (1.31) 25 –0.32 (1.49) –0.35 (–0.99 to 0.29)
ONS
occupational
status
Level 1 31 –7.03 (13.45) 22 –1.91 (18.35) –0.38 (–1.05 to 0.30) 0.915
Level 2 35 –6.40 (12.83) 36 –5.86 (11.60) –0.17 (–0.74 to 0.40)
Level 3 38 –8.24 (17.13) 41 –3.32 (13.27) –0.36 (–0.90 to 0.17)
Level 4 12 –4.67 (7.64) 13 –4.54 (5.98) –0.06 (–1.02 to 0.89)
ONS, Office for National Statistics; SIMD, Scottish Index of Multiple Deprivation.
a Adjusted for centre and DAFNE course.
b The p-value from the interaction test.
Notes
English Index of Multiple Deprivation (2010) displayed for English centres only.
Scottish Index of Multiple Deprivation (2012) displayed for Scottish centres only.
Level 1: elementary trade, service and administration roles; level 2: construction, building trade and agricultural, caring,
protective services, public service workers or equivalent; level 3: managerial positions, public service professionals, skilled
construction, building trace and electrical trades, health and social welfare professionals, science and technology
professionals or equivalent; level 4: corporate managers and directors, research and teaching professionals, business and
public service higher level professionals or equivalent.
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During each time period, more participants in the pump arm experienced AEs than in the MDI arm. A total
of 142 AEs were recorded for the pump group during the first 6 months of follow-up in comparison with
84 in the following 6 months, and 94 in the final 12 months of follow-up, suggesting that more AEs
occurred during the early ‘settling in’ period on pump therapy.
Table 40 shows the AEs that were classified as being SAEs. The distribution of SAEs was similar across
the treatment groups, with the exception that more participants experienced DKA in the pump group.
Table 41 shows SAEs by study time period. Again, for the pump group, more SAEs were recorded in
the first 6 months (n = 17) than in the following 6 months (n = 11) or when compared with the last
12 months (n = 17).
TABLE 35 Subgroup evaluation (demographics): change in HbA1c (mmol/mol) at 24 months within subgroup and
subgroup treatment interaction tests
Variable Subgroup
Treatment group
MD in changea
(95% CI) p-valueb
Pump MDI
n Mean (SD) n Mean (SD)
Sex Male 75 –6.0 (11.6) 73 –3.5 (11.7) –2.1 (–6.4 to 2.3) 0.441
Female 53 –9.8 (16.7) 47 –5.0 (14.6) –4.7 (–9.9 to 0.6)
Level of
education
Up to A level/
equivalent
43 –10.6 (16.5) 40 –2.9 (15.8) –7.4 (–13.2 to –1.5) 0.07
Vocational/
beyond A level
82 –5.6 (12.5) 75 –4.8 (11.6) –0.8 (–5.1 to 3.6)
English IMDc Below median 22 –2.6 (14.7) 23 0.6 (13.4) –2.7 (–10.4 to 5.0) 0.929
Above median 54 –6.2 (13.6) 49 –3.9 (12.3) –2.3 (–7.4 to 2.8)
SIMDd Below median 24 –13.2 (14.3) 24 –5.4 (14.5) –5.9 (–14.1 to 2.3) 0.351
Above median 25 –8.4 (13.1) 22 –8.0 (11.4) –0.7 (–8.7 to 7.2)
Age (years) < 35 43 –9.7 (17.4) 42 –3.9 (14.8) –5.8 (–11.5 to –0.1) 0.538
35 to 49 49 –6.5 (13.0) 55 –4.7 (12.6) –1.6 (–6.8 to 3.5)
≥ 50 36 –6.5 (10.7) 23 –3.0 (9.7) –2.4 (–9.3 to 4.5)
BMI (kg/m2) Normal < 25 45 –7.1 (15.6) 47 –5.6 (13.4) –1.1 (–6.6 to 4.4) 0.626
Overweight/
25–29.9
53 –7.5 (12.7) 48 –2.9 (10.2) –4.6 (–9.8 to 0.6)
Obese ≥ 30 30 –8.4 (14.3) 25 –3.5 (16.3) –3.8 (–10.9 to 3.2)
ONS
occupational
statuse
Level 1 31 –7.0 (13.5) 22 –1.9 (18.3) –4.1 (–11.5 to 3.2) 0.915
Level 2 35 –6.4 (12.8) 36 –5.9 (11.6) –1.9 (–8.1 to 4.3)
Level 3 38 –8.2 (17.1) 41 –3.3 (13.3) –4.0 (–9.9 to 1.9)
Level 4 12 –4.7 (7.6) 13 –4.5 (6.0) –0.7 (–11.1 to 9.7)
IMD, Index of Multiple Deprivation; ONS, Office for National Statistics; SIMD, Scottish Index of Multiple Deprivation.
a Adjusted for centre and DAFNE course.
b The p-value from the interaction test.
c English IMD (2010) displayed for English centres only.
d The SIMD (2012) displayed for Scottish centres only.
e Level 1: elementary trade, service and administration roles; level 2: construction, building trade and agricultural, caring,
protective services, public service workers or equivalent; level 3: managerial positions, public service professionals, skilled
construction, building trade and electrical trades, health and social welfare professionals, science and technology
professionals or equivalent; level 4: corporate managers and directors, research and teaching professionals, business and
public service higher-level professionals or equivalent.
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Note: All of the DKAs that occurred were reported as SAEs and resulted in hospitalisation. All of the SAEs
have a corresponding AE; however, in some cases, a DKA SAE had a corresponding AE that was not
labelled as DKA, which is why there are more DKA SAEs recorded than DKA AEs.
Characteristics of participants by missing data status
Tables 42 and 43 show baseline characteristics of patients with missing data.
TABLE 36 Subgroup evaluation (diabetes characteristics): change in HbA1c (%) at 24 months within subgroup and
subgroup treatment interaction tests
Variable Subgroup
Treatment Group
MD in change
(95% CI)a p-valueb
Pump MDI
n Mean (SD) n Mean (SD)
Diabetes
duration (years)
< 15 59 –7.25 (16.51) 59 –2.69 (12.66) –0.43 (–0.87 to 0.02) 0.364
≥ 15 69 –7.86 (11.62) 61 –5.48 (13.03) –0.15 (–0.58 to 0.27)
Experience of
lead DAFNE
course educatorc
Less
experienced
– – 10 0.90 (13.37) – –
More
experienced
128 –7.58 (14.03) 110 –4.56 (12.79) –0.26 (–0.59 to 0.06)
Insulin dose
(IU/weight)
< 0.7 68 –5.56 (10.48) 57 –3.32 (9.03) –0.22 (–0.65 to 0.20) 0.607
≥ 0.7 60 –9.87 (17.00) 63 –4.83 (15.60) –0.38 (–0.81 to 0.05)
HbA1c (%) < 7.5 13 0.59 (0.78) 11 0.14 (0.66) 0.42 (–0.47 to 1.31) 0.183
≥ 7.5 to < 8.5 34 –0.10 (0.82) 39 0.05 (0.65) –0.12 (–0.63 to 0.38)
≥ 8.5 81 –1.15 (1.27) 70 –0.70 (1.36) –0.42 (–0.77 to –0.07)
Symptoms of
hypoglycaemia
usually occur at
blood glucose
level (mmol/l)
≥ 3 92 –7.37 (13.94) 85 –3.41 (13.31) –0.33 (–0.70 to 0.04) 0.660
< 3 or do not
feel symptoms
36 –8.11 (14.46) 35 –5.80 (11.75) –0.18 (–0.75 to 0.38)
Use of bolus
advisor
Never or rarely 18 –0.44 (0.84) 55 –0.32 (1.23) –0.18 (–0.81 to 0.46) 0.736
Sometimes 10 –0.39 (1.49) 5 0.27 (1.94) –0.72 (–2.00 to 0.55)
Often or always 100 –0.77 (1.33) 60 –0.48 (1.05) –0.21 (–0.60 to 0.18)
Moderate
hypoglycaemic
episodesd
0 41 –9.73 (15.92) 36 –4.14 (13.57) –0.45 (–0.98 to 0.09) 0.795
1 29 –7.17 (11.44) 33 –4.09 (12.80) –0.26 (–0.85 to 0.33)
2 or 3 30 –9.07 (15.01) 25 –3.52 (9.67) –0.35 (–0.98 to 0.29)
4–9 16 –8.13 (11.59) 19 –5.79 (15.62) –0.41 (–1.20 to 0.37)
≥ 10 12 3.25 (9.42) 7 –1.57 (14.58) 0.32 (–0.77 to 1.42)
a Adjusted for centre and DAFNE course.
b The p-value from the interaction test.
c ‘Less experienced’, leading six courses or fewer within previous 3 years, or completed DEP within the previous year;
‘more experienced’, seven or more courses within the previous 3 years or having continuous educator status for
> 6 years.
d Number of moderate hypoglycaemic episodes recorded in the 4 weeks prior to baseline.
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Findings of the fidelity assessment
Course characteristics
All eight REPOSE centres were fidelity tested. Four centres were fidelity tested on their second pump
course and two centres were fidelity tested on their first pump course. One centre was fidelity tested on
their third and final course as a result of personal circumstances of the FA precluding the assessment being
undertaken on the second pump course. Nottingham ran one pair of courses and, thus, FT took place on
its only pump course.
The number of REPOSE participants on the fidelity-tested pump courses ranged from 3 to 7 (for course
sizes, see Table 44). The range of participants on the remaining pump courses was 3–8, with a mean
of 5.7.
One pump course (Cambridge) included a non-REPOSE participant who had been on a pump for 10 years
and was very keen to do DAFNE.
TABLE 37 Subgroup evaluation (diabetes characteristics): change in HbA1c (mmol/mol) at 24 months within
subgroup and subgroup treatment interaction tests
Variable Subgroup
Treatment group
MD in changea
(95% CI) p-valueb
Pump MDI
n Mean (SD) n Mean (SD)
Diabetes
duration (years)
< 15 59 –7.3 (16.5) 59 –2.7 (12.7) –4.7 (–9.5 to 0.2)
≥ 15 69 –7.9 (11.6) 61 –5.5 (13.0) –1.7 (–6.3 to 3.0) 0.364
Experience of
lead DAFNE
course educator
Less experienced – – 10 0.9 (13.4) –
More experienced 128 –7.6 (14.0) 110 –4.6 (12.8) –2.9 (–6.4 to 0.7) –
Insulin dose
(IU/weight)
< 0.7 68 –5.6 (10.5) 57 –3.3 (9.0) –2.4 (–7.1 to 2.2)
≥ 0.7 60 –9.9 (17.0) 63 –4.8 (15.6) –4.1 (–8.8 to 0.6) 0.607
HbA1c (%) < 7.5 13 6.5 (8.6) 11 1.5 (7.2) 4.6 (–5.2 to 14.4)
≥ 7.5 to < 8.5 34 –1.1 (8.9) 39 0.6 (7.1) –1.4 (–6.9 to 4.2)
≥ 8.5 81 –12.5 (13.9) 70 –7.6 (14.9) –4.6 (–8.5 to –0.8) 0.183
Symptoms of
hypoglycaemia
usually occur at
blood glucose
level
≥ 3mmol/l 92 –7.4 (13.9) 85 –3.4 (13.3) –3.6 (–7.7 to 0.4)
< 3mmol/l or
do not feel
symptoms
36 –8.1 (14.5) 35 –5.8 (11.8) –2 (–8.2 to 4.2) 0.660
Use of bolus
advisor
Never or rarely 18 –4.8 (9.2) 55 –3.5 (13.4) –1.9 (–8.9 to 5.0)
Sometimes 10 –4.3 (16.3) 5 3.0 (21.2) –7.9 (–21.8 to 6.0)
Often or always 100 –8.4 (14.5) 60 –5.3 (11.5) –2.3 (–6.6 to 2.0) 0.736
Moderate
hypoglycaemic
episodesc
0 41 –9.7 (15.9) 36 –4.1 (13.6) –4.9 (–10.7 to 1.0)
1 29 –7.2 (11.4) 33 –4.1 (12.8) –2.9 (–9.3 to 3.6)
2 or 3 30 –9.1 (15.0) 25 –3.5 (9.7) –3.8 (–10.7 to 3.1)
4–9 16 –8.1 (11.6) 19 –5.8 (15.6) –4.5 (–13.1 to 4.1)
≥ 10 12 3.3 (9.4) 7 –1.6 (14.6) 3.5 (–8.5 to 15.6) 0.795
a Adjusted for centre and DAFNE course.
b The p-value from interaction test.
c Number of moderate hypoglycaemic episodes recorded in the 4 weeks prior to baseline.
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Sex
Male
Female
Level of education
Up to A-level/equivalent
Vocational/beyond A-level
IMD
IMD below median
IMD above median
SIMD
SIMD below median
SIMD above median
Age (years)
< 35
35–49
> 50
BMI (kg/m2)
Normal/ < 25
Overweight/25–29.9
Obese/ > 30
ONS occupational status
Level 1
Level 2
Level 3
Level 4
Characteristic
–0.19 (–0.59 to 0.21)
–0.43 (–0.91 to 0.05)
–0.67 (–1.21 to –0.14)
–0.07 (–0.47 to 0.33)
–0.25 (–0.95 to 0.46)
–0.21 (–0.68 to 0.26)
–0.54 (–1.29 to 0.21)
–0.07 (–0.80 to 0.66)
–0.53 (–1.05 to –0.01)
–0.15 (–0.62 to 0.32)
–0.22 (–0.85 to 0.41)
–0.10 (–0.60 to 0.40)
–0.42 (–0.90 to 0.05)
–0.35 (–0.99 to 0.29)
–0.38 (–1.05 to 0.30)
–0.17 (–0.74 to 0.40)
–0.36 (–0.90 to 0.17)
–0.06 (–1.02 to 0.89)
Difference (95% CI)
MCID
0.00
Favours pump Favours MDI
–1.50 –1.25 –1.00 –0.75 –0.50 –0.25 0.25 0.50 0.75
FIGURE 11 Subgroup evaluation (demographic characteristics) MD in HbA1c change (%) at 24 months by
demographic subgroup. MCID, minimum clinically important difference; ONS, Office for National Statistics;
SIMD, Scottish Index of Multiple Deprivation. Reproduced from The REPOSE Study Group 2017.23 This is an Open
Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0)
license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their
derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
See: http://creativecommons.org/licenses/by-nc/4.0/.
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Diabetes duration (years)
< 15
> 15
Experience of lead DAFNE course educator
Less experienced
More experienced
Insulin dose (IU/weight)
< 0.7
> 0.7
Symptoms of hypoglycaemia usually 
occur at blood glucose level (mmol/l)
> 3
< 3 or do not feel symptoms
HbA1c category (%)
< 7.5
> 7.5 to < 8.5
> 8.5
Use of bolus advisor
Never or rarely
Sometimes
Often or always
Moderate hypoglycaemic episodes
0
1
2 or 3
4–9
Characteristic
–0.43 (–0.87 to 0.02)
–0.15 (–0.58 to 0.27)
–0.26 (–0.59 to 0.06)
–0.22 (–0.65 to 0.20)
–0.38 (–0.81 to 0.05)
–0.33 (–0.70 to 0.04)
–0.18 (–0.75 to 0.38)
0.42 (–0.47 to 1.31)
–0.12 (–0.63 to 0.38)
–0.42 (–0.77 to –0.07)
–0.18 (–0.81 to 0.46)
–0.72 (–2.00 to 0.55)
–0.21 (–0.60 to 0.18)
–0.45 (–0.98 to 0.09)
–0.26 (–0.85 to 0.33)
–0.35 (–0.98 to 0.29)
–0.41 (–1.20 to 0.37)
> 10 0.32 (–0.77 to 1.42)
Difference (95% CI)
MCID
0.00
Favours pump Favours MDI
–1.50 –1.25 –1.00 –0.75 –0.50 –0.25 0.25 0.50 0.75
FIGURE 12 Subgroup evaluation (diabetes characteristics): MD in HbA1c change (%) at 24 months by subgroup.
MCID, minimum clinically important difference. Reproduced from The REPOSE Study Group 2017.23 This is an Open
Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0)
license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their
derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
See: http://creativecommons.org/licenses/by-nc/4.0/.
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TABLE 38 Safety analysis: AEs
Outcome Classification
Treatment group
Total
(N= 267)
Pump
(N= 132)
MDI
(N= 135)
Participants with ≥ 1 AE, n (%) Any AE 87 (65.9) 50 (37.0) 137 (51.3)
Increase in hypoglycaemic episode frequency 11 (8.3) 8 (5.9) 19 (7.1)
Blood glucose reading > 30mmol/l 55 (41.7) 16 (11.9) 71 (26.6)
Raised blood glucosea 16 (12.1) 6 (4.4) 22 (8.2)
Suspicion of pump malfunction 23 (17.4) – 23 (8.6)
Pregnancy 6 (4.5) 4 (3.0) 10 (3.7)
Infection at pump cannula site 2 (1.5) – 2 (0.7)
DKA 7 (5.3) 2 (1.5) 9 (3.4)
Other 28 (21.2) 28 (20.7) 56 (21.0)
Participants with ≥ 1 AE related
to study drug, n (%)
Any AE 40 (30.3) 14 (10.4) 54 (20.2)
Increase in hypoglycaemic episode frequency 4 (3.0) 5 (3.7) 9 (3.4)
Blood glucose reading > 30mmol/l 27 (20.5) 5 (3.7) 32 (12.0)
Raised blood glucoseb 5 (3.8) 1 (0.7) 6 (2.2)
Suspicion of pump malfunction 13 (9.8) – 13 (4.9)
Pregnancy – – –
Infection at pump cannula site 1 (0.8) – 1 (0.4)
DKA 1 (0.8) – 1 (0.4)
Other 3 (2.3) 3 (2.2) 6 (2.2)
Number of AEsb 321 102 423
a Unexplained constantly raised blood glucose readings.
b Four events in the pump group occurred while the participant was on MDI; 10 events in the MDI group occurred while
the participant was on pump.
TABLE 39 Safety analysis: AEs by post-course time window
Participants with ≥ 1 AE Follow-up period (months)
Treatment group
Total (N= 267)Pump (N= 132) MDI (N= 135)
Any AE, n (%) 0–6 57 (28.9) 22 (15.0) 79 (23.0)
6–12 48 (24.4) 16 (10.9) 64 (18.6)
12–24 46 (23.4) 23 (15.6) 69 (20.1)
Number of AEsa 0–6 142 37 179
6–12 84 22 106
12–24 94 42 136
a Six months – three events in the pump group occurred while the participant was on MDI, one event in the MDI group
occurred while the participant was on pump; 12 months – one event in the pump group occurred while the participant
was on MDI, one event in the MDI group occurred while the participant was on pump; 24 months – no events in the
pump group occurred while the participant was on MDI, eight events in the MDI group occurred while the participant
was on pump. Two AEs had missing dates and so were excluded from this table.
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TABLE 40 Safety analysis: SAE
Outcome Classification
Treatment group
Total (N= 267)Pump (N= 132) MDI (N= 135)
Participants with ≥ 1 SAE, n (%) Any SAE 31 (23.5) 26 (19.3) 57 (21.3)
DKA 17 (12.9) 5 (3.7) 22 (8.2)
MI 2 (1.5) – 2 (0.7)
Severe hypoglycaemia – 1 (0.7) 1 (0.4)
Foot ulcer 1 (0.8) – 1 (0.4)
Renal disease 1 (0.8) – 1 (0.4)
Abdominal pain 1 (0.8) 2 (1.5) 3 (1.1)
Pregnancya 4 (3.0) 3 (2.2) 7 (2.6)
Hyperglycaemia 3 (2.3) 4 (3.0) 7 (2.6)
Migraine – 1 (0.7) 1 (0.4)
Overdose/suicide attempt 1 (0.8) 1 (0.7) 2 (0.7)
Chest pain 2 (1.5) 1 (0.7) 3 (1.1)
Infection 2 (1.5) 2 (1.5) 4 (1.5)
Other 5 (3.8) 12 (8.9) 17 (6.4)
Participants with ≥ 1 SAE related
to a treatment, n (%)
All 5 (3.8) 2 (1.5) 7 (2.6)
Participants with ≥ 1 SAE by
intensity, n (%)
Mild 6 (4.5) 6 (4.4) 12 (4.5)
Moderate 20 (15.2) 18 (13.3) 38 (14.2)
Severe 9 (6.8) 5 (3.7) 14 (5.2)
Participants with ≥ 1 treatment-
related SAE by intensity, n (%)
Mild – – –
Moderate 4 (3.0) 2 (1.5) 6 (2.2)
Severe 1 (0.8) – 1 (0.4)
Number of SAEs All 45b 44b 89b
Number of SAEs related to
treatment
Definite 4 1 5
Probable 1 1 2
Possible 5 2 7
Unlikely 14 13 27
Unrelated 21 27 48
Number of SAEs by intensity Mild 6 8 14
Moderate 29 26 55
Severe 10 10 20
a Pregnancy is included when there was a hospital admission.
b Two events in the pump group occurred while the participant was on MDI; seven events in the MDI group occurred
while the participant was on the pump.
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TABLE 41 Safety analysis: SAEs by post-course time window
Outcome Classification
Follow-up period
(months)
Treatment group
Total (N= 267)Pump (N= 132) MDI (N= 135)
Participants with
≥ 1 SAE, n (%)
Any SAE 0–6 14 (10.1) 7 (5.1) 21 (7.6)
6–12 10 (7.2) 5 (3.6) 15 (5.4)
12–24 13 (9.4) 17 (12.3) 30 (10.9)
DKA 0–6 8 (5.8) 1 (0.7) 9 (3.3)
6–12 7 (5.1) – 7 (2.5)
12–24 4 (2.9) 4 (2.9) 8 (2.9)
Number of SAEsa 0–6 17 10 27
6–12 11 5 16
12–24 17 29 46
a Six months – one event in the pump group occurred while the participant was on MDI, one event in the MDI group
occurred while the participant was on pump; 12 months – one event in the pump group occurred while the participant
was on MDI, one event in the MDI group occurred while the participant was on the pump; 24 months – no events in
the pump group occurred while the participant was on MDI, five events in the MDI group occurred while the participant
was on the pump.
TABLE 42 Continuous baseline characteristics by treatment group and 24-month missing data status
Variable Statistic
Non-completers, n (%) Completers, n (%)
Pump
(N= 4)
MDI
(N= 15) All (N= 19)
Pump
(N= 128)
MDI
(N= 120)
All
(N= 248)
Age (years) Mean (SD) 33.4 (15.4) 32.6 (10.9) 32.8 (11.5) 41.7 (14.2) 40.8 (12.4) 41.3 (13.3)
Median (IQR) 27.7
(22.9–44.0)
29.9
(23.6–39.8)
29.9
(23.0–39.8)
40.9
(29.0–52.3)
42.8
(30.9–49.1)
41.9
(30.2–49.5)
Diabetes
duration
(years)
Mean (SD) 21.6 (18.2) 13.8 (9.6) 15.4 (11.7) 18.5 (12.8) 18.0 (12.3) 18.2 (12.5)
Median (IQR) 17.3
(9.7–33.5)
12.4
(5.4–20.2)
14.2
(5.4–20.2)
16.5
(7.8–27.7)
15.4
(8.2–25.9)
15.9
(7.9–26.7)
HbA1c
(mmol/mol)
Mean (SD) 94.0 (24.3) 83.4 (17.5) 85.6 (18.9) 77.4 (20.8) 73.7 (15.1) 75.6 (18.3)
Median (IQR) 97
(73.5–114.5)
85
(68.0–97.0)
85
(68.0–103.0)
73
(65.0–87.0)
71
(64.0–82.0)
71.5
(64.0–85.0)
HbA1c (%) Mean (SD) 10.8 (2.2) 9.8 (1.6) 10.0 (1.7) 9.2 (1.9) 8.9 (1.4) 9.1 (1.7)
Median (IQR) 11.0
(8.9–12.6)
9.9
(8.4–11.0)
9.9
(8.4–11.6)
8.8
(8.1–10.1)
8.6
(8.0–9.7)
8.7
(8.0–9.9)
BMI (kg/m2) Mean (SD) 29.8 (12.4) 27.0 (5.1) 27.6 (6.9) 27.3 (4.7) 27.0 (5.0) 27.1 (4.8)
Median (IQR) 25.8
(22.5–37.2)
26.9
(22.3–29.8)
26.4
(22.3–29.8)
27.2
(23.8–29.7)
26.5
(23.7–29.2)
27
(23.8–29.5)
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Pump pre-course session
All participants attended the pump pre-course session to learn the mechanics of pump therapy and to
programme and load the pump with saline to enable practice and familiarisation prior to undertaking the
course. This session was scheduled to run for 2 hours and 30 minutes (± 15 minutes). Seven out of the
eight centres ran sessions within this duration window. The centre that did not (Nottingham) ran a pump
pre-course session of 2 hours and so was 15 minutes short of the specified duration window.
The majority of centres delivered the pump pre-course session solely by REPOSE educators (diabetes
specialist nurses and dietitians). Two centres (Glasgow and Edinburgh) had a Medtronic representative
present to provide technical support and help with elements of pump set-up. One centre (Glasgow) also
had the PI present.
All pump pre-course session lesson plans were evaluated by the FA as relating to the objectives set for
this session.
Insulin switchover
Participants were asked to switch over their pump from saline to insulin the evening before their pump
DAFNE course if they felt happy to do so.
TABLE 43 Categorical baseline characteristics by treatment group and 24-month missing data status
Variable Scoring
Non-completers, n (%) Completers, n (%)
Pump
(N= 4)
MDI
(N= 15)
All
(N= 19)
Pump
(N= 128)
MDI
(N= 120)
All
(N= 248)
Sex Male 3 (75.0) 9 (60.0) 12 (63.2) 75 (58.6) 73 (60.8) 148 (59.7)
Female 1 (25.0) 6 (40.0) 7 (36.8) 53 (41.4) 47 (39.2) 100 (40.3)
Smoking status Smoker 2 (50.0) 5 (33.3) 7 (36.8) 21 (16.4) 25 (20.8) 46 (18.5)
Ex-smoker 1 (25.0) 6 (40.0) 7 (36.8) 41 (32.0) 21 (17.5) 62 (25.0)
Never smoker 1 (25.0) 4 (26.7) 5 (26.3) 66 (51.6) 74 (61.7) 140 (56.5)
Ethnicity White British 4 (100.0) 14 (93.3) 18 (94.7) 121 (94.5) 105 (87.5) 226 (91.1)
Other – 1 (6.7) 1 (5.3) 3 (2.3) 11 (9.2) 14 (5.6)
Prefer not to say – – – 1 (0.8) 3 (2.5) 4 (1.6)
TABLE 44 Size of fidelity-tested pump courses
Centre Number of participants on fidelity-tested course
Cambridge 7
Dumfries 7
Edinburgh 4
Glasgow 7
Harrogate 6
London (King’s College Hospital) 3
Nottingham 4
Sheffield 7
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All course participants switched the evening before their course at three centres (Nottingham, Edinburgh
and Harrogate). At Glasgow, all participants switched to insulin on the morning of course. This was a
decision taken by the personnel at that centre who, after already having run one pump course, felt that
this approach worked best, and course participants had not expressed any preference for the Sunday
evening. At the remaining centres, the majority of participants switched to insulin the night before their
course. Those who did not cited the following reasons:
l unsure of how to fit reservoir
l started in previous week but stopped, as wanted support from health professionals
l anxiety regarding change
l timing issues and technical problems with pump
l pump failure/motor alarming problem
l ran out of consumables and had cannula problems.
Pump courses
The pump course timetable was reviewed by the FA. All centres provided timetables that were evaluated
as incorporating all elements of the pump DAFNE curriculum in a logical order. Based on the times
allocated for sessions on the pump course timetable, all centres planned to deliver the curriculum in the
specified duration window of ≥ 1870 minutes but ≤ 2280 minutes. The mean course duration was 2006
minutes, that is 33 hours and 26 minutes.
All sessions planned to be observed were reviewed during the fidelity visit and their lesson plans
were reviewed.
The sick day rules lesson plan was reviewed for each centre. Seven of the eight centres were evaluated as
having no issues with this session lesson plan, with only minor problems noted, for example no aims or
objectives listed, timings not written on. One centre (Glasgow) was evaluated as having an issue with the
sick day rule lesson plan. The lesson plan was lifted directly from the pump DAFNE curriculum without
personalisation. The Glasgow educator explained that there was no time to personalise the lesson plan but
agreed to remedy for future courses.
Essential learning outcomes
The FA recorded (with evidence) if all essential learning outcomes were met in the sessions observed.
Sessions were recorded as having met all learning outcomes: ‘yes’ or ‘no’ or partially achieving essential
learning outcomes. Table 45 provides a summary.
For three sessions (‘Insulin dose adjustment theory and basal rate testing’, ‘Setting up the bolus wizard’
and ‘Alcohol’) all of the centres met all of the essential learning outcomes. For the ‘Exercise’ session,
seven centres met the essential learning outcomes and the remaining centre (Sheffield) met 95% of
learning outcomes.
For the dose escalation and reduction sessions, all of the centres either met or partly met all of the
essential learning outcomes. For the centres that partly met the learning outcomes for these sessions,
80–98% of learning outcomes were met.
The essential learning outcomes for the session ‘Daily goals, blood glucose results and insulin doses’ were
partly met at seven of the eight centres and fully met at one centre (100%). It is important to note for
this session, which is delivered at the beginning and end of each day, it is expected that some essential
learning outcomes will not be covered in one session, as it is guided by situations that the patients have
recorded in their diaries. During the DAFNE course, as new situations are observed, further essential
learning outcomes are generally covered.
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Although not essential for the FT, the FA observed the ‘Lunchtime CP (carbohydrate portion)’ and the
‘Corrections’ sessions at some centres.
Overall fidelity assessment concerns and action plans
The FA was asked to make an overall assessment of whether or not there were any major concerns about
the delivery of the pump course and, if there were, any recommended actions to be taken. These are
summarised by centre in Table 46.
TABLE 46 Concerns and actions required per centre
Centre Concerns Action
Sheffield Main issue was timing. Bolus wizard set-up also took
longer than timetabled
Team to discuss and consider
allocating more time for these
London (King’s
College Hospital)
Pump set-up lesson plan not seen, as not available on the
day. Some learning outcomes not observed on the day
but not a cause for concern
Pump set-up plan to be e-mailed
Cambridge No concerns. Discussion regarding CP estimation and
corrections that were not observed, as covered in detail
on other days at beginning of the week. No deviation
from curriculum
None
Harrogate Discussed timings around pump set-up session. Some
learning outcomes were covered earlier in the week or
will be covered in other sessions, especially around dose
adjustment
Educators to reflect on the week and
consider group evaluation and
timings, etc.
Nottingham Some lesson plans were not very detailed, for example
dose escalation and reduction, and so some essential
learning outcomes were left out. Educator agreed and
noted that no internal QA had been done for a while
because of the inconsistency of staffing levels
This is a priority to rewrite lesson plans
and to think about QA once their new
DAFNE educator has run some courses
and had the training
Glasgow Term ‘rebound hyperglycaemia’ used, that is, when blood
glucose level is normal at bedtime but high in the
morning. Educator said it is due to hypoglycaemic
episodes in the night and the liver releasing glucose.
DAFNE does not say this and educator referred to p. 134
of curriculum escalation. Educator said that they did not
know that this was the case and will make it clear to
educators that the explanation will be overtreatment of a
hypoglycaemia/dawn phenomenon/basal rate not correct
Lesson plan for sick day rules not personalised
Some DA practice escalation and reduction essential
learning outcomes not covered
Personalisation of sick days rules
lesson plan
Educator to ensure that all of the
team knows not to use ‘rebound
hyperglycaemia’ term
Edinburgh No major concerns regarding delivery. Lots of questions
from participants on one session, so it went over time.
Rebound hyperglycaemia (after night-time hypoglycaemia
and increased blood glucose in the morning) was used
Explained that the term ‘rebound
hyperglycaemia’ was not used in the
DAFNE curriculum. The group
understood, however, that they
should not correct a raise of blood
glucose following an episode of
hypoglycaemia
Dumfries Rebound hyperglycaemia term being used (i.e. raised
blood glucose in the morning after a normal bedtime
reading owing to rebound after night-time
hypoglycaemia); discussed that not used in DAFNE and
educator confirmed that they had not wished it to come
over like this but patients obviously interpreting as such
Discussed the need to word things
differently and educators agreed to
make sure that the group understood
this over the rest of the course
DA, dose adjustment; QA, quality assessment.
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Conclusion
Overall, the pump courses appear to have been delivered according to the pump course curriculum. The
pump courses observed seem representative of pump courses on REPOSE in terms of course characteristics.
The pre-course session was delivered consistently and met the objectives set. All pump courses were
planned to run in a logical order within the time frame specified. There were problems with the term
‘rebound hyperglycaemia’ being used (three centres) and non-personalisation of lesson plan (one centre).
Generally, essential learning outcomes were consistently delivered during the sessions. The session ‘Daily
goals, blood glucose results and insulin doses’ had the lowest percentage of essential outcomes met. This is
not unusual for this session, when learning outcomes are met during the week of the course. In standard
care, learning outcomes may also be omitted in other sessions during the week of the DAFNE course, but
are subsequently covered in other sessions. This can be for various reasons, for example more pressing
issues and questions raised by the participants. With appropriate timetabling and timings allocated to
sessions, there should be sufficient time for experienced educators to deliver all of the essential learning
outcomes for all sessions. The key thing is that educators have awareness of any learning outcomes that
have been missed and can produce a strategy for how they will incorporate the missed content at another
relevant stage of the week, or indeed at the 6-week follow-up session if necessary.
The quality assurance programme for MDI DAFNE courses in standard care audits the entire DAFNE course
week, whereas the REPOSE FT was restricted to 1 day of the course. Therefore, although the quality
assurance programme of MDI courses can examine if missed learning outcomes are covered in later
sessions, this was not possible for the REPOSE FT of the pump courses, and is a limitation. Nevertheless,
the number of missed learning outcomes was still low.
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Chapter 6 Results of the economic evaluation
Cost of insulin pumps and consumables
The weighted average cost of an insulin pump from the pump costing survey was £2571. The cost of
insulin pumps was converted into a yearly cost using annuitisation. The lifetime of the insulin pumps
was taken to be 4.5 years and the discount rate was that used by NICE (3.5%).22 This gave a weighted
average yearly cost of insulin pumps to be £627. The weighted average yearly cost of insulin pump
consumables was £1433.
Within-trial cost-effectiveness analysis
Base-case analysis
The results of the within-trial cost-effectiveness analysis are presented using a confidence ellipse in Figure 13.
In the base case, pump + DAFNE was dominated by MDI + DAFNE, as pump + DAFNE produced fewer
mean QALYs at a higher mean cost. The confidence ellipse shows that pump + DAFNE was associated with
statistically significantly higher costs than MDI + DAFNE at the 5% significance level, as the confidence
ellipse does not cross the x-axis at £0. The confidence ellipse also shows that pump + DAFNE was not
associated with statistically significantly lower QALYs than MDI + DAFNE at the 5% significance level. This is
because the confidence ellipse crosses the y-axis of the graph at 0. Another point to note is that the
confidence ellipses do not cross a threshold ICER of £20,000 per QALY gained; therefore, the ICER of
pump + DAFNE compared with MDI + DAFNE is greater than £20,000 per QALY gained at the 95%
confidence level.
The cost-effectiveness acceptability curve is presented in Figure 14. It shows that pump + DAFNE has a
0.0% chance of being considered cost-effective at threshold ICERs of £20,000 per QALY gained and
£30,000 per QALY gained. This is important as, based on the data in the REPOSE Trial, pump + DAFNE has
a 0% probability of being cost-effective at the thresholds used by NICE in the UK for decision-making.22
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Table 47 presents the incremental cost and QALY outcomes of pump + DAFNE compared with
MDI + DAFNE in each year of the trial and for both years combined. In the base case, the incremental cost
in year 2 is lower than the cost in year 1. This is probably due to (1) treatment switching and (2) the rate of
DKAs and severe hypoglycaemic events being noticeably lower in the pump + DAFNE arm in the second
year than in the first year. The incremental QALYs are negative in the first year and positive in the second
year. However, in neither year is this result statistically significant and, in both years, the central estimates
are less than one-hundredth of a QALY. This is not unusual in diabetes trials, in which the crucial QALY
gains due to an intervention come much later in the patient experience because of a reduced risk of
long-term complications.
Summary of the scenario analyses
The following scenario analyses were undertaken to explore structural uncertainty in the base-case
analysis:
1. per-protocol population
2. missing cost and QALY data were imputed
3. QALYs measured by the SF-6D were used instead of QALYs measured using the EQ-5D
4. imputed data and QALYs measured by SF-6D QALYs
5. pump costs measured by Riemsma et al.8 were used
6. Riemsma et al.8 pump costs were used and missing data were imputed
7. the cost of pumps and consumables are 25% lower
8. the cost of pumps and consumables are 25% lower in a per-protocol population
9. the cost of pumps and consumables are 50% lower
10. the cost of pumps and consumables are 50% lower in a per-protocol population.
In the first scenario, EEACT was conducted in the per-protocol population as this was a pre-specified
subgroup analysis (see Chapter 2, Population and subgroups for analysis). In the second scenario, missing
cost and QALY data were imputed to explore the uncertainty that may result from having incomplete data,
as in the base-case analysis only 78.85% of people had complete cost and QALY data. Details of the
imputation procedure used are provided in Chapter 3 (see Estimating the within-trial cost effects and
Estimating within-trial quality-adjusted life-year effects using the EuroQol-5 Dimensions and the Short Form
questionnaire-12 items). A further sensitivity analysis was conducted, for which the SF-6D measure, instead
of the EQ-5D, was used to calculate QALYs. This scenario analysis was conducted to explore if changing
the preference-based measure of health changed the estimated QALY values significantly enough to
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potentially change the conclusions on cost-effectiveness (see Chapter 3, Estimating within-trial
quality-adjusted life-year effects using the EuroQol-5 Dimensions and the Short Form questionnaire-12
items). Uncertainty in insulin pump costs was also explored, to see if significant discounts from the prices
observed at the REPOSE Trial sites would lead to pump + DAFNE being considered to be cost-effective
compared with MDI + DAFNE. Several of these uncertainties were also combined in other scenarios to
determine if the joint effect of the uncertainties had any meaningful effect on the conclusions.
Results of the scenario analyses
The results of the scenario analyses are also presented in Table 47. It is clear that pump + DAFNE
compared with MDI + DAFNE generated fewer QALYS at a higher cost in all analyses, apart from those
scenarios conducted in the per-protocol population. The lowest ICER is observed in the scenario for which
the per-protocol population is used, and there is a cost reduction in insulin pumps and consumables of
50%. The ICER in this scenario is £552,866, which is above the £20,000–30,000 per QALY gained
threshold considered by NICE.22 Therefore, based on the data observed directly in the REPOSE Trial,
pump + DAFNE would be unlikely to be considered cost-effective if it were to be assessed by NICE.
Clinical evidence used to inform the cost-effectiveness of
pump +Dose Adjustment For Normal Eating compared with
multiple daily injection +Dose Adjustment For Normal Eating
This section details the results of the statistical models fitted to estimate the incidence of treatment
switching, HbA1c, the risk of severe hypoglycaemia, the risk of DKA, the cost of insulin, the cost of
diabetes-related contacts and the cost of insulin pumps. The parameters presented in these statistical
models were directly included in the long-term health economic model, except for the risk of severe
hypoglycaemia and the risk of DKA, for which simulations of the expected number of events were
inputted into the long-term health economic model. In the PSA, the uncertainty in the parameters of
these statistical models was assumed to follow a multivariate normal distribution. Variance–covariance
matrices are available from the authors on request.
Treatment switching
The results of the exponential and Weibull parametric survival models for individuals randomised to
MDI + DAFNE and pump + DAFNE are given in Table 48. The results for the Gompertz, log-logistic and
log-normal parametric models are given in Appendix 14. It was not possible to estimate a survival curve
using a generalised gamma distribution, as the model did not converge in either trial arm.
In the pump + DAFNE arm, it was predicted that an individual was more likely to switch treatment if they
had a severe hypoglycaemic event or if they had a higher HbA1c. It was also observed that an individual
was less likely to switch from CSII to MDI if they had experienced a DKA event in the previous year. All of
these results are statistically significant at the 5% level in the Weibull and exponential models, except for
the effect of HbA1c on the probability of switching in the exponential model.
In the MDI + DAFNE arm, the relationships between HbA1c, number of severe hypoglycaemic episodes in
the year prior to switching and the number of DKAs in the year prior to switching worked in a similar way
to the pump + DAFNE arm. It should be noted that the effect sizes are different in the two arms for
different covariates. In the MDI + DAFNE arm, all of the coefficients were statistically significant at the
5% level.
Table 49 shows the AIC and BIC for the different survival models fitted to pump + DAFNE individuals
and MDI + DAFNE individuals. In the pump + DAFNE arm, the curve with lowest AIC and BIC was the
exponential model. For the MDI + DAFNE individuals, the curve with the lowest AIC was the Weibull model
and the curve with the lowest BIC was the exponential model.
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TABLE 48 Results of the exponential and Weibull parametric survival models fitted to individuals in both arms of
the REPOSE Trial
Parameter Coefficient Robust SE 95% CI
Pump +DAFNE
Exponential model
HbA1c 0.222 0.241 –0.251 to 0.695
Number of DKAs –0.972 0.474 –1.901 to –0.042
Number of severe hypoglycaemic events 0.427 0.087 0.257 to 0.598
Constant –4.616 2.125 –8.781 to –0.451
Weibull model
HbA1c 0.221 0.234 0.016 to 0.694
Number of DKAs –0.981 0.471 –7.113 to –4.910
Number of severe hypoglycaemic events 0.404 0.085 0.337 to 0.684
Constant –4.460 2.100 –10.607 to –4.696
ln-scale parameter –0.258 0.220 0.111 to 1.377
MDI +DAFNE
Exponential model
HbA1c 0.336 0.164 0.014 to 0.657
Number of DKAs –5.555 0.561 –6.655 to –4.455
Number of severe hypoglycaemic events 0.460 0.074 0.315 to 0.605
Constant –6.725 1.450 –9.567 to –3.884
Weibull model
HbA1c 0.355 0.173 0.016 to 0.694
Number of DKAs –6.012 0.562 –7.113 to –4.910
Number of severe hypoglycaemic events 0.510 0.089 0.337 to 0.684
Constant –7.652 1.508 –10.607 to –4.696
ln-scale parameter 0.744 0.323 0.111 to 1.377
ln, natural logarithm.
TABLE 49 Summary of the AIC and the BIC for the fitted survival curves used in the long-term modelling
Distribution AIC BIC
Pump +DAFNE
Exponential 145.77 157.24
Weibull 146.46 160.80
Gompertz 147.25 161.59
Log-logistic 147.49 161.83
Log-normal 148.48 162.82
MDI +DAFNE
Exponential 64.36 75.77
Weibull 62.55 76.81
Gompertz 63.76 78.02
Log-logistic 63.78 78.04
Log-normal 64.97 79.23
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The visual plot of the survival curves for remaining on the initially allocated treatment for the pump+ DAFNE
and MDI + DAFNE individuals are presented in Figures 15 and 16, respectively. The curves fitted to the
treatment switching data show a reasonable fit to the Kaplan–Meier curves for individuals who were
randomised to pump + DAFNE and MDI + DAFNE. A visual inspection of curves showed that the exponential
curve for pump + DAFNE showed the best fit to the Kaplan–Meier curve at the 1- and 2-year time points,
although a visual check does not indicate that it has the best fit for all of the time points. A visual inspection
of the curves in the MDI + DAFNE arm shows that all curves had a reasonable fit to the Kaplan–Meier curve,
except the exponential curve, which had a poor fit to the Kaplan–Meier curve, especially in the first year.
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FIGURE 15 A visual plot of the Kaplan–Meier and parametric survival curves for those individuals who were
randomised to pump with DAFNE. (a) Exponential curve; (b) Weibull curve; (c) Gompertz curve; (d) log-logistic
curve; and (e) log-normal curve. (continued )
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FIGURE 15 A visual plot of the Kaplan–Meier and parametric survival curves for those individuals who were
randomised to pump with DAFNE. (a) Exponential curve; (b) Weibull curve; (c) Gompertz curve; (d) log-logistic
curve; and (e) log-normal curve.
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FIGURE 16 A visual plot of the Kaplan–Meier and parametric survival curves for those individuals who were
randomised to MDI with DAFNE. (a) Exponential curve; (b) Weibull curve; (c) Gompertz curve; (d) log-logistic curve;
and (e) log-normal curve. (continued )
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FIGURE 16 A visual plot of the Kaplan–Meier and parametric survival curves for those individuals who were
randomised to MDI with DAFNE. (a) Exponential curve; (b) Weibull curve; (c) Gompertz curve; (d) log-logistic curve;
and (e) log-normal curve.
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In the base case, the exponential model will be used to model the treatment switching of individuals in the
pump + DAFNE arm, and the Weibull model will be used to model the treatment switching of individuals
in the MDI + DAFNE arm. Uncertainties in the coefficients of these models were included in the PSA using
a multivariate normal distribution. Scenario analyses were conducted when the risk of switching treatment
was estimated directly from the Kaplan–Meier curves at years 1 and 2. The risk of switching treatment for
a pump individual, given that he/she was receiving pump therapy at the start of the year, was 6.94% at
year 1 and 6.89% at year 2. The risk of switching for a MDI individual, given that they were receiving MDI
at the start of the year, was 1.58% in year 1 and 5.13% in year 2.
Glycated haemoglobin
The results of the beta regressions used to model the effectiveness of pump + DAFNE versus MDI + DAFNE
in the ITT population is given in Table 50. Pump + DAFNE has a coefficient on HbA1c reduction of –0.056
at year 1 and –0.018 at year 2; neither result was statistically significant at the 5% significance level. These
coefficients are not easily interpretable, as changes in HbA1c, as the mean effects are estimated using a
logit link function.
In the per-protocol population as in this group, the statistical analysis showed a significant improvement
in HbA1c for pump + DAFNE. The results of the beta regression fitted to the per-protocol population is
given in Table 51. Pump + DAFNE was associated with a coefficient of –0.056 in year 1 and –0.047 in
year 2. Neither of these coefficients was statistically significant at the 5% level. The uncertainty in the
coefficients in these statistical models was included in the PSA of the Sheffield Type 1 Diabetes Model
by sampling the coefficients from a multivariate normal distribution using the known variance
covariance matrices.
Severe hypoglycaemia and diabetic ketoacidosis
The results of the negative binomial regressions for the incidence of severe hypoglycaemia are given in
Table 52. The regression predicts that the number of severe hypoglycaemic events increases as a patient’s
HbA1c decreases; however, this result is not statistically significant at the 5% level in the second year.
Pump + DAFNE compared with MDI + DAFNE was associated with a higher incidence of severe
hypoglycaemia in year 1 and a lower incidence of severe hypoglycaemia in year 2. Neither result was
statistically significant at the 5% level.
The results of the negative binomial regressions for the incidence of DKA are given in Table 53. The
predicted number of DKAs increase with a patient’s HbA1c. This result is statistically significant in the first
year, but not in the second year. Pump + DAFNE when compared with MDI + DAFNE was associated with
a higher incidence of DKA in year 1 and a lower incidence of DKA in year 2. Neither result was statistically
significant at the 5% level.
Cost of insulin, diabetes-related contacts and insulin pumps
The results of the analyses on the cost of insulin used in the long-term modelling are given in Table 54.
Pump treatment was associated with a reduction in insulin costs of around £500 per annum in years 1 and
2 compared with MDI treatment. This result was statistically significant in both years. Switching from pump
to MDI treatment was associated with an increase in insulin costs of around £550 in year 1 and £150 in
year 2. No coefficient could be estimated on whether or not a MDI individual switched to pump, as this
parameter was collinear with model parameters. Switching from MDI to pump was associated with a
decrease in insulin costs of around £350 in year 2. All of these results were statistically significant at the
5% level.
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TABLE 50 Effect of pump compared with MDI for all individuals in the ITT population
HbA1c Coefficient SE t p> t 95% CI
At 1 year (beta scale)
Mean effect (Mu)
Treatment allocation
(1 = pump+ DAFNE, 0=MDI + DAFNE)
–0.056 0.038 –1.49 0.137 –0.131 to 0.018
Baseline HbA1c (beta scale) 3.978 0.248 16.01 0 3.491 to 4.465
Constant –2.223 0.088 –25.28 0 –2.395 to –2.050
Centre effects (Cambridge is the
reference centre):
Dumfries and Galloway –0.025 0.074 –0.33 0.738 –0.171 to 0.121
Edinburgh –0.019 0.065 –0.3 0.768 –0.147 to 0.108
Glasgow –0.154 0.099 –1.55 0.12 –0.348 to 0.040
Harrogate 0.022 0.041 0.52 0.602 –0.060 to 0.103
London (King’s College Hospital) 0.013 0.065 0.21 0.837 –0.114 to 0.140
Nottingham 0.214 0.060 3.58 0 0.097 to 0.331
Sheffield 0.066 0.057 1.17 0.241 –0.045 to 0.178
Natural logarithm of the dispersion parameter [ln(phi)]
Baseline HbA1c (beta scale) –2.996862 0.9980645 –3 0.003 –4.954 to –1.040
Constant 4.912 0.332 14.79 0 4.261 to 5.563
At 2 years (beta scale)
Mean effect (Mu)
Treatment allocation
(1 = pump+ DAFNE, 0=MDI + DAFNE)
–0.018 0.035 –0.52 0.603 –0.086 to 0.050
1-year HbA1c (beta scale) 0.797 0.318 2.51 0.012 0.175 to 1.419
Baseline HbA1c (beta scale) 3.599 0.342 10.51 0 2.927 to 4.271
Constant –2.380 0.091 –26.14 0 –2.558 to –2.201
Centre effects (Cambridge is the
reference centre):
Dumfries and Galloway 0.047 0.093 0.5 0.617 –0.137 to 0.230
Edinburgh 0.067 0.085 0.8 0.426 –0.098 to 0.233
Glasgow 0.137 0.097 1.42 0.155 –0.052 to 0.327
Harrogate 0.123 0.087 1.41 0.158 –0.048 to 0.294
London (King’s College Hospital) 0.079 0.087 0.9 0.366 –0.092 to 0.249
Nottingham 0.120 0.110 1.09 0.279 –0.098 to 0.337
Sheffield 0.156 0.080 1.96 0.05 0.000 to 0.312
Natural logarithm of the dispersion parameter [ln(phi)]
1-year HbA1c (beta scale) –4.667 1.129 –4.13 0 –6.881 to –2.453
Constant 5.422 0.277 19.56 0 4.879 to 5.966
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TABLE 51 Effect of pump compared with MDI for all individuals in the per-protocol population
HbA1c Coefficient SE t p> t 95% CI
At 1 year (beta scale)
Mean effect (Mu)
Treatment allocation
(1 = pump+ DAFNE, 0=MDI + DAFNE)
–0.056 0.044 –1.37 0.171 –0.148 to 0.026
Baseline HbA1c (beta scale) 3.938 0.255 13.62 0 2.978 to 3.980
Constant –2.219 0.093 –23.94 0 –2.401 to –2.038
Centre effects (Cambridge is the
reference centre):
Dumfries and Galloway –0.019 0.078 –0.25 0.805 –0.172 to 0.134
Edinburgh 0.020 0.056 0.37 0.714 –0.089 to 0.130
Glasgow –0.129 0.095 –1.36 0.175 –0.315 to 0.057
Harrogate 0.025 0.040 0.62 0.534 –0.054 to 0.104
London (King’s College Hospital) 0.018 0.064 0.28 0.779 –0.107 to 0.143
Nottingham 0.172 0.039 4.46 0 0.096 to 0.247
Sheffield 0.084 0.064 1.31 0.191 –0.042 to 0.209
Natural logarithm of the dispersion parameter [ln(phi)]
Baseline HbA1c (beta scale) –3.504 1.050 –3.34 0.001 –5.563 to –1.446
Constant 5.062 0.351 14.41 0 4.373 to 5.751
At 2 years (beta scale)
Mean effect (Mu)
Treatment allocation
(1 = pump+ DAFNE, 0=MDI + DAFNE)
–0.047 0.035 –1.35 0.177 –0.116 to 0.021
1-year HbA1c (beta scale) 3.475 0.340 10.23 0 2.809 to 4.141
Baseline HbA1c (beta scale) 1.053 0.351 3 0.003 0.365 to 1.740
Constant –2.382 0.092 –26.01 0 –2.562 to –2.203
Centre effects (Cambridge is the
reference centre):
Dumfries and Galloway 0.022 0.088 0.26 0.799 –0.150 to 0.194
Edinburgh 0.076 0.085 0.89 0.374 –0.091 to 0.243
Glasgow 0.105 0.096 1.1 0.271 –0.082 to 0.293
Harrogate 0.092 0.085 1.08 0.28 –0.075 to 0.258
London (King’s College Hospital) 0.053 0.085 0.62 0.538 –0.115 to 0.220
Nottingham 0.109 0.100 1.1 0.276 –0.089 to 0.308
Sheffield 0.157 0.078 2.02 0.043 0.005 to 0.310
Natural logarithm of the dispersion parameter [ln(phi)]
1-year HbA1c (beta scale) –4.809 1.231 –3.9 0 –7.223 to –2.394
Constant 5.474 0.302 18.13 0 4.882 to 6.066
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The model uses the parameters in the regression model presented in Table 53 to estimate their cost of
insulin. For example, the formula used to estimate the cost of insulin beyond the second year in a
deterministic analysis is as follows:
Cost of insulin = £324:53 + £1:04 (patient0s baseline cost of insulin)
+£12:81 [patient0s baseline HbA1c (DCCT% scale)]
+−£527:64 (1 =was receiving a pump at the start of the year, 0 = otherwise)
+£153:35 (1 = switched from pump to MDI this year, 0 = otherwise)
+−£353:27 (1 = switched from MDI to pump this year, 0 = otherwise).
(7)
The results of the analyses on the cost of diabetes-related contacts are given in Table 55. Pump + DAFNE
was associated with an increase in the cost of diabetes-related contacts of £130 per annum in year 1 and
£90 per annum in year 2 compared with MDI. These results were not statistically significant in year 1 or 2.
Switching from insulin pump therapy to MDI was associated with an increase in diabetes-related contact
costs of £280 per annum in year 1 and a decrease of £50 per annum in year 2. Switching from MDI to
insulin pump therapy was associated with an increase in diabetes-related contact costs of £730 per annum
in year 1 and £300 per annum in year 2. None of the treatment switching coefficients was statistically
significant at the 5% significance level.
TABLE 52 Negative binomial model fitted to the incidence of severe hypoglycaemia at baseline, 1 and 2 years
Severe hypoglycaemia Coefficient SE z-value p> z
Year 1
Treatment allocation (1 = pump+ DAFNE, 0=MDI + DAFNE) 0.2861 0.5149 0.556 0.578
1-year HbA1c (DCCT% scale) –0.5010 0.2323 2.157 0.03
Number of severe hypoglycaemic events experienced in the
year prior to baseline
2.0708 0.5638 3.673 > 0.000
Constant 1.2689 1.8676 0.679 0.49687
Year 2
Treatment allocation (1 = pump+ DAFNE, 0=MDI + DAFNE) –1.1141 0.7202 –1.547 0.122
2-year HbA1c (DCCT% scale) –0.2019 0.2668 –0.757 0.449
Constant –0.6367 2.2625 –0.281 0.778
TABLE 53 Negative binomial model fitted to the incidence of DKA at baseline, 1 and 2 years
DKA Coefficient SE z-value p> z
Year 1
Treatment allocation (1 = pump+ DAFNE, 0=MDI + DAFNE) 0.3369 0.4786 0.704 0.481
1-year HbA1c (DCCT% scale) 0.4089 0.1246 3.283 0.001
Constant –5.9443 1.1879 –5.004 > 0.00
Year 2
Treatment allocation (1 = pump+ DAFNE, 0=MDI + DAFNE) –0.07564 0.70426 –0.107 0.914
2-year HbA1c (DCCT% scale) 0.32667 0.19447 1.680 0.093
Number of DKAs in year 1 0.86618 0.51682 1.676 0.094
Constant –5.98206 1.82156 –3.284 0.01
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TABLE 54 Result of seemingly unrelated regression on insulin costs (£) in years 1 and 2
Parameter Coefficient Robust SE 95% CI
Year 1
Baseline insulin cost 0.97 0.14 0.69 to 1.25
Baseline HbA1c (DCCT% scale) 5.08 6.65 –7.95 to 18.10
Randomised treatment group (1 = pump+ DAFNE,
0=MDI + DAFNE)
–517.91 25.57 –568.02 to –467.80
Did the individual switch from pump to MDI in year 1?
(1 = switched, 0= did not switch)
554.47 114.26 330.53 to 778.41
Constant 381.77 70.20 244.19 to 519.36
Year 2
Baseline insulin cost 1.04 0.11 0.82 to 1.26
Baseline HbA1c (DCCT% scale) 12.81 8.72 –4.27 to 29.90
Patient’s treatment at 1 year follow-up (1 = pump, 0 =MDI) –527.64 30.22 –586.87 to –468.42
Did the individual switch from pump to MDI in year 2?
(1 = switched, 0= did not switch)
153.35 55.96 43.67 to 263.02
Did the individual switch from MDI to pump in year 2?
(1 = switched, 0= did not switch)
–353.27 80.06 –510.18 to –196.36
Constant 324.53 79.15 169.40 to 479.66
TABLE 55 Result of seemingly unrelated regression on diabetes-related contact costs (£) in years 1 and 2
Parameter Coefficient Robust SE 95% CI
Year 1
Baseline diabetes-related contacts cost 0.11 0.04 0.04 0.18
Baseline HbA1c (DCCT% scale) –21.66 20.72 –62.27 18.94
Randomised treatment group (1 = pump+ DAFNE,
0=MDI + DAFNE)
129.08 68.35 –4.88 263.05
Did the individual switch from pump to MDI in year 1?
(1 = switched, 0= did not switch)
280.16 368.38 –441.86 1002.17
Did the individual switch from MDI to pump in year 1?
(1 = switched, 0= did not switch)
733.95 633.94 –508.55 1976.45
Constant 415.46 132.54 155.69 675.24
Year 2
Baseline diabetes-related contacts cost 0.03 0.02 –0.02 0.07
Baseline HbA1c (DCCT% scale) 12.15 25.18 –37.20 61.50
Patient’s treatment at 1 year follow-up (1 = pump, 0 =MDI) 88.99 69.17 –46.58 224.56
Did the individual switch from pump to MDI in year 2?
(1 = switched, 0= did not switch)
–47.10 66.92 –178.25 84.05
Did the individual switch from MDI to pump in year 2?
(1 = switched, 0= did not switch)
299.80 153.43 –0.92 600.52
Constant 201.93 171.22 –133.64 537.51
DOI: 10.3310/hta21200 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 20
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Heller et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
111
The cost of DRCs for each individual was predicted using the values in Table 55. For example, in a
deterministic model run, a patient’s cost of DRCs in the first year was given by the following formula:
Cost of DRCs = £415:46 + £0:11 (patient0s baseline cost of DRC)
+−21:66 [patient0s baseline HbA1c (DCCT% scale)]
+£129:08 (1 = randomised to pump + DAFNE, 0 = otherwise)
+£280:16 (1 = switched from pump to MDI in year 1, 0 = otherwise)
+£733:95 (1 = switched from MDI to pump in year 1, 0 = otherwise).
(8)
The results of the analyses on the cost in insulin pump therapy (includes the yearly cost of the pump and
the associated consumables) is given in Table 56. Insulin pump therapy was associated with a cost per
annum of £2056 in year 1 and £2051 in year 2. Switching from insulin pump therapy to MDI was
associated with a decrease in insulin pump therapy costs of £1140 in year 1 and a reduction of £910 in
year 2. Switching from MDI to insulin pump therapy was associated with an increase in costs of £840 in
year 1 and £130 in year 2. All of these results were statistically significant at 5% level.
The coefficients in these statistical models were included in the model to predict the cost of insulin,
diabetes-related contact and insulin pump therapy. The uncertainty in these parameters was included in
the PSA by using a multivariate normal distribution for each regression equation.
TABLE 56 Result of seemingly unrelated regression on insulin pump therapy costs (£) in years 1 and 2
Parameter Coefficient Robust SE 95% CI
Year 1
Randomised treatment group (1 = pump+ DAFNE,
0=MDI + DAFNE)
2056.11 15.54 2025.65 to 2086.56
Did the individual switch from pump to MDI in year 1?
(1 = switched, 0= did not switch)
–1143.68 287.44 –1707.04 to –580.31
Did the individual switch from MDI to pump in year 1?
(1 = switched, 0= did not switch)
804.57 208.95 395.03 to 1214.11
Constant 0.00 0.00 0.00 to 0.00
Year 2
Patient’s treatment at 1 year follow-up (1 = pump, 0 =MDI) 2050.99 13.79 2023.97 to 2078.01
Did the individual switch from pump to MDI in year 2?
(1 = switched, 0= did not switch)
–905.03 226.55 –1349.07 to –461.00
Did the individual switch from MDI to pump in year 2?
(1 = switched, 0= did not switch)
1134.27 152.67 835.04 to 1433.49
Constant 0.00 0.00 0.00 to 0.00
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Long-term cost-effectiveness
Base-case analysis
The results of the long-term cost-effectiveness analysis base case results using the PSA is shown in Table 57.
For the pump arm, the mean costs of the intervention are £42,143 discounted over the lifetime horizon,
which compares with £20,398 for the MDI arm. The difference between the intervention costs for the two
arms is £21,745. AE costs are slightly lower in the pump arm, £1040 versus £1509, a mean lifetime saving
of £470 per person. Complication costs are also lower £57,435 versus £59,877, a mean lifetime saving of
£2443 per person, which is mostly due to reductions in the occurrence of end-stage renal failure in the
nephropathy complications. The net incremental lifetime cost of pump versus MDI is therefore estimated as
£18,832 (95% CI £535 to £34,978) per person.
TABLE 57 Base-case PSA results from the Sheffield Type 1 Diabetes Policy Model
MDI+DAFNE Pump+DAFNE Incremental (95% CI)
Mean lifetime discounted costs per person (£)
Intervention costs
Insulin 12,542 5634 –6908 (–8329 to –5344)
Diabetes-related contacts 5166 6451 1285 (–426 to 3108)
Insulin pumps and consumables 2327 29,667 27,339 (22,771 to 31,368)
DAFNE course 363 392 29 (29 to 29)
Subtotal intervention costs 20,398 42,143 21,745 (17,321 to 25,569)
AE costs
Severe hypoglycaemia 136 42 –94 (–221 to –54)
DKA 1373 998 –375 (–1811 to 285)
Subtotal cost of AEs 1509 1040 –470 (–1880 to 160)
Long-term complication costs
Nephropathy 51,515 49,139 –2376 (–19,397 to 11,957)
Neuropathy 1975 1915 –60 (–419 to 255)
Retinopathy+macular oedema 2212 2203 –8 (–85 to 58)
MI 1996 1994 –2 (–258 to 206)
HF 663 666 2 (–76 to 89)
Stroke 278 278 0 (–43 to 41)
Angina 1238 1239 1 (–143 to 123)
Total cost of long-term complications 59,877 57,435 –2443 (–20,177 to 12,381)
Total costs 81,785 100,617 18,832 (535 to 34,978)
Mean discounted QALYs per person
QALYs lived (excluding decrements due to
complications)
14.2894 14.3898 0.1005 (–0.6522 to 0.8383)
QALYs lost because of AEs
Severe hypoglycaemia –0.0014 –0.0004 0.0010 (0 to 0.0042)
DKA –0.0088 –0.0064 0.0024 (–0.0018 to 0.0171)
Subtotal QALYs due to AEs –0.0102 –0.0068 0.0034 (–0.0009 to 0.0174)
continued
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The ‘QALYs lived without diabetic complications’ captures all of the QALYs gains from the increased life
expectancy of patients who receive pump + DAFNE prior to adjusting their utility downwards for the
incidence of diabetic complications. The ‘QALYs lived without complications’ in the pump + DAFNE
arm is 14.3898 QALYs compared with 14.2894 QALYs in the MDI + DAFNE arm, a mean increase of
0.1005 QALYs. The QALYs lost because of AEs are slightly lower in the pump + DAFNE arm than in the
MDI + DAFNE arm, –0.0068 versus –0.0102 QALYs, leading to a mean increase of 0.0034 QALYs in favour
of pump + DAFNE. The overall QALYs lost because of the incidence of diabetic complications was again
slightly lower in the pump + DAFNE arm than in the MDI + DAFNE arm, –1.2725 versus –1.2947 QALYs,
a mean increase in lifetime QALYs of 0.0222. However, pump + DAFNE is not associated with a mean
increase in QALYs for each of the individual long-term diabetic complications. This is because although the
incidence of the complications is expected to be lower in the pump + DAFNE arm, as they have a lower
HbA1c, people are also expected to live longer in the pump + DAFNE arm, so they may be at a greater
overall risk of suffering a diabetic complication within their lifetime. The net incremental QALY gain per
person is 0.1260 QALYs (95% CI –0.7381 to 0.9705 QALYs) per person.
Pump + DAFNE generated more QALYs – 0.1260 QALYs (95% CI –0.7381 to 0.9705 QALYs) – at a higher
incremental cost of £18,832 (95% CI £535 to £34,978) than MDI + DAFNE. The ICER associated with
pump+ DAFNE was £149,483 per QALY gained. This is outside the range of £20,000–30,000 per QALY gained
at which NICE would usually consider to be cost-effective. Figure 17 shows the base-case cost-effectiveness
plane for the PSA. It is clear that, when using the £20,000 per QALY gained threshold, most PSA runs lie in
the region where pump + DAFNE would not be considered to be cost-effective, as they are above the
£20,000 per QALY gained line. The cost-effectiveness acceptability curve presented in Figure 18 shows the
probability that pump + DAFNE and MDI + DAFNE are cost-effective across a range of cost-effectiveness
thresholds.152 It is clear that MDI + DAFNE has a higher probability of being cost-effective than
pump + DAFNE at all cost-effectiveness thresholds in the range of £0–50,000 per QALY gained.
TABLE 57 Base-case PSA results from the Sheffield Type 1 Diabetes Policy Model (continued )
MDI+DAFNE Pump+DAFNE Incremental (95% CI)
QALYs lost because of complications
Nephropathy –0.2179 –0.2105 0.0074 (–0.0527 to 0.0714)
Neuropathy –0.3301 –0.3210 0.0091 (–0.0387 to 0.0629)
Retinopathy and macular oedema –0.5202 –0.5139 0.0064 (–0.0292 to 0.0488)
MI –0.0647 –0.0649 –0.0002 (–0.0072 to 0.0067)
HF –0.0420 –0.0422 –0.0002 (–0.0062 to 0.0055)
Stroke –0.0376 –0.0378 –0.0002 (–0.0065 to 0.0061)
Angina –0.0821 –0.0822 –0.0001 (–0.0081 to 0.0084)
Subtotal QALYs lost because of complications –1.2947 –1.2725 0.0222 (–0.112 to 0.1773)
Total QALYs 12.9845 13.1105 0.1260 (–0.7533 to 0.9705)
Summary
Total mean discounted costs per person (£) 81,785 100,617 18,832
Total mean discounted QALYs per person 12.9845 13.1105 0.1260
ICER (£/QALY gained) – – 149,483
Probability (%) that pump+ DAFNE is cost-effective
at a threshold of £20,000 per QALY gained
– – 15.4
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The modelled lifetime incidence of diabetic complications in the PSA is given in Table 58. Pump + DAFNE
was associated with fewer diabetic complications than MDI + DAFNE. However, this is to be expected, as
the treatment effect coefficient was negative in the beta regression that was used to estimate HbA1c in
the model (see Tables 50 and 51). It should also be noted that the incidence of proliferative retinopathy,
macular oedema and blindness were higher in the pump + DAFNE arm than the MDI + DAFNE arm. This
seems to be counterintuitive; however, there are two effects. The first is that, in a given year, patients in the
pump + DAFNE arm are at a lower risk of these complications. The second effect is that as the HbA1c of
patients in the pump + DAFNE arm is, on average, lower than the MDI + DAFNE arm then they are expected
to live longer, increasing their absolute risk of experiencing a complication. For the proliferative retinopathy,
macular oedema and blindness complications, the increased risk as a result of living longer outweighs the
decreased annual risk of a complication as a result of these patients having a lower HbA1c value.
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Summary of the scenario analyses in the long-term model
The following scenario analyses were conducted in the long-term modelling:
1. pump costs estimated using data in Riemsma et al.8 on the yearly cost of insulin pump therapy
2. a 25% price reduction in insulin pumps and consumables
3. a 50% price reduction in insulin pumps and consumables
4. the ITT estimate of treatment effect was used
5. the ITT estimate of treatment effect was used and there was no change in HbA1c if an individual
switches treatment
6. post-trial HbA1c progression in both arms is estimated from the DCCT at +0.045% per annum
7. individuals return to their baseline HbA1c after 3 years and experience no progression in their
HbA1c thereafter
8. HbA1c effects occur one model cycle earlier
9. individuals return to baseline risk of hypoglycaemic episodes and DKA at 3 years
10. treatment switching probabilities were estimated directly from the Kaplan–Meier curves
11. subgroup – individuals with a baseline HbA1c of < 8.5% (69 mmol/mol)
12. subgroup – individuals with a baseline HbA1c of ≥ 8.5% (69 mmol/mol)
TABLE 58 Lifetime incidence of diabetic complications per 100 years for an adult with T1DM in the base-case
economic model
Diabetic complication MDI+DAFNE Pump+DAFNE Incremental
Microalbuminuria 2.1610 2.0818 –0.0792
Macroalbuminuria 1.9461 1.8419 –0.1042
ESRD 1.7084 1.6162 –0.0922
Death due to ESRD 1.0070 0.9474 –0.0597
Clinical neuropathy 1.6179 1.5292 –0.0888
PAD with amputation 0.4526 0.4320 –0.0205
Background retinopathy 1.1388 1.0645 –0.0743
Proliferative retinopathy 0.0441 0.0457 0.0015
Macular oedema 0.0385 0.0398 0.0013
Blindness 0.0252 0.0254 0.0002
First cardiovascular disease 1.9191 1.9106 –0.0085
Cardiovascular disease 4.7381 4.7198 –0.0183
MI 2.4818 2.4709 –0.0110
First MI 1.6111 1.6048 –0.0062
Fatal MI 1.2331 1.2306 –0.0025
Stroke 0.3251 0.3241 –0.0010
First stroke 0.2924 0.2915 –0.0008
Fatal stroke 0.0713 0.0713 0.0000
HF 0.5720 0.5695 –0.0025
First HF 0.4601 0.4581 –0.0020
Fatal HF 0.0334 0.0330 –0.0004
Angina 1.3592 1.3553 –0.0039
Severe hypoglycaemia 4.3911 1.2783 –3.1128
DKA 7.0059 4.6286 –2.3773
Life expectancy (years) 29.7615 30.0851 0.3236
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13. subgroup – individuals with a baseline HbA1c of ≥ 7.5% (58 mmol/mol)
14. subgroup – individuals with a baseline HbA1c of ≥ 7.5% (58 mmol/mol) and < 8.5% (69 mmol/mol)
15. subgroup – individuals with a baseline HbA1c of ≥ 8.5% (69 mmol/mol) and < 9.5% (80 mmol/mol)
16. subgroup – individuals with a baseline HbA1c of ≥ 9.5% (80 mmol/mol)
17. subgroup – individuals in the per-protocol population
18. subgroup – individuals in the per-protocol population and no treatment switching is included in the model.
Structural uncertainty and potential subgroup effects were explored in the scenario analyses with the
long-term model.
Much like the EEACT, uncertainty due to potential decreases in price of insulin pumps was explored in
these scenario analyses.
Four further scenario analyses were conducted around the different methods that could be used to
estimate each patient’s HbA1c in the model. A scenario analysis was conducted in which HbA1c was
estimated using beta regression in the ITT population rather than the per-protocol population. As the ITT
population includes switchers in their originally assigned treatment groups, a further scenario analysis was
conducted using the regression estimated in the ITT population where the individuals in the model did
not experience a change in HbA1c when they switched treatment, as these effects were already included in
the estimate of the relative treatment effect of pump + DAFNE versus MDI + DAFNE. Uncertainty in the
long-term changes in HbA1c was explored by using data observed in the DDCT trial for both of the model
arms. As there was no information in the DCCT trial on different HbA1c trajectories for pump or MDI users,
the same trajectory was used in both model arms, which effectively assumes that the treatment effect for
pump users in the REPOSE Trial is maintained for a lifetime. Uncertainty in the HbA1c of individuals after
the REPOSE Trial was also explored by assuming that all individuals returned to their baseline HbA1c after
the third model year. This is a very conservative assumption, but gives some idea of the least favourable
scenario to pump + DAFNE. The effect of assuming that changes in HbA1c occurred one model cycle
(1 year) earlier than the base case on the model outcomes was explored. Full details on the reason for
and rationale behind scenario analyses 4–8 are given earlier (see Chapter 3, Estimation of each individual’s
glycated haemoglobin and Duration of treatment effectiveness beyond the trial period).
The effect of assuming that the second-year risk functions for severe hypoglycaemia and DKA were
applied for the rest of an individual’s lifetime was tested by instead assuming that individuals in both arms
returned to their risk of severe hypoglycaemia and DKA at baseline. Full details on this scenario analysis is
given earlier (see Chapter 3, Estimating severe hypoglycaemic events and diabetic ketoacidosis events).
Finally, the validity of the treatment switching models was testing by assuming directly using the risks of
switching observed in the Kaplan–Meier curves. In this scenario, treatment switching was a random event
that did not depend on HbA1c, number of severe hypoglycaemic episodes in the last year and number
of DKAs last year, as was used in the base case. Full details on this scenario analysis are given earlier
(see Chapter 3, Incorporating treatment switching).
Further to the one-way scenario analyses, a threshold analysis was conducted to determine the HbA1c fall
that future pumps would need to have to be considered cost-effective. Full details on this threshold
analysis are given earlier (see Chapter 3, Threshold analysis).
Results of the one-way scenario analyses
The one-way scenario analyses are presented in Table 59. The ICER did not fall below £30,000 per QALY
gained in any of the scenario analyses. Furthermore, the subgroup analyses did not indicate that the ICER
for pump + DAFNE compared with MDI + DAFNE will fall below £30,000 per QALY gained for any
identified pre-specified subgroup in the REPOSE Trial patient population. The most favourable ICER to
pump + DAFNE was observed when a 50% reduction in the price of insulin and insulin pump consumables
was modelled; however, the ICER in this scenario was £46,578, which is above the maximum acceptable
DOI: 10.3310/hta21200 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 20
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Heller et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
117
TABLE 59 One-way sensitivity analyses and subgroup analyses conducted using the Sheffield Type 1 Diabetes
Policy Model
Analysis
MDI+DAFNE Pump+DAFNE Incremental
Total
discounted
costs (£)
Total
discounted
QALYs
Total
discounted
costs (£)
Total
discounted
QALYs
Total
discounted
costs (£)
Total
discounted
QALYs
ICER
(£ per QALY
gained)
Base case
PSA 81,785 12.9845 100,617 13.1105 18,832 0.1260 149,483
Deterministic 70,132 12.6719 90,581 12.8166 20,448 0.1447 141,312
Scenario
Pump prices were
estimated from
Riemsma et al.8
70,083 12.6719 89,759 12.8166 19,677 0.1447 135,977
25% price reduction
in insulin pumps and
consumables
69,690 12.6719 83,285 12.8166 13,594 0.1447 93,945
50% price reduction
in insulin pumps and
consumables
69,248 12.6719 75,989 12.8166 6740 0.1447 46,578
ITT estimate of
treatment effect
71,238 12.7130 91,307 12.7935 20,069 0.0805 249,338
ITT estimate of
treatment effect and
no change in HbA1c
if an individual
switches treatment
70,994 12.8239 70,994 12.6475 19,390 0.1764 109,897
Post-trial HbA1c
progression in both
arms is estimated
from the DCCT
69,382 12.7211 89,523 12.8412 20,141 0.1202 167,613
Individuals return to
their baseline HbA1c
after 3 years and no
progression thereafter
67,471 12.9472 88,462 12.9162 20,991 –0.0310 Dominated
HbA1c effects occur
one model cycle
earlier
71,220 12.6514 90,589 12.7528 19,369 0.1014 190,974
Individuals return to
their baseline risk of
hypoglycaemic
episodes and DKA at
3 years
70,102 12.6725 90,719 12.8565 20,616 0.1841 111,998
Switching
probabilities were
estimated directly
from the
Kaplan–Meier curves
69,318 12.6740 90,904 12.7735 21,586 0.0995 216,871
Subgroup
Individuals with a
baseline HbA1c
< 8.5%
54,473 13.2733 76,758 13.3434 22,284 0.0701 317,893
Individuals with a
baseline HbA1c
≥ 8.5%
82,769 12.1320 100,508 12.2979 17,739 0.1659 106,909
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ICER range of £20,000–30,000 that is usually used by UK decision-makers when deciding whether or not
a health technology is cost-effective. Although the ICERs are more favourable to pump + DAFNE in the
long-term modelling than in the EEACT, the long-term modelling does not indicate that pump + DAFNE is
likely to be considered a cost-effective treatment pathway if it were to be appraised by NICE.
An important scenario to note is the one in which the HbA1c effects occur one model cycle earlier.
Results of the threshold analysis
The results of the two-way price and effectiveness threshold analysis for a certain reduction in HbA1c are
given in Table 60. When the annual pump cost is assumed to be £2060 then the analysis shows that the
reduction in HbA1c (for CSII compared with MDI) would need to be ≥ 11 mmol/mol (1.0%) for pumps to
be considered cost-effective (ICER £22,757). When the annual cost is 25% lower (£1545) then a HbA1c
reduction of > 7.7 mmol/mol (0.7%) would be needed to have an ICER of < £20,000 per QALY gained.
When the annual cost is halved (£1030) then a HbA1c reduction of 4.4 mmol/mol (0.4%) would be sufficient
to have an ICER of < £20,000 per QALY gained.
The results of the two-way price and effectiveness threshold analysis for when the uncertainty in the
treatment effect is estimated using the dispersion parameter formula used in the REPOSE Trial is given in
Table 61. When the annual cost is assumed to be £2060 then the analysis shows that the reduction in
HbA1c (for pumps vs. MDI) would need to be > 9.8 mmol/mol (0.9%) for pumps to have an ICER of
< £30,000 per QALY gained. When the annual cost of insulin pumps and consumables is 25% lower
(£1545), then a HbA1c reduction of 7 mmol/mol (0.6%) would be needed to have an ICER of < £30,000
per QALY gained. When the annual cost is halved (£1030) then a HbA1c reduction of 4.4 mmol/mol (0.4%)
would be sufficient to have an ICER of < £20,000 per QALY gained.
TABLE 59 One-way sensitivity analyses and subgroup analyses conducted using the Sheffield Type 1 Diabetes
Policy Model (continued )
Analysis
MDI+DAFNE Pump+DAFNE Incremental
Total
discounted
costs (£)
Total
discounted
QALYs
Total
discounted
costs (£)
Total
discounted
QALYs
Total
discounted
costs (£)
Total
discounted
QALYs
ICER
(£ per QALY
gained)
Individuals with a
baseline HbA1c
≥ 7.5%
73,944 12.4866 92,481 12.6614 18,536 0.1747 106,090
Individuals with a
baseline HbA1c
≥ 7.5% and < 8.5%
58,654 12.9513 79,560 13.0973 20,906 0.1460 143,214
Individuals with a
baseline HbA1c
≥ 8.5% and < 9.5%
62,515 13.3038 83,006 13.4234 20,491 0.1195 171,447
Individuals with a
baseline HbA1c
≥ 9.5%
97,111 11.5164 111,862 11.6564 14,751 0.1400 105,351
Individuals in the
per-protocol
population
69,739 12.5982 89,363 12.7142 19,623 0.1160 169,143
Individuals in the
per-protocol
population and no
treatment switching
69,874 12.6018 92,601 12.7380 22,727 0.1362 166,831
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The threshold analysis indicates if a future study of pumps + DAFNE versus MDI + DAFNE were to be
conducted then the cost of insulin pumps and their associated consumables should be taken into account
when determining the appropriate effect size to power the study on. At current prices, per-protocol effect
sizes of > 5.5 mmol/mol would be required in the whole population who would be eligible for pump
therapy for insulin pumps to have an ICER in the £20,000–30,000 per QALY gained range at which NICE is
likely to consider them to be a cost-effective use of NHS resources.
Summary of the economic analysis results
None of the analyses conducted in the EEACT or the long-term modelling had an ICER of < £30,000 per
QALY gained. Furthermore, no subgroup was identified for which the ICER was < £30,000 per QALY
gained. This indicates that pump + DAFNE is unlikely to be considered to be a cost-effective use of NHS
resources by NICE in the UK compared with the current practice of MDI + DAFNE, as the ICERs are all
above the ICER range of £20,000–30,000 per QALY gained, which is usually used by NICE to determine
the cost-effectiveness of health technologies. The findings of this analysis are consistent with the current
recommended care pathway for adults with T1DM in the UK, who should be offered structured education
with MDI, ideally around 12 months after diagnosis (but failing that at any later stage).
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Chapter 7 Results of the psychosocial evaluation
Completion rates and final sample
Quantitative data
Questionnaires were administered to all of the participants at all of the time points. Table 62 shows
completion rates at each time point. High levels of questionnaire completeness were observed across all
questionnaires and follow-up (around 90% completed at each follow-up). A total of 264 participants of
TABLE 62 Questionnaire completeness stratified by treatment group and follow-up
Questionnaire Follow-up
Treatment group, n (%)
Total (N= 267), n (%)Pump (N= 132) MDI (N= 135)
SF-12 Baseline 131 (99.2) 132 (97.8) 264 (98.9)
6 months 128 (97.0) 120 (88.9) 248 (92.9)
12 months 121 (91.7) 119 (88.1) 240 (89.9)
24 months 124 (93.9) 117 (86.7) 241 (90.3)
DSQOL Baseline 131 (99.2) 132 (97.8) 264 (98.9)
6 months 129 (97.7) 120 (88.9) 249 (93.3)
12 months 121 (91.7) 119 (88.1) 240 (89.9)
24 months 124 (93.9) 116 (85.9) 240 (89.9)
WHOQOL-BREF Baseline 131 (99.2) 132 (97.8) 264 (98.9)
6 months 129 (97.7) 120 (88.9) 249 (93.3)
12 months 121 (91.7) 119 (88.1) 240 (89.9)
24 months 124 (93.9) 117 (86.7) 241 (90.3)
HFS Baseline 131 (99.2) 132 (97.8) 264 (98.9)
6 months 129 (97.7) 120 (88.9) 249 (93.3)
12 months 121 (91.7) 119 (88.1) 240 (89.9)
24 months 124 (93.9) 117 (86.7) 241 (90.3)
HADS Baseline 131 (99.2) 132 (97.8) 264 (98.9)
6 months 129 (97.7) 120 (88.9) 249 (93.3)
12 months 121 (91.7) 119 (88.1) 240 (89.9)
24 months 124 (93.9) 117 (86.7) 241 (90.3)
EQ-5D Baseline 131 (99.2) 132 (97.8) 264 (98.9)
6 months 128 (97.0) 120 (88.9) 248 (92.9)
12 months 120 (90.9) 116 (85.9) 236 (88.4)
24 months 124 (93.9) 116 (85.9) 240 (89.9)
DTSQ Baseline 131 (99.2) 132 (97.8) 264 (98.9)
6 months 128 (97.0) 119 (88.1) 247 (92.5)
12 months 121 (91.7) 118 (87.4) 239 (89.5)
24 months 124 (93.9) 116 (85.9) 240 (89.9)
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the 267 participants attending the DAFNE course completed at least one of the psychosocial
questionnaires (n = 128 pump, n = 117 MDI), with a minimum of 236 participants completing
questionnaires at all time points. The lowest completion rate on any individual measure was 86% of
participants. The completion rate was slightly higher for participants who were allocated to pump than
participants allocated to MDI, which reflects the slightly higher dropout rate in the MDI group.
Qualitative interviews
A total of 45 patients were recruited, of whom 25 were randomised to the pump and 20 to the MDI arm
of the trial. Full details of the sample are provided in Table 63. Three participants (two ‘pump’, one ‘MDI’)
could not be contacted for round 2 interviews.
The final educator sample comprised 12 nurses and six dietitians; owing to staff leave it was not possible
to interview the dietitian in one of the centres. See Table 64 for full details of the educator sample. As can
be seen from this table, there was diversity among the educators in terms of diabetes, DAFNE and pump
experience. All of the educators were women.
Findings
The findings of the mixed-methods study are structured and reported under the six original study aims, with
qualitative and/or quantitative data drawn on, as appropriate, to answer and address particular questions.
TABLE 63 Demographic and clinical characteristics of patient sample at baseline
(qualitative substudy)
Variable Scoring Total (N= 45)
Age (years) Mean (SD) 40 (12.8)
Range 19–66
Sex (%) Female 48.9
Diabetes duration (years) Mean (SD) 17.4 (12.4)
Range 1 to 41
Occupation, n (%) Professional 14 (31)
Semiskilled 16 (35.5)
Student 4 (9)
Unemployed 4 (9)
Unskilled 7 (15.5)
HbA1c
mmol/mol Mean (SD) 71 (14)
Range 46–109
% Mean (SD) 8.6 (1.3)
Range 6.4–11.7
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Study aims 1 and 2
1. To establish whether or not, and why, there are differences in QoL and other psychological outcomes
between patients using pump and MDI regimens.
2. To examine whether or not, and why, QoL and other outcomes change over time.
Overview
Material that is relevant to addressing aims 1 and 2 has been combined in this final report because of the
strong overlaps in the content. In this section we begin by presenting quantitative data on ≥ 236 participants
before going on to draw on patients’ interview accounts to aid interpretation of quantitative findings.
Quantitative data
Tables 65–67 show QoL outcomes at 6, 12 and 24 months, respectively. Table 68 shows DTSQ data at the
same time points.
Improvement was seen across most psychosocial outcomes and time points for both treatment groups.
There were no statistically significant differences at 6 months between the pump and MDI cohorts on any
psychosocial measure. Participants in the pump group had better improvement in treatment satisfaction
at all time points using DTSQ, but not using DSQOL; however, the difference was statistically significant
only at 12 and 24 months (p = 0.067 at 6 months; p < 0.001 at both 12 and 24 months). Furthermore,
participants in the pump group reported statistically improved diabetes-specific QoL at 24 months
compared with the MDI group (p = 0.006); however, this was not the case at 6 or 12 months and could
be due to chance rather than the treatment effect. We note that, if 6-month treatment satisfaction is
reanalysed using a mixed-effects linear regression adjusted for baseline score, HbA1c, centre and course,
as was done for the other Qol measures (rather than a non-parametric test), the treatment difference
is similar and is statistically significant (p = 0.004), in part due to the increased precision from covariate
adjustment.
There were some statistically significant differences on some subdomains, using p < 5% as the level for
statistical significance. A caveat is required concerning the number of variables examined and tests
performed, as multiple testing was not adjusted for. A statistically significant difference was observed on
the social relations domain of the WHOQoL-BREF generic QoL measure in favour of the pump participants
(p = 0.026), but this was seen only at 6 months, was one of 12 tests of significance and is likely to be a
chance finding.
TABLE 64 Educator sample (qualitative substudy)
Variable Scoring Total (N= 18)
Occupation, n (%) Nurse 12 (67)
Dietitian 6 (33)
Experience of working in T1DM (years) Mean (SD) 14 (7.7)
Range 5–29
Experience of DAFNE (years) Mean (SD) 7.9 (4.3)
Range 1–15
Experience of pump therapy (years) Mean (SD) 4 (4.3)
Range 0–15
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The DSQOL results (see Table 69) at 24 months showed statistically significant improvements (reductions)
in both the pump (mean reduction of 8.2, 95% CI 5.84 to 10.50; p < 0.00001) and MDI (mean reduction
4.2, 95% CI 1.71 to 6.61; p = 0.001) groups, but with greater improvements in the pump group in the
overall score (difference 3.8; p = 0.006) and some subdomains. The improvement in DSQOL diet
restrictions was larger for the pump group than the MDI group at both 12 and 24 months (12-month
adjusted MD in change from baseline –4.1, 95% CI –7.2 to –1.0; p = 0.010; 24-month adjusted MD in
change from baseline –5.1, 95% CI –8.6 to –1.6; p = 0.004: lower scores represent better outcomes).
A slightly smaller difference was observed at 6 months, which was not statistically significant (adjusted MD
–3.3, 95% CI –6.9 to 0.2; p = 0.061). The pump group also had better improvement in DSQOL daily hassle
TABLE 65 Quality-of-life secondary outcomes: MD in change from baseline at 6 months
QoL outcome Domain
Treatment group
Adjusted
differencea
(95% CI) p-value
Pump MDI
n Mean (SD) n Mean (SD)
SF-12 PCS 127 1.2 (6.1) 116 0.5 (8.6) 0.3 (–1.4 to 2.0) 0.721
MCS 127 0.2 (8.8) 117 0.9 (9.9) –0.8 (–2.9 to 1.3) 0.452
DSQOL Total score 128 –5.2 (12.2) 117 –4.4 (11.2) –0.1 (–2.8 to 2.6) 0.935
Social relations 128 –2.2 (11.8) 117 –3.0 (13.2) 1.5 (–1.2 to 4.2) 0.276
Leisure time
restrictions and
flexibility
128 –5.1 (16.6) 117 –4.4 (18.5) –0.1 (–3.8 to 3.7) 0.968
Physical complaints 128 –6.0 (17.0) 117 –4.8 (13.8) –0.1 (–3.5 to 3.3) 0.953
Worries about the
future
128 –7.9 (20.4) 117 –7.5 (19.4) –0.7 (–5.5 to 4.1) 0.779
Daily hassle of
functions
128 –6.3 (18.9) 117 –5.0 (18.7) –0.8 (–5.0 to 3.4) 0.700
Diet restrictions 128 –11.3 (18.3) 117 –6.4 (16.0) –3.3 (–6.9 to 0.2) 0.061
Treatment
satisfaction (PWTSS)
118 2.1 (4.4) 109 2.1 (4.8) 0.1 (–0.7 to 1.0) 0.791
WHOQOL-BREF Physical health 127 0.4 (2.3) 117 0.2 (2.3) 0.1 (–0.4 to 0.6) 0.740
Psychological 128 0.1 (1.9) 117 0.4 (2.2) –0.3 (–0.7 to 0.2) 0.225
Social relationships 127 –0.3 (2.7) 117 0.3 (3.0) –0.7 (–1.3 to –0.1) 0.026
Environment 128 0.1 (1.7) 117 0.4 (1.6) –0.3 (–0.7 to 0.1) 0.170
HFS Behaviour score 127 –1.7 (4.9) 117 –0.2 (4.8) –0.9 (–2.0 to 0.1) 0.074
Worry score 128 –4.0 (10.9) 117 –2.8 (9.5) –0.1 (–2.4 to 2.1) 0.906
HADS Anxiety score 128 –0.2 (3.0) 117 –0.6 (3.3) 0.4 (–0.3 to 1.1) 0.260
Depression score 128 –0.3 (2.9) 117 –0.2 (2.5) 0.1 (–0.5 to 0.7) 0.735
EQ-5D Utility index 127 –0.02 (0.17) 117 –0.01 (0.18) –0.02 (–0.06 to 0.02) 0.382
MCS, Mental Component Summary; PCS, Physical Component Summary; PWTSS, Preference-Weighted Treatment
Satisfaction Score.
a Calculated using mixed-effects regression adjusted for baseline QoL score, centre, DAFNE course and baseline HbA1c.
The SF-12 summaries are scored on a scale from 0 (poor) to 100 (good). The DSQOL domains and total score are scored
on a 0 (good) to 100 (poor) scale and DSQOL treatment satisfaction is scored on a scale from 0 (poor) to 100 (good).
WHOQOL-BREF domains are scored from 0 (poor) to 100 (good). The HFS behaviour score is scaled from 10 to 50 and
the HFS worry score is scaled from 17 to 85; in both cases, higher scores represent more fear. HADS domains are scored
from 0 (good) to 21 (poor) scale. The EQ-5D score is measured on a scale from –0.56 to 1.00 (good health).
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or functions at both 12 and 24 months: at 24 months the score had decreased by 9.6 points in the pump
group compared with 3.6 points in the MDI group (adjusted MD –6.3, 95% CI –10.9 to –1.8; p = 0.006).
However, there was a wide spread of changes in DSQOL, with some patients in both groups reporting
deterioration at 24 months compared with baseline, as shown in Figure 19.
TABLE 66 Quality-of-life secondary outcomes: MD in change from baseline at 12 months
QoL outcome Domain
Treatment group
Adjusted
differencea
(95% CI) p-value
Pump MDI
n Mean (SD) n Mean (SD)
SF-12 PCS 119 0.7 (7.7) 115 1.1 (6.9) –0.4 (–2.1 to 1.3) 0.669
MCS 121 –1.1 (10.8) 116 –1.0 (10.9) –0.1 (–2.6 to 2.3) 0.912
DSQOL Total score 121 –5.8 (11.4) 116 –3.6 (10.1) –1.5 (–4.0 to 1.1) 0.254
Social relations 121 –2.9 (12.4) 116 –1.5 (11.2) –0.7 (–3.6 to 2.1) 0.620
Leisure time
restrictions and
flexibility
121 –5.2 (17.7) 115 –4.5 (15.9) 0.0 (–3.8 to 3.7) 0.981
Physical complaints 121 –5.6 (15.2) 115 –4.4 (13.0) –0.4 (–3.5 to 2.8) 0.824
Worries about the
future
121 –8.1 (21.7) 116 –6.4 (20.9) –2.0 (–7.0 to 2.9) 0.421
Daily hassle or
functions
121 –9.1 (19.4) 116 –3.5 (18.7) –5.0 (–9.2 to –0.8) 0.019
Diet restrictions 121 –12.8 (17.1) 115 –7.0 (16.7) –4.1 (–7.2 to –1.0) 0.010
Treatment
satisfaction (PWTSS)
109 1.5 (4.6) 112 1.4 (4.4) 0.1 (–0.8 to 1.0) 0.839
WHOQOL-BREF Physical health 121 0.0 (2.0) 116 0.1 (2.2) –0.1 (–0.6 to 0.4) 0.596
Psychological 121 –0.1 (1.9) 116 0.1 (2.0) –0.2 (–0.7 to 0.2) 0.341
Social relationships 121 –0.2 (3.0) 116 –0.1 (2.5) –0.3 (–0.9 to 0.4) 0.375
Environment 121 0.2 (1.7) 116 0.3 (1.7) –0.1 (–0.5 to 0.3) 0.727
HFS Behaviour score 120 –1.2 (5.2) 116 –0.1 (5.1) –1.0 (–2.1 to 0.2) 0.091
Worry score 121 –4.3 (12.5) 116 –3.3 (10.7) –0.6 (–3.1 to 1.8) 0.602
HADS Anxiety score 121 –0.1 (3.2) 116 –0.3 (3.1) 0.2 (–0.6 to 0.9) 0.664
Depression score 121 –0.3 (3.3) 116 0.4 (2.9) –0.5 (–1.2 to 0.2) 0.180
EQ-5D Utility Index 120 –0.03 (0.15) 113 –0.02 (0.17) 0.00 (–0.04 to 0.04) 0.876
MCS, Mental Component Summary; PCS, Physical Component Summary; PWTSS, Preference-Weighted Treatment
Satisfaction Score.
a Calculated using mixed-effects regression adjusted for baseline QoL score, centre, DAFNE course and baseline HbA1c.
The SF-12 summaries are scored on a scale from 0 (poor) to 100 (good). The DSQOL domains and total score are scored
on a 0 (good) to 100 (poor) scale and the treatment satisfaction is scored on a scale from 0 (poor) to 100 (good).
WHOQOL-BREF domains are scored from 0 (poor) to 100 (good). The HFS behaviour score is scaled from 10 to 50 and
the HFS worry score is scaled from 17 to 85; in both cases, higher scores represent more fear. HADS domains are scored
from 0 (good) to 21 (poor) scale. The EQ-5D score is measured on a scale from –0.56 to 1.00 (good health).
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The HFS showed no difference in behaviour score but less worry about hypoglycaemia in the pump arm at
24 months only (p = 0.01). Higher treatment satisfaction by DTSQ was reported by pump users at all time
points, and although this was not statistically significant at 6 months, statistical significance was reached at
12- and 24-month follow-up periods, although the absolute difference at 24 months was small at 4.0.
EQ5D, SF-12, WHOQOL-BREF and HADS scores showed no differences between groups at any time.
TABLE 67 Quality-of-life secondary outcomes: MD in change from baseline at 24 months
QoL outcome Domain
Treatment group
Adjusted
differencea
(95% CI) p-value
Pump MDI
n Mean (SD) n Mean (SD)
SF-12 PCS 122 0.3 (7.9) 112 1.0 (8.3) –0.4 (–2.1 to 1.3) 0.657
MCS 123 2.1 (11.2) 114 0.5 (10.3) 1.6 (–0.7 to 4.0) 0.175
DSQOL Total score 123 –8.2 (13.1) 114 –4.2 (13.2) –3.8 (–6.5 to –1.1) 0.006
Social relations 123 –5.7 (12.9) 113 –2.7 (14.8) –2.5 (–5.4 to 0.4) 0.092
Leisure time
restrictions and
flexibility
123 –8.1 (17.0) 113 –3.6 (19.7) –4.6 (–8.4 to –0.9) 0.016
Physical complaints 123 –8.7 (17.2) 113 –4.8 (16.6) –3.6 (–7.3 to 0.0) 0.049
Worries about the
future
123 –11.9 (23.3) 113 –7.8 (21.2) –4.8 (–9.7 to 0.2) 0.058
Daily hassle or
functions
123 –9.6 (21.2) 113 –3.6 (21.5) –6.3 (–10.9 to –1.8) 0.006
Diet restrictions 123 –12.8 (19.5) 113 –6.9 (19.3) –5.1 (–8.6 to –1.6) 0.004
Treatment
satisfaction (PWTSS)
113 1.9 (4.5) 108 1.5 (5.4) 0.5 (–0.5 to 1.4) 0.317
WHOQOL-BREF Physical health 123 0.5 (2.4) 114 –0.1 (2.2) 0.5 (0.0 to 1.0) 0.067
Psychological 123 0.5 (2.5) 114 0.3 (2.4) 0.2 (–0.4 to 0.7) 0.567
Social relationships 123 0.0 (3.3) 114 0.1 (2.9) –0.2 (–0.9 to 0.5) 0.627
Environment 122 0.4 (2.2) 114 0.3 (2.0) 0.3 (–0.2 to 0.8) 0.211
HFS Behaviour score 122 –1.4 (5.6) 114 –0.6 (5.1) –0.4 (–1.5 to 0.7) 0.442
Worry score 123 –6.7 (13.0) 114 –2.9 (12.5) –3.4 (–6.0 to –0.8) 0.010
HADS Anxiety score 123 –1.0 (4.0) 114 –0.5 (3.5) –0.5 (–1.3 to 0.4) 0.255
Depression score 123 –1.0 (3.8) 114 –0.2 (3.3) –0.7 (–1.5 to 0.1) 0.105
EQ-5D Utility Index 123 0.00 (0.18) 113 –0.02 (0.18) 0.02 (–0.03 to 0.06) 0.464
MCS, Mental Component Summary; PCS, Physical Component Summary; PWTSS, Preference-Weighted Treatment
Satisfaction Score.
a Calculated using mixed-effects regression adjusted for baseline QoL score, centre, DAFNE course, baseline HbA1c.
The SF-12 summaries are scored on a scale from 0 (poor) to 100 (good). THE DSQOL domains and total score are scored
on a 0 (good) to 100 (poor) scale and the treatment satisfaction is scored on a scale from 0 (poor) to 100 (good).
WHOQOL-BREF domains are scored from 0 (poor) to 100 (good). The HFS behaviour score is scaled from 10 to 50 and
the HFS worry score is scaled from 17 to 85; in both cases, higher scores represent more fear. HADS domains are scored
from 0 (good) to 21 (poor) scale. The EQ-5D score is measured on a scale from –0.56 to 1.00 (good health).
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Per-protocol results
Some patients switched from pump to MDI and vice versa, and they may be atypical. We therefore carried
out an exploratory per-protocol analyses of psychosocial outcomes after excluding those who switched,
and obtained, the following results.
Both groups showed statistically significant improvements in DSQOL as shown in Table 69.
The findings were similar with HADS-anxiety – both groups showed small improvements but this reached
statistical significance only in the pump arm (Table 70). Large improvements would not be expected
because baselines scores were quite low (pump 6.8, MDI 6.1)
Hospital Anxiety and Depression Scale-depression scores improved in both groups but the change only reached
statistical significance in the pump group (Table 71). Again, baseline scores were low (pump 4.4, MDI 3.7).
Qualitative interpretation: cross-cutting improvements in quality of life
We turn now to qualitative data to (1) help explain the general improvements found across most
psychosocial outcomes for both treatment groups and (2) aid the interpretation of those findings that
reached statistical significance at more than one time point (i.e. findings relating to treatment satisfaction,
dietary restrictions and daily hassles of function).
TABLE 68 Quality-of-life secondary outcomes: DTSQ change from baseline at 6 and 24 months, DTSQc raw scores at
12 months
Follow-up
(months) QoL outcome
Treatment group
Differencea
(95% CI) p-valueb
Pump MDI
n Median (IQR) n Median (IQR)
6 Perceived frequency of
hyperglycaemia
126 –1 (–2 to 0) 116 –1 (–2 to 1) 0.0 (–1.0 to 0.0) 0.182
Perceived frequency of
hypoglycaemia
127 0 (–1 to 1) 116 –1 (–2 to 0) 0.0 (0 to 1.0) 0.296
Treatment satisfaction 126 8 (3 to 12) 116 5 (1 to 10) 2.0 (1.0 to 4.0) 0.067
12 Perceived change in
frequency of
hyperglycaemia
121 0 (–2 to 1) 118 1 (–1 to 2) 0.0 (0.0 to 1.0) 0.131
Perceived change in
frequency of
hypoglycaemia
121 –1 (–2 to 0) 118 –1 (–2 to 0) 0.0 (0.0 to 1.0) 0.345
Treatment satisfaction
(change)
121 16 (13 to 18) 118 12 (7 to 16) –3.0 (–4.0 to –1.0) < 0.001
24 Perceived frequency of
hyperglycaemia
122 –1 (–2 to 0) 113 –1 (–2 to 0) 0.0 (–1.0 to 0.0) 0.071
Perceived frequency of
hypoglycaemia
123 0 (–1 to 1) 113 0 (–2 to 0) 0.0 (0.0 to 1.0) 0.504
Treatment satisfaction 122 8 (3 to 12) 113 5 (0 to 9) 4.0 (2.0 to 5.0) < 0.001
a Calculated as described in Newson 2006.139
b Calculated using Wilcoxon–Mann–Whitney U-test. DTSQ treatment satisfaction is scored from 0 to 36 and DTSQc
treatment satisfaction (change) is scored from –18 to 18; in both cases, higher scores represent better outcomes. DTSQ
perceived frequency scores are scaled from 0 (infrequent) to 6 (frequent). DTSQc perceived change in frequency scores
are scaled from –3 (less often) to 3 (more often).
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TABLE 69 Overall change in DSQOL within arms at 24 months
Treatment group n Mean change (SD) 95% CI p-valuea
MDI 114 –4.16 (13.20) –6.61 to –1.71 0.0010
Pump 123 –8.17 (13.07) –10.50 to –5.84 < 0.00001
a Calculated using a paired t-test.
TABLE 70 Overall change in HADS-anxiety within arms at 24 months
Treatment group n Mean change (SD) 95% CI p-value
MDI 114 –0.51 (3.49) –1.16 to 0.14 0.1221
Pump 123 –0.95 (3.95) –1.66 to –0.25 0.0087
TABLE 71 Overall change in HADS-depression within arms at 24 months
Treatment group n Mean change (SD) 95% CI p-value
MDI 114 –0.15 (3.35) –0.77 to 0.47 0.6355
Pump 123 –0.99 (3.79) –1.67 to –0.31 0.0044
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FIGURE 19 Changes in overall DSQOL at 24 months. (a) Pump; and (b) MDI.
RESULTS OF THE PSYCHOSOCIAL EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
130
The overarching improvements in QoL observed in this study mirror those experienced by other cohorts of
patients who have attended the DAFNE programme2,78,124,153 and, arguably, are largely attributable to
conversion to a DAFNE approach. Indeed, when they were interviewed after their courses and 6 months
later, patients in both arms reported very similar benefits and improvements to their lives. For example,
patients in both arms – like other DAFNE graduates who have taken part in longitudinal qualitative
research154 – reported a renewed enthusiasm for managing their diabetes after attending their courses and
being more open to discussing aspects of their condition and self-management practices with family and
friends. As a consequence, patients also discussed being more open to seeking and accepting support
from these family members and friends.
Patients in both arms – like other DAFNE graduates143 – also reported feeling more in control of their
diabetes/blood glucose levels and more committed to adhering to their treatment regimens (e.g. undertaking
SMBG, administering insulin to cover the carbohydrate content of meals/snacks). Notably, however, although
participants in the MDI arm tended to attribute these kinds of benefits and improvements to the education
and instruction in DAFNE principles received during their courses, those in the pump arm – such as the
participant quoted below – tended to accredit them to use of the insulin pump:
Because the pumps given me more awareness, like well if I do eat this and I give myself some insulin
for it I’ll need to know what my blood sugar is then, so I will test, so I’ve been doing more tests as a
result of doing more insulin with the pump.
P43.2
In addition, patients in both arms reported similar improvements in QoL arising from use of their
automated bolus advisors. As described in detail elsewhere,143 patients who lacked confidence in their
mathematical skills, or whose concentration could be compromised by high/low blood glucose, described
the benefits and ‘peace of mind’ that arose from having the advisor to calculate their insulin doses for
them. Those who were more confident about their mathematical ability also described liking and
benefiting from using their advisor as these devices saved time and effort when calculating doses. Others
still reported liking the data storage facility, as this reduced the burden of maintaining a paper diary.155
Diabetes Treatment Satisfaction Questionnaire: treatment satisfaction (better for patients using
pump therapy) After attending their course, patients in both arms reported high levels of satisfaction
with their new regimens. Specifically, patients using pump and MDI – like other cohorts of DAFNE
graduates143 – described feeling more confident and in control of their condition by virtue of having been
given what they saw as a more logical approach and a better toolkit for managing their diabetes:
And I think the DAFNE course gave, gave me the confidence to, to manipulate my dosing . . . be more
consistent with corrections. And once, and better carb-counting so once the corrections . . . once
you’re right then it’s, you don’t need the corrections. I’ve found it much easier to maintain now.
M01.1
I’m testing me blood sugars a lot more, I’m counting, I’ve learnt how to count me carbohydrate
properly. And I’ve learnt how to manage, if I ever get really sick, really bad sick days, I’ve learnt how to
control them and deal with them a lot better, a lot better.
P13.1
However, patients using pump therapy also reported treatment benefits that were specific to using the
pump, which helps explain the higher treatment satisfaction levels reported by those in the pump arm of
the trial. For example, patients described how the pump delivered a drip-feed of insulin, which, as P04
suggested, enabled them to enjoy a more flexible lifestyle than had been possible using an injection
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regimen because they no longer had to adhere to routines to maintain their supply of background insulin
by injecting at similar times each day:
Having the basal has just been amazing, just having that constant [supply] and being able to see your
sugars just so constant. And not having to get up at . . . like I used to try and take mine at ten in the
morning and ten at night . . . Whereas now I can just, if I want to sleep in till midday and not eat
anything and I can still wake up with blood sugars at 6 and 7 and be totally fine.
P04.1
Patients using insulin pumps also described liking and valuing having access to a method of insulin delivery
that enabled them to avoiding the pain and discomfort of injecting five or six times a day, as well as being
able to administer insulin doses effortlessly and discreetly, and without the inconvenience of having to find
somewhere private to inject:
. . . if I get taken out to lunch with a client or a supplier, then I don’t need to excuse myself or I don’t
need to say sorry . . . I can do it from where I stand and, and taking something off your belt and so
easy to do in so little time is, is, is great.
P17.1
I can just take my pump out of my pocket and key it, key it in and stick it back in my pocket. I don’t
have to, I don’t have to get my needles out at dinner time and that’s quite nice. And it is nice for it
not to be such a big issue and not to have to get half undressed every time you, you want to have
some insulin.
P01.2
Some patients who engaged in sporting activities described how the device provided them with a more
effective self-management tool to undertake such activities than was possible with MDI. Specifically,
such individuals described liking being able to use a regimen that allowed them to suspend or adjust the
rate of insulin infusion, depending on blood glucose readings, both to take into account the effects of
long-duration physical activity, or, in P09’s case, to permit spontaneous visits to the gym:
Going skiing and having the pump . . . to have that and to be able to just tweak it constantly
throughout the day if just great.
P04.2
Before if you were wanting to go to the gym you’d have to know hours and hours before it, before
your last [background] insulin so that you could either reduce that . . . whereas now you can just say
right I’m going to the gym I’ll just reduce it now or . . . take it off even.
P09.2
The above accounts stood in contrast to those of some individuals in the MDI arm, who identified exercise
and physical activity as areas in which they continued to struggle to manage their blood glucose
effectively, despite making the changes recommended during their DAFNE course:
I wasn’t given that much confidence with regard to doing physical activity and adjusting the dosage.
Um, because my workout varies day in day out, so one time I go to the gym I might be there for an
hour, um, but then one time I go to the gym on the weekend I might be there for an hour plus an
hour in the pool or something like that. And it was just . . . the near enough generic way they give you
of, um, adjusting your dosage, it’s like drop it by 10% or something like that, I didn’t find that that
was effective [ . . . ] that side of things [exercise], it hasn’t really had much of, any impact on.
M09.2
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The greater treatment satisfaction found in the pump arm of the trial can also be explained by patients’
perceptions of the added benefits of pump technology over MDI. These data are considered further under
Study aim 3.
Diabetes-specific quality of life: dietary restrictions (more flexibility and freedom for patients
using pump therapy) Mirroring the accounts of other cohorts of DAFNE graduates,146 patients in both
arms described how their newly acquired knowledge and skills had allowed them to be more flexible and
spontaneous in their food choices. For instance, patients in both arms described feeling more confident
about eating less carbohydrate (which, for some, eliminated a perceived need to eat a snack before going
to bed) and, in certain circumstances, skipping consumption of carbohydrates entirely. Relatedly, patients
also described being more able to alter the timing of meals, as they no longer feared hypoglycaemia if
they did not eat at specified times:
I was so happy the first night I was thinking ‘Oh I don’t need to eat a snack, that’s brilliant, I can just
go to my bed if I want to go to my bed’. Whereas before I’d to wait till like 9, half past 9, to have my
last insulin and have my snack before I went to bed and I was like ‘This is fantastic! I don’t even need
to eat anything before I go to my bed!’.
P18.1
[I] was always very strict, ‘this is what I need to eat, it’s eight o’clock, I need to eat, otherwise there’s
going to be trouble’ . . . I’ve definitely found some freedom in that I don’t have to eat when I don’t
want to eat.
M07.2
However, patients in the pump arm highlighted additional benefits that appeared to be more specific to
using an insulin pump, and which can be used to help explain the greater improvement in DSQOL diet
restrictions in this arm of the trial. For instance, patients using the pump described how they could now
eat a carbohydrate-based snack and administer a bolus accordingly, whereas, when using a MDI regimen,
some reported having skipped a snack because they did not want to have a further injection:
I would rather have a pump than keep on injections and stuff, and it does mean I can have a snack.
Um, you know, I don’t, I don’t really want to, let’s say, have a bag, have a bag of crisps and then
inject myself, it wasn’t very appealing.
P31.2
Some such patients also discussed how, since moving on to pump therapy, they no longer had to restrict
consumption of snacks containing carbohydrates to near to a mealtime in order to avoid having to inject
more than once:
Before, if you were having something to eat, if you wanted something sweet, you’d have it with a
meal, whereas it’s a lot more flexible now. If you want to go out in the afternoon and have a cake or
something, you could . . . you could have a cake and just have a bit of insulin for it.
P25.2
Patients also described feeling more confident and able to dine out because the pump afforded an easy
means of administering a separate bolus for each course. As P27 observed, this made it easier to make an
impromptu decision to have a dessert without the burden of also having to administer a further injection.
Others, such as P33.2, described how the ease with which they could stagger their insulin doses during a
meal meant that they no longer had to worry about hypoglycaemia, particularly if a course arrived later
than expected:
The pump is good because you can make fine adjustments, fine-tuning. You go out for a meal in the
evening and decide to have a dessert at the last minute, so you just take, you know, a few more units
in the bolus. Far nicer than getting out the pen and all of that.
P27.2
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Some people would take it [a single dose] before their meal and then if their meal doesn’t come for so
long, they sit and go, ‘right, where’s the cans of Coke’ but I just feel as if you’ve got more freedom.
You can actually stagger your insulin over a meal, which is good. I find, maybe if you’re sitting for a
long meal, a couple of hours, you can stagger your insulin so it’s, you’re not getting too much
at once.
P33.2
Diabetes-specific quality of life: daily hassles of functions (better for patients using pump
therapy) Although there were no statistically significant differences at 6 months, patients did highlight
factors and experiences in their 6-month interview accounts that might help to explain why the pump
group also had better improvement in the DSQOL daily hassle of functions at both 12 and 24 months.
Notably, patients using pump therapy reflected on how using a pump to administer insulin required less
time and effort, and was ‘less of a chore’ (P25.2) than using pens. This was partly because pressing a
button to administer insulin was a more convenient and expedient option than ‘having the hassle and
worry of getting the needle out’ (P04) and ‘having to crank it up on the pen and then inject’ (P33.2). In
addition, patients, including P30.2, highlighted the advantages of no longer having to take time of out of
their everyday activities to find private locations in which to inject (see also aim 4):
‘Cos when I went to work, with pens, I’d often go into the locker room to inject myself. And now with
the pump, I’ll just take it out of my shirt pocket, type in what I am having, put it back in my shirt
pocket and it’s done.
P30.2
Some patients also described how pump therapy was a less burdensome and time-consuming option
because of the ability to use, set and alter basal rates:
If I was on the pen, you know, I’d be having to take an extra insulin mid-morning, you know,
if my blood sugar was rising . . . So for me it’s just so much easier to be able to set things on a
temporary basis.
P39.2
Cos I’m going to bed and I reach to take my insulin before I go to bed, and it’s like, ‘no, no that
doesn’t have to happen anymore’, so it’s good.
P40.1
Patients also highlighted the advantages of having ‘less paraphernalia to lug around’ (P06.2) by virtue of
using the pump, whether this be when travelling to and from work (P03) or, in P04’s case, when
undertaking recreational activities, such as skiing on a recent holiday:
You’ve for that freedom with the pump, you can do anything whereas [with] the injections you’ve got to
take your pen, you’ve got to take your needles, you’ve got to take your sharps bin, you’ve got to make
sure you’ve got a spare pen in case that one don’t work. Whereas with your pump, I always carry a spare
quick inserter [cannula], a spare tube insert, just in case you’ve any problems or get a blockage or
whatever . . . but they’re nothing, they’ll slip in a rucksack or in your pocket.
P03.2
There is no stress, it’s there, it’s attached. Going skiing and having the pump on was on me was just
so much better than having pens, having to take pens and needles and stuff up the mountain . . .
you’ve just got this thing attached to you and that’s it done with now.
P04.2
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Study aim 3
3. To understand and explore the added benefit (if any) of pump technology over MDI from patients’ and
educators’ perspectives.
Qualitative data are drawn on to address this study aim; here we begin with patients’ perspectives before
moving on to those of staff.
Patients’ perspectives
Preconceptions about insulin pumps
Many patients described having had misconceptions prior to the trial about how the pump worked and
how it could be used to manage their diabetes. Specifically, some described how they had thought that
the pump would be a small device implanted under the skin. Others had perceived the pump as being
more akin to a closed-loop system, which would alleviate much of the burden of diabetes management by
monitoring blood glucose and calculating and administering insulin doses:
I actually thought the pump was some kind of implant . . . and I thought it was something you
connected . . . some kind of pipe or cannula and you filled up this implant and then once it was full
you disconnected it and then you just had like a remote [control].
P09.1
I think my preconceived ideas were slightly wrong . . . I thought it would be a continuous monitoring
system and adjust accordingly . . . And I didn’t realise that you had to keep on testing yourself.
P14.1
Despite some such patients’ initial hopes and expectations not being met, most of those who used pump
therapy during the trial described the pump as offering benefits over a MDI regimen. Although some of
the benefits described by these patients were also highlighted by those in the MDI arm of the trial (and,
hence, arguably were due to the use of the DAFNE approach rather than pump therapy per se), some did
appear to arise specifically from use of an insulin pump and these are considered below.
Drip-feeding basal insulin and altering basal rates
Most patients using pump therapy described feeling that they had better control over their blood glucose
levels because the device supplied a constant drip-feed of basal insulin, which, as they suggested, more
accurately mimicked the natural release of insulin by the pancreas.
Now, because it’s such a little trickle, it’s really, I think, that’s made a huge difference, because it’s
made me operate, my body operates more like somebody that’s got a, you know, a pancreas
that works.
P24.2
Some patients also highlighted the benefits of being able to set different rates of basal insulin infusion
during the day and night. This included P09, who described using a lower basal rate for a specific period
of time to counter recurring nocturnal hypoglycaemia, and P19, who reported using higher basal rates to
counter rises in blood glucose during periods of inactivity and lower rates when more active (e.g. at weekends):
. . . it’s a lot easier, like, at the moment, my blood sugar tends to dip between midnight and four in
the morning, so the pump slightly reduces the insulin . . . whereas on the pen [MDI] then I’d have to
reduce the whole of the insulin from before I go to bed until I get up in the morning.
P09.2
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[During the week] I’ll sit at my desk until lunchtime, whereas obviously at the weekend I’ll get up,
have breakfast, and then I’ll probably go out and about and do something active, so that was . . .
weekends were my problem for blood sugar. But that, you know, now I’ve changed that, I’ve put on
temporary, er, temporary basals for then, during the morning, and er, it’s been fine.
P19.2
Others highlighted the clinical and personal benefits gained from being able to use a temporary basal rate
to accommodate sporting and other physical activities (see Study aims 1 and 2) or, in P18’s case, to
minimise the risk of hypoglycaemia after drinking alcohol:
I’d set a temporary basal on it because I was having a drink and so I lowered the basal so as that I
could, to stop me hypo-ing through the night sort of thing.
P18.1
Fine-tuning and administering small doses of bolus insulin
As well as being able to alter basal rates, some patients reported additional benefits arising from being
able to administer very small and/or precise bolus doses of insulin. Reflecting back on their experiences
using an injection regimen, such patients described how this feature had enabled them to more precisely
match insulin doses to carbohydrate intake in order to fine-tune their blood glucose control:
I love that you can, you can just give 0.1 of a unit now and before I was on, like, you know, 1 unit, so
the accuracy’s much better . . . I’m excited that you can just fine-tune it so much . . . the control that
it’s given me already is just fab.
P04.1
. . . it’s more clinical isn’t it, so, you know, it’s easier to be, to be able to drill down into it and to fine-
tune it, which is, which is what really I need to do, it doesn’t need to be massive changes, it just needs
to be slight, you know, slight changes to make it that much better.
P19.2
As a consequence of being able to administer very precise and small doses, some patients who were
sensitive to insulin also described how using the pump had lessened their perceived risk of hypoglycaemia:
If you’re on the edge of going hypo[glycaemic] and you’re having something to eat . . . so you take your
insulin, that half a, extra half a unit can send you down again. Whereas on this [pump] you can, like I say,
you can fine-tune it to half a unit, so you know exactly what you’re taking. If you need one and a half
units for a sausage roll, you’re not trying to think, ‘well, do I take 1 or do I take 2?’. You can take one
and a half.
P13.1
Advanced settings: dual- and square-wave boluses
A small number of patients also suggested that they benefited from using advanced pump settings, such
as the dual- or square-wave function, to offset the delayed effect of carbohydrate-dense foods, such as
pasta, or when eating a meal over an extended period of time:
Then there was the dual wave, you know like when we’ve, if we’ve had pasta and you know your
carb[ohydrate]s are going to be long acting and things like that, I think that’s brilliant, whereas before
when I were having injections, you just had your injection and then 3, 3 hours later your blood sugar
would still be really high.
P05.2
At Christmas time, parties, right? Buffets and things like that, this is a lot easier because you can put it
on a dual wave or a square bolus or something and you can forget, you know, right, I’ve dealt with
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the insulin, and then you can just eat little bits over however many hours, um, and I did that and it
worked . . . you couldn’t do that with injections.
P07.1
Wearing the pump prompts patients to perform self-management practices
Although some patients described disliking being connected to the device (see Study aim 5) an additional
benefit identified by some individuals was that the pump’s presence prompted them to undertake
DAFNE-specific self-management practices, such as SMBG:
. . . it’s a very useful kind of physical manifestation of the fact that, ah, you have this, you have this
condition and you’re eating right now, and so do something about your blood test, do something
about what you’re eating . . . It’s a very, kind of very useful as a, as a way of, er, reminding you to,
you to employ the, er, the techniques . . . that we’re that we’re taught on the DAFNE course.
P23.2
No need to inject
Aside from perceived clinical benefits, many patients reported personal benefits arising from no longer
having to inject. Despite having to insert a cannula every 2–3 days, most suggested that this procedure
was much less onerous than having to inject five or six times a day:
I know you have to mess about with putting the cannulas in every 3 days, but that’s the biggest
hardship. It’s still, you know, going from that . . . er, to like four injections a day, morning, lunchtime,
teatime and night-time, when you’re out you’ve got to pull the injection out, stick it in you and stuff
like that, it’s, it’s totally different.
P10.1
As reported earlier, in Diabetes Treatment Satisfaction Questionnaire: treatment satisfaction (better for
patients using pump therapy) and Diabetes-specific quality of life: daily hassles of functions (better for
patients using pump therapy), patients using pumps also described benefits and satisfaction arising from
being able to administer insulin without having to inject in front of others and/or to find somewhere
private to administer an injection when in a public place. As such, and like the adolescent pump users
studied by Lowes et al.,156 patients also described feeling less noticeable, stigmatised and, hence, detached
from others as a consequence:
It’s actually more discreet . . . one person thought it was an iPod [Apple Inc., Cupertino, CA, USA] . . .
I find it more discreet because you can take a bolus before a meal without having to expose your skin,
which, not everybody likes you injecting in public, it’s easier to take your dose in that way, and it
means it’s much easier to fit in.
P12.2
Educators’ expectations and perspectives
Educators’ perspectives have already been reported in detail elsewhere;147 hence, readers may wish to
reference this work for more detail about particular findings or to access additional quoted material.
Added benefit of pump therapy
All staff were keen to emphasise that a MDI regimen, taught in conjunction with a DAFNE or similar
educational approach, presented a very good and effective toolkit for undertaking diabetes self-management.
Hence, educators also suggested that, if they were taught to use a MDI regimen effectively, most patients
would neither need nor gain added clinical benefit from using pump therapy:
I think we can maximise most people on DAFNE and it’s wonderful, we really are DAFNE advocates
and we’ve had a lot of improvements and reductions in hypos.
D4
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However, all educators also noted that, because of the constant drip-feed of insulin, the ability to alter
basal rates, and also the ability to titrate and deliver very small insulin doses, pump therapy could
potentially help certain groups of patients to improve and/or fine-tune their glycaemic control. As
educators described, these individuals were principally those who met current NICE criteria for pump
referral,13 such as those who suffered from the dawn phenomenon, were very insulin sensitive and/or who
undertook a lot of sporting activities that exposed them to risk of hypoglycaemia:
People whose insulin requirements are really small, really low, where sort of injected longer-acting
insulin, background insulin, you just can’t adjust them finely enough . . . a pump is great for them
because you’ve got the really, you know, minute basal adjustments.
N02
Those that are maybe quite intense when it comes to exercise, you know, there’s definitely a potential
for them. Equally, those that are maybe finding that they are on really small doses of insulin because it
[the pump] does give them that opportunity to fine-tune.
D05
However, all educators pointed out that, to gain added clinical benefit from using a pump, patients had to
be willing and able to their use the pump’s features otherwise, as N3 suggested:
They will just sit on the pump and use it as another method of delivering insulin and they’ll be no
better off than on injections.
N3
As is described further later (see Study aim 4), educators also highlighted the difficulties of predicting which
patients, or groups of patients, would have this willingness and ability to use the pump to optimal effect.
Study aim 4
4. To look at why some patients may do better than others using pump therapy.
To address this aim, we begin by presenting quantitative data before drawing on educator accounts to
reinforce and support the quantitative findings.
In addition to the pre-specified subgroup analyses presented in Chapter 5, Subgroup analysis, we
undertook exploratory analyses investigating the relationship between continuous baseline variables and
outcome, using scatter plots with superimposed regression splines (Figures 20–22).
Unsurprisingly, those with the highest HbA1c at baseline tended to have the largest reductions in HbA1c at
24 months in both groups. There were no clear associations seen between HbA1c reduction and age at
entry, duration of diabetes, BMI or age at onset in either group. As with HbA1c, no clear patterns were
seen between DSQOL at 24 months and mean age at baseline, duration of diabetes, BMI or age of
onset. The biggest reduction was seen in those with highest DSQOL at baseline, who had more scope
to gain.
The lack of association between duration of diabetes and benefit after DAFNE is an important finding,
which supports the recommendation in the updated NICE guideline that structured education should be
provided to all patients, not just those recently diagnosed.
We hypothesised that greater use of the facilities in the pump might be an indicator of engagement with
self-management. However, we found no association between the number of basal rates used and change
in HbA1c (Figure 23).
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We found considerable variability of changes in both HbA1c (see Figure 4) and DSQOL (see Figure 19), with
some individuals making very considerable improvements and others deteriorating over time. However,
exploratory analysis of factors that might be influencing the changes did not find anything of significance.
Qualitative findings: educator accounts
In advance of the trial, educators described holding certain preconceptions about who would do well
on a pump and make full and effective use of its features to optimise glycaemic control. These
preconceptions, as will be described, were subsequently challenged and revised in light of educators’
trial delivery experiences.
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Pre-trial views about pump candidacy
As indicated earlier (see Study aim 3) educators described having had preconceptions in advance of the trial
about the kinds of individuals who would do well on a pump. Specifically, educators discussed how,
in their routine clinical practice, in addition to using NICE and other clinical criteria, they had tended to
recommend individuals for pump therapy based on tacit and informal assumptions about whether or not they
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had the right aptitude and technical ability to use the pump to optimal effect. These individuals, as educators
also noted, had tended to be those who were younger, technologically savvy and academically able:157
. . . people who [are] more numerate and the more, the more intelligent, the more, you know, sort of
educationally able to take on board all the information.
D03
For similar reasons, educators also described how, despite meeting clinical criteria for pump referral, they
had not generally recommended individuals for pump therapy in routine clinical practice if they had a poor
history of diabetes self-management, were older or were less academically able.157 This was a result of
their concerns that such individuals would be unwilling or unable to ‘put in the extra work required to
use a pump properly’ (N11) and, hence, would not gain any added clinical benefit from the pump as
compared with MDI.
Revising preconceptions as a result of trial participation
Educators also described how, as a result of their participation in the REPOSE Trial (for which a
randomisation process rather than their own judgement was used to determine who was moved onto the
pump), they had been exposed to individuals using pumps who they would not have put forward for this
regimen in routine clinical practice. As educators further noted, this kind of exposure had led them to
reconsider which kinds of people might gain clinical benefit from using a pump. Specifically, and as detailed
elsewhere,157 educators recounted experiences during which they had observed individuals during the trial
‘doing really, really well on pump therapy who we would have predicted would have really struggled’ (D2),
as well as those ‘such as the likes of the young lad who was desperate for a pump and he’s just not using it’
(N9). As a consequence, some educators described how they ‘had stopped having preconceptions about
who it will suit and who it won’t’ (N3), whereas others suggested that, in light of their trial experiences,
they now thought that motivation – rather than age, technological aptitude or academic ability – should be
used as the main criterion (alongside clinical criteria) for determining future pump referrals:
I’ve found that when you actually sit down, show them it, work way through it, actually they become
more efficient. So in a way I don’t think there’s anybody that shouldn’t do well on a pump as long as
they are keen and motivated.
D4
Others still noted from their experiences of observing patients during the REPOSE Trial that use of a pump
could itself act as a tipping point for increased disease self-management among some erstwhile seemingly
demotivated patients. As a consequence, such individuals described having reached the conclusion that
pumps ‘should potentially be made available to everyone [meeting clinical criteria] because you simply
can’t predict, so maybe you need to give everyone a chance?’ (D1).147
Summary
Educator accounts thus highlight the difficulties of identifying and using patient characteristics to predict
potential clinical success using an insulin pump, thereby reinforcing the findings of the quantitative
analysis, which showed that it is not possible to determine which patients, compared with others, are likely
to do better on the pump.
Study aim 5
5. To explore acceptability of, and reasons for, discontinuing (pump) treatment.
To address this study aim, we draw on the interview accounts of patients in the pump arm of the trial.
Acceptability
As described in Study aims 1 and 2, very high levels of treatment satisfaction were reported by patients
using pump therapy. However, at baseline, and over time, a small number of individuals did describe
DOI: 10.3310/hta21200 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 20
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Heller et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
141
having struggled to adapt to the presence of the pump and discussed how they had disliked being
attached to the device, as it acted as a constant reminder of their disease state:
. . . it just makes me feel like I’ve got, I know I have a disease, but like a diseased person with this
thing, a machine attached to me.
P12.2
Although most patients found the pump to be a discreet form of treatment, a few also reported feeling
self-conscious when using the device in public settings:
. . . before, obviously, you’ve got nothing . . . there’s nothing on you to say, ‘I’m a diabetic’ and now
you’ve got this pump, people are a little bit more . . . inquisitive.
P09.2
In some cases, and mirroring findings reported by Hayes et al.,158 patients described how they had found
the pump inconvenient to carry on their person and awkward to stow in their clothes, both during the day
and when in bed. Others spoke about having experienced pain if they had accidentally bumped the site
where the cannula had been inserted and/or if they had caught the cannula needle/tubing when
performing everyday activities. This included occasions when patients had been in bed asleep, driving,
playing with children, wearing tight-fitting clothing, having sex or undertaking sporting activities:
. . . sometimes when I’ve lifted the kids they’ve caught themselves on the tubing . . . and having to say to
them ‘you need to watch mummy’s pump’ so they don’t kick it or something when we’re carrying on.
P18.2
It’s not nearly as convenient . . . it’s in the way. And it’s also awkward at night . . . . So I’m still getting
to grips with that, and as I, when I played tennis this week I took it off, when I play golf I tend to put
it in the pocket and the same with gardening.
P11.1
Despite many patients reporting having experienced practical difficulties, most also indicated that they had
quickly adapted to wearing the pump. To do this, patients described having altered where they had stowed
the pump or having adapted clothing to ensure the device was more secure or tubing less likely to snag:
I’m mostly wearing it tucked into a belt. And one of the things I have changed recently is I now tend
to wear it at the side or even slightly behind the side.
P11.2
I think at first it’s obtrusive because it’s there, isn’t it and it’s in bed and ‘where do the, where the hell
do I put it . . . and it’s been under my pillow. But now I’ve got used to it. And as I say, I’ve got some
elastic to get it tucked away at night-time.
P05.1
Furthermore, although many patients described how the pump could be a ‘bit of a nuisance sometimes’
(P14.2), most also suggested that the practical inconvenience of having it attached to their body was
outweighed by their perception that the device had enabled them to achieve better glycaemic control, and
a more flexible lifestyle than was possible using a MDI regimen (see Chapter 9, Research question 3):
I thought ‘oh I’m not sure I’m going to like having something attached to my body the whole time’.
But I think, after doing the week [DAFNE course], you can see the benefits that it had in terms of
being able to manage your diabetes and make subtle changes in the amount of insulin you have that
you can’t really do with pen injections, you know, that kind of outweighed for me the fact that I’m
RESULTS OF THE PSYCHOSOCIAL EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
142
going to have . . . and you just get used to it, like I don’t really feel it on me now so you just kind of
get used to it.
P21.1
Similarly, patients who described difficulties siting and inserting a cannula contrasted this level of
inconvenience with a MDI regimen, which they considered to be much more cumbersome:
When it comes time for me to change the pump [cannula], I’m like, I can’t be bothered doing this!
But then I think to myself, ‘well, it’s either do this or else do six injections a day’ and then I just have a
wee argument with myself and tell myself to shut up [laughs]!
P18.2
Limiting the use of the pump
Although none of the patients who participated in the qualitative study reported having discontinued
using the pump entirely, there were two individuals, both young women, who reported struggling with
disruption to their body image: ‘it’s like having a colostomy bag attached to you’ (P01.1), ‘I think I was
like, “oh, this thing’s attached to me and I’m getting fed up with it, I need a break from it otherwise it’ll
drive me insane”’ (P04.2).
As a result, both of these individuals described temporarily reverting to MDI on some occasions during the
6-month period of study. They also identified specific trigger points, similar to those reported by Hayes
et al.,158 which had resulted in them disconnecting the pump, including when there was little time
available to change a cannula or when a tight-fitting dress had had to be worn and ‘every lump and
bump’ was visible. However, despite the unease they had experienced when wearing the pump, both
women reported removing the device for only relatively brief periods of time before subsequently
reattaching it because, as P04 explained, ‘all the positives outweigh the negatives’.
Study aim 6
6. To enhance understanding and assist in the interpretation of trial outcomes (e.g. differences in HbA1c
between the two arms).
As there were no significant differences in HbA1c between the two arms, we are unsurprisingly cautious in
drawing any major contributions from the psychosocial work in relation to these outcomes, although it
should be noted that, because of our restricted funding, we were limited by our inability to interview
patients beyond 6 months. The perceived benefits of the pump user group, both in terms of the qualitative
work and the limited benefits in terms of treatment satisfaction and some DSQOL domains, are described
in detail within study aims 1–5.
Summary
We used a mixed-methods approach with questionnaires and interviews, and had a good response to
questionnaires, with approximately 94% completion in the pump group and 86% in the MDI group.
There was also a very good response to invitations to take part in interviews, and attrition in this part of
the study was low with only three of 45 recruits not completing the round 2 interviews.
We found little difference in quantitative psychosocial outcomes between the pump and MDI arms, largely
because improvements were observed in both following DAFNE. There were some statistically significant
differences in the subdomains of the DSQOL in favour of pump therapy, those being leisure time
restrictions and flexibility, daily hassle and dietary restrictions.
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Treatment satisfaction also improved in both arms, but statistically significantly more in the pump arm.
These observations were supported by findings from the qualitative interviews. There was also a greater
reduction in the ‘hypoglycaemia worry’ score in the pump arm. The qualitative findings were that patients
in both arms felt more in control of their diabetes.
Patients in both arms reported benefiting from automated bolus advisors, although, as reported elsewhere,
there may be unintended consequences to giving people access to this technology.155
A recurrent theme was that after doing the DAFNE course, patients in both arms felt more in control and
more confident in self-management. However, those on the pump reported some additional benefits from
the pump, mentioning increased flexibility of lifestyles, avoidance of the frequent injections with MDI,
more effective self-management around sporting activities and dietary variations, and the ability to
administer very small doses of insulin, with different basal rates, at different times of day and night.
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Chapter 8 Discussion
Statement of principal findings
We carried out a randomised trial of pump versus MDI in a group of adults with T1DM referred for
structured training in flexible insulin therapy because of suboptimal diabetes control. Both groups received
training ensuring that education was balanced across the arms. The main results were:
l The pump group had a slightly greater mean reduction in HbA1c of 0.85% (9.3 mmol/mol) than 0.42%
(4.5 mmol/mol) on MDI. After adjusting for baseline difference and accounting for missing data, the MD
at 2 years did not reach statistical significance –0.24% (95% CI –0.53% to 0.05%) or –2.7 mmol/mol
(95% CI –5.8 to 0.5 mmol/mol).
l Overall, participants in the trial achieved a clinically worthwhile fall in HbA1c of 0.6% (7mmol/mol) at 2 years.
l Some patients switched treatments during the trial and the per-protocol analysis showed a statistically
significant MD of –0.36% (95% CI –0.64% to –0.07%) or –3.9 mmol/mol (95% CI –7.0 to –0.8 mmol/mol)
in favour of pump therapy (p= 0.015). The 95% CI includes the 5% clinically important effect and so we
cannot claim equivalence of pump and MDI in this population.
l The proportions achieving HbA1c of ≤ 7.5% at 24 months were relatively low in both groups at 25%
on pump and 23% on MDI.
l The frequency of severe hypoglycaemia fell in both groups, although more so in the pump group
during months 12–24.
l At 24 months, there were no significant differences in BMI, insulin dose or lipid levels.
l Both groups demonstrated improved psychological outcomes over a range of different scales, which
included treatment satisfaction and DSQOL. Treatment satisfaction and two subdomains of the DSQOL
(daily hassle, diet restrictions) improved to a greater extent in those allocated to pump therapy both at
12 months and 2 years.
l The qualitative work found that patients in both arms felt more in control of their diabetes and benefited
from automated bolus advisors. A recurrent theme was that after undertaking the DAFNE course,
participants in both arms felt more in control and more confident in self-management. Those on pump
therapy reported some additional benefits from the pump, including increased flexibility of lifestyles,
more effective self-management around sporting activities and dietary variations, and the ability to
administer very small doses of insulin. These findings are reflected in the differences in the quantitative
outcomes, but did not result in significant differences in glycaemic control.
Thus, in terms of the primary outcome, there were no significant differences in change from baseline to
24 months between those randomised to pump therapy or those using MDI, indicating that pump
treatment provided no significant additional biomedical benefit over DAFNE skills training.23
Rates of severe hypoglycaemia were halved in both groups, a benefit maintained to 24 months with no
difference between the groups in this or in rates of moderate hypoglycaemia.23 However, we noted that
between months 12 and 24, rates of severe hypoglycaemia were lower in the pump group, although this
comparison had not been pre-specified. There were no other differences in biomedical outcomes apart
from slightly greater reductions in insulin doses in those randomised to pump treatment.23 Contrary to
most previous studies, insulin dose fell in the MDI arm.
Summary of trial- and model-based estimates of cost-effectiveness
Both the trial- and model-based estimates of cost-effectiveness showed that the addition of pump therapy
to a structured training course was not cost-effective compared with the £20,000–30,000 per QALY gained
threshold used by NICE.22 These results were robust to all scenario analyses.
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In the base-case EEACT, the addition of insulin pump therapy to structured education for adults with
suboptimally controlled diabetes was dominated by current practice as, on average, it produced fewer
discounted QALYs over the 2 years (–0.004) at a higher discounted cost (£2959). The lowest ICER was
observed in the scenario analyses, in which a 50% reduction in the cost of insulin pumps and insulin pump
consumables in the per-protocol population was conducted. The ICER of this strategy was £552,866,
indicating that, even with substantial discounts in price, insulin pump therapy was not a cost-effective
addition to structured education for adults with suboptimally controlled T1DM.
Any differences in the rates of diabetic complications in the long term are not included in the estimates of
cost and QALYs in a within-trial analyses, as they will occur after the last follow-up period. To address this
issue, the lifetime costs and QALYs were estimated using the Sheffield Type 1 Diabetes Policy Model.
In the long-term modelling, the addition of insulin pump therapy to structured education for adults with
suboptimally controlled diabetes generated more incremental discounted QALYs (0.1447) at a higher
incremental cost (£20,448), producing an ICER of £141,312 per QALY gained. The lowest ICER was observed
in the scenario in which the prices of insulin pumps and insulin pump consumables were reduced by 50%.
The ICER of this strategy was £46,578, again indicating that even with substantial discounts in price, insulin
pump therapy was not a cost-effective addition to structured education for adults with suboptimally
controlled T1DM.
Strengths and weaknesses of the research
Our study had a robust, multisite design, involved larger participant numbers and had a 2-year follow-up
period, which was longer than previous trials of pump therapy and therefore more clinically meaningful.
Participants in both arms used analogue insulins and bolus calculators.23 The study was conducted in
secondary care centres, reflecting a range of experience delivering pump therapy and involving attendance
at a structured training intervention that has consistently shown improved biomedical and psychological
outcomes and is well established across the UK. It included a main outcome measured in a central
laboratory and a comprehensive psychological evaluation with high levels of data completeness. The
pragmatic study design thus provides good external validity, particularly as participating in the educational
course led to sustained improvements in glycaemic control, reduced rates of severe hypoglycaemia and
improved psychological outcomes across a range of scales.23
The follow-up period, although longer than other studies, could have been lengthened to 3 years,
as evidence from some previous studies indicates a waning of the effect of pumps over time.63
It is not possible to blind a trial in which insulin delivery systems are fundamentally different, and this could
lead to a bias in any RCT involving pumps. A trial studying individuals who have expressed a desire for
pump treatment is likely to struggle to recruit participants if one arm continues on MDI. Those randomised
to MDI may also either drop out or exhibit poor outcomes due to ‘disappointment’ and lack of motivation.
We studied individuals who had not specifically requested pump therapy, but who were awaiting a course
in diabetes self-management to help them improve their glycaemic control. Thus, our aim was to
determine any added benefit of pumps above MDI while controlling for the training itself.23
An important additional limitation is that those randomised to pump treatment might have been
insufficiently motivated to make the most of any technological benefit, as they had not expressed a
particular wish to use a pump. Anecdotally, one common reason given by patients for not wanting to
participate was reluctance to use an insulin pump. However, educators encouraged participants to use
pump features and provide additional input if this was requested. Overall, we reasoned that as participants
had signed up for a course to improve their glucose control, any additional benefits of pump treatment
would emerge.23
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Comparison with other research
Two appraisals of pumps by NICE have reviewed the evidence on clinical effectiveness and cost-effectiveness.
The first14 noted that there were no trials of pumps against ‘best MDI’ with long- and short-acting analogue
insulins; some trials had unequal amounts of education in the arms (with more in the pump arms); and the
trials had focused on easily measurable outcomes, such as HbA1c, rather than on benefits in terms of
flexibility of lifestyle and QoL. The report recommended trials of pumps against analogue-based MDI. A more
recent report9 found only three trials in adults: one a pilot and the second involving 39 adults with T1DM,
already on pump therapy, who were randomised to stay on pump therapy or to switch to glargine-based
MDI; patients had 4 months on each form of treatment. A third trial recruited 57 adults who were
randomised to pump or analogue MDI in an equivalence study. None showed any difference in HbA1c. Thus,
the evidence base from trials for comparing pumps and ‘best MDI’ was weak in terms of numbers, with a
total of only 103 patients and short follow-up. (This paragraph is reproduced from The REPOSE Study Group
2017.23 This is an Open Access article distributed in accordance with the Creative Commons Attribution Non
Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work
non-commercially, and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.)
The literature on the cost-effectiveness of insulin pump therapy has solely been based on comparisons of
insulin pump therapy to MDI rather than ‘optimised MDI’. A recent systematic review on the cost-effectiveness
of pump therapy in different countries identified four studies that were conducted in a UK setting, three of
which presented an ICER.19 The base-case ICERs in these studies ranged from £37,712 to £11,461 per QALY
gained. These ICERs are much lower than those estimated in the analyses based on the REPOSE Trial data.
However, the ability of these studies to determine the cost-effectiveness of insulin pump therapy as a
treatment for all adults with suboptimally controlled T1DM is limited, as the effectiveness used in these
analyses does not compare insulin pump therapy to ‘best MDI’. Hence, the REPOSE health economic study is
the first known evaluation of insulin pumps in the type of individuals enrolled in the REPOSE Trial.
There is limited evidence on the increases in HbA1c that adults with T1DM may experience beyond the trial
period. Much of the existing evidence is based on observational studies of adults with T1DM, who received
either best-practice MDI or insulin pump therapy. None of these long-term observational studies made a
comparison between those adults with T1DM who received MDI and those who received insulin pump
therapy. The applicability of this evidence to the individuals in the REPOSE Trial may be limited, especially
as, by design, we excluded patients with a clinical indication for a pump as recommended by NICE.13
Thus, information presented in the observational studies is probably the best available evidence to inform
long-term trends in HbA1c for the economic modelling.
The advantage of the observational studies of adults switching to pumps for clinical indications lies in
measuring change in glycaemic control and hypoglycaemia in those who have most to gain. These studies
showed improved HbA1c of the order of around 0.5%. Bias in observational studies is more of a problem
and results must be treated with caution.23 Furthermore, of 48 observational studies, only nine reported
QoL. Study numbers were small, with, at most, 35 patients, and duration was usually short, often ≤ 6
months. The longest study noted that initial benefits from pump therapy might not be sustained. The
REPOSE Trial has thus addressed a number of these concerns, with large numbers in an adequately
powered trial and a virtually complete data set for both biomedical and psychological outcomes.23
Discussion of results
Our study suggests that extending the availability of pumps to adults with T1DM with suboptimal glycaemic
control and no firm desire to use this form of insulin delivery is unlikely to result either in lower levels of
glycaemia as measured by HbA1c or lower rates of hypoglycaemia, or be cost-effective. The results would
appear to support the current clinical pathway as proposed by NICE,18 in which people desiring improved
diabetes control should undertake structured education in flexible insulin therapy with MDI alone.23
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Clearly some patients improved more than others in terms of glucose control or hypoglycaemia and we
explored whether or not there were any demographic differences in those who did particularly well. There
was no reliable evidence of any plausible subgroup effects or interactions between the pump and MDI group,
and the baseline characteristics of those whose glycaemic control improved to < 7.5% during the trial were
no different from the pump population as a whole. (This text, from ‘Clearly’ to ‘whole’, is reproduced from
The REPOSE Study Group 2017.23 This is an Open Access article distributed in accordance with the Creative
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix,
adapt, build upon this work non-commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/
by-nc/4.0/.) Those using insulin pumps did show some QoL benefits, reporting fewer restrictions in diet and
daily hassles in the DSQOL, and greater treatment satisfaction. Nevertheless, the differences were modest and
observed in comparison to a group given no novel technology. As they were not associated with other
positive treatment outcomes, they are probably insufficient to justify a major alteration in guidelines for the
use of pumps.23
One of the more striking results of this trial was the generally high level of HbA1c among adults in the UK
enrolling for self-management training in flexible insulin therapy. Participation in the courses produced
significant and sustained improvement, but still fell well short of the target recommended by NICE,
recently reduced from 7.5% to 6.5%.159 There is an urgent need to explore the barriers to successful
self-management in adults with T1DM in the UK and understand why referral for appropriate training is
often left so long. This was also the conclusion of our recently completed research programme, funded by
NIHR.27 The results of the REPOSE Trial show that these problems cannot be overcome merely by providing
additional technology in the form of pumps.23
The possible lack of engagement among some individuals assigned to pump therapy may also explain the
increased numbers of episodes of DKA in those randomised to insulin pumps. In the earliest trials of insulin
pumps in the 1980s, rates of DKA were also raised among those who had agreed to try a pump when
offered. A psychological analysis, undertaken at the time, suggested that those who experienced DKA
expressed less personal responsibility for their care. Importantly, in the REPOSE Trial, both MDI and pump
courses included instruction in ‘sick day rules’, designed to prevent the development of DKA in the case of
illness. Pump courses also included specific guidance in dealing with an interruption of the insulin infusion,
although there was no guarantee that participants would follow these.
A detailed review of DKA cases indicated that:
l more patients on pumps had multiple episodes (five vs. two)
l differences were confined to the first year; there were comparable numbers of episodes (four in each
group) during year 2
l three episodes occurred in two patients switching to pump and one in a single person switching
to MDI
l most DKA episodes were due to infections; in pump patients, 18% were due to ‘set failure’
l only five episodes occurred when all sick day rules were implemented.
Implications for health care
The NICE Type 1 diabetes guideline159 states:
1.3.1 Offer all adults with type 1 diabetes a structured education programme of proven benefit,
for example the DAFNE (dose-adjustment for normal eating) programme. Offer this programme
6–12 months after diagnosis.
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1.3.2 If a structured education programme has not been undertaken by an adult with type 1 diabetes
by 12 months after diagnosis, offer it at any time that is clinically appropriate and suitable for the
person, regardless of duration of type 1 diabetes.
The REPOSE Trial provided DAFNE to both arms, and we observed significant improvements in both arms,
which persisted for the 24 months of the study. The improvements were both in glycaemic control,
as reflected by HbA1c, falls in severe hypoglycaemia and measures of QoL, providing support for NICE
recommendation 1.3.1.
We found no relationship between duration of diabetes and benefit from DAFNE, which supports NICE
recommendation 1.3.2 – that all patients should be offered structured education.
The recent update of the T1DM guideline recommends that people be supported to aim for a tight target
of glycaemic control in recommendation 1.6.6159 [6.5% (48 mmol/mol)], which is lower than the treatment
target of 7.5% set when the REPOSE Trial was being run. Despite recent evidence dissociating lower HbA1c
in T1DM from increasing severe hypoglycaemia rates, fear of hypoglycaemia remains a barrier. The
combination of recommendations 1.6.6 and 1.6.8 will be challenging, and is likely to require an increase in
the use of insulin pumps as approved under the current NICE technology appraisal guidance.13 However,
we would point out that DAFNE structured training also reduces rates of severe hypoglycaemia.
The REPOSE Trial excluded patients who met the NICE criteria for a pump. We also excluded patients
who had a strong desire to use an insulin pump. Therefore the results of REPOSE are not relevant to the
recommendations of TA151,13 they apply to a group of patients with a lower level of need.
The results of the REPOSE Trial showed improvements in both arms. The pump group showed slightly
greater improvements than the MDI arm, but most of the differences were not statistically significant, and
the difference in HbA1c did not reach a clinically meaningful level. Our cost-effectiveness analysis shows
that in the type of patients in REPOSE, pumps will not be cost-effective.
It is important to note that the REPOSE Trial may be reported as a ‘negative trial’ of pumps, but the failure
to show a significant benefit of pump over MDI was because both groups improved following DAFNE
training. The results indicate that, in adults with high levels of HbA1c, training them to self-manage their
diabetes with structured training programmes is more useful than providing them with insulin pumps.
Implications for the National Institute for Health and Care Excellence
The implications for NICE guidelines and guidance are:
1. The guideline on the importance of providing structured training programmes is reinforced.
Considerable evidence has been found for the effectiveness (and cost-effectiveness) of offering
evidence-based structured education to individuals with T1DM.
2. There are no implications for TA151 on insulin pumps. The REPOSE Trial results do not apply to the
patient groups to which TA151 refers.
Future research needs
There remains a clinical and economic need to improve the glycaemic control of adults with suboptimally
controlled T1DM. The results in the UK, for example in terms of proportions of people reaching HbA1c
targets, are poorer than in some other European countries. We need to explore the differences in clinical
practice and patient behaviour that underlie these differences. The DAFNEplus programme of research is
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aiming to develop and evaluate the current DAFNE course (based on previous research, behaviour change
theory and technological support). This programme is not expected to report until September 2021.
In both arms of the REPOSE Trial there were marked variations in HbA1c, with some people showing
marked improvement and others showing deterioration. Further research is needed to explain why some
people do so well, whereas others do not.
We found no relationship between duration and benefit from structured education. This raises a question
as to why patients who have been attending diabetic clinics for many years – even decades – have not
been offered structured training in diabetes self-management.
More extensive qualitative research should be considered to:
1. explore the issues that influence patients’ use and rejection of technologies, such as insulin pumps
and CGM
2. examine patients’ perspectives on both the impact of withdrawal of technology (e.g. pumps and CGM),
both at the end of trials and in clinical practice when they are deemed not to meet NICE criteria
3. compare the views of both professionals and patients in other European countries that appear to
achieve far better glucose control.
The Cochrane review of pumps by Misso et al.31 is now well out of date and should be replaced by an
up-to-date, but much more focused, review of pump versus analogue MDI, which would include the
REPOSE Trial.
Conclusions
In conclusion, people with T1DM might be better served by ensuring far greater availability of high-quality,
structured self-management training, which is currently accessed by < 10% of adults with T1DM in the
UK.160 Participants may recognise the limitations of insulin delivery by MDI only once they are attempting
to maintain flexible intensive insulin therapy following training. Those individuals could then be offered
pump therapy to help them reach the stringent glucose targets that are necessary to achieve an optimal
HbA1c or overcome problematic hypoglycaemia.23
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Chapter 9 The challenges of closing out a clinical
trial after which treatments may be withdrawn:
qualitative study of staff involved in closeout of the
REPOSE Trial
Background
Clinical trials are considered the ‘gold standard’ method for assessing the efficacy and safety of
pharmaceutical treatments and other health-care interventions. It is common practice for qualitative
research to be undertaken with patients and staff who are involved in clinical trials.161,162 This research
usually takes place during a trial’s pilot or early phases to improve recruitment, patients’ understanding of
trial processes and the solicitation of informed consent.163–168 Qualitative research has also been undertaken
during trial delivery to explore adherence to trial protocols and treatments, and aid interpretation of trial
findings.169,170 Although the closeout of a trial potentially presents challenges for both patients and health
professionals, especially when patients may be required to stop using the treatment(s) under investigation,
this aspect of trial participation and delivery remains surprisingly under-researched. The limited work
undertaken to date suggests that patients may experience a form of trial bereavement on closeout,171 and
some may wish to continue using trial treatment(s) despite the trial failing to show clinical benefit.172
How staff address closeout issues with patients, and what their own information and support needs are,
remain unknown.
Closing out REPOSE
Recruitment to the REPOSE study commenced in November 2011 and the first trial centre began to close
out patients [i.e. commenced 2-year (final) follow-up appointments] in April 2014, with the final centre
closeout appointment in June 2015. The insulin pumps used during the REPOSE study were provided free
of charge by Medtronic, with a warranty that covered only the trial’s 2-year duration. After extensive
negotiations, pump consumables were funded at a local or national level (e.g. by the DH, Chief Scientist
Office or a primary care trust) for the duration of the trial and on the understanding that pump therapy
would be withdrawn post trial unless a clinical benefit could be demonstrated for individual patients and
local funding provided. This was communicated to potential trial participants in the patient information
sheet for the trial (see Appendix 8). On closeout, each REPOSE centre was advised (as per the trial’s SOP
for closeout; see Appendix 15) to make their own clinical decisions about which patients should remain on
a pump and who should revert to a MDI regimen, with centres having to find local funding for patients
who remained on pump therapy.86 It was also agreed (as formalised in the SOP) that the patients would
not be told whether or not they would keep their pump until after their data had been collected at the
final 2-year appointment because of concerns that this knowledge might influence how they completed
their questionnaires.
Early reports from trial staff and ongoing review of trial data indicated a large variation in closeout
practices between the REPOSE centres (listed in Table 11). Although, in some centres, most or all patients
remained on pump therapy, in others, the majority of patients had pump therapy withdrawn and were
reverted to a MDI regimen. Early anecdotal reports from staff also indicated that patients’ emotional
reactions to withdrawal of pump therapy were variable, with some presenting major challenges to staff.
Specifically, some staff expressed concerns about the lack of guidelines, procedures and support structures
for themselves to manage and support patients effectively at closeout when withdrawing pump therapy.
In light of these reports, it was decided to systematically evaluate staff experiences of closeout to generate
insights and recommendations to support the conduct and closeout of future trials, especially those where
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an expensive health technology is being tested that may be withdrawn at the end of the trial period.
A case was made to the funder to undertake this additional piece of qualitative work using some
underspend within the grant. Approval from the funder for this substudy was given on 13 April 2015.
Aims
This qualitative study drew on the experiences, understandings and views of health professionals who
were involved in closeout of the REPOSE Trial in order to:
l better understand variations in practices between trial centres on closeout and establish whether or not,
and to what extent, these arise from local clinical guidelines and practices, individual physician/health
professional beliefs and/or other factors and considerations
l inform guidance and support for staff involved in the closeout of future clinical trials, particularly those
in which investigated treatment(s)/device(s) may be withdrawn.
Research questions
1. What are health professionals’ experiences of closing out the REPOSE Trial? What (if any) practical/
ethical/other issues arose for staff, and how did they attempt to address these?
2. What factors and considerations informed health professionals’ decisions to continue or discontinue
pump treatment in individual patients?
3. What processes and procedures do staff think should be put in place to support patients and staff
involved in the closeout of future clinical trials, especially those where expensive health technologies are
being investigated and may be withdrawn?
Overview
The qualitative work was completed to plan and on schedule, enabling a comprehensive investigation of
staff members’ experiences of closeout in the seven main REPOSE centres. Although it had originally also
been our intention to include patients’ views, we were unable to involve this group because of the limited
time available to gain NHS research ethics and R&D approvals at the REPOSE centres, and undertake the
data collection and analysis. One journal article has been accepted for publication, which reports key
findings from the following analysis (Lawton et al.173).
Study design and methods
In-depth interviews were used to collect data about staff experiences of study closeout, as these afforded the
flexibility needed for participants to raise and discuss issues that they perceived as being salient, including
those unforeseen at the study’s outset.142,174 The use of one-to-one interviews also afforded privacy, allowing
participants to share their views about the processes and procedures for closeout at their study centre.
The study was informed by the principles of Grounded Theory140 and entailed simultaneous data collection;
this allowed the areas explored in the later interviews to be revised in light of emerging findings.
Recruitment and sample
Working closely with the CTRU to identify relevant individuals, we targeted all staff members (physicians,
diabetes specialist nurses and dietitians) in the REPOSE centres, who were thought to have been actively
involved in closeout appointments. Staff were recruited from seven of the eight participating centres. The
eighth centre was not included because it was a reserve centre that was added at the end of the trial to
deliver two courses only, and this centre had only one patient using a pump at the end of the trial.
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Staff were recruited via written (e-mail) invitations accompanied by information sheets and opt-in forms.
When staff had opted in, NH contacted them to arrange an interview.
Data collection and analysis
The University of Edinburgh’s Centre for Population Health Sciences, Ethics Review Group granted ethics
approval for this study in June 2015. The interviews took place between June and August 2015.
Participants were offered the choice of a telephone or face-to-face interview at a time/place most
convenient to them; only six (29%) staff members requested a face-to-face interview.
Interviews were informed by a topic guide that was developed in light of literature reviews and findings from
qualitative research conducted earlier in the trial,147,155 and were revised in light of emergent findings from
the early interviews. The final version of the topic guide is appended to this final report (see Appendix 16).
Interviews lasted for ≈60–90 minutes. The key areas in the topic guide were covered and explored in depth
in all interviews. Interviews were digitally recorded (with consent) and transcribed in full for in-depth analysis.
By the time recruitment and interviewing had stopped, data saturation had been achieved, that is, no new
findings or themes were identified in new data collected.
The interviews were analysed thematically by NH and JL using the method of constant comparison.148
Individual interviews were read through repeatedly to look at differences and similarities in individuals’
perspectives and experiences before being cross-compared to identify common issues and experiences
across and within study centres. NH and JL wrote separate reports before meeting (both during and after
data collection) to discuss and reach agreement on key themes, identify emerging findings requiring more
detailed exploration and develop a coding frame. The qualitative analysis software package NVivo10
(QSR International, Warrington, UK) was used to facilitate data coding and retrieval. Coded data sets were
subjected to further, in-depth analysis to identify subthemes and illustrative quotations.
The findings presented below are structured under our original research questions. To safeguard participants’
confidentiality, pseudonyms for individuals, Dr X (diabetes specialist) or EDX (DAFNE educator – diabetes
specialist nurse/dietitian), and centres (A–G) are used throughout this report, and all identifying information
has been removed or deliberately altered.
Findings
Participants
Twenty-four staff members were invited to participate. In one case a staff member said that they had no
direct experience of closeout/end-of-trial consultations. Two others opted in, but an interview could not be
arranged at a convenient time, hence 21 (87.5%) staff members were interviewed. Full details of the final
sample are provided in Appendix 17.
As can be seen from Appendix 17, we achieved good representation of different types of staff: clinical
diabetes specialists, diabetes specialist nurses and dietitians. Between two and five (mode three) members
of staff were interviewed at each centre. With the exception of centre A, at least one DAFNE educator and
one diabetes specialist was interviewed from each centre.
Staff experience of delivering DAFNE varied from 5 to 17 years (mean 10 years). There was also variability
with regard to individuals’ experience of pump therapy, ranging from 2 to 37 years (mean 10 years).
It should be noted that the majority of staff interviewed at centres D and E had relatively little experience
of pump therapy prior to delivering REPOSE. Although many staff had previous experiences of working on
clinical trials, few had been involved with studies that had required new technologies to be withdrawn at
the end of the trial. The main exceptions were those staff members (n = 5) who belonged to the three
study centres that had been involved in the delivery of a DAFNE pump pilot study. This 12-month study27 –
6 months’ recruitment and 6 months’ follow-up – had taken place between 2009 and 2010.
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In order to understand staff members’ experiences of closing out REPOSE, it is necessary to provide an
account of what happened at the end of the trial in the various centres. Thus, prior to answering the
research questions, we will describe the variations in closeout practices that staff described in the
different centres.
Background: closeout practices in REPOSE centres
As noted above, the CTRU issued a SOP for closeout (see Appendix 15), which outlined what was to
happen up to the point at which all trial procedures were completed (i.e. final blood samples were taken,
QoL measures collected and data from the pump downloaded). What happened to trial participants
afterwards – whether or not they remained on MDI/pump, whether or not they had pump therapy
withdrawn or initiated – was a clinical decision, taken by staff at the individual centres. In other words, the
decision to leave patients on, start or terminate pump therapy was not a trial decision. However, many of
the staff involved in delivering REPOSE experienced these post-trial treatment decisions and, more
specifically, patients’ reactions to them, as part of their trial experience. Thus, for the purpose of this
chapter, we will talk about post-trial treatment decisions as part of the closeout process because this is
how the staff perceived and interpreted them.
To ensure that resources (i.e. pumps) were allocated appropriately and fairly at the end of the trial, most
centres put site-specific procedures in place for closeout (i.e. what would occur after the final downloads
had been logged). Some centres adopted very formalised operational procedures for decision-making
about post-trial treatment. In these centres, decisions about individual participants were made at a
multidisciplinary team (MDT) meeting, involving all of the research team and other staff members, and
which took place a couple of weeks before the closeout of each of the groups. The MDTs’ decisions were
governed by strict NICE/Scottish Intercollegiate Guidelines Network (SIGN) criteria (see Research question 2)
and (normally) documented. Each patient then attended a post-trial consultation with a clinician/educator
after the final data collection session to discuss his/her treatment plan.
Other centres took a less formal approach to closing out their patients. Dr H described what happened in
one such centre (centre B):
I guess it wasn’t a formal MDT. But yeah it was just a chat with the educators and myself about each
individual patient as they were coming up for the end of the study, about who/what the best way
forward was for them.
In some of these centres, the whole research team met in advance of the post-trial appointments to
discuss what might happen in individual cases; in others, the educators briefly spoke to the clinician after
the patient had provided their final download and before they went in for their post-trial consultation.
In these centres, although some, or all, trial team members had some input into post-trial treatment
decisions, it was individual clinicians who made the final decision during the post-trial consultation,
often taking the patient’s views into account:
We started a fairly neutral conversation about how it been and what would they want to do if the
option were that they could keep it. And then if they said well you know, they’d really like to stay on
pump therapy then I said ‘OK, well you know, let’s have a look at how you’ve got on with it’ and
obviously I’d got a feel for that already. So before they came in [educator] and I sat down and looked
through and looked at how they’d got on, and what had happened to hypoglycaemia frequency,
what had happened to HbA1c, and then obviously they came through and told us how they felt in
terms of, the impact on quality of life and things.
Dr G
In all of the centres, the clinical appointment to discuss post-trial treatment occurred after the final
appointment to collect trial data. In some cases, patients were seen on the same day on which they came
in for their final trial appointment; in others, this clinical appointment occurred a couple of weeks later.
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Research question 1
l What are health professionals’ experiences of closing out the REPOSE Trial? What (if any) practical/
ethical/other issues arose for staff and how did they attempt to address these?
What are health professionals’ experiences of closing out the REPOSE Trial?
Staff who had been involved in follow-up appointments during the trial, primarily the educators, said that
they had become increasingly aware that withdrawal of pump therapy at closeout/the end of the trial
would be difficult. This was a result of their observations (see ED7 below) that patients were becoming
increasingly emotionally attached to their pumps as the trial progressed, an issue which became
particularly apparent from the 12-month follow-up appointment onwards.
. . . at the kind of the routine REPOSE follow-ups when we asked them how they were feeling about
the pump, they all reported that they loved the pump, that they felt it was making their life so much
easier, and that they couldn’t imagine going back to having to inject multiple times a day . . . So they
were all very vocal that they really wanted to stay on their pump. And that they would be prepared to
fight for it, if needs be.
ED7
For this reason, some staff reported worries and concerns about how patients might react to the
withdrawal of the pump at the end of the trial: ‘I knew it was going to be difficult and I wasn’t looking
forward to it’ (ED11).
Dealing with stressful situations
The ways staff experienced these post-trial consultations varied, and was related to whether or not
patients were able to remain on their preferred therapy and, as will be described later [see What (if any)
practical/ethical/other issues arose for staff and how did they attempt to address these?], whether or not
staff had put pre-emptive measures in place to manage and prevent problems arising from the withdrawal
of pump therapy. In some cases, when patients who wanted to remain on a pump were told they would
have to revert to MDI, staff members, including Dr C, described situations that had been stressful and
difficult to manage because patients had become upset and/or angry:
I had trouble in the course, because one lady when she came to the end of her trial, her HbA1c was
appalling. I mean it was appalling. There was no way you could justify leaving her on pump, because
she was getting no benefit from it biomedically. What she needed was a complete change in how she
managed her life. And she was very upset to have the pump removed. But what was fascinating was
she did not say that at the closeout interview . . . . Next thing I know she’s written streams of letters of
complaints to all and everybody, because we removed the pump from her, and refused to give her any
supplies after 3 months.
Dr C
Later in the interview, Dr C reflected on how this and other similar experiences had ‘. . . kind of tainted
the whole study for me, because it was really quite difficult for a little while. It was very uncomfortable’.
Dr B reported a similarly stressful encounter with a patient:
The one locally that really didn’t go well, was a gentleman whose control had got worse on the pump.
And I was explaining that in fact on balance it was actually more dangerous for him to remain on
pump. And he was the one that walked out. He didn’t shout or give me any indication. He just stood
up and said ‘OK’ and walked out.
Dr B
Like Dr C, Dr B had been taken aback by this experience: they had been ill prepared for it, primarily
because, like the other clinicians in the study, they had been less involved in the trial follow-up visits,
which had been mainly carried out by educators.
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Smooth transitions
However, the withdrawal of pump therapy was not always experienced as generating such negative
reactions; indeed, a small group of patients, across the centres, were described as having been ‘happy’ to
revert to MDI, with some requesting this transition at the end of the trial. Moreover, in another centre
(centre A) at which pump therapy had been withdrawn from the majority of patients, staff said that
closeout had been relatively straightforward and non-confrontational. As will be described further later
[see What (if any) practical/ethical/other issues arose for staff and how did they attempt to address these?],
this appeared to be due to staff having put procedures in place to pre-empt, prevent and manage
disappointment among those patients.
In approximately half of the centres, patients received the treatment that they wanted at the end of the
trial, and closeout, as a result, was experienced as raising few issues for staff. This was particularly the case
in Scottish centres where, in 2012, the Scottish Government had made funding available for pump
therapy, with a target of ≈5% of patients with T1DM to be using pump therapy between 2013 and 2015.
As Dr E reflected, because of the Scottish Government’s largesse, closeout was very straightforward in that
centre because the majority of patients were able to remain on pump therapy if they wished to do so:
Our closeout has probably been less complex than most places. And that’s because of this impetus to
increase the number of people with pumps . . . Happily for us, because the timing was just perfect, so
that the end of the trial was within this expansion up, we were actually able to fairly straightforwardly
continue with pumps on a routine NHS way for all of the patients who wished to.
Dr E
ED3, from another resource-rich centre, similarly said ‘I think it [closeout] went well. There was nothing
certainly from our side in [site D]. I don’t think there were any issues for us’.
Staff at the Scottish centres did comment that, had government funding not been put in place during the
trial, closeout would have been more challenging and problematic:
Well I guess we would have been in the same situation as other centres where there was no funding
stream to continue patients. And we would have had to say: ‘sorry. We don’t have any money for you
to continue on this’. And I think it would be very difficult. I mean obviously I would imagine in other
places it’s caused a bit of damage to the doctor or health-care professional relationship . . . I guess
people having invested a lot of time in it over the course of the study you’d feel a bit let down if
somebody’s told that there’s no money. Sorry, give it back.
Dr H
Although staff at such centres did not generally have to manage patients’ reactions to the withdrawal of
the pump, they did have other issues with which to contend. First, as Dr E noted, they had problems
providing timely training for all MDI patients who were offered, and accepted, pump therapy at the end of
the trial: ‘Most of our control patients were really quite keen to go on pumps, afterwards. And the, you
know, there’s a degree of work just dealing with that’. Second, even though patients usually received the
therapy they wanted after closeout, the staff said they still had to reassure and ‘calm down’ patients when
they came in for their final downloads because they were anxious about losing their pumps:
On the day of their final visit I think they were all extremely heightened, they were very worried I think
most of the patients who came in. We kind of had to almost calm folk down a little bit. We had quite
a few who were walking in the door at that final visit very, very scared because they knew it was the
end of the trial and they didn’t know what was going to happen now.
ED6
As ED6 commented, dealing with patients’ anxiety throughout the trial was particularly difficult in their
centre, as although staff realised that most people would have their pump therapy funded after the trial,
they still had to follow the trial SOP, which required staff to be more circumspect when patients asked
about post-trial treatment during follow-up visits.
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Differences of opinion within multidisciplinary teams
Finally, with regard to their closeout experiences, some staff indicated a lack of consensus within some
research teams regarding the decision to keep particular individuals on pump therapy at the end of the trial:
And I think there was a difference in how some of the team viewed it as well, in that some seemed to
say: well, it’s a trial for 2 years. And then they come off the pump and we see how they do. And then
we may put them back on the pump. Whereas others are saying: well no there’s been significant
improvement, So we’ll keep them on the pump. So I had kind of extremes.
ED12
I think others (in our site) were much more, I . . . I think that they thought that they were going to
stick to the letter of the law and they’d take pumps away and that would be tricky . . . but then that’s
their individual practice it’s not for me to tell colleagues particularly consultants how they should
practice, and the practice is very different it’s such a personal thing.
Dr A
This particularly applied to those centres that had adopted less formalised closeout procedures, specifically
where final decisions were taken by clinicians alone. In such centres, not only were disparities in
decision-making between different team members noted, but also some team members described having
not always agreed with their colleagues’ decision to keep individual patients on pump therapy. Several
staff commented that they were not always convinced that patients were benefiting over and above what
could be achieved using a MDI regimen and DAFNE education. Indeed, some such staff indicated that they
would rather have used stricter guidelines for pump allocation at the end of the trial to ensure that NHS
resources were distributed in a fair and transparent way in their centre (see Research question 3).
In summary, the interviews confirmed differences in staff experiences of closeout across the study centres.
First, in centres at which pump therapy was routinely withdrawn from all but a few patients, staff had
needed to manage some of the patients’ negative emotional reactions and some had felt ill prepared for
this experience. Second, there was evidence that some centres had managed patient expectations about
post-trial treatment more successfully than others, thereby pre-empting patients’ disappointment at having
pump therapy withdrawn (see Research question 2). Finally, in centres where ample funding for pump
therapy was available, the issues arising at trial closeout focused on calming anxious patients before final
data collection and providing timely training for MDI patients commencing pump therapy.
What (if any) practical/ethical/other issues arose for staff and how did they attempt to
address these?
Staff identified a couple of issues that may have affected their own and patients’ experience of the trial
and closeout; these included the length of the trial and the ethical challenges arising from withdrawal of
the pump. Although some of these issues had been identified and addressed prior to, or during, the main
trial, others emerged only during the interviews, as staff reflected upon their trial experiences.
Length of trial
Some staff, as already indicated, reported that they did not really start picking up on patients’ anxiety
about the removal of pump therapy until they attended their 12-month follow-up. Thus, the length of the
trial, or, specifically the length of time spent on pump therapy, was identified as an issue by a number of
staff who questioned that this may have affected patients’ emotional reactions at closeout:
I have been involved with trials where the treatment has been withdrawn, but it’s been a shorter
period of time. I think 2 years is quite a long time and people get very used to things, don’t they.
And then they do start to think that the pump’s theirs. So I think that’s more difficult. When I’ve been
involved with other trials of equipment it’s been more like a few weeks, 6 weeks or something like
that. And so patients are very aware that it’s just for that trial period.
ED11
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Although ED11, like others, saw the length of time spent on the pump as affecting patients’ reactions at
closeout, ED1 regarded the trial’s relatively long duration as indirectly influencing some of clinicians’
decisions to continue pump therapy for certain individuals in their centre:
The REPOSE SOP for the end of the study was based on what we did for the pilot. And the only thing
I could say, I hadn’t really thought about that until just this morning. And whether there was
something to do with the length of the trial, the duration, which made it more difficult to make that
decision [to remove pump therapy] at the end.
ED1
Learning from experience gained during the pilot study
Three of the centres in the main trial had been involved in the pilot,27 and staff who had taken part in the
pilot talked about how these earlier experiences had influenced the ways that they approached the main
trial. These staff described how they had entered the trial with some, but perhaps not enough, awareness
that terminating pump therapy at closeout might be problematic, and how this had led them to putting
some pre-emptive measures in place to prepare patients for removal of their pumps:
When we did the pilot . . . some people were really devastated that they couldn’t keep the pump,
even though we told them. So we were much clearer we think, this time round with: you’re not, you
know – although everything was signed – with the fact that they needed to give the pump back. And
I think we were before. But I think we just reiterated it throughout the process more.
ED10
Indeed, in one such centre (centre A) staff designed a clear formal protocol for ending the trial, which not
only set out criteria for who was to stay on pump therapy (see Research question 2), but also helped them
to manage patients’ expectations throughout the trial and their emotions at closeout. This centre had
reverted the majority of patients to MDI at closeout and they had followed strict procedures for this
including explaining why pumps were being removed, what removal meant and how reversion to MDI
might be a temporary state of affairs, which could be revisited in the future. This centre also provided
patients with spare consumables so that they could continue to use their pumps in the immediate short
term before reverting to MDI at a convenient time, thereby giving them a chance to adjust psychologically
and practically to the transition. These strategies appeared to work, for although this centre had
withdrawn pump therapy from most patients, the staff reported that this had gone reasonably smoothly:
So that we didn’t switch them there and then on that 24-month visit. We reminded them, we had a
few people were quite upset and grumpy about it. And we said: look, how can we? We have some kit
we can give you that can tide you over for another month or 6 weeks, while we sort out your pens
and getting you back – to switch you back onto MDI and doing it in a supportive as way as possible.
We didn’t rip the pump off them at that appointment and say: there’s your pens back, off you go.
And so having that discussion at the meetings [MDT] before for all of them just helped us come up
with a kind of individual plan to sort of, damage limitation really.
ED14
Leaving the door open to revisit patients’ eligibility for a pump
Although centre A was the only centre to consistently allow patients a lead-in period to revert back to
MDI, staff in other centres described how they had tried to manage anxiety and disappointment by making
patients aware that they could make a case for them to have the pump reinstated in the future if they
struggled to manage their diabetes using DAFNE +MDI:
And we did say to him, as we said to others. This is does not mean that pump therapy is completely
closed to you. You know, what you need to do now is go back on injections, really apply DAFNE.
You know, monitor, keep records, make adjustments, and you know, down the line, if you’re still not
managing to achieve an HbA1c or you’re getting hypos, then we can consider a pump again. But you
need to put the work in.
ED1
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Staff in all of the centres, but especially those in pilot centres, also talked about how they had tried to
manage patients’ expectations about closeout throughout the trial, particularly the likelihood that they
may not continue on the pump:
Cause we did – had done the pilot as well we’d sort of expected – we knew what to expect, cause
you know, we’d done the pilot before REPOSE. So we’d been involved and the same sort of thing had
happened: people you know, of course if they liked the pump, they like the pump and want to keep
it. So it was really about just reminding people of the rules and we tried to do that each time we met
them as well, just to remind them that this was about the trial, this was about seeing if the pump was
effective and if they didn’t meet NICE criteria the pump would go back. So we tried to talk about that
at each meeting time as well, not just leave it to the end.
ED11
In a couple of centres, in addition to raising the issue of withdrawal of the pump during trial visits, patients
in the pump arm were given encouragement several weeks before closeout to use the remaining period
of the trial to demonstrate that they could use their pumps more effectively by the time of their final
download or, as Dr H described, to prepare patients for closeout and ease their disappointment if a clinical
benefit could not be evidenced:
I think we just felt better that we’d given them the opportunity. You know if you’re pre-warned that
there’s going to be an exam[ination] result in another 3 months kind of thing, then if you don’t do so
well in it, you think: oh well, at least they told me kind of thing. I think we were just thinking that a
warning shot is quite a good idea. And might make the that’s all, no you can’t have a pump any more
discussions easier.
Dr H
The ethical challenges of withdrawing pump therapy
For some staff closing out the REPOSE Trial was seen as throwing up distinctive ethical challenges not only
because the patients had time to get used to pump treatment, but also because of the nature of the
treatments involved. As Dr H noted, unlike drug trials through which treatments might be replaced by
seemingly similar forms of therapy, REPOSE required the withdrawn treatment to be replaced by a very
different therapeutic option, which, as they noted, may be seen by some patients as not really an option at all:
I mean it doesn’t really have parallels to other studies. I mean I guess if you’re on a new tablet for x, y
or z at the end of the study you might not be able to continue it, but there’s usually an alternative.
And it’s you know tablet versus tablet instead of you know, pump versus another way of giving insulin
which is very different . . . as I say it’s not like this is trying one pump versus another pump, and you at
the end of the study you go back to the old pump. But you take away the new fancy one. This is like
something, getting something versus getting nothing.
Dr H
Dr A raised further ethical issues regarding the withdrawal of pump therapy. This clinician, like others,
argued that if individuals were benefiting, or even perceived themselves as benefiting, in ways that went
beyond the clinical criteria outlined in the NICE/SIGN guidelines then it would not be right to remove
pump therapy at the end of the trial period, not least because these individuals had given their time to
take part in a research project. In other words, as long as patients were using their pump safely then they
had the right to keep it after the trial had finished:
Just because we’re doing a research project doesn’t mean you don’t continue to have a therapeutic
relationship with people and I mean you can call me a softy, but I think we owe it to our patients who
participate in research to do the best by them, and as I said at the beginning you can get a pump for
anybody if you want, and I just think making a judgement that they don’t benefit therefore they
should stop. If they think they’re benefiting, then I’m not comfortable saying I know better than you.
Dr A
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Dr A, like others, also stressed that removing pump therapy at the end of the trial could potentially undermine
an ongoing therapeutic relationship with a patient – especially as was the case for this doctor, when health
professionals delivering the trial were also responsible for providing patients’ routine diabetes care.
Although Dr A was based in a centre at which access to funding for pump therapy was limited and some
patients had pump therapy removed at the end of REPOSE, ED5’s centre, in contrast, had plenty of
funding available and the majority of patients had stayed on the pump following closeout. ED5, however,
was acutely aware of the different funding situations across the trial centres and commented that the
removal of pump therapy at the end of the trial in some centres and not others was just further evidence
of the existence of what they regarded as an unethical ‘postcode lottery’:
That’s the state of the NHS that really at the end of the day if the patient’s benefiting then I feel it’s quite
sad that someone can remove something from someone that they’re benefiting from. And I think that it
just highlights in the NHS a bit of a postcode lottery really regarding pumps, and that hopefully in the
future that’s going to be more standardised. Because your care really wherever you are should be equitable.
ED5
In summary, staff in all of the centres anticipated that closeout and the withdrawal of pump therapy might
be an issue for patients and, hence, had developed a range of potential solutions to address these,
including developing strict protocols for managing expectations and emotions, and reminding patients that
pump therapy was a research intervention whenever they attended trial visits. In addition, staff identified a
couple of ethical issues, such as the problem of withdrawing treatment from patients who perceived
themselves as benefiting from it, potentially compromising an ongoing therapeutic relationship, and the
inequity of the postcode lottery for funding treatments in the UK.
Research question 2
l What factors and considerations informed health professionals’ decisions to continue or discontinue
pump treatment in individual patients?
Variability between centres
The number of patients staying on pumps after closeout varied markedly between centres and, as noted in
Research question 1, it was clear that the staff in the different centres, including ED10, were aware of this:
ED10: And there are always going to be clinical judgement and exceptions. But it feels a bit like
people [sites] have done things slightly differently at the end.
I: What did you do at the end?
ED10: We said to everybody, you have to give it back.
Ultimately, it was the availability of resources, specifically the availability of funding to keep/move patients
on to pumps in routine clinical practice, which determined what happened to individual patients at the
end of the trial. In centres E, B, D and F, for which generous funding was available, the majority of REPOSE
patients stayed on/commenced pump therapy if they wanted to:
So we were very fortunate in that sort of financially there wasn’t going to be any problem here about
asking patients for the pump back at the end of the study. It was agreed that it would be daft to do
that and then restart them again on a pump 3 months later or something. So although the patients
didn’t know and obviously we wouldn’t say to them, because that wasn’t, that wouldn’t have been
good. You know within the group it was realised that there was a sort of secure funding stream to
continue those that were benefiting from the pumps at the end of the study.
Dr H
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In centres A, C and G, for which funding was scarce, staff were acutely aware that pump therapy needed
to be rationed and restricted to those patients who demonstrated a clinical need or benefit, independent
of the patient’s wishes:
[Dr] was quite cut and dried about it. Unless there was a medical reason or unless they met NICE
[criteria] already from a hypo[glycaemia] point of view they had to come off. And you know if there
was any, you know, trouble, they would come down and talk to the patient themselves if necessary.
ED14
Different interpretations of National Institute for Health and Care Excellence/
Scottish Intercollegiate Guidelines Network criteria
The interviews suggested that staff in resource-rich and resource-limited centres tended to use different
criteria when making decisions about individual patient’s post-trial therapy. Two resource-limited centres
adopted very strict criteria for allocating pump therapy at the end of the trial so that, in general, only
those patients with a clinical need who met NICE/SIGN criteria,13,175 as tightly defined (namely, HbA1c
> 8.5%, attempts to reach target with MDI resulting in disabling hypoglycaemia), continued using pump
therapy following closeout. The remaining patients in these centres were informed that they would revert
to MDI:
My view was that if they had shown significant benefit in terms of HbA1c and, and/or reduction in
hypoglycaemia frequency, then we would continue them on pump therapy. And that’s effectively
what we did . . . . they had to effectively fulfil what NICE would expect. So the NICE guidance is based
on an expectation of a 0.9% reduction in HbA1c, and I felt that was what they should be achieving for
us to say that they should continue pump therapy.
Dr G
There were some that we knew had done really well on the pump. We knew that they’d really
enjoyed being on the pump, that we knew that because they had never had, kind of from a NICE
guidance point of view, a period of time having had what we would consider a, you know having
done DAFNE and seeing if DAFNE works first, before putting them on a pump, and had never seen
that, we couldn’t justify it from a hypo[glycaemia] point of view. They had done really well no doubt.
But we couldn’t justify it from NICE to keep them on the pump.
ED14
This approach contrasts with that adopted by resource-rich centres that applied a much looser or
subjective interpretation of the NICE/SIGN criteria when determining who remained on pump therapy.
In one of these centres, nearly all of the patients in the pump group were allowed to remain on the
pump when the trial finished, with some individuals, such as Dr F, justifying their decision by referring to
the ambiguity inherent in the NICE/SIGN criteria:
Yeah. I think it was difficult to remove something that somebody’s doing well with, and wants to
continue. If you know you have that funding available. And as I say SIGN and NICE are very vague.
So you know, you, I felt I could justify it.
Dr F
Using quality-of-life criteria to inform decisions
These centres frequently took QoL issues, as well as biomedical criteria, into account when deciding who
should remain on pump therapy. Dr F, for example, commented that they took into consideration how
‘well’ people were doing on pump therapy when making treatment allocation decisions in their centre:
I: What do you mean by doing well?
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Dr F: It’s interesting isn’t it. So doing well might be having good blood glucose values. But doing well
might just be engaging with their diabetes better than they did before. So we had a couple of quite
chaotic people who don’t have perfect glycaemic control, but they’re testing, they’re entering
information and they’re keeping in touch with us in a way that before they weren’t. So I guess you
know, doing well can be something over and above what their blood sugar’s telling us. And certainly
their control, it’s not perfect, it’s better and safer than it was before. So I think that’s what I would
sort of class as doing well.
Likewise, Dr H, from another resource-rich centre, described how decisions about post-trial therapy at
their centre were governed by the team’s ‘global impressions’ about how individuals had coped on
pump therapy:
We didn’t have any sort of hard criteria. It was going to be more just a sort of global impression
taking into account of all the team’s views. You know, for instance this guy . . . early on in the study
I think everybody would have said if he ever makes it to the end of the study, when he gets there he
shouldn’t be on a pump. But he eventually got there with using it. So the people kind of relaxed a bit
more about it. But I think he was the only person potentially that we would have taken off.
Dr H
Ensuring patient safety
Finally, independently of the availability of resources to fund pump therapy, decisions around individuals’
continuation on pump therapy following the trial were primarily affected by consideration of safety issues.
As ED3, who was based in a well-resourced centre, indicated:
So as a team we reviewed all the people on pumps and made the decision about whether we felt,
based on the information that we had and their downloads etc. they were using the pump first of all
safely, cause that’s the key priority really is, the safeness and then whether they were getting any
benefit from it.
ED3
Indeed, in resource-rich centres, safety appears to have been the only reason for removing people from
pump therapy at the end of the trial, unless patients requested to come off the pump:
Oh it was definitely individual, definitely. I mean if we had funding but thought that person wasn’t
safe. It wouldn’t have mattered if the funding was in place.
ED4
In summary, post-trial treatment decisions in all centres were influenced by assessments of patient safety
and efficacy plus the availability of funding for pump therapy. Access to resources ultimately dictated the
decision-making strategy that was adopted by the different centres; in resource-limited centres individual
treatment decisions were NICE/SIGN-guideline driven and based on strict, objective efficacy criteria,
whereas in resource-rich centres, decisions about individuals were based on looser, subjective views of
efficacy or patient benefit and a desire to safeguard an ongoing therapeutic relationship.
Research question 3
l What processes and procedures do staff think should be put in place to support patients and staff
involved in the closeout of future clinical trials, especially those where expensive health technologies
are being investigated and may be withdrawn?
Strategies used in REPOSE
As already outlined above (see Research question 1), staff had developed some strategies either proactively
or during REPOSE to manage and prepare patients for potential withdrawal of the pump. In the main, staff
QUALITATIVE STUDY OF STAFF INVOLVED IN CLOSEOUT OF THE REPOSE TRIAL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
162
saw these strategies as having been helpful, effective and appropriate, and said they would use them (and
recommend them to others for use) in future trials of a similar nature to REPOSE. Such strategies included
preparing patients for closeout by reminding them, at the outset, that pump therapy was only funded for
the duration of the trial:
. . . it’s about the expectations those people had from the start. And I do think that if you’re very clear
from the outset, if people’s expectations are at a certain level, then those conversions (post trial) are
much easier. But it’s about being very clear from the outset.
ED14
In addition, staff recommended that patients be given reassurance that they will be monitored to
determine whether or not they needed a pump in the future so that a case could be made for them to
access one; separating (ideally in space and time) the clinical appointment to discuss post-trial treatment
from the final trial appointment and, if possible [see What (if any) practical/ethical/other issues arose for
staff and how did they attempt to address these?] giving patients a window of time after closeout to
adapt before therapy was removed:
You know maybe there should have been a wash-out period or something afterwards, you know like
this is the end of the trial maybe you’ll have 2 or 3 months or something to discuss with your team the
way forward or whatever rather than people thinking right on the day it finishes and that’s it, it’s very
difficult to just whip something off somebody and say here you are go back to your pen so I think that
might have been the only thing, and that’s just feedback from the patients really.
ED6
Staff also identified two general areas in which they felt that their practice could have been improved
and which could help support patients and staff involved in closing out future trials involving potential
withdrawal of treatment. These were formalising post-trial procedures and improving communication
between/within teams and with patients.
Formal post-trial procedures
Staff at a number of centres commented that the post-trial period is relatively neglected in trial planning
compared with trial set-up and delivery. In light of their experiences of working on REPOSE, these staff
members highlighted a need to acknowledge and prepare for the ending of a trial from the outset:
Maybe if I’d been in a trial where something had been taken away, we would have formalised this a
bit more . . . But it’s difficult to envisage that when you’re writing a protocol so far in advance isn’t it?
At that point the major thing is: can we get enough people into the study. That’s always the major
hurdle. And in hindsight we probably ought to have sorted out the closeout in more detail once
we were up and running. And set aside time to actually do that. With amendments or whatever
it needed.
Dr B
There was widespread acknowledgement that thinking about closeout in advance and adopting a more
detailed or formalised set of procedures for decision-making about ending/continuing trial therapy would
have been helpful for staff managing this process. Some staff commented that appropriate costings/
resources would also be required for this and to ensure staff had dedicated time to manage the closeout
effectively rather than trying to fit it into already busy work schedules:
And that we had enough time for it – I think one of the issues as well is, because we’re such a busy
clinical team and this was kind of fitted in as part of our clinical work as well. Although there was
some backfill and things it was still a very busy time for us. So making sure that we did have the time
and it was given to that
ED13
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Staff in resource-limited centres, in particular, highlighted a need to develop a more formalised process
with regard to decision-making about post-trial therapy, suggesting that this would enable staff to support
each other when making difficult treatment allocation decisions and communicating them to patients:
But the final decision [post-trial treatment] was made by different people. In hindsight potentially I
think all of the educators and the PI should have been probably together for all of them. And
discussed them . . . I would have definitely met and gone through the SOP and gone through
everything and checked that everyone was clear with what we were doing. And probably together
supported each other and probably have continual meetings with those people particularly involved in
the trial.
ED10
Local guidelines
As indicated earlier, staff also thought that having local guidelines in place was important to avoid
inconsistent practices within centres and to help promote parity in decision-making, fair allocation of
scarce resources (pumps) and also to help prevent potential disagreements and tensions within the team.
Staff in resource-rich centres also suggested that having more formalised procedures at the end of the trial
could be useful and result in more transparent and accountable post-trial treatment decisions:
Would I have put something in at the end to kind of reassess, to kind of see whether or not there
was, was it right to allow a participant who’d been given a pump to remain on a pump . . . So
perhaps something that perhaps brought a bit more structure into that . . . But that perhaps would
have been one thing to kind of do a fuller or a more structured assessment about whether or not it
was the right thing to keep them on a pump.
ED8
The staff speculated that adopting more formalised procedures for closing out patients would ensure
that staff with the requisite skills were available following closeout to train patients to use different
technologies, if required, as well as provide emotional support:
When I saw the patients my team weren’t there. So, and that was a technical problem, because I had
to teach people how to use MDI and how to use the bolus calculators . . . I struggled a bit, ’cause I’m
not a trained educator . . . And it just wasn’t done properly. And that’s entirely my fault, because we
didn’t set it up to do it. We didn’t think it through I don’t think. And they were the last patients.
So we didn’t get the chance to improve it.
Dr C
Finally, some staff also indicated an explicit need for training/role play to deal with patients’ emotional
reactions at closeout and suggested that this training could be usefully incorporated into the costings and
design of future trials:
And I guess maybe yeah, just kind of sort of, kind of how to deal maybe with – if people are being – if
something’s being withdrawn from the person as well, in terms of a sort of a therapy, how to kind of
sort of handle that as well, and what kind of the, so maybe a little bit of training about kind of the
best way to kind of present that to people.
ED13
Improving communication
Finally, nearly all of the interviewees talked about the need for better communication about closeout at
the end of the trial. As Dr C said, ‘Most of our problems came from breakdowns in communication, I
think’. First, many staff noted that better communication across trial centres would have been helpful in
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the REPOSE Trial, as this would have enabled staff in the different centres to prepare for, and alert others
to, patients’ reactions and develop more consistent protocols and/or guidelines for good practice:
I think the only thing I might have done better is we might have had more of a discussion about the
scenarios and shared the experiences so people got a more consistent message.
Dr A
Consensus and communication within centre teams was also seen as important for managing closeout
effectively. Some staff noted that there had been a communication breakdown in their centre, with the
result that some team members were not aware when pump therapy was scheduled to be withdrawn,
and that this had caused problems for the staff and patients involved.
I think that was, that was, that was all not – we didn’t manage that very well, if I’m honest, because
Dr did it on a day when I was on leave. And Dr didn’t – I didn’t know Dr was going to take the pumps
off them there and then. So I would have, I would have liked to have seen them to have gone
through their regimes on pens with them. And to have given them a bolus calculator meter, which
would be like the bolus calculator on their pumps that they were used to. So we didn’t – I didn’t
know they were going to walk into the consultation with a pump and leave without one.
ED12
Other staff members at this centre commented that better communication within the team would have
enabled them to better support each other through the closeout process:
I think probably there should have been more of a team effort at the close. Because there was a lot of
people involved in the team, but it was more or less left to you know, the educators and the dietitian.
And then the consultant saw them later. But I think you know, if the whole team were involved there
wouldn’t have been so much awkwardness at the close.
ED10
Finally, staff argued that closeout of these sorts of trials would be potentially easier if there was better
communication with research participants. As indicated earlier, some advocated continually reminding
participants that pump treatment was funded only for the trial’s duration [see What (if any) practical/
ethical/other issues arose for staff and how did they attempt to address these?]. Others, who supported
adopting more formalised end-of-trial processes, suggested that these could be explained to patients so
they are made aware in advance of how decisions about their post-trial therapy would be made:
You need to let the patients know this, you know, you could have some fixed set criteria for whether
they keep the pump or not. Or we say, at the end of the trial, you come off the pump for 3 months.
And after the 3 months your diabetes control will be reviewed again to see if the pump therapy is
suitable for you. So that they actually – and that might be the better way to do it – so that everybody
knows they’re going to come off the pump for 3 months. And then they’ll get a review, rather
than this.
ED12
As noted earlier [see What (if any) practical/ethical/other issues arose for staff and how did they attempt to
address these?], staff made a related point when they argued that it might be useful to make patients
aware during the trial when they were currently not reaching the criteria for post-trial treatment (pump) so
that they were prepared for the possibility of their treatment being withdrawn:
If we’d had the same conversations all along: your HbA1c‘s no better. You only bolus twice a day. And
you have that conversation three or four times, then the patient is going to come to the conclusion:
yeah I’m not going to keep the pump. I can’t do this. They would have got to that point themselves.
Dr B
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Dedicated trial clinics
Although all staff regarded communication between staff and patients as a crucial factor in facilitating trial
closeout, some acknowledged that developing relationships with trial participants is difficult, particularly in
the larger trial centres. To overcome this, one member of staff suggested that, in the future, trials should
set up clinics for trial participants, which, they reflected, would have been helpful in the REPOSE Trial when
communicating with patients, particularly when terminating pump therapy:
Whoever finished the trial with the patient and communicated to them the decision should have
known the patient. Just so that it was a – it was much more of a more – the way you would clinically,
. . . the person who did know the patient should have been there at the time [the end] to support the
patient through the transition. I don’t think we really realised how the patient would perceive the
difficulty of the transition . . . unlike other studies that I’ve done I personally didn’t feel that I was
engaged with the study’s subjects, which probably is correct from the point of view of the outcomes,
but it did make the ending of the study a bit more difficult.
Dr C
As Dr C further suggested, having dedicated trial clinics would result in continuity of care across the trial
and thus make it easier at closeout because staff involved would be known to the patients and vice versa:
‘I think the person who is terminating the study should have been involved throughout it – that would
have made all of the difference’.
Dr B similarly commented that involving educators who were known to the patients in the post-trial
consultations was helpful when it came to communicating with, and managing, patients’ emotional reactions:
I think, she [educator] knew some of the patients better than I did because she’d done the course with
some of them. And so she was warning which ones might be tricky. And you know, she is a good
judge of character. So that was really helpful I guess. I think one of the other times we ran into a
problem where it, the doctor that didn’t know the background to the patient. You know, so if you,
I suppose not had the pre-warning, if we’ve not had that discussion beforehand, it would come
across, or could be, come across really quite cold and so I think that was helpful.
Dr B
Role of the Clinical Trials Research Unit
Finally, one member of staff, ED11, suggested that CTRUs have a major role to play in communicating and
co-ordinating information about trial closeout by offering/co-ordinating training, hosting meetings/
teleconferences to allow staff to share experiences of closeout, offering examples of good closeout
practices, making sure that there is adequate resourcing to do the closeout/post-trial appointments
properly and reminding centres that closeout is approaching so that they can make preparations,
particularly for potential negative reactions to the withdrawal of treatment:
I think everyone should have been advised to have those difficult conversation – you know had the
conversation about not being able to keep the pump at the end, being advised to do that at every visit
and every opportunity, so that people had their expectations managed. [And] . . . maybe a reminder
that we needed to meet and discuss who was going to stay on the pumps and who wasn’t. You
know, so just a reminder to say: have you had that conversation with your team? Has the patient been
primed? Something like that would have been helpful.
ED11
During the trial there were opportunities for staff to share experiences during regular TMG meetings
involving local PIs and some lead educators from all of the centres, as well as during regular educator
teleconferences. However, these teleconferences primarily focused on issues relating to trial delivery.
Although closeout was discussed in advance in both types of teleconference, the educator teleconferences
were stopped just before the start of the closeout period, as it was thought that, by this point, further
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meetings would not be necessary (a decision that may have been partly due to a lack of awareness of the
problems which would arise for some staff at closeout). Hence, there were limited opportunities for some
staff members at the different centres to share and discuss the difficulties they went on to encounter when
withdrawing treatment.
In summary, although most staff did not regard themselves as having needed support for the closeout of
the REPOSE Trial, they outlined a number of ideas that they felt would facilitate closeout in trials when
treatments are withdrawn. In addition to the strategies they had already developed during REPOSE, staff
suggested that more formalised procedures for ending trials should be adopted; specifically, procedures for
post-trial treatment decision-making and for transitioning research participants back into clinical care.
Second, they advocated for improved communication among trial staff both between and within centres
and with patients.
Key findings
This study has highlighted and explored differences in staff members’ experiences of closeout, both within
and across the REPOSE centres. In most of the centres with limited funding for pump therapy, all but a
few patients were reverted to MDI at the end of the trial. In some such cases, staff had had to manage
patients’ negative emotional reactions to the withdrawal of pump therapy. In other centres at which
funding for pumps was more readily available, all patients who were safely using the pump, who wished
to continue using it and who were benefiting, as broadly defined from pump therapy, were allowed to
continue this treatment following trial closeout. As patients in these centres were able to remain on the
pump if they wanted to, closeout in these centres was perceived as less challenging.
Most staff, but particularly those involved in the pilot phase, anticipated that the withdrawal of pump
therapy might be an issue for patients, and hence had developed a range of potential solutions to address
this. These included developing strict protocols for managing patients’ expectations and pre-empting
potential disappointment/anger by reminding patients that pump therapy was a research intervention that
may terminate at the end of trial whenever they attended trial appointments.
All centres developed site-specific procedures for decision-making about post-trial treatment, although
some were more formalised than others. These decisions were influenced by assessments of patient safety
and efficacy plus the availability of funding for pump therapy. Access to resources ultimately dictated the
decision-making strategy adopted by the different centres (and, in some cases, by different individuals
within those centres); in resource-limited centres individual treatment decisions were NICE/SIGN-guideline
driven and based on objective efficacy criteria, whereas in resource-rich centres the treatment decisions
were based on more subjective views of efficacy or patient benefit and a desire to safeguard an ongoing
therapeutic relationship.
Staff described a number of ethical questions and issues concerning the withdrawal of treatment, which
they felt had emerged in closing out the REPOSE Trial. These included whether or not it was right to
remove a therapy if patients were deriving some benefit, or perceived themselves as benefiting, from it;
the fact that removal of therapy might undermine the trust and confidence in an ongoing therapeutic
relationship; and the existence of inequity in funding for post-trial treatment.
Staff identified a number of things that they felt could facilitate closeout of future trials when treatments
may be withdrawn. In addition to the particular strategies they had developed during the REPOSE Trial, staff
suggested that more formalised procedures for ending trials should be adopted; specifically, procedures for
post-trial treatment decision-making and for transitioning research participants back into clinical care.
Second, they advocated for improved communication among trial staff, both between and within centres,
and with patients. In addition, staff highlighted the potential value of having several team members
involved in post-trial consultations, including staff who had contact with patients during the trial.
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Key recommendations
1. Planning for closeout should begin at a trial’s inception. Closeout should be addressed in the risk
assessment for the trial, and consideration given to whether or not there may be ethical and practical
issues related to removing a trial treatment.
2. Ensuring that the necessary resources, training and protocols are in place will require that realistic
costings for closeout (e.g. training for staff, making sure they have dedicated time for post-trial clinic
appointments and MDTs) are included in the grant application or are negotiated with trusts during the
planning stage.
3. Having formal closeout procedures for decision-making about post-trial treatment and transitioning
patients back into clinical care/other therapies may increase accountability and transparency, and aid
the communication of treatment decisions to patients.
4. Consensus and communication within centre teams is important for managing closeout effectively.
5. If closeout is staggered across/within centres then regular meetings/debriefs during the closeout period
would allow staff to share and learn from each others’ experiences.
6. If a treatment may be withdrawn at the end of the trial, trial staff should communicate this to patients
at every opportunity during the trial to prevent/pre-empt disappointment.
7. Information about the potential withdrawal of treatment should be included in formal trial materials
(e.g. the patient information sheet, see Appendix 8), as occurred in REPOSE, as well as informal trial
communications (e.g. trial newsletters). Participants could also receive a separate (local) closeout
information sheet before the end of the trial, which explains the timescales involved, the training/
support provided and arrangements for future monitoring of (new) treatment. Consideration could
also be given to whether or not a statement about the potential withdrawal of treatment should be
included on the consent form.
8. Continuity of care across the trial could be encouraged; this could take the form of running dedicated
clinics for trial participants or, at the very least, ensuring that staff closing out the trial are known to
the patients.
9. Research appointments to collect trial data and clinical appointments to discuss post-trial therapy
should be distinct; if possible, these should occur at different times and in different places.
10. Allowing patients a period of time after the trial is ended to continue on trial therapy and adjust to
the idea of the withdrawal of treatment may be valuable. Funding for this period of adjustment may
need to be included in the grant application.
11. Examples of good and bad practice at closeout could be documented and used to create scenarios
for role play/training staff involved in the closeout of future trials involving potential withdrawal
of treatments.
Strengths and limitations
This study had very high opt-in levels from staff, providing us with a sample size sufficient to achieve data
saturation and allowing good representation of a diverse range of views. Recruitment from the seven main
trial centres enabled us to identify a number of variations in practice in closing out the trial and the impact
of contextual (e.g. availability of funding for pumps), as well as individual, factors (previous experience of
delivering pilot, exposure/lack of exposure to patients during follow-ups, etc.) on closeout experiences and
practices. This wide-ranging approach also enabled us to identify broader cross-cutting ethical issues and
challenges, experienced in most/all of the centres.
There are, however, a couple of limitations that must be considered. First, in some cases there was a time
lag between closeout and the interviews; hence, some of the accounts may have been subject to a recall
bias. Second, the interviews required staff to reflect on what proved, for some, to be sensitive experiences.
This may have impacted on staff willingness to discuss these issues in too much depth, although this was
not evident in the interviews. Third, the fact that all of the staff interviewed come from a relatively small
research community has affected the material that we are able to report because of our ethical mandate
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to safeguard confidentiality. Finally, one major limitation of this study is that we were unable to interview
REPOSE patients about their closeout experiences because, as noted above, there was insufficient time
available to secure ethical and other approvals and to collect the data.
In summary, the REPOSE Trial, presented an opportunity to undertake research on the experiences, views
and information/support needs of staff members involved in the closeout of a trial, which potentially
involved the withdrawal of trial treatments, thereby allowing us to provide data on a much neglected
topic. All of the objectives of this qualitative study were achieved, and all of the original research questions
answered. A peer-reviewed journal article is in press.173
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Appendix 1 Search methods
The Ovid MEDLINE search strategy was adapted, as appropriate, to the other databases.
1. ((continuous or subcutaneous) adj3 insulin adj3 infusion).mp.
2. (csii or insulin pump*).mp. [mp=title, abstract, original title, name of substance word, subject heading
word, keyword heading word, protocol supplementary concept word, rare disease supplementary
concept word, unique identifier]
3. (insulin and pump*).m_titl.
4. Insulin Infusion Systems/
5. 1 or 2 or 3 or 4
6. Diabetes Mellitus, Type 1/ or type 1.mp.
7. random*.tw.
8. randomized controlled trial.pt.
9. 7 or 8
10. 5 and 6 and 9
11. limit 10 to yr=“2007-Current”
The searches yielded 1341 records, and 749 remained after duplicates were removed. After screening the
titles and abstracts to exclude studies not in adults, 180 records remained, and the titles and abstracts of
these were screened by two authors. Only 128 were RCTs. We excluded trials for the reasons reported in
Chapter 2 (see Methods). Twenty-three papers were included in the table of previous trials. Some trials
were reported in more than one paper.
We also checked inclusion lists of six past systematic reviews (Colquitt et al.,14 Cummins et al.,9 Pickup
et al.,28 Monami et al.,18 Fatourechi et al.29 and the Cochrane review by Misso et al.31).
Searches were run in Ovid MEDLINE for observational and audit studies of insulin pumps from 2012 to
7 January 2016.
The search strategy was
1. ((continuous or subcutaneous) adj3 insulin adj3 infusion).mp.
2. (csii or insulin pump*).mp. [mp=title, abstract, original title, name of substance word, subject heading
word, keyword heading word, protocol supplementary concept word, rare disease supplementary
concept word, unique identifier]
3. (insulin and pump*).m_titl.
4. Insulin Infusion Systems/
5. 1 or 2 or 3 or 4
6. *Diabetes Mellitus, Type 1/
7. type 1 diabet*.tw.
8. 6 or 7
9. 5 and 8
10. limit 9 to yr=“2012-Current”
11. (editorial or letter or randomized controlled trial).pt.
12. (10 not (editorial or letter or randomized controlled trial)).pt.
This retrieved 603 records and, after screening, 33 were retained for screening by a second reviewer.
Of these 22 were included.
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Appendix 2 Regulatory approvals
Research Ethics Committee approval was obtained for the study from the Liverpool East REC on 26 April2011. MHRA approval was received on the 26 May 2011.
The relevant R&D departments were approached and approval was given for the relevant primary care
trusts/trusts on the following dates:
R&D department Date of approval
Sheffield Teaching Hospitals NHS Foundation Trust 27 October 2011
NHS Greater Glasgow and Clyde 10 January 2012
King’s College Hospital NHS Trust 13 January 2012
Cambridge University Hospitals NHS Foundation Trust 26 October 2011
Harrogate and District NHS Foundation Trust 20 January 2012
NHS Dumfries & Galloway 24 October 2011
NHS Lothian 5 January 2012
Nottingham University Hospitals NHS Trust 31 October 2012
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Appendix 3 Consent forms
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Appendix 4 Sample of data collection booklet:
24-month follow-up
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Appendix 5 Blood glucose diary: pump arm
DOI: 10.3310/hta21200 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 20
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Heller et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
209
 APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
210
 DOI: 10.3310/hta21200 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 20
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Heller et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
211
 APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
212
 DOI: 10.3310/hta21200 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 20
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Heller et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
213
 APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
214
DOI: 10.3310/hta21200 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 20
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Heller et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
215

Appendix 6 Ongoing data collection booklet
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Appendix 8 Participant Information Sheets
Participant Information Sheet – Main Study 
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Appendix 9 Qualitative substudy topic guides
Qualitative substudy – topic guide for patient interviews at baseline.
VERSION 01 07JAN2011  
 
 
DAFNE pump study (REPOSE) 
Interview sub-study 
 
 
 
 
Interview Topic Guide for Patients – Post course 
Patient ID: . 
Location: .............. 
Date: .. 
 
Note: the contents of the topic guide might be revised in light of issues 
identified during an on-going analysis of interview data. This is standard 
procedure in a qualitative study employing an emergent design. 
 
 
Background and history of diabetes 
 
 Background: can you tell me a bit about yourself, such as who you live with 
and what you do? When did you first find out you had diabetes? 
 
 Support needs: 
o What contact have you had with health services and healthcare 
professionals (HCPs) since diagnosis? 
o How have you felt about past advice and support from HCPs? 
o What types of support have you received from family/friends? 
o Have you sought any additional information and support? From where? 
 
 Living with and managing diabetes since your diagnosis: 
o What sorts of things have you done to manage your diabetes over 
time? (e.g. taking insulin, SMBG; food/alcohol, physical activity) 
o Has your treatment (i.e. type of insulin and timing of injections etc) 
changed over time? In what ways? How did you feel about this? 
o Before DAFNE, what was your self-management of diabetes like? 
o Over time, what things have affected your diabetes self-management? 
o Tell me about your experiences and responses to episodes of 
hypoglycaemia in the past? 
 
 
Food choices, dietary patterns and physical activity (pre-course) 
 
 Background food choices before starting DAFNE: 
o Can you tell me about the types of foods you usually eat, starting with 
the first meal of the day (Explore meal contents, when/where eaten, 
variation in choices, snacking, routines)? 
o Who choses and prepares your food? Are there any exceptions to this? 
o Are there any circumstances that impact on mealtimes and dietary 
patterns? (Explore family-, social-, work-life). 
o When did you normally choose to inject surrounding eating? 
 
 What types of sports/physical activities were you involved in before your 
course? 
o How did you manage your diabetes when you were doing these 
activities? 
 
Decisions to attend DAFNE, pre-course 
 
 Approaches regarding DAFNE and decision to enrol 
o How and by whom were you approached? 
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VERSION 01 07JAN2011  
 
 
o What did you hope and expect to gain from the course? Why did you 
decide to attend? 
o What did you think when told it would be a group education course? 
 
 Had you previously received any education on or relating to any of the 
information you received on the DAFNE course – e.g. carb counting? 
 
 
Views about the trial and decision-making surrounding attendance 
 
 At what point in the process of waiting to hear about your place on a course 
were you invited to take part in the trial? 
 
 How were you approached and what did you think/feel at the time? 
o What was your understanding of the purpose of the trial? 
o Why did you agree to take part? 
 
 When informed about the trial, did you have a preference for attending a 
standard DAFNE course or a pump course? (probe to establish whether 
patients had ever talked to HCPs about the possibility of moving onto a pump 
prior to being approached to take part in the trial) 
 
• How did you feel after finding out which course you had been allocated to? 
o At any point did you consider withdrawing from the trial? Why? 
 
 Any other hopes, expectations or concerns about taking part in the trial? 
 
 
 
Views on the course attended 
 
 Looking back at the course you’ve just attended, which aspects did you find 
helpful and unhelpful? (e.g. timing /duration of course, specific aspects of the 
curriculum) 
 
 Did the course fulfil your initial expectations? (Explore any assumptions made 
regarding course type in advance of randomisation). 
 
 [If relevant, why did the participant not feel able to complete the full course?] 
 
 What new skills did you learn when attending the course? 
o What barriers might affect your use of specific skills taught on the 
course (e.g. carb counting, SMBG, diary keeping, using a pump (if 
relevant)) 
o What kinds of adjustments did you make to your treatment (e.g 
changes to ratios) during the course? How did you feel about making 
these changes? 
 Views on group education and comparisons with previous experiences 
o What aspects of the group education format did you like and dislike? 
(explore normalising / sharing of experience, emotional support given 
and received, increased self-efficacy, pro’s/cons of group?). 
o How did you feel about the review sessions and group environment? 
o How able were you to participate and have an active role? 
o How does DAFNE training compare with your past experiences of 
educational instruction? 
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VERSION 01 07JAN2011  
 
 
• Views on how diabetes is managed following the course attended 
o Following your course, have you made any changes to how you think 
about and self-manage your diabetes? What are these changes? 
o What impacts do think the skills and education received on the course 
might have on your daily life in the coming months? (e.g. meal choices, 
family life, social life) 
o Have you made any immediate changes to dietary patterns? What 
changes have you made, and why? 
o How do you think using the DAFNE principles will fit within your 
everyday life? (e.g. impact of family-life, pressures of work) 
o How do you feel about continuing to record your CPs and BG readings 
in the diary? 
o What were the goals that you set during the course? How did you 
decide upon these? Have any of them changed since the course? How 
realistic / achievable are they? 
o Has your approach to managing hypos changed at all following the 
DAFNE course? Why? 
o After DAFNE, have there been any changes in how you approach food 
/ exercise / injection timing? Might this change in future? 
 
 
 
 What is the main message you took from your course? 
 
 How, if at all, do you see your diabetes impacting upon your health in future? 
 
 
For patients who attend the pump course 
 
 What’s it been like moving onto a pump? How do you think using a pump 
compares with experiences of managing your diabetes using injections? 
 
 Has using the pump been different to what you imagined it would be like 
o Any unanticipated benefits/problems to using the pump 
o Impact on lifestyle compared to previous experiences of injection 
regimens 
 
 How have other people reacted to you moving onto a pump? 
 
 Are you wanting and willing to remain on a pump (for the duration of the trail, 
in the long term), why? 
 
 
 
 
 
Future developments 
 
 
 Do you have any ideas/suggestions for how the course you’ve just attended 
could be improved? 
 
 What support might help you to continue using the skills and training received 
on the course? (Explore support from HCPs, family and friends) 
 
 What are your hopes and expectations for the future 
 
 Is there anything else you would like to add that you think I haven’t covered? 
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DAFNE Pump study (REPOSE) 
Interview sub-study 
 
 
 
 
Interview Topic Guide for Patients – 6 month follow- 
up 
 
 
 
 
Patient ID: . 
Location: .............. 
Date: .. 
 
 
N.B. the follow-up interviews will be tailored to individual patients and in light of their 
specific responses in their previous interview. 
 
 
 
Introductory questions: 
 
 What’s been happening in your life since we last spoke? 
o Have there been any changes in your circumstances – job, family, 
living arrangements – tailor for those you have knowledge of. Do you 
have any significant events coming up in the near future? 
 
 
 
Living with diabetes post-course 
 
 Can you tell me what it’s been like for you in managing your diabetes since we 
last spoke in [month] when you had completed the course? 
 
 How, if at all, has your management of diabetes changed over the last six 
months since attending the course? 
 
 To what extent are you testing your BG and keeping a DAFNE diary (BGs and 
CPs)? What affects your testing regimen and diary keeping? If 
recording/testing: How manageable have you found this to be? 
 
 How are you determining CPs? What has got in the way? Do they use the 
course book at all? How? 
 
 How, if at all, have you made adjustments to insulin doses over time? [Check 
for changes to background insulin and/or QA ratios. Are adjustments being 
made short-term – corrections, or are they following a stepwise approach? If 
completing diaries then do they use these to determine patterns? If not, why 
not?] 
 
 Do you look for patterns? What has helped/hindered you in making 
adjustments? (i.e. understanding of insulin peaks/profile; pattern 
spotting/recording; support). 
 
 Do you feel that you are following DAFNE or adapting its rules for yourself? 
 
 How, if at all, do the DAFNE targets feature in your management? 
 
 Can you remember the goals that you set following the course? How have you 
progressed with regards this goal? Have you set any further goals? 
 
 How much of the information do you remember from the course? 
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
240
VERSION 01 07JAN2011  
 
 What have been the main successes of your approach? And what have been 
the main challenges you have encountered? Explore any ‘disappointments’. 
 
 What do you feel is the impact of diabetes on your daily life now? What about 
the impact of diabetes on significant others (partner/family/friends)? 
 
 How do you feel about your role in managing your diabetes, six months after 
completing the course? Has it changed? 
 
 How have you felt about being able to continue using the DAFNE principles? 
 
 What is your current experience of hypoglycaemia and how are you currently 
treating your hypos? 
 
 Are there specific aspects of the education received on the course which you 
have put into practice to help you manage your diabetes? (hypo treatment; 
sick day rules, correctives) Any aspects that you had more difficulty in 
implementing? Why? 
 
 Have you had any recent HbA1c readings taken? When was this? Why did 
you have the test done at this point in time? [Why did you hold off having it?] 
What was this? What effect, if any, did this reading have for you? Explore in 
relation to the patient’s previous results? Are they better/worse? 
o What effect has your HbA1c reading had on your views of DAFNE? 
 
 Can you think of any ways in which your current diabetes management has 
affected your life/lifestyle? What are these / why? 
 
 
 
Tailored questions for pump users 
 Explore likes/dislikes of using a pump; how this compares with previous 
experiences of managing diabetes using injections 
 If relevant, explore reasons for discontinuing pump usage 
 
 
 
 
Food, exercise and lifestyle in general 
 
 Have you made any changes to your food choices since attending your 
course? What are these changes and what prompted them? (Explore: food 
cooked in the house; eating out; daily routines and at weekends; snacking 
behaviour). 
 
 Have there been any changes to the way that you relate to food / the sorts of 
foods that you eat? What are these? Why? 
 
 Tell me about your food choices for breakfast, lunch and dinner? 
 
 DAFNE also contained advice on exercise. Have you found the advice that 
was offered to be of use? In what ways? How do you now approach exercise? 
 
 How have you managed with alcohol and the DAFNE guidance provided? 
 
 
 
Support structures and environment 
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 Can you tell me about the follow-up support – did you attend the meeting? If 
so, then of what use was it to you? Why/why not? 
o How did you find meeting up with the group again at the follow-up 
event? How were others doing? How did this affect you? 
 
 Any further contact with any of the group outside of DAFNE? What did this 
consist of and did you find it beneficial? 
 
 Over the last six months, what experiences/contact have you had with 
healthcare professionals? (Who, are they DAFNE trained? DAFNE educators; 
for pump users – have these HCPs been familiar with pump usage) 
 
 Have you had contact with other HCPs outside of DAFNE? What effect, if any, 
has your DAFNE training had on these encounters? 
 
 Have you attended/received any further follow-up events since attending the 
DAFNE course; what are you views about this? 
 
 What support do you feel would be of benefit to you at this point in time and in 
the near future? (Exploring unmet needs). What might have helped earlier? 
 
 
 
Summary questions 
 
 How, if at all, do you see you disease impacting upon your current health and 
your health in the future? 
 
 Looking back six months to the time when you attended the DAFNE course, is 
there anything that might have been done differently 1) on the course itself or 
looking at how it was structured, 2) by yourself following the course? 
 
 What would you like to happen next? Preferences for future treatment (pumps 
Vs MDIs) 
 
 What’s in been like taking part in the trail so far? 
 
o Views about randomisation outcome 
o Willingness to complete questionnaires etc. 
 
 Anything else you would like to add? 
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DAFNE Pump study (REPOSE) 
Interview sub-study 
 
 
 
Interview Topic Guide for DAFNE Educators 
 
 
Note: the contents of the topic guide might be revised in light of issues 
identified during an on-going analysis of interview data. This is standard 
procedure in a qualitative study employing an emergent design. 
 
 
 
Background and involvement in DAFNE 
 
• To get some background, can you tell me a bit about your career to date? 
o How, and why, did you first get involved in working with patients with 
type 1 diabetes? 
 
• When and why did you decide to train as a DAFNE educator? 
o Tell me about your training and what it consisted of? 
o How much experience do you have of working on DAFNE courses? 
o What do you think you personally bring to the course? 
o What previous experiences do you have of moving patients onto 
pumps? 
 
• What do you think are the biggest and / or most typical challenges T1DM 
patients encounter in managing their disease? 
 
 
Background and involvement in the trial 
 
o Can you tell be a bit about how, and why,you come to be involved in the pump 
trial? 
 
 
o Were you involved in recruiting patients onto the trial? 
o What were patients’ responses to being approached to take part? 
o Was there any sense that patients had a preference for one type of course 
(pump course vs standard DAFNE) rather than another? 
o Did any patients decline to take part in the trial? Why? 
 
 
Experiences of delivering DAFNE pump courses 
 
o How does your experience of delivering the pump course compare with your 
experiences of delivering standard DAFNE courses? Were there any 
differences in delivery? 
 
• Has the pump course and your delivery of it panned out in the ways that you 
had had initially expected? 
 
• Did any issues arise delivering the pump course which you had not expected, 
what were these; how did you deal with these? 
 
• What do you think about the way in which the curriculum has been adapted for 
pump course? Do you think that further refinements and adaptations are 
needed? What are these? 
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Views about course dynamics 
 
• Do you think there are any obvious differences in how patients interact and 
support one another on pump courses compared with the standard DAFNE 
course? 
 
• Do you think there are any differences in the kinds of insulin adjustments (to 
background, quick acting doses and ratios) made and in how these are 
considered by patients? 
 
• Do you think the adjustments are more or less conservative on pump course 
compared to a standard DAFNE course? Why? 
 
• Do you perceive any other obvious differences and/or similarities between how 
patients have received and responded to the two types of course? 
 
 
The DAFNE course: attributes of success / failure 
 
• Drawing on examples from a the most recent pump course you have 
delivered, which elements did you think patients found the most beneficial? 
Why do you think this? Do you think there were any differences in benefits 
received on pump course compared to a standard DAFNE course? 
 
• Which features of the course do you think patients find the most difficult to 
implement? Why do you think this is? (Draw on specific examples, e.g. CHO 
counting  SMBG, occurrences of hypos) Did this differ from your experience of 
difficulties surrounding a standard DAFNE course? 
Patients experiences of managing the diabetes on a pump 
 
• What sorts of patients, in your opinion would benefit from being moved onto a 
pump? 
 
• Based on your experiences to date, what do you think the main issues and 
challenges patients confront managing their diabetes after moving onto a 
pump? 
 
• Do you think some patients adapt better to pumps than others? Why? 
 
• What kinds of input and support do you think patients need to manage their 
diabetes using a pump over time? 
 
• Based on your experience, why do you think some patients discontinue using 
pumps? 
 
Future courses/other points 
 
 
• Do you have any suggestions for ways in which this method of delivering a 
DAFNE pump course might be improved? (e.g. content of curriculum, timing of 
courses). 
 
 
• Do you anticipate there being any differences in outcomes between patients 
attending the standard DAFNE courses and patients attending a pump 
course? (Explore differences in clinical / psychological outcomes) Why? 
 
• Do you have anything else you would like to add that I haven’t covered? 
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Appendix 10 Summary of amendments
Amendment
number and
type
Date
submitted Summary of amendment Documents changed Date approved
Substantial
amendment 1
13 June 2011 To allow ethical review of the consent
forms, patient information sheets and
interview topic guides for the
qualitative substudy/component of the
REPOSE Trial
None 20 June 2011
Substantial
amendment 2
6 July 2011 Protocol:
1. General information: PI and
centre details
2. Protocol amendment
summary details
3. Trial introductory paragraph,
p. 11: to make text agree with
Figure 1
4. Urine samples and ACR: clarified
that this test will be taken during
the trial
5. Inclusion and exclusion criteria: one
inclusion and one exclusion
criteria added:
¢ extra inclusion criteria –
has a need for structured
education to optimise diabetes
control in the opinion of
the investigator
¢ extra exclusion criteria – has
a need for pump therapy
in the opinion of the
investigator
6. DAFNE pre-course pump session:
clarified when pump use on saline
would be taking place
7. Appendices A–X removed and
considered as stand-alone
documents from now on
8. Typographical errors corrected (e.g.
clarification of the cut-off points for
the HbA1c categories)
Protocol to v3,
28 June 2011
20 July 2011
Patient information sheet:
1. Geographical areas for the trial have
been amended according to centre
removal and additions, p. 2:
sentence inserted to clarify that ACR
will be measured by urine sample
2. Sentence amended to clarify process
of continuation of pump therapy in
England and Scotland
Northwest 3 REC-Liverpool East listed
as ethics committee for which approval
has been granted
Patient information sheet
to v3, 28 June 2011
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Amendment
number and
type
Date
submitted Summary of amendment Documents changed Date approved
REPOSE leaflet:
1. Addition to clarify that urine
samples will be taken in addition to
blood samples at baseline, 6, 12
and 24 months
¢ Minor amendments included as
notification: consent form –
version and date of the
appropriate patient information
sheet has been amended
REPOSE leaflet, to v3,
28 June 2011; participant
consent form, to v3,
28 June 2011; baseline
hypoglycaemic recall forms:
1 × severe, 2 ×moderate,
to v2, 28 June 2011;
follow-up hypoglycaemic
recall forms: 1 × severe,
2 ×moderate, to v2,
28 June 2011
CTA:
1. Centres amended
2. Inclusion/exclusion criteria added
3. Contact details, typographical errors
and updated details (ethics approval
details, ISRCTN number) added
CTA
No changes made to the following
documents, but omitted from original
application to ethics:
l follow-up instructions for filling in
your diary, v1, 7 January 2011
l DTSQc (validated questionnaire)
Substantial
amendment 3
8 August 2011 To allow ethical review of a consent
form, patient information sheet and
interview topic guide for interviews
undertaken with two to three
participants who were involved in a
pump pilot study (a smaller-scale
version of the REPOSE Trial)
No documents changed
but the following
documents were
reviewed:
l informed consent
form for REPOSE
video clip, v1,
2 August 2011
l patient information
sheet for REPOSE
video clip, v1,
2 August 2011
l interview topic guide
for REPOSE video clip,
v1, 2 August 2011
l other REPOSE video
elements: foreword
and closing statement
from chief investigator,
v1, 2 August 2011
22 August 2011
The aim was to create a short video clip
to show to potential participants for
the REPOSE Trial at local information
meetings for the trial
The aim of the video clips is to give
potential participants an understanding
of what it is like to take part in a clinical
trial and be on pump therapy to control
their diabetes, from the perspective of
someone who has taken part in a similar
trial (i.e. the pump pilot)
In addition, the video clip is introduced
and ended by short foreword and
ending by the chief investigator
Substantial
amendment 4
6 September
2011
1. To add and remove centres:
¢ addition of Royal Infirmary of
Edinburgh (PI: Dr Alan Jaap)
¢ removal of University of
Edinburgh (Dr Julia Lawton)
and Monklands Hospital
(Dr Thekkepat Sandeep)
N/A 7 September 2011
2. Notification that Harrogate and
District NHS Foundation Trust (PI:
Dr Peter Hammond) are delivering
part of the trial intervention using
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Amendment
number and
type
Date
submitted Summary of amendment Documents changed Date approved
a venue that is not owned by
Harrogate and District NHS
Foundation Trust: Henshaws Society
for Blind People, Bogs Lane,
Harrogate, North Yorkshire,
HG1 4ED
Substantial
amendment 5
12 September
2011
Protocol:
1. General information, p. 4: change to
details of PIs and sponsor contact
2. Protocol amendment details, p. 6:
text inserted to detail protocol
amendments from v3 to v4
3. Trial summary, p. 7: list of centres
amended to correspond with
removal/addition of centre
4. Demographic measures, p. 14:
removal of religion as part of the
demographic analyses
5. Randomisation, p. 23: time at which
REPOSE educator finds out which
treatment arm participants has been
allocated to altered from 1 month
to 6 weeks
6. Table 1: Documents for Data
collection, pp. 26–30 – details of
severe and moderate hypoglycaemic
episodes recording process amended
in table
7. Typographical errors and formatting:
references to appendices removed
from protocol; formatting of
figures undertaken
l Protocol to v4,
1 September 2011
NRES, 19
September 2011
Participant consent form l Participant consent
form, v4,
1 September, 2011
REPOSE participant information sheet l REPOSE invitation
letter to be sent with
patient information
sheet, v2,
1 September 2011
l REPOSE participant
information sheet, v4,
1 September 2011
SAE contact card l SAE contact card, v2,
1 September 2011
Psychosocial questionnaire l Psychosocial
questionnaire, v2,
1 September 2011
Follow-up instructions for filling in your
diary
l Follow-up instructions
for filling in
your diary, v2,
1 September 2011
Minor amendments included for
notification:
l REPOSE invitation letter to be sent
with patient information sheet
l Consent for qualitative study
l Consent for
qualitative study, v2,
1 September 2011
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Amendment
number and
type
Date
submitted Summary of amendment Documents changed Date approved
New documents:
1. Non-participation form, v1,
1 September 2011 (replaces
non-participation details in REPOSE
invitation letter to be sent with
patient information sheet, v1,
7 January 2011)
2. Instructions for recording
hypoglycaemic episodes, v1,
1 September 2011 (replaces
baseline instructions for filling in
your diary, v1, 7 January 2011)
Severe hypoglycaemic episodes log, v1,
1 September 2011, and moderate
hypoglycaemic episodes form, v1,
1 September 2011 (replaces baseline
hypoglycaemic recall forms: 1 × severe,
2 ×moderate, v2, 28 June 2011)
l Non-participation
form, v1, 1
September 2011
l Instructions for
recording
hypoglycaemic
episodes, v1, 1
September 2011
l Severe hypoglycaemic
episodes log, v1,
1 September 2011
l Moderate
hypoglycaemic
episodes form, v1,
1 September 2011
CTA l CTA
Minor
amendment 1
24 October
2011
1. Reformatting or minor changes to
the following documents:
NRES approval:
N/A; notified in
substantial
amendment 6REPOSE leaflet, v3, 7 October 2011
(previously v2, 28 June 2011)
REPOSE leaflet, v3,
7 October 2011
REPOSE poster, v2, 7 October 2011
(previously v1, 7 January 2011)
REPOSE poster, v2,
7 October 2011
SAE contact card, v3, 7 October 2011 SAE contact card, v3,
7 October 2011
2. Name changes of centres:
The names of some centres on the
CTA are listed slightly incorrectly
(e.g. Cambridge centre is listed as
Cambridge University rather than
Cambridge University Hospitals NHS
Foundation Trust)
Minor
amendment 2
3 November
2011
Consent, v6, 3 November 2011: revised
so the participant ID is now the
participant’s DAFNE number
Consent, v6, 3 November
2011
NRES approval:
N/A; notified in
substantial
amendment 6
Minor
amendment 3
9 January
2012
REPOSE invite letter, v3, 6 January
2012: addition of an optional sentence
to inform potential participants the date
of local recruitment evenings/afternoons.
REPOSE invitation letter, v3,
6 January 2012
NRES approval:
N/A; notified in
substantial
amendment 6
Minor
amendment 4
12 January
2012
REPOSE GP letters – MDI and pump:
minor amendments so the trial name
listed is REPOSE not the pump pilot
study
REPOSE GP letter: MDI,
v2, 9 January 2012
NRES approval:
N/A; notified in
substantial
amendment 6REPOSE GP letter: Pump,
v2, 9 January 2012
Minor
amendment 5
18 January
2012
Agreed in risk assessment meeting with
Sponsor on 9 January 2012 –
amendments to the REPOSE protocol:
(a) Clarification of the IMP management
during the trial, including tracking,
accountability and labelling
(b) Clarification to one of the exclusion
criteria – that only patients with a
NRES approval:
N/A; notified in
substantial
amendment 6
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Amendment
number and
type
Date
submitted Summary of amendment Documents changed Date approved
strong need for a pump will be
excluded from taking part in the trial
(c) Clarification as to what constitutes
the AE ‘Unexplained constantly high
blood glucose readings’, which is
defined as three consecutive
readings > 20mmol and over
12 hours
(d) Change to the SAE reporting
process. SAE forms are to be faxed
to the Sheffield CTRU instead of
the sponsor (as delegated by
the sponsor)
(e) Addition of pump site infection as
an AE
(f) At present there are two
outcomes listed as primary
outcomes. It was discussed at our
TSC that there should only be one
primary outcome. Therefore, we
have downgraded ‘The proportion
of participants reaching the NICE
target of a HbA1c level of 7.5%
(58 mmol/mol) or less’ to a
secondary outcome
(g) In addition, minor typographical
corrections and formatting have
been undertaken
Substantial
amendment 6
17 January
2012
1. Questionnaire: amendment to
question listing qualifications and
educational attainment so applicable
to both England and Scotland
2. Time allocation revealed to patients:
from 2 weeks before their DAFNE
course to 4 weeks before their course,
to allow the participant a greater
amount of time to know their
allocation to a pump or MDI.
In addition, this change will allow
pump participants more time to
organise attendance of a family
member or friend for support at their
first appointment when the participant
switches to pump therapy (this often
happens in standard clinical care)
Psychosocial
questionnaire, v3, 16
January 2012; protocol,
v5, 4 January 2012
6 February 2012
Notification of minor amendments 1–5
Minor
amendment 6
18 January
2012
The lost to follow-up definition (p. 33)
has been amended to clarify that lost to
follow-up participants are those who
fail to attend more than two follow-up
visits, including the 24-month follow-up
appointment (previous definition was
participants who failed to attend more
than two follow-up visits)
REPOSE protocol, v6,
16 January 2012
NRES approval:
N/A; notified in
substantial
amendment 7
Substantial
amendment 7
17 January
2012
1. Blinded review of HbA1c (measure of
the level of blood glucose control):
To allow the trial statistician to
conduct a blinded review after course
2, 4 and 5 to examine the proportions
of recruited participants who are in
each HbA1c category (i.e. ≥ 7.5%
REPOSE protocol, v6,
16 January 2012
6 February 2012
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Amendment
number and
type
Date
submitted Summary of amendment Documents changed Date approved
or< 7.5%). The trial statistician will
look at the proportions in each HbA1c
category, and numbers of participants
with a HbA1c of ≥ 7.5% threatens
the ability of the trial to detect a
difference in primary outcome (i.e.
there are substantially more subjects
recruited with a HbA1c of < 7.5%
than anticipated), then an additional
inclusion criteria will be added to limit
recruitment only to participants with a
HbA1c of ≥ 7.5% in order to ensure
that the trial can detect a difference in
the primary outcome
2. Withdrawal from the pump criteria:
Removal of ‘Participant becomes
pregnant’ as a reason for
withdrawal from the pump.
Amended so that the decision
whether or not a participant who
becomes pregnant during the trial
stays on the pump is purely a clinical
decision based on the participant’s
blood glucose control on the pump
(i.e. if the participant was managing
their diabetes well on the pump,
they remain on the pump)
3. Consent process:
Amended to allow the witnessing of
the consent by the educator can
take place when the consent form
(signed by the participant) is
received in the post (instead of at
the baseline appointment)
Notification of minor amendment 6
Substantial
amendment 8
23 January
2012
Amendment to the psychosocial
questionnaire so that the HFS and
DSQOL are exact copies of the
validated versions
Psychosocial
questionnaire, v4,
20 January 2012
6 February 2012
Minor
amendment 7
7 February
2012
1. Qualitative substudy consent form –
amended so that the participant ID
is now the DAFNE number (as for
the main trial consent form: minor
amendment 2): v3, 7 February 2012
2. REPOSE pump diary, v2, December
2011. The REPOSE participants
complete a blood glucose diary and
are taught this during their normal
DAFNE course. The blood glucose
diary for the MDI participants is the
standard version that is used during
non-trial DAFNE courses. For the
pump participants, this diary has
been slightly modified so that it is
applicable to pump participants
Qualitative substudy
consent form, v3,
7 February 2012
Submitted with
substantial
amendment 9 to
REC
(Please note that no other versions of
the pump diary have been used. The v2
pump diary reflects internal editing at
DAFNE, who modified the MDI diary)
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Amendment
number and
type
Date
submitted Summary of amendment Documents changed Date approved
Minor
amendment 8
13 April 2012 Clarification of the exclusion criteria of
having used pump therapy in the last
3 years
REPOSE protocol, v7,
3 April 2012
Submitted with
substantial
amendment 9 to
REC
Clarified that this must be ‘significant
use’, which is defined as no more than
2 weeks use of the pump in the last
3 years
Discussed and agreed this definition
with the TMG today
Substantial
amendment 9
16 April 2012 Creation of a new participant letter to
be sent with the follow-up psychosocial
questionnaire
Psychosocial questionnaire
letter, v1, 11 April 2012
1 May 2012
Addition of Nottingham as a research
centre
Notification to REC of minor
amendments 7 and 8
Minor
amendment 9
24 May 2012 Change of sponsor/lead NHS R&D
details from Jim Lithgow to Erica Wallis
None Ethics approved
on 24 May 2012
Substantial
amendment 10
29 May 2012 Change of PI at KCH centre from
Professor Stephanie Amiel to Dr Pratik
Choudary
None 27 June 2012
Minor
amendment 10
12 June 2012 Increased number of centres where
qualitative research will take place from
3–4 to 7
REPOSE protocol, v7.1,
12 June 2012
Submitted with
substantial
amendment 10 to
REC
Altered time the educators find out
about treatment allocation from
6 weeks to 4–6 weeks
Clarified inclusion criteria regarding
having a 12-month history of diabetes:
participants must have had a 12-month
history of diabetes by the time of
baseline/DAFNE course
Minor
amendment 11
6 July 2012 Clarification that the review of baseline
HbA1c is not blinded, as it does not
need to be
Clarification of severe needle phobia
exclusion criteria: clarification that the
severity of phobia assessed considering
if the phobia might preclude full
participation in either treatment arm or
influence the participant’s preference
for pump therapy
Clarification of unstable psychological
problems: clarification that such
conditions are active enough to
preclude the participant safely taking
part in the trial (based on investigatory
judgement)
KCH course 3 and 4: change of venue
for DAFNE course, Springfield Medical
Centre
REPOSE protocol, v7.2,
9 July 2012
Submitted with
substantial
amendment 11 to
REC
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Amendment
number and
type
Date
submitted Summary of amendment Documents changed Date approved
Substantial
amendment 11
7 August 2012 Creation of a participant newsletter to
be issued just before each of the
scheduled follow-up appointments, (i.e.
6, 12 and 24 months post baseline)
6-month follow-up
participant newsletter, v1,
24 July 2012
Ethics approval:
21 August 2012
Substantial
amendment 12
24 August 2012 To increase the number recruited to the
study. Dropouts are occurring prior to
DAFNE course attendance and thus
these participants do not count towards
the ITT. This change does not increase
the number of participants who will
receive the intervention or comparator
treatment.
REPOSE protocol, v8,
20 August 2012
Ethics approval:
12 September
2012
Minor
amendment 12
24 August 2012 Psychosocial questionnaire, v4.1,
28 June 2012:
l Minor formatting to make some
text bold to highlight that
participants choose one option only
for qualifications and employment
questions
Psychosocial
questionnaire, v4.1,
28 June 2012
Submitted with
substantial
amendment
number 12 to REC
REPOSE protocol v8:
l The time for follow-up questionnaires
to be sent prior to a follow-up
appointment has been changed from
4 weeks to two to 6 weeks to allow
for holiday periods
REPOSE protocol, v8,
20 August 2012
Minor
amendment 13
12 November
2012
To amend the patient information sheet
to include the new research centre
(Nottingham); the consent form
references the patient information
sheet and it is therefore necessary to
amend this
Patient information sheet,
v5.1, 4 September 2012
Submitted with
substantial
amendment 13 to
RECInformed consent form,
v6.1, 4 September 2012
Substantial
amendment 13
9 November
2012
Change of PI at KCH centre, back to
Professor Stephanie Amiel from Dr
Pratik Choudhary
None Ethics approval:
12 November
2012
Substantial
amendment 14
12 January
2013
Creation of a participant newsletter to
be issued just before the 12-month
follow-up appointment
12-month follow-up
participant newsletter, v1,
7 January 2013
Ethics approval:
13 February 2013
Substantial
amendment 15
20 May 2013 REPOSE protocol v9:
l Data collection procedure: added
letters as a method of reminding
participants of appointments and
removed specified time frame
for reminders
l Participant retention and return of
data: in cases when it has not been
possible for a participant to attend
their follow-up visit, attempts will
be made by the educator to collect
appropriate data from the
participant over the telephone, and/
or to obtain the relevant data from
the participant’s medical records
l A second questionnaire will be
posted to the participant with a
pre-paid reply envelope when the
participant-completed psychosocial
questionnaire has not been returned
REPOSE protocol, v9,
9 May 2013
Ethics approval:
10 June 2013
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Amendment
number and
type
Date
submitted Summary of amendment Documents changed Date approved
l Participant identification centres
will be used at some centres to
assist in the identification of
suitable participants
l Amendment to KCH PI
Substantial
amendment 16
26 July 2013 Creation of a letter and supporting
documentation to send to all REPOSE
participants reminding them of how to
deal with illness and other problems
that may occur
REPOSE Ketone
Management Reminder
2013 – CSII – v1, 28 June
2013
Ethics approval: 5
August 2013
REPOSE Ketone
Management Reminder
2013 – MDI – v1, 28 June
2013
REPOSE Ketone
Management Reminder
Letter – CSII v1,
28 June 2013
REPOSE Ketone
Management Reminder
Letter – MDI v1,
28 June 2013
Substantial
amendment 17
23 September
2013
Creation of a participant newsletter
to be issued 18 months post course
18-month follow-up
participant newsletter, v1,
15 August 2013
Ethics approval: 3
October 2013
Substantial
amendment 18
24 December
2013
Three additional questionnaires to be
added to the psychosocial
questionnaire pack at the 24-month
time point only:
l DAFNE principles questionnaire
l use of bolus
calculators questionnaire
l pump use questionnaire
DAFNE principles
questionnaire, v1,
12 December 2013
Ethics approval: 3
February 2014
Use of bolus calculators
questionnaire, v1,
12 December 2013
Pump use questionnaire,
v1, 12 December 2013
Creation of a new participant letter to
be sent with the follow-up psychosocial
questionnaire prior to the 24-month
follow-up appointment incorporating
information regarding:
l reporting severe
hypoglycaemic episodes
l enclosure of a £10 gift voucher
24-month psychosocial
questionnaire letter, v2,
22 January 2014
REPOSE protocol v10:
l Inserted details regarding the three
additional questionnaires: adherence
to DAFNE principles, use of bolus
calculators, use of pump features
Amended Table 1 – documents for data
collection to include a separate post
psychosocial questionnaire pack for the
2-year follow-up visit
REPOSE protocol, v10,
11 December 2013
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Amendment
number and
type
Date
submitted Summary of amendment Documents changed Date approved
Substantial
amendment 19
24 December
2013
Creation of a participant newsletter to
be issued 24 months post course
24-month follow-up
participant newsletter, v1,
3 December 2013
Ethics approval:
13 January 2014
Creation of a letter to send to all
REPOSE participants reminding them of
how to use their bolus calculator
Bolus Calculator
Intervention Letter, v1,
11 December 2013
Substantial
amendment 20
5 March 2014 REPOSE Protocol v11.1:
l Clarified withdrawal from
treatment criteria for participants
who develop the need for renal
replacement therapy or who are
found to be abusing alcohol
or drugs
l Clarified that pregnancies will be
recorded as SAEs and that they are
exempt from immediate reporting
l Participant retention and return of
data: when it is difficult for the
participant to attend the hospital,
appropriate research staff may offer
the participant the opportunity to
visit them in their home or at an
alternative NHS location to carry
out data collection
REPOSE protocol, v11.1,
31 March 2014
Ethics approval:
4 April 2014
Minor
amendment 14
23 March 2015 REPOSE protocol v11.2:
l Further details will be collected
from patient notes on episodes of
DKA, when such data have not
been recorded on the SAE.
Additional data will be collected on
cause; whether or not sick day rules
were implemented; bicarbonate on
admission; pH on admission; most
recent HbA1c prior to admission; if
on pump, whether or not there
was a malfunction; whether or not
the patient was at home or away;
and, number of previous episodes
of DKA
REPOSE protocol, v11.2,
24 March 2015
Acknowledgement
received from REC:
8 April 2015
CTA, Clinical Trials Authorisation; FU, follow-up; KCH, King’s College Hospital; N/A, not applicable; NRES, National
Research Ethics Service.
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Appendix 11 Diabetic ketoacidosis/illness letter
and troubleshooting documents issued to participants
DKA letter issued to pump participants 
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DKA troubleshooting document issued to pump participants 
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DKA letter issued to MDI participants
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DKA troubleshooting document issued to MDI participants
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Appendix 12 Twenty-four month letter
incorporating information about severe
hypoglycaemia reporting
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Appendix 13 Bolus calculator letter issued to
participants
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Appendix 14 Results of the Gompertz,
log-logistic and log-normal parametric survival
models used to predict treatment switching
TABLE 74 The results of the Gompertz, log-logistic and log-normal parametric survival models fitted to individuals
in the CSII arm of the REPOSE Trial
Parameter Coefficient Robust SE 95% CI
Gompertz model
HbA1c 0.220 0.236 –0.243 to 0.684
Number of DKAs –0.983 0.468 –1.901 to –0.065
Number of severe hypoglycaemic events 0.407 0.090 0.230 to 0.584
Constant –4.307 2.232 –8.682 to 0.068
Gamma parameter –0.316 0.479 –1.256 to 0.624
Log-logistic model
HbA1c –0.294 0.286 –0.855 to 0.267
Number of DKAs 1.406 0.676 0.081 to 2.730
Number of severe hypoglycaemic events –0.554 0.170 –0.887 to –0.220
Constant 5.637 2.510 0.718 to 10.557
ln gamma parameter 0.215 0.230 –0.235 to 0.665
Log-normal model
HbA1c –0.307 0.292 –0.879 to 0.264
Number of DKAs 1.867 0.755 0.387 to 3.347
Number of severe hypoglycaemic events –0.656 0.180 –1.009 to –0.304
Constant 6.406 2.520 1.466 to 11.346
ln sigma parameter 1.002 0.206 0.598 to 1.405
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TABLE 75 The results of the Gompertz, log-logistic and log-normal parametric survival models fitted to individuals
in the MDIs arm of the REPOSE Trial
Parameter Coefficient Robust SE 95% CI
Gompertz model
HbA1c 0.350 0.170 0.016 to 0.683
Number of DKAs –6.009 0.562 –7.110 to –4.908
Number of severe hypoglycaemic events 0.512 0.094 0.329 to 0.696
Constant –8.080 1.471 –10.963 to –5.197
Gamma parameter 1.055 0.669 –0.256 to 2.366
Log-logistic model
HbA1c –0.181 0.121 –0.418 to 0.055
Number of DKAs 2.609 0.799 1.044 to 4.175
Number of severe hypoglycaemic events –0.232 0.070 –0.368 to –0.095
Constant 3.676 1.317 1.094 to 6.258
ln gamma parameter –0.780 0.317 –1.401 to –0.160
Log-normal model
HbA1c –0.190 0.107 –0.400 to 0.021
Number of DKAs 1.617 0.517 0.603 to 2.630
Number of severe hypoglycaemic events –0.283 0.101 –0.481 to –0.086
Constant 4.117 1.291 1.587 to 6.647
ln sigma parameter 0.066 0.338 –0.596 to 0.728
ln, natural logarithm.
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Appendix 15 End of trial for pump participants:
standard operating procedure
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Appendix 16 Closeout qualitative substudy:
staff topic guide
Demographic
l Role/occupation.
l Years of diabetes/DAFNE experience.
l Years of experience of working with insulin pumps prior to the trial.
Clinical use of pumps in site
l How are pumps usually funded in your centre?
l What clinical and other criteria are used to determine who is referred for a pump?
¢ Prompt NICE/SIGN: how are NICE guidelines on pumps interpreted at your centre/by you? Why
interpreted in this way?
REPOSE
l Tell me about your work on REPOSE – how were you involved (recruitment, training, delivery, contact
with patients during the trial, closeout)?
¢ Was recruitment difficult in your centre? How did it end up regarding pumps and MDI?
l Why do you think the patients recruited from your centre agreed to take part in the trial?
(Probe patients’ preferences: what did you think about this and how did you manage this?)
¢ Do you think more patients really wanted pumps even if they did not’ fess up at the time?
l What do you think about the inclusion/exclusion criteria used in REPOSE and the fact that the trial’s
criteria were different to NICE criteria?
l What do you think about these differences? How did these make you feel about dealing with these patients?
l Any problems and difficulties encountered during the trial (e.g. patient complaints, withdrawals)? How
did you address these?
l Impact of trial on clinical practice? CLOSEOUT
l What do you think about the information given at recruitment about closeout (probe around
information about potential withdrawal of pump at end of trial)?
l How did patients recruited react to this at the time?
l What expectations did you have about closeout? WHY?
¢ What did you think closeout would be like? WHY?
¢ What problems or challenges did you think might arise at closeout? WHY? When did these change?
¢ What expectations did patients in your site have about closeout do you think?
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So what happened in the end? Can you talk me through your experiences of closeout?
l What happened in your site?
l Did you have a SOP/protocol for closeout? How did this differ from trial protocol? Why?
l What decisions were made about whether to continue or discontinue pump treatment in your site?
To what extent were NICE guidelines used/followed?
¢ How were they made? Who made them? Why?
l Were these decisions about closeout made in general or on a case to case basis – WHY?
l How did patients react to closeout decisions?
¢ How did you manage their reactions?
l In hindsight, what would you have done differently at closeout? Why?
General topics
l What did you think of the trial? (Design, rationale.)
l Do you think the trial will work? Why?
l How did people do in the MDI arm?
l Do you think there will be a difference between pump and MDI arms?
l If you think there are benefits in clinical outcomes, why do you think they have occurred?
Generic experiences and needs
l What information and support did you receive when closing out REPOSE? Where/from whom did it
come? (CTU, local PI.)
l What unmet needs for support did you have and how could these be addressed in future trials?
(Prompt debriefing – pre-empting? Who should provide?)
l Experiences of working on and closing out other trials before or since to RESPOSE? Issues or problems
that have arisen on the closeout of earlier trials. How did REPOSE differ and why?
l Anything missed out?
l Anything to add?
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Appendix 17 Closeout qualitative substudy:
participants
Variable n %
REPOSE centres
Number of centres 7
Interviewees per centre range 1–5
Interviewees per centre mode 3
Role
Diabetes consultants 7 33
DAFNE educators 14 66
Diabetes specialist nurses-to-dietitians 8 : 6 38 : 29
DAFNE experience, years
5–10 14 66
10–15 4 21
> 15 3 14
Pump therapy experience, years
< 5 5 24
5–10 9 42
10–15 5 24
> 15 2 10
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